US20230151068A1 - Peptide compositions and methods of use thereof for disrupting tead interactions - Google Patents
Peptide compositions and methods of use thereof for disrupting tead interactions Download PDFInfo
- Publication number
- US20230151068A1 US20230151068A1 US17/873,510 US202217873510A US2023151068A1 US 20230151068 A1 US20230151068 A1 US 20230151068A1 US 202217873510 A US202217873510 A US 202217873510A US 2023151068 A1 US2023151068 A1 US 2023151068A1
- Authority
- US
- United States
- Prior art keywords
- seq
- peptide
- tead
- amino acid
- residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 1056
- 238000000034 method Methods 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims description 52
- 230000003993 interaction Effects 0.000 title abstract description 40
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 45
- 230000004655 Hippo pathway Effects 0.000 claims abstract description 29
- 210000004027 cell Anatomy 0.000 claims description 348
- 230000027455 binding Effects 0.000 claims description 292
- 108700038175 YAP-Signaling Proteins Proteins 0.000 claims description 114
- 235000018417 cysteine Nutrition 0.000 claims description 61
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 46
- -1 poly(2-propylacrylic acid) Polymers 0.000 claims description 46
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 41
- 230000004927 fusion Effects 0.000 claims description 37
- 101710149951 Protein Tat Proteins 0.000 claims description 20
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 19
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 19
- 101710175789 Tafazzin Proteins 0.000 claims description 18
- 210000004899 c-terminal region Anatomy 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 9
- 108700020796 Oncogene Proteins 0.000 claims description 8
- 230000017945 hippo signaling cascade Effects 0.000 claims description 8
- 102000016776 Midkine Human genes 0.000 claims description 7
- 108010092801 Midkine Proteins 0.000 claims description 7
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 101710164760 Chlorotoxin Proteins 0.000 claims description 6
- 101710158651 Opicalcin-2 Proteins 0.000 claims description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 6
- QPAKKWCQMHUHNI-GQIQPHNSSA-N chlorotoxin Chemical compound C([C@H]1C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]4CSSC[C@@H](C(N[C@@H](CCSC)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC4=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N3)=O)NC(=O)[C@@H](N)CCSC)C1=CC=C(O)C=C1 QPAKKWCQMHUHNI-GQIQPHNSSA-N 0.000 claims description 6
- 229960005534 chlorotoxin Drugs 0.000 claims description 6
- 101710165822 Hadrucalcin Proteins 0.000 claims description 5
- 101710119392 Hemicalcin Proteins 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- KCCDSHMVQWPFBC-QQUOXUDESA-N (2s,3s)-2-[[(2s)-2-[[(2s)-3-(4-hydroxyphenyl)-2-[[(2s)-3-methyl-2-[[(2s)-3-phenyl-2-[[(2s)-pyrrolidine-2-carbonyl]amino]propanoyl]amino]butanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H]1NCCC1)C(C)C)C1=CC=C(O)C=C1 KCCDSHMVQWPFBC-QQUOXUDESA-N 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 101710158642 Opicalcin-1 Proteins 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 108010026382 trypsin inhibitor MCoTI-II Proteins 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 230000002103 transcriptional effect Effects 0.000 claims description 3
- FYEHYMARPSSOBO-UHFFFAOYSA-N Aurin Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(O)=CC=1)=C1C=CC(=O)C=C1 FYEHYMARPSSOBO-UHFFFAOYSA-N 0.000 claims description 2
- 241001060848 Carapidae Species 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 101710118867 Maurocalcin Proteins 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 229940105132 myristate Drugs 0.000 claims description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 2
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 claims description 2
- 108010062760 transportan Proteins 0.000 claims description 2
- 102100026508 Tafazzin Human genes 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 341
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 24
- 201000011510 cancer Diseases 0.000 abstract description 21
- 201000010099 disease Diseases 0.000 abstract description 20
- 230000010261 cell growth Effects 0.000 abstract description 13
- 238000004519 manufacturing process Methods 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 description 112
- 102000004169 proteins and genes Human genes 0.000 description 105
- 235000001014 amino acid Nutrition 0.000 description 96
- 125000005647 linker group Chemical group 0.000 description 93
- 235000018102 proteins Nutrition 0.000 description 92
- 229940024606 amino acid Drugs 0.000 description 80
- 150000001413 amino acids Chemical class 0.000 description 80
- 125000000539 amino acid group Chemical group 0.000 description 72
- 238000000684 flow cytometry Methods 0.000 description 70
- 230000035772 mutation Effects 0.000 description 65
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 63
- 239000000725 suspension Substances 0.000 description 62
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 52
- 239000013543 active substance Substances 0.000 description 49
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 39
- 239000003795 chemical substances by application Substances 0.000 description 39
- 238000006467 substitution reaction Methods 0.000 description 39
- 102000035195 Peptidases Human genes 0.000 description 38
- 108091005804 Peptidases Proteins 0.000 description 38
- 239000012634 fragment Substances 0.000 description 37
- 230000002829 reductive effect Effects 0.000 description 37
- 125000003275 alpha amino acid group Chemical group 0.000 description 34
- 239000004365 Protease Substances 0.000 description 32
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 30
- 235000004279 alanine Nutrition 0.000 description 29
- 239000013598 vector Substances 0.000 description 28
- 239000002953 phosphate buffered saline Substances 0.000 description 27
- 229940126697 YAP-TEAD PPI inhibitor Drugs 0.000 description 26
- 210000004940 nucleus Anatomy 0.000 description 26
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 25
- 239000000872 buffer Substances 0.000 description 25
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 25
- 239000003814 drug Substances 0.000 description 25
- 230000014509 gene expression Effects 0.000 description 25
- 230000035515 penetration Effects 0.000 description 25
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 24
- 238000012216 screening Methods 0.000 description 24
- 235000004400 serine Nutrition 0.000 description 23
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 description 22
- 230000015556 catabolic process Effects 0.000 description 22
- 238000013461 design Methods 0.000 description 22
- 238000004128 high performance liquid chromatography Methods 0.000 description 22
- 230000001976 improved effect Effects 0.000 description 22
- 238000002703 mutagenesis Methods 0.000 description 22
- 231100000350 mutagenesis Toxicity 0.000 description 22
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 22
- 238000011282 treatment Methods 0.000 description 22
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 21
- 238000006731 degradation reaction Methods 0.000 description 21
- 239000000975 dye Substances 0.000 description 21
- 238000011534 incubation Methods 0.000 description 21
- 229940079593 drug Drugs 0.000 description 19
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 18
- 230000006870 function Effects 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 18
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 17
- 229960002685 biotin Drugs 0.000 description 17
- 239000011616 biotin Substances 0.000 description 17
- 238000010494 dissociation reaction Methods 0.000 description 17
- 230000005593 dissociations Effects 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 16
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 16
- 102100027548 WW domain-containing transcription regulator protein 1 Human genes 0.000 description 16
- 230000021615 conjugation Effects 0.000 description 16
- 150000007523 nucleic acids Chemical class 0.000 description 16
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 15
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 15
- 239000000499 gel Substances 0.000 description 15
- 238000010384 proximity ligation assay Methods 0.000 description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 14
- 239000011230 binding agent Substances 0.000 description 14
- 238000007069 methylation reaction Methods 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 108010039471 Fas Ligand Protein Proteins 0.000 description 13
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 13
- 239000003638 chemical reducing agent Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 13
- 230000011987 methylation Effects 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 230000009467 reduction Effects 0.000 description 13
- 238000006722 reduction reaction Methods 0.000 description 13
- 230000008685 targeting Effects 0.000 description 13
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 12
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 239000013604 expression vector Substances 0.000 description 12
- 229960003180 glutathione Drugs 0.000 description 12
- 230000007935 neutral effect Effects 0.000 description 12
- 235000019419 proteases Nutrition 0.000 description 12
- 239000011347 resin Substances 0.000 description 12
- 229920005989 resin Polymers 0.000 description 12
- 150000003355 serines Chemical class 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 108091006146 Channels Proteins 0.000 description 11
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 11
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 11
- 239000004472 Lysine Substances 0.000 description 11
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 11
- 102000004142 Trypsin Human genes 0.000 description 11
- 230000002378 acidificating effect Effects 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 11
- 108010033706 glycylserine Proteins 0.000 description 11
- 235000018977 lysine Nutrition 0.000 description 11
- 239000011159 matrix material Substances 0.000 description 11
- 230000000149 penetrating effect Effects 0.000 description 11
- 230000004850 protein–protein interaction Effects 0.000 description 11
- 239000003053 toxin Substances 0.000 description 11
- 231100000765 toxin Toxicity 0.000 description 11
- 108700012359 toxins Proteins 0.000 description 11
- 238000001262 western blot Methods 0.000 description 11
- 108090000631 Trypsin Proteins 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 10
- 239000000562 conjugate Substances 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 238000000159 protein binding assay Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000012588 trypsin Substances 0.000 description 10
- 229960001322 trypsin Drugs 0.000 description 10
- 102100032231 Caveolae-associated protein 2 Human genes 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical group NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 9
- 101000869050 Homo sapiens Caveolae-associated protein 2 Proteins 0.000 description 9
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 238000007385 chemical modification Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 238000004088 simulation Methods 0.000 description 9
- 125000006850 spacer group Chemical group 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000002435 venom Substances 0.000 description 9
- 231100000611 venom Toxicity 0.000 description 9
- 210000001048 venom Anatomy 0.000 description 9
- 108090000317 Chymotrypsin Proteins 0.000 description 8
- 101100087538 Homo sapiens RHOU gene Proteins 0.000 description 8
- 108010067372 Pancreatic elastase Proteins 0.000 description 8
- 102000016387 Pancreatic elastase Human genes 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 102100038399 Rho-related GTP-binding protein RhoU Human genes 0.000 description 8
- 239000012190 activator Substances 0.000 description 8
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 229960002376 chymotrypsin Drugs 0.000 description 8
- 230000001086 cytosolic effect Effects 0.000 description 8
- 235000013922 glutamic acid Nutrition 0.000 description 8
- 239000004220 glutamic acid Substances 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000010647 peptide synthesis reaction Methods 0.000 description 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 102220323254 rs150140303 Human genes 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 229920003169 water-soluble polymer Polymers 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 108010067902 Peptide Library Proteins 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 210000000172 cytosol Anatomy 0.000 description 7
- 210000001163 endosome Anatomy 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- 241000712898 Machupo mammarenavirus Species 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- 206010061309 Neoplasm progression Diseases 0.000 description 6
- 241000239226 Scorpiones Species 0.000 description 6
- 102000007238 Transferrin Receptors Human genes 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 238000000126 in silico method Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 230000004807 localization Effects 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 6
- 239000002105 nanoparticle Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 230000005751 tumor progression Effects 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- 235000002374 tyrosine Nutrition 0.000 description 6
- 238000010200 validation analysis Methods 0.000 description 6
- 229910052727 yttrium Inorganic materials 0.000 description 6
- DLZKEQQWXODGGZ-KCJUWKMLSA-N 2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetic acid Chemical group OC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DLZKEQQWXODGGZ-KCJUWKMLSA-N 0.000 description 5
- 241000239290 Araneae Species 0.000 description 5
- 102000005600 Cathepsins Human genes 0.000 description 5
- 108010084457 Cathepsins Proteins 0.000 description 5
- 101000761145 Cheiracanthium punctorium DELTA-miturgitoxin-Cp1a Proteins 0.000 description 5
- 101000930491 Cyriopagopus schmidti Tau-theraphotoxin-Hs1a Proteins 0.000 description 5
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
- 108010024636 Glutathione Proteins 0.000 description 5
- 101000648267 Hadronyche infensa Pi-hexatoxin-Hi1a Proteins 0.000 description 5
- 101000801512 Hadronyche infensa Pi-hexatoxin-Hi1b Proteins 0.000 description 5
- 101000801469 Hadronyche infensa Pi-hexatoxin-Hi1c Proteins 0.000 description 5
- 101000801459 Hadronyche infensa Pi-hexatoxin-Hi1d Proteins 0.000 description 5
- 102000013519 Lipocalin-2 Human genes 0.000 description 5
- 108010051335 Lipocalin-2 Proteins 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 239000000611 antibody drug conjugate Substances 0.000 description 5
- 229940049595 antibody-drug conjugate Drugs 0.000 description 5
- 235000003704 aspartic acid Nutrition 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
- 230000008499 blood brain barrier function Effects 0.000 description 5
- 210000001218 blood-brain barrier Anatomy 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 239000002738 chelating agent Substances 0.000 description 5
- 230000001268 conjugating effect Effects 0.000 description 5
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 150000002019 disulfides Chemical class 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 210000003712 lysosome Anatomy 0.000 description 5
- 230000001868 lysosomic effect Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000002611 ovarian Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 230000004481 post-translational protein modification Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000001542 size-exclusion chromatography Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 4
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- 101001086405 Bos taurus Rhodopsin Proteins 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000002149 Elafin Human genes 0.000 description 4
- 108010015972 Elafin Proteins 0.000 description 4
- 108010060309 Glucuronidase Proteins 0.000 description 4
- 102000053187 Glucuronidase Human genes 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 108010006035 Metalloproteases Proteins 0.000 description 4
- 102000005741 Metalloproteases Human genes 0.000 description 4
- BAQMYDQNMFBZNA-UHFFFAOYSA-N N-biotinyl-L-lysine Natural products N1C(=O)NC2C(CCCCC(=O)NCCCCC(N)C(O)=O)SCC21 BAQMYDQNMFBZNA-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 4
- 229910052772 Samarium Inorganic materials 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 101710162629 Trypsin inhibitor Proteins 0.000 description 4
- 229940122618 Trypsin inhibitor Drugs 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 229910052767 actinium Inorganic materials 0.000 description 4
- QQINRWTZWGJFDB-UHFFFAOYSA-N actinium atom Chemical compound [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- BAQMYDQNMFBZNA-MNXVOIDGSA-N biocytin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCC[C@H](N)C(O)=O)SC[C@@H]21 BAQMYDQNMFBZNA-MNXVOIDGSA-N 0.000 description 4
- 229910052797 bismuth Inorganic materials 0.000 description 4
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 4
- 238000001142 circular dichroism spectrum Methods 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 239000002872 contrast media Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 description 4
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 150000002678 macrocyclic compounds Chemical class 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 235000013930 proline Nutrition 0.000 description 4
- 229910052705 radium Inorganic materials 0.000 description 4
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- 239000004332 silver Substances 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 229910052712 strontium Inorganic materials 0.000 description 4
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 4
- 235000008521 threonine Nutrition 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 239000002753 trypsin inhibitor Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- 102220510638 APC membrane recruitment protein 1_G15Q_mutation Human genes 0.000 description 3
- 239000012114 Alexa Fluor 647 Substances 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102100024940 Cathepsin K Human genes 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- 241001157778 Haplopelma schmidti Species 0.000 description 3
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 108010033576 Transferrin Receptors Proteins 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 229920001222 biopolymer Polymers 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000749 co-immunoprecipitation Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 235000001671 coumarin Nutrition 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000000412 dendrimer Substances 0.000 description 3
- 229920000736 dendritic polymer Polymers 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 125000002228 disulfide group Chemical group 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000012933 kinetic analysis Methods 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 3
- 210000005265 lung cell Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002887 multiple sequence alignment Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000005305 organ development Effects 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 239000000863 peptide conjugate Substances 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 229920001308 poly(aminoacid) Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 230000006432 protein unfolding Effects 0.000 description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 3
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 3
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 3
- 238000006485 reductive methylation reaction Methods 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 239000012146 running buffer Substances 0.000 description 3
- 238000012772 sequence design Methods 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 150000003852 triazoles Chemical class 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000010798 ubiquitination Methods 0.000 description 3
- 230000034512 ubiquitination Effects 0.000 description 3
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 3
- 229960001183 venetoclax Drugs 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 description 2
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 description 2
- RAVVEEJGALCVIN-AGVBWZICSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RAVVEEJGALCVIN-AGVBWZICSA-N 0.000 description 2
- UTQHLYJFMFKSGI-UBINZTMLSA-N (2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s,3r)-3-[(2s,4r,5r,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)-4-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2-[2-[[(2s)-4-amino-2-[[(2s)-2-[[2-[[2-[[(2s)-4-carbo Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)C(C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H]1NC(=O)CC1)[C@@H](C)O[C@@H]1C([C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1)NC(C)=O)C1=CC=C(O)C=C1 UTQHLYJFMFKSGI-UBINZTMLSA-N 0.000 description 2
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- AUUIARVPJHGTSA-UHFFFAOYSA-N 3-(aminomethyl)chromen-2-one Chemical compound C1=CC=C2OC(=O)C(CN)=CC2=C1 AUUIARVPJHGTSA-UHFFFAOYSA-N 0.000 description 2
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical compound C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 description 2
- JKMWZKPAXZBYEH-JWHWKPFMSA-N 5-[3-[4-(aminomethyl)phenoxy]propyl]-2-[(8e)-8-(1,3-benzothiazol-2-ylhydrazinylidene)-6,7-dihydro-5h-naphthalen-2-yl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(CN)=CC=C1OCCCC1=C(C(O)=O)N=C(C=2C=C3C(=N/NC=4SC5=CC=CC=C5N=4)/CCCC3=CC=2)S1 JKMWZKPAXZBYEH-JWHWKPFMSA-N 0.000 description 2
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 2
- XRTHAPZDZPADIL-UHFFFAOYSA-N 8-[(5-chloro-2-hydroxybenzoyl)amino]octanoic acid Chemical compound OC(=O)CCCCCCCNC(=O)C1=CC(Cl)=CC=C1O XRTHAPZDZPADIL-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- IKYJCHYORFJFRR-UHFFFAOYSA-N Alexa Fluor 350 Chemical compound O=C1OC=2C=C(N)C(S(O)(=O)=O)=CC=2C(C)=C1CC(=O)ON1C(=O)CCC1=O IKYJCHYORFJFRR-UHFFFAOYSA-N 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- WHVNXSBKJGAXKU-UHFFFAOYSA-N Alexa Fluor 532 Chemical compound [H+].[H+].CC1(C)C(C)NC(C(=C2OC3=C(C=4C(C(C(C)N=4)(C)C)=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C=C1)=CC=C1C(=O)ON1C(=O)CCC1=O WHVNXSBKJGAXKU-UHFFFAOYSA-N 0.000 description 2
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 2
- 239000012115 Alexa Fluor 660 Substances 0.000 description 2
- 239000012116 Alexa Fluor 680 Substances 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- HAUGRYOERYOXHX-UHFFFAOYSA-N Alloxazine Chemical compound C1=CC=C2N=C(C(=O)NC(=O)N3)C3=NC2=C1 HAUGRYOERYOXHX-UHFFFAOYSA-N 0.000 description 2
- 229910052695 Americium Inorganic materials 0.000 description 2
- 102000008128 Apolipoprotein E3 Human genes 0.000 description 2
- 108010060215 Apolipoprotein E3 Proteins 0.000 description 2
- 101710190711 Bubble protein Proteins 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 108010006303 Carboxypeptidases Proteins 0.000 description 2
- 102000005367 Carboxypeptidases Human genes 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 241000701489 Cauliflower mosaic virus Species 0.000 description 2
- 206010048832 Colon adenoma Diseases 0.000 description 2
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 2
- 101000894572 Conus marmoreus Chi-conotoxin MrIA Proteins 0.000 description 2
- 101000983966 Conus tulipa Rho-conotoxin TIA Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 150000008574 D-amino acids Chemical group 0.000 description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102400001329 Epiregulin Human genes 0.000 description 2
- 101800000155 Epiregulin Proteins 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- 102000015212 Fas Ligand Protein Human genes 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 229910052688 Gadolinium Inorganic materials 0.000 description 2
- 206010056740 Genital discharge Diseases 0.000 description 2
- BCCRXDTUTZHDEU-UHFFFAOYSA-N Glycyl-Serine Chemical group NCC(=O)NC(CO)C(O)=O BCCRXDTUTZHDEU-UHFFFAOYSA-N 0.000 description 2
- 101000623875 Grammostola rosea M-theraphotoxin-Gr1a Proteins 0.000 description 2
- WVDNTWXIIKNMHY-UHFFFAOYSA-N GsMTx4 Chemical compound O=C1NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCCCN)C(=O)NC(C(NC(CC(N)=O)C(=O)N2CCCC2C(=O)NC(CC(N)=O)C(=O)NC(CC(O)=O)C(=O)NC(CC(O)=O)C(=O)NC(CCCCN)C(=O)NC(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(CO)NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CO)C(=O)NC(CC=3C=CC=CC=3)C(N)=O)C(=O)N3)=O)CSSCC2NC(=O)C(CCCCN)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C3CSSCC(NC(=O)CN)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC1CC1=CC=CC=C1 WVDNTWXIIKNMHY-UHFFFAOYSA-N 0.000 description 2
- 208000002927 Hamartoma Diseases 0.000 description 2
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 description 2
- 101000653735 Homo sapiens Transcriptional enhancer factor TEF-1 Proteins 0.000 description 2
- 101000597045 Homo sapiens Transcriptional enhancer factor TEF-3 Proteins 0.000 description 2
- 101000597035 Homo sapiens Transcriptional enhancer factor TEF-4 Proteins 0.000 description 2
- 101000597043 Homo sapiens Transcriptional enhancer factor TEF-5 Proteins 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 229910052765 Lutetium Inorganic materials 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 206010054949 Metaplasia Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 102100030919 Phosphatidylcholine:ceramide cholinephosphotransferase 1 Human genes 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 101100163901 Rattus norvegicus Asic2 gene Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 101000910357 Scorpio palmatus Maurocalcin Proteins 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 108010076818 TEV protease Proteins 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102100029898 Transcriptional enhancer factor TEF-1 Human genes 0.000 description 2
- 102100035148 Transcriptional enhancer factor TEF-3 Human genes 0.000 description 2
- 102100035146 Transcriptional enhancer factor TEF-4 Human genes 0.000 description 2
- 102100035147 Transcriptional enhancer factor TEF-5 Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229940125666 actinium-225 Drugs 0.000 description 2
- QQINRWTZWGJFDB-YPZZEJLDSA-N actinium-225 Chemical group [225Ac] QQINRWTZWGJFDB-YPZZEJLDSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 108091005764 adaptor proteins Proteins 0.000 description 2
- 102000035181 adaptor proteins Human genes 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- LXQXZNRPTYVCNG-UHFFFAOYSA-N americium atom Chemical compound [Am] LXQXZNRPTYVCNG-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 2
- 229910052793 cadmium Inorganic materials 0.000 description 2
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2
- 229930195731 calicheamicin Natural products 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- HTBKFGWATIYCSF-QGXIKSNHSA-N conantokin g Chemical compound NC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CC(C(O)=O)C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN HTBKFGWATIYCSF-QGXIKSNHSA-N 0.000 description 2
- 230000030944 contact inhibition Effects 0.000 description 2
- 229960000956 coumarin Drugs 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- HSMMSDWNEJLVRY-INIZCTEOSA-N dodecyl (2s)-2-(dimethylamino)propanoate Chemical compound CCCCCCCCCCCCOC(=O)[C@H](C)N(C)C HSMMSDWNEJLVRY-INIZCTEOSA-N 0.000 description 2
- 229940116896 dodecyl-2-n,n-dimethylaminopropionate Drugs 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 150000002118 epoxides Chemical group 0.000 description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 102000047202 human LCN2 Human genes 0.000 description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 2
- 229960004657 indocyanine green Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229910052741 iridium Inorganic materials 0.000 description 2
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- WABPQHHGFIMREM-BKFZFHPZSA-N lead-212 Chemical compound [212Pb] WABPQHHGFIMREM-BKFZFHPZSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 208000006178 malignant mesothelioma Diseases 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 230000015689 metaplastic ossification Effects 0.000 description 2
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 2
- HQCYVSPJIOJEGA-UHFFFAOYSA-N methoxycoumarin Chemical compound C1=CC=C2OC(=O)C(OC)=CC2=C1 HQCYVSPJIOJEGA-UHFFFAOYSA-N 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 229950004847 navitoclax Drugs 0.000 description 2
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 208000007538 neurilemmoma Diseases 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000006911 nucleation Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000001048 orange dye Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 108010043655 penetratin Proteins 0.000 description 2
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 150000003058 platinum compounds Chemical class 0.000 description 2
- 229910052699 polonium Inorganic materials 0.000 description 2
- HZEBHPIOVYHPMT-UHFFFAOYSA-N polonium atom Chemical compound [Po] HZEBHPIOVYHPMT-UHFFFAOYSA-N 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 150000004053 quinones Chemical class 0.000 description 2
- 239000002534 radiation-sensitizing agent Substances 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 201000010174 renal carcinoma Diseases 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000000518 rheometry Methods 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 description 2
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 2
- 206010039667 schwannoma Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006104 solid solution Substances 0.000 description 2
- 238000007614 solvation Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229910052713 technetium Inorganic materials 0.000 description 2
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 2
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 229910052716 thallium Inorganic materials 0.000 description 2
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 2
- 108091006108 transcriptional coactivators Proteins 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 108091058552 ω-conotoxin CVID Proteins 0.000 description 2
- 108091058538 ω-conotoxin MVIIA Proteins 0.000 description 2
- OVJBOPBBHWOWJI-FYNXUGHNSA-N (2S)-2-[[(2S)-1-[(2S)-2-[[(aS,1R,3aS,4S,10S,16S,19R,22S,25S,28S,34S,37S,40R,45R,48S,51S,57S,60S,63S,69S,72S,75S,78S,85R,88S,91R,94S)-40-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-25,48,78,88,94-pentakis(4-aminobutyl)-a-(2-amino-2-oxoethyl)-22,63,72-tris(3-amino-3-oxopropyl)-69-benzyl-37-[(1R)-1-hydroxyethyl]-34,60-bis(hydroxymethyl)-51,57,75-trimethyl-16-(2-methylpropyl)-3a-(2-methylsulfanylethyl)-2a,3,5a,9,15,18,21,24,27,33,36,39,47,50,53,56,59,62,65,68,71,74,77,80,87,90,93,96,99-nonacosaoxo-7a,8a,42,43,82,83-hexathia-1a,2,4a,8,14,17,20,23,26,32,35,38,46,49,52,55,58,61,64,67,70,73,76,79,86,89,92,95,98-nonacosazahexacyclo[43.35.25.419,91.04,8.010,14.028,32]nonahectane-85-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CO)NC(=O)[C@@H](NC1=O)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N3)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC2=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O OVJBOPBBHWOWJI-FYNXUGHNSA-N 0.000 description 1
- LGNCNVVZCUVPOT-FUVGGWJZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 LGNCNVVZCUVPOT-FUVGGWJZSA-N 0.000 description 1
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 description 1
- CVCLJVVBHYOXDC-IAZSKANUSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole Chemical compound COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C CVCLJVVBHYOXDC-IAZSKANUSA-N 0.000 description 1
- HDXJBHKUPVMLDS-DKWTVANSSA-L (5S)-5-amino-1,3,2lambda2-dioxaplumbepane-4,7-dione Chemical compound [Pb+2].N[C@@H](CC(=O)[O-])C(=O)[O-] HDXJBHKUPVMLDS-DKWTVANSSA-L 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- KLCLIOISYBHYDZ-UHFFFAOYSA-N 1,4,4-triphenylbuta-1,3-dienylbenzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)=CC=C(C=1C=CC=CC=1)C1=CC=CC=C1 KLCLIOISYBHYDZ-UHFFFAOYSA-N 0.000 description 1
- FUHCFUVCWLZEDQ-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid Chemical compound O=C1CCC(=O)N1OC(=O)C(S(=O)(=O)O)CCSSC1=CC=CC=N1 FUHCFUVCWLZEDQ-UHFFFAOYSA-N 0.000 description 1
- DYZYNUQMTZWZAO-UHFFFAOYSA-N 1-(2-phenylethynyl)anthracene Chemical compound C1=CC=CC=C1C#CC1=CC=CC2=CC3=CC=CC=C3C=C12 DYZYNUQMTZWZAO-UHFFFAOYSA-N 0.000 description 1
- IMMCAKJISYGPDQ-UHFFFAOYSA-N 1-chloro-9,10-bis(phenylethynyl)anthracene Chemical compound C12=CC=CC=C2C(C#CC=2C=CC=CC=2)=C2C(Cl)=CC=CC2=C1C#CC1=CC=CC=C1 IMMCAKJISYGPDQ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- YKBSQULHVVNVBI-UHFFFAOYSA-N 2-(4-ethoxyphenyl)-6-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-benzimidazole;trihydrate;trihydrochloride Chemical compound O.O.O.Cl.Cl.Cl.C1=CC(OCC)=CC=C1C1=NC2=CC(C=3NC4=CC=C(C=C4N=3)N3CCN(C)CC3)=CC=C2N1 YKBSQULHVVNVBI-UHFFFAOYSA-N 0.000 description 1
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
- 125000003816 2-hydroxybenzoyl group Chemical group OC1=C(C(=O)*)C=CC=C1 0.000 description 1
- NYHNVHGFPZAZGA-UHFFFAOYSA-N 2-hydroxyhexanoic acid Chemical compound CCCCC(O)C(O)=O NYHNVHGFPZAZGA-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- WMAXWOOEPJQXEB-UHFFFAOYSA-N 2-phenyl-5-(4-phenylphenyl)-1,3,4-oxadiazole Chemical class C1=CC=CC=C1C1=NN=C(C=2C=CC(=CC=2)C=2C=CC=CC=2)O1 WMAXWOOEPJQXEB-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- XFOFHELUDYDYMX-UHFFFAOYSA-N 3-imino-4h-chromen-2-one Chemical compound C1=CC=C2OC(=O)C(=N)CC2=C1 XFOFHELUDYDYMX-UHFFFAOYSA-N 0.000 description 1
- AJNUQUGWNQHQDJ-UHFFFAOYSA-N 4',5'-bis(1,3,2-dithiarsolan-2-yl)-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound S1CCS[As]1C=1C(O)=CC=C(C23C4=CC=CC=C4C(=O)O3)C=1OC1=C2C=CC(O)=C1[As]1SCCS1 AJNUQUGWNQHQDJ-UHFFFAOYSA-N 0.000 description 1
- LWXYOERUKGQNKQ-IQDTYCCDSA-N 4-[2-[(1E,3E,5E,7Z)-7-[3-[6-[4-[(1R,4R,5aR,8aS,9R,12S,17aS,18S,20aS,21R,24S,27S,30S,33S,36S,39S,42S,45S,48S,51S,54R,59R,62S,65S,74S,77R,80S,86S,92S)-9-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-39,62-bis(3-amino-3-oxopropyl)-24-benzyl-5a-[[(1S)-4-carbamimidamido-1-carboxybutyl]carbamoyl]-48,51,86,92-tetrakis(3-carbamimidamidopropyl)-17a,20a,33-tris(carboxymethyl)-27,30-bis[(1R)-1-hydroxyethyl]-74-[(4-hydroxyphenyl)methyl]-36-(1H-imidazol-4-ylmethyl)-45-methyl-8a-(2-methylpropyl)-12,42-bis(2-methylsulfanylethyl)-a,3,7a,10,10a,13,15a,18a,19,21a,22,25,28,31,34,37,40,43,46,49,52,61,64,70,73,76,79,82,85,88,91,94,97-tritriacontaoxo-2a,3a,6,7,12a,13a,56,57-octathia-2,6a,9a,11,14,16a,19a,20,22a,23,26,29,32,35,38,41,44,47,50,53,60,63,69,72,75,78,81,84,87,90,93,96,99-tritriacontazahexacyclo[57.41.10.84,54.421,77.014,18.065,69]docosahectan-80-yl]butylamino]-6-oxohexyl]-1,1-dimethylbenzo[e]indol-2-ylidene]hepta-1,3,5-trienyl]-1,1-dimethylbenzo[e]indol-3-ium-3-yl]butane-1-sulfonate Chemical compound CSCC[C@H](N)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]3CSSC[C@@H]4NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]5CCCN5C(=O)CNC(=O)[C@H](Cc5ccc(O)cc5)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCSC)NC1=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N3)NC(=O)[C@H](CCCCNC(=O)CCCCCN1\C(=C/C=C/C=C/C=C/C3=[N+](CCCCS([O-])(=O)=O)c5ccc6ccccc6c5C3(C)C)C(C)(C)c3c1ccc1ccccc31)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC4=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC2=O LWXYOERUKGQNKQ-IQDTYCCDSA-N 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical group FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- MWZTVLNYXAKUKY-LBEKAKSKSA-N 4-hydroxy-N-[2-[(1R,13S)-3-methyl-8-oxo-11-azatetracyclo[8.4.0.01,13.02,7]tetradeca-2,4,6,9-tetraene-11-carbonyl]imidazo[1,2-a]pyridin-6-yl]benzamide Chemical compound C=1([C@]23C[C@@H]3C3)C(C)=CC=CC=1C(=O)C=C2N3C(=O)C(N=C1C=C2)=CN1C=C2NC(=O)C1=CC=C(O)C=C1 MWZTVLNYXAKUKY-LBEKAKSKSA-N 0.000 description 1
- CMUGHZFPFWNUQT-HUBLWGQQSA-N 6-[5-(2-oxo-hexahydro-thieno[3,4-d]imidazol-4-yl)-pentanoylamino]-hexanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)O)SC[C@@H]21 CMUGHZFPFWNUQT-HUBLWGQQSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 102100023247 60S ribosomal protein L23a Human genes 0.000 description 1
- HSUDWURBWSUCOB-NUDIOSPNSA-N 7-(2′,3′′-dihydroxypropyl carbonoxy)paclitaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](OC(=O)OCC(O)CO)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 HSUDWURBWSUCOB-NUDIOSPNSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 102220554198 APC membrane recruitment protein 1_E25A_mutation Human genes 0.000 description 1
- NASQJISZQAKPTC-UHFFFAOYSA-N ATTO 610-7 Chemical compound [O-]Cl(=O)(=O)=O.C1=C2CCC[N+](CCCC(=O)NCCCCCNC(=O)CCCCC3C4NC(=O)NC4CS3)=C2C=C2C1=CC1=CC=C(N(C)C)C=C1C2(C)C NASQJISZQAKPTC-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000238898 Agelenopsis aperta Species 0.000 description 1
- 239000012109 Alexa Fluor 568 Substances 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 239000012112 Alexa Fluor 633 Substances 0.000 description 1
- 239000012117 Alexa Fluor 700 Substances 0.000 description 1
- 239000012118 Alexa Fluor 750 Substances 0.000 description 1
- 239000012119 Alexa Fluor 790 Substances 0.000 description 1
- 231100000729 Amatoxin Toxicity 0.000 description 1
- 241000239238 Androctonus australis Species 0.000 description 1
- 102000043902 Angiomotin Human genes 0.000 description 1
- 108700020509 Angiomotin Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 101100295091 Arabidopsis thaliana NUDT14 gene Proteins 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 108091005502 Aspartic proteases Proteins 0.000 description 1
- 102000035101 Aspartic proteases Human genes 0.000 description 1
- 241000238895 Atrax robustus Species 0.000 description 1
- 102100027936 Attractin Human genes 0.000 description 1
- 101710134735 Attractin Proteins 0.000 description 1
- 241001263178 Auriparus Species 0.000 description 1
- 229940126077 BACE inhibitor Drugs 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940122035 Bcl-XL inhibitor Drugs 0.000 description 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
- 102100021257 Beta-secretase 1 Human genes 0.000 description 1
- 208000018240 Bone Marrow Failure disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001493374 Buthus occitanus israelis Species 0.000 description 1
- 241000239325 Buthus occitanus tunetanus Species 0.000 description 1
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical class C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 1
- 229960005532 CC-1065 Drugs 0.000 description 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 229940121981 Carboxypeptidase inhibitor Drugs 0.000 description 1
- 101710127041 Carboxypeptidase inhibitor Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 102000003902 Cathepsin C Human genes 0.000 description 1
- 108090000267 Cathepsin C Proteins 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 102000004178 Cathepsin E Human genes 0.000 description 1
- 108090000611 Cathepsin E Proteins 0.000 description 1
- 108090000610 Cathepsin F Proteins 0.000 description 1
- 102000004176 Cathepsin F Human genes 0.000 description 1
- 108090000619 Cathepsin H Proteins 0.000 description 1
- 102000004175 Cathepsin H Human genes 0.000 description 1
- 108090000625 Cathepsin K Proteins 0.000 description 1
- 108090000624 Cathepsin L Proteins 0.000 description 1
- 102000004172 Cathepsin L Human genes 0.000 description 1
- 102100026540 Cathepsin L2 Human genes 0.000 description 1
- 101710177066 Cathepsin O Proteins 0.000 description 1
- 102100035654 Cathepsin S Human genes 0.000 description 1
- 108090000613 Cathepsin S Proteins 0.000 description 1
- 108010061112 Cathepsin W Proteins 0.000 description 1
- 102000011933 Cathepsin W Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 101000997261 Centruroides margaritatus Potassium channel toxin alpha-KTx 2.2 Proteins 0.000 description 1
- 241000239328 Centruroides noxius Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000486761 Chilobrachys Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 229940122644 Chymotrypsin inhibitor Drugs 0.000 description 1
- 101710137926 Chymotrypsin inhibitor Proteins 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 1
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 1
- FKUPPRZPSYCDRS-UHFFFAOYSA-N Cyclopentadecanolide Chemical compound O=C1CCCCCCCCCCCCCCO1 FKUPPRZPSYCDRS-UHFFFAOYSA-N 0.000 description 1
- 101000972324 Cynodon dactylon Leaf protein Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-SAYSVMKTSA-N Desacetylvinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 NDMPLJNOPCLANR-SAYSVMKTSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100034239 Emerin Human genes 0.000 description 1
- 201000009344 Emery-Dreifuss muscular dystrophy Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102100038516 FERM domain-containing protein 6 Human genes 0.000 description 1
- 241000272186 Falco columbarius Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108091005503 Glutamic proteases Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000038548 Grammostola rosea Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241001657448 Hadronyche infensa Species 0.000 description 1
- 241000238894 Hadronyche versuta Species 0.000 description 1
- 241000478297 Hadrurus gertschi Species 0.000 description 1
- 241001374408 Haplopelma Species 0.000 description 1
- 241001259058 Haplopelma hainanum Species 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 241001611414 Heterometrus laoticus Species 0.000 description 1
- 241001653768 Heteropoda venatoria Species 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001115494 Homo sapiens 60S ribosomal protein L23a Proteins 0.000 description 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000761509 Homo sapiens Cathepsin K Proteins 0.000 description 1
- 101000983577 Homo sapiens Cathepsin L2 Proteins 0.000 description 1
- 101000910979 Homo sapiens Cathepsin Z Proteins 0.000 description 1
- 101000744174 Homo sapiens DNA-3-methyladenine glycosylase Proteins 0.000 description 1
- 101001030537 Homo sapiens FERM domain-containing protein 6 Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101001050472 Homo sapiens Integral membrane protein 2A Proteins 0.000 description 1
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 1
- 101001092982 Homo sapiens Protein salvador homolog 1 Proteins 0.000 description 1
- 101001047642 Homo sapiens Serine/threonine-protein kinase LATS1 Proteins 0.000 description 1
- 101001047637 Homo sapiens Serine/threonine-protein kinase LATS2 Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 241000239309 Hottentotta judaicus Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- KGHNSNSWRMJVND-UHFFFAOYSA-N Hypocrellin Natural products COC1=CC(=O)C2=C3C4C(C(C(=O)C)C(C)(O)Cc5c(OC)c(O)c6C(=O)C=C(OC)C(=C13)c6c45)C(=C2O)OC KGHNSNSWRMJVND-UHFFFAOYSA-N 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000629631 Isometrus maculatus Species 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229930186657 Lat Natural products 0.000 description 1
- 241000239271 Leiurus quinquestriatus hebraeus Species 0.000 description 1
- 102100031775 Leptin receptor Human genes 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 102000016799 Leukocyte elastase Human genes 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 241001481690 Mesobuthus eupeus Species 0.000 description 1
- 241001481692 Mesobuthus martensii Species 0.000 description 1
- 101710140999 Metallocarboxypeptidase inhibitor Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 206010061533 Myotonia Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- IXQIUDNVFVTQLJ-UHFFFAOYSA-N Naphthofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C(C=CC=1C3=CC=C(O)C=1)=C3OC1=C2C=CC2=CC(O)=CC=C21 IXQIUDNVFVTQLJ-UHFFFAOYSA-N 0.000 description 1
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 1
- AWZJFZMWSUBJAJ-UHFFFAOYSA-N OG-514 dye Chemical compound OC(=O)CSC1=C(F)C(F)=C(C(O)=O)C(C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)=C1F AWZJFZMWSUBJAJ-UHFFFAOYSA-N 0.000 description 1
- 101710089460 OTU domain-containing protein 5 Proteins 0.000 description 1
- 102100025194 OTU domain-containing protein 5 Human genes 0.000 description 1
- 101710090551 OTU domain-containing protein 5-A Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241001411624 Opistophthalmus carinatus Species 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 101000933784 Pandinus imperator Imperacalcin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101000865553 Pentadiplandra brazzeana Defensin-like protein Proteins 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- FADYJNXDPBKVCA-STQMWFEESA-N Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 FADYJNXDPBKVCA-STQMWFEESA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 238000006929 Pictet-Spengler synthesis reaction Methods 0.000 description 1
- 241001575945 Pireneitega Species 0.000 description 1
- 208000021161 Plasma cell disease Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100022309 Protein KIBRA Human genes 0.000 description 1
- 102100032783 Protein cereblon Human genes 0.000 description 1
- 101710145046 Protein kibra Proteins 0.000 description 1
- 102100036193 Protein salvador homolog 1 Human genes 0.000 description 1
- 102100021674 Protein scribble homolog Human genes 0.000 description 1
- 101710169810 Protein scribble homolog Proteins 0.000 description 1
- 241000790242 Psalmopoeus cambridgei Species 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 101150042605 RYR2 gene Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000010757 Reduction Activity Effects 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229930001406 Ryanodine Natural products 0.000 description 1
- WPDOZYZAJKUVRZ-NRYSMURASA-N S-[(2R,3S,4S,6S)-6-[[(2R,3S,4S,5R,6R)-5-[(2S,4S,5S)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-4-hydroxy-6-[[(2S,5Z,9R)-9-hydroxy-12-(methoxycarbonylamino)-13-[2-(methyltrisulfanyl)ethylidene]-11-oxo-2-bicyclo[7.3.1]trideca-1(12),5-dien-3,7-diynyl]oxy]-2-methyloxan-3-yl]amino]oxy-4-hydroxy-2-methyloxan-3-yl] 4-[(2S,3R,4R,5S,6S)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5-iodo-2,3-dimethoxy-6-methylbenzenecarbothioate Chemical compound CCN([C@H]1CO[C@H](C[C@@H]1OC)O[C@@H]1[C@@H](O)[C@H](NO[C@H]2C[C@H](O)[C@H](SC(=O)c3c(C)c(I)c(O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](OC)[C@H]4O)c(OC)c3OC)[C@@H](C)O2)[C@@H](C)O[C@H]1O[C@H]1C#C\C=C/C#C[C@]2(O)CC(=O)C(NC(=O)OC)=C1C2=CCSSSC)C(C)=O WPDOZYZAJKUVRZ-NRYSMURASA-N 0.000 description 1
- 240000005499 Sasa Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102100024031 Serine/threonine-protein kinase LATS1 Human genes 0.000 description 1
- 102100024043 Serine/threonine-protein kinase LATS2 Human genes 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 235000019892 Stellar Nutrition 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 101150112794 Stk3 gene Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102220482570 TP53-regulated inhibitor of apoptosis 1_F27A_mutation Human genes 0.000 description 1
- 108091005501 Threonine proteases Proteins 0.000 description 1
- 102000035100 Threonine proteases Human genes 0.000 description 1
- 102100031013 Transgelin Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 101000956366 Trimeresurus stejnegeri Cysteine-rich venom protein Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 108091005956 Type II transmembrane proteins Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 description 1
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- GRRMZXFOOGQMFA-UHFFFAOYSA-J YoYo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3O2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2O1 GRRMZXFOOGQMFA-UHFFFAOYSA-J 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000008065 acid anhydrides Chemical group 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000002009 alkene group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- ROLZYTOAMYXLMF-UHFFFAOYSA-N amino(benzyl)carbamic acid Chemical class OC(=O)N(N)CC1=CC=CC=C1 ROLZYTOAMYXLMF-UHFFFAOYSA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- SMZVEGAKSTTZDO-QYIPWQSGSA-N atto 680-biotin Chemical compound C1([C@H]2NC(=O)N[C@H]2CS1)CCCCC(=O)NCCCCCNC(=O)CCCN1C(C)(C)C=C(CS([O-])(=O)=O)C2=C1C=C1OC3=CC4=[N+](CC)CCCC4=CC3=NC1=C2 SMZVEGAKSTTZDO-QYIPWQSGSA-N 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 150000004036 bacteriochlorins Chemical class 0.000 description 1
- XJHABGPPCLHLLV-UHFFFAOYSA-N benzo[de]isoquinoline-1,3-dione Chemical class C1=CC(C(=O)NC2=O)=C3C2=CC=CC3=C1 XJHABGPPCLHLLV-UHFFFAOYSA-N 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 150000001649 bromium compounds Chemical group 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- WLZRMCYVCSSEQC-UHFFFAOYSA-N cadmium(2+) Chemical compound [Cd+2] WLZRMCYVCSSEQC-UHFFFAOYSA-N 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 229960000772 camostat Drugs 0.000 description 1
- FSEKIHNIDBATFG-UHFFFAOYSA-N camostat mesylate Chemical compound CS([O-])(=O)=O.C1=CC(CC(=O)OCC(=O)N(C)C)=CC=C1OC(=O)C1=CC=C([NH+]=C(N)N)C=C1 FSEKIHNIDBATFG-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000298 carbocyanine Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000002655 chelation therapy Methods 0.000 description 1
- BHONFOAYRQZPKZ-LCLOTLQISA-N chembl269478 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 BHONFOAYRQZPKZ-LCLOTLQISA-N 0.000 description 1
- VYXSBFYARXAAKO-WTKGSRSZSA-N chembl402140 Chemical compound Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N/CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-WTKGSRSZSA-N 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 108091006116 chimeric peptides Proteins 0.000 description 1
- 150000001805 chlorine compounds Chemical group 0.000 description 1
- 150000004035 chlorins Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 description 1
- 150000001838 cholestanes Chemical class 0.000 description 1
- 150000001839 cholestenes Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 108010002696 circulin Proteins 0.000 description 1
- YLHJFOAQDDQFIU-UHFFFAOYSA-N circulin Chemical compound CCC(C)C1NC(=O)C(CC(C)C)NC(=O)C(CCN)NC(=O)C(NC(=O)C(CCN)NC(=O)C(NC(=O)C(CCN)NC=O)C(C)O)CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC1=O YLHJFOAQDDQFIU-UHFFFAOYSA-N 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 238000011490 co-immunoprecipitation assay Methods 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- XVLXYDXJEKLXHN-UHFFFAOYSA-M dioc6 Chemical compound [I-].O1C2=CC=CC=C2[N+](CCCCCC)=C1C=CC=C1N(CCCCCC)C2=CC=CC=C2O1 XVLXYDXJEKLXHN-UHFFFAOYSA-M 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 239000000386 donor Substances 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- JKMBMIMLVFMXRW-LYYFRFARSA-N epicocconone Chemical compound C1=C2C[C@@H](CO)OC=C2C(=O)[C@]2(C)C1=C(C(/O)=C/C(=O)/C=C/C=C/C=C/C)C(=O)O2 JKMBMIMLVFMXRW-LYYFRFARSA-N 0.000 description 1
- JKMBMIMLVFMXRW-UHFFFAOYSA-N epicocconone Natural products C1=C2CC(CO)OC=C2C(=O)C2(C)C1=C(C(O)=CC(=O)C=CC=CC=CC)C(=O)O2 JKMBMIMLVFMXRW-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- WTOSNONTQZJEBC-UHFFFAOYSA-N erythrosin Chemical compound OC(=O)C1=CC=CC=C1C(C1C(C(=C(O)C(I)=C1)I)O1)=C2C1=C(I)C(=O)C(I)=C2 WTOSNONTQZJEBC-UHFFFAOYSA-N 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229950006566 etanidazole Drugs 0.000 description 1
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 150000002211 flavins Chemical class 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 150000002222 fluorine compounds Chemical group 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229910003472 fullerene Inorganic materials 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- TWYVVGMYFLAQMU-UHFFFAOYSA-N gelgreen Chemical compound [I-].[I-].C1=C(N(C)C)C=C2[N+](CCCCCC(=O)NCCCOCCOCCOCCCNC(=O)CCCCC[N+]3=C4C=C(C=CC4=CC4=CC=C(C=C43)N(C)C)N(C)C)=C(C=C(C=C3)N(C)C)C3=CC2=C1 TWYVVGMYFLAQMU-UHFFFAOYSA-N 0.000 description 1
- JGBUYEVOKHLFID-UHFFFAOYSA-N gelred Chemical compound [I-].[I-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCCCC(=O)NCCCOCCOCCOCCCNC(=O)CCCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 JGBUYEVOKHLFID-UHFFFAOYSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 102000005396 glutamine synthetase Human genes 0.000 description 1
- 108020002326 glutamine synthetase Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 108010088252 hanatoxin Proteins 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229920005669 high impact polystyrene Polymers 0.000 description 1
- 239000013628 high molecular weight specie Substances 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 239000004797 high-impact polystyrene Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000000879 imine group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- JGIDSJGZGFYYNX-YUAHOQAQSA-N indian yellow Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC1=CC=C(OC=2C(=C(O)C=CC=2)C2=O)C2=C1 JGIDSJGZGFYYNX-YUAHOQAQSA-N 0.000 description 1
- PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical group 0.000 description 1
- 229940126181 ion channel inhibitor Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 150000004037 isobacteriochlorins Chemical class 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- JHDGGIDITFLRJY-UHFFFAOYSA-N laurdan Chemical compound C1=C(N(C)C)C=CC2=CC(C(=O)CCCCCCCCCCC)=CC=C21 JHDGGIDITFLRJY-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003202 long acting thyroid stimulator Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical compound [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920003240 metallophthalocyanine polymer Polymers 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- VWKNUUOGGLNRNZ-UHFFFAOYSA-N methylbimane Chemical compound CC1=C(C)C(=O)N2N1C(C)=C(C)C2=O VWKNUUOGGLNRNZ-UHFFFAOYSA-N 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical class [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- OBBCSXFCDPPXOL-UHFFFAOYSA-N misonidazole Chemical compound COCC(O)CN1C=CN=C1[N+]([O-])=O OBBCSXFCDPPXOL-UHFFFAOYSA-N 0.000 description 1
- 229950010514 misonidazole Drugs 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- SHXOKQKTZJXHHR-UHFFFAOYSA-N n,n-diethyl-5-iminobenzo[a]phenoxazin-9-amine;hydrochloride Chemical class [Cl-].C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=[NH2+])C2=C1 SHXOKQKTZJXHHR-UHFFFAOYSA-N 0.000 description 1
- HKRNYOZJJMFDBV-UHFFFAOYSA-N n-(6-methoxyquinolin-8-yl)-4-methylbenzenesulfonamide Chemical compound C=12N=CC=CC2=CC(OC)=CC=1NS(=O)(=O)C1=CC=C(C)C=C1 HKRNYOZJJMFDBV-UHFFFAOYSA-N 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229950006584 obatoclax Drugs 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 108010038765 octaarginine Proteins 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000021368 organ growth Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000065 osmolyte Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 108010052853 pVEC peptide Proteins 0.000 description 1
- 238000002888 pairwise sequence alignment Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000012753 partial hepatectomy Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 description 1
- 150000003014 phosphoric acid esters Chemical group 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- QWYZFXLSWMXLDM-UHFFFAOYSA-M pinacyanol iodide Chemical compound [I-].C1=CC2=CC=CC=C2N(CC)C1=CC=CC1=CC=C(C=CC=C2)C2=[N+]1CC QWYZFXLSWMXLDM-UHFFFAOYSA-M 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- KXXXUIKPSVVSAW-UHFFFAOYSA-K pyranine Chemical compound [Na+].[Na+].[Na+].C1=C2C(O)=CC(S([O-])(=O)=O)=C(C=C3)C2=C2C3=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1 KXXXUIKPSVVSAW-UHFFFAOYSA-K 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229940124553 radioprotectant Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- XFKVYXCRNATCOO-UHFFFAOYSA-M rhodamine 6G Chemical compound [Cl-].C=12C=C(C)C(NCC)=CC2=[O+]C=2C=C(NCC)C(C)=CC=2C=1C1=CC=CC=C1C(=O)OCC XFKVYXCRNATCOO-UHFFFAOYSA-M 0.000 description 1
- 239000001022 rhodamine dye Substances 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229930187593 rose bengal Natural products 0.000 description 1
- YYMBJDOZVAITBP-UHFFFAOYSA-N rubrene Chemical compound C1=CC=CC=C1C(C1=C(C=2C=CC=CC=2)C2=CC=CC=C2C(C=2C=CC=CC=2)=C11)=C(C=CC=C2)C2=C1C1=CC=CC=C1 YYMBJDOZVAITBP-UHFFFAOYSA-N 0.000 description 1
- JJSYXNQGLHBRRK-SFEDZAPPSA-N ryanodine Chemical compound O([C@@H]1[C@]([C@@]2([C@]3(O)[C@]45O[C@@]2(O)C[C@]([C@]4(CC[C@H](C)[C@H]5O)O)(C)[C@@]31O)C)(O)C(C)C)C(=O)C1=CC=CN1 JJSYXNQGLHBRRK-SFEDZAPPSA-N 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000013363 skeletal muscle disease Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960005480 sodium caprylate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical class [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- OSQUFVVXNRMSHL-LTHRDKTGSA-M sodium;3-[(2z)-2-[(e)-4-(1,3-dibutyl-4,6-dioxo-2-sulfanylidene-1,3-diazinan-5-ylidene)but-2-enylidene]-1,3-benzoxazol-3-yl]propane-1-sulfonate Chemical compound [Na+].O=C1N(CCCC)C(=S)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 OSQUFVVXNRMSHL-LTHRDKTGSA-M 0.000 description 1
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical class [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- ZTUXEFFFLOVXQE-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O ZTUXEFFFLOVXQE-UHFFFAOYSA-N 0.000 description 1
- QOFZZTBWWJNFCA-UHFFFAOYSA-N texas red-X Chemical compound [O-]S(=O)(=O)C1=CC(S(=O)(=O)NCCCCCC(=O)O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 QOFZZTBWWJNFCA-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002849 thermal shift Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- 229950002376 tirapazamine Drugs 0.000 description 1
- QVMPZNRFXAKISM-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 239000012443 tonicity enhancing agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000008648 triflates Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- YKSGNOMLAIJTLT-UHFFFAOYSA-N violanthrone Chemical compound C12=C3C4=CC=C2C2=CC=CC=C2C(=O)C1=CC=C3C1=CC=C2C(=O)C3=CC=CC=C3C3=CC=C4C1=C32 YKSGNOMLAIJTLT-UHFFFAOYSA-N 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000001018 xanthene dye Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/20—Protein or domain folding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Definitions
- HIPPO signaling pathway is important for cell growth, cell contact inhibition, and organogenesis. If the HIPPO pathway is disrupted, oncogenes can be left unchecked, causing overexpression of downstream genes that favor cell proliferation, tumor progression, and metastasis. As such, there is need for inhibitors of the HIPPO pathway with high affinity and specificity so that unchecked oncogenes can be suppressed.
- HIPPO pathway modulators including inhibitors, can be used to prevent or treat cancers, tumor progression, metastasis, or other disease or condition associated with a dysregulated HIPPO pathway.
- the present disclosure provides compositions and methods for disrupting TEAD interactions.
- the present disclosure provides a composition, comprising a non-naturally occurring, synthetic, or engineered peptide capable of binding to TEAD, or a variant, homolog, or analog thereof.
- the peptide binds to TEAD and disrupts TEAD interactions.
- the TEAD interactions comprise TEAD interaction with TAZ, YAP, or any combination thereof.
- the peptide disrupts or inhibits one or more components of a HIPPO signaling pathway. In other aspects, the peptide modulates one or more components of a HIPPO signaling pathway. In some aspects, the peptide suppresses an oncogene in a HIPPO signaling pathways.
- the peptide comprises from 1 to 10 contiguous amino acids from YAP peptide.
- the from 1 to 10 contiguous amino acids are selected from one or more of amino acid residues: 53-55, 55-57, 64-68, 64-69, 86-89, or 94-96 of the B chain of PDB 3KYS.
- the from 1 to 10 contiguous amino acids is grafted onto a peptide comprising three disulfide cross-linkers.
- the peptide comprising three disulfide cross-linkers is a knottin.
- the from 1 to 10 contiguous amino acids is grafted onto a cell-penetrating peptide.
- the cell-penetrating peptide is maurocalcin, imperatoxin, hadrucalcin, hemicalcin, opicalcin-1, opicalcin-2, midkine (62-104), MCoTI-II, or chlorotoxin.
- the cell-penetrating peptide comprises at least 60%, 70%, 80%, 90%, 95%, or 100% sequence identity with any one of SEQ ID NO: 168-SEQ ID NO: 176.
- the peptide comprises a sequence of any one of SEQ ID NO: 1-SEQ ID NO: 42, or a variant or fragment thereof. In further aspects, the peptide comprises a sequence that has at least 80% sequence identity with any one of SEQ ID NO: 1-SEQ ID NO: 42, or a variant or a fragment thereof. In still further aspects, the peptide comprises a sequence that has at least 85%, at least 90%, or at least 95% sequence identity with any one of SEQ ID NO: 1-SEQ ID NO: 42 or a variant or a fragment thereof.
- the peptide comprises a sequence of any one of SEQ ID NO: 43-SEQ ID NO: 84, or a variant or a fragment thereof. In further aspects, the peptide comprises a sequence that has at least 80% sequence identity with any one of SEQ ID NO: 45-SEQ ID NO: 84, or a variant or a fragment thereof. In still further aspects, the peptide comprises a sequence that has at least 85%, at least 90%, or at least 95% sequence identity with any one of SEQ ID NO: 43-SEQ ID NO: 84 or a variant or a fragment thereof. In some aspects, the peptide is a knotted peptide or is derived from a knotted peptide.
- the peptide competes with YAP or TAZ for binding to TEAD.
- the peptide sequesters TEAD or prevents another protein from binding to TEAD.
- the peptide has equal or greater affinity or specificity for TEAD as compared to that of YAP or TAZ.
- the peptide has equal or lower dissociation constant for TEAD as compared to that of YAP or TAZ.
- the peptide has a K D of less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 1 nM, or less than 0.1 nM.
- the peptide can penetrate or localize into a target cell. In other aspects, the peptide penetrates or localizes into a target cell by formulation with, fusion to, or conjugation to a cell-penetrating moiety.
- the cell-penetrating moiety comprises polycations, polyorganic acids, endosomal releasing polymers, poly(2-propylacrylic acid), poly(2-ethylacrylic acid), Tat peptide, Arg patch, a knotted peptide, CysTAT, S19-TAT, R8 (SEQ ID NO: 146), pAntp, Pas-TAT, Pas-R8 (SEQ ID NO: 149), Pas-FHV, Pas-pAntP, F2R4 (SEQ ID NO: 152), B55, aurin, IMT-P8, BR2, OMOTAG1, OMOTAG2, pVEC, SynB3, DPV1047, C105Y, Transpotan, MTS
- the cell-penetrating moiety comprises at least 80%, 90%, 95%, 98%, or 100% sequence identity with any sequence of SEQ ID NO: 143-SEQ ID NO: 176.
- the peptide fusion to the cell-penetrating moiety comprises at least 80%, 90%, 95%, 98%, or 100% sequence identity with SEQ ID NO: 85-SEQ ID NO: 142 or SEQ ID NO: 222-SEQ ID NO: 279.
- the peptide can localize into a target cell's nucleus. In further aspects, the peptide localizes into the target cell's nucleus by formulation with, fusion to, or conjugation to a nuclear localization signal peptide or moiety. In some aspects, the peptide is further conjugated to, linked to, or fused to a moiety or a second peptide that targets, homes, or selectively penetrates a cancer cell. In some aspects, the moiety or a second peptide is a knotted peptide or variant or fragment thereof. In further aspects, the knotted peptide targets or homes the peptide across the blood brain barrier.
- the peptide is conjugated to, linked to, or fused to a moiety that targets TEAD inactivation or degradation.
- the moiety that targets TEAD inactivation or degradation results in post-translational modification of TEAD.
- the post-translational modification of TEAD comprises ubiquitination.
- the target cell is a cell with a dysregulated HIPPO pathway. In some aspects, the target cell is a cell with uncontrolled or dysregulated cell growth. In some aspects, the target cell is a cancerous cell or a tumor cell. In other aspects, the target cell is a pancreatic cell, liver cell, colon cell, ovarian cell, breast cell, lung cell, brain cell, or any combination thereof.
- the peptide comprises a disulfide through disulfide knot. In some aspects, the peptide comprises a plurality of disulfide bridges formed between cysteine residues. In some aspects, the peptide comprises three or more disulfide bridges formed between cysteine residues, wherein one of the disulfide bridges passes through a loop formed by two other disulfide bridges. In other aspects, the peptide comprises no disulfide bond or a disulfide knot.
- At least one amino acid residue of the peptide is in an L configuration or, wherein at least one amino acid residue is in a D configuration.
- the peptide comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 positively charged residues.
- the peptide comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 consecutive positively charged residues.
- the positively charged residues are Arg, Lys, or any combination thereof.
- the peptide comprises an Arg patch. In some aspects, the peptide comprises two or more consecutive Arg residues at the N-terminus. In some aspects, the peptide comprises a Tat peptide, or a fragment thereof. In some aspects, the Tat peptide comprises a sequence YGRKKRRQRRR (SEQ ID NO: 195), GRKKRRQRRR (SEQ ID NO: 143), or a fragment or variant thereof.
- the Tat peptide is appended to the N-terminus or C-terminus of the peptide using a linker having a sequence of (GS) x (SEQ ID NO: 282) or G x S y (SEQ ID NO: 283), wherein x and y is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- the Tat peptide is appended to any residue of the peptide.
- the Tat peptide is appended to any residue of the peptide without interfering with TEAD-binding activity.
- the peptide comprises at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, or at least 16 cysteine residues. In other aspects, the peptide comprises one, two, three, four, five, or six Cys residues.
- the peptide comprises, is mutated to comprise, or is grafted to comprise LX 1 X 2 LF (SEQ ID NO: 217), wherein X 1 and X 2 is any amino acid.
- X 1 and X 2 in the LX 1 X 2 LF (SEQ ID NO: 217) comprises EA, IC, EC, MC, VC, or FC.
- the peptide comprises, is mutated to comprise, or is grafted to comprise a LX 1 X 2 LF (SEQ ID NO: 217) motif, wherein X 1 and X 2 is any amino acid.
- X 1 and X 2 in the LX 1 X 2 LF (SEQ ID NO: 217) motif comprises EA, IC, EC, MC, VC, or FC.
- the peptide comprises a mutation at positions: L23, L26, and F27.
- the peptide comprises a mutation at positions: G15, Y23, E25, G28, and P40.
- the peptide comprises a mutation at positions: G15, Y23, and P40.
- the peptide comprises a mutation at position P40.
- the peptide comprises one or more mutations selected from the group consisting of: G15Q, Y23I, E25D, G28K, and P40W.
- the peptide comprises E25D, G28K, and P40W.
- the peptide comprises one or more regions of negatively charged residues. In some aspects, the peptide comprises one or more regions of positively charged residues. In some aspects, the peptide sequence comprises at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58 residues, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, at least 65,
- the peptide comprises or is derived from the group consisting of: chlorotoxins, brazzeins, circulins, stecrisps, hanatoxins, midkines, hefutoxins, potato carboxypeptidase inhibitors, bubble proteins, attractins, ⁇ -GI, ⁇ -GID, ⁇ -pIIIA, ⁇ -MVIIA, ⁇ -CVID, ⁇ -MrIA, ⁇ -TIA, conantokin G, conantokin G, conantokin G, conantokin G, conantokin G, conantokin G, conantokin G, conantokin G, conantokin G, conantokin G, conantokin G, conantokin G, conantokin G, conantokin G, conantokin G, conantokin G, conantokin G, conantokin G, conantokin G, conantokin G, conantokin G, conantokin G, conantokin G, conant
- the peptide comprises or is derived from a human protein or peptide. In some aspects, the peptide is arranged in a multimeric structure with at least one other peptide. In further aspects, the multimeric structure comprises a dimer, trimer, tetramer, pentamer, hexamer, or heptamer.
- the peptide comprises an isoelectric point within a range from about 3.0 to about 10.0. In other aspects, the peptide comprises an isoelectric point within a range from about 4.5 to about 8.9. In some aspects, the peptide comprises a non-uniform charge distribution. In some aspects, the peptide is stable at physiological or intracellular pH values. In other aspects, the peptide is stable at pH of about 7 or 7.5. In still other aspects, the peptide is stable at pH of about 6.5 to 7.5.
- the peptide is stable at pH values less than or equal to about 5.0, less than or equal to about 3.0, or within a range from about 3.0 to about 5.0. In other aspects, the peptide is stable at pH values within a range from about 5.0 to about 7.0. In some aspects, the peptide comprises a hydrophobic core.
- the peptide is resistant to protease degradation.
- the protease is any one of pepsin, trypsin, chymotrypsin, serum proteases, intracellular proteases, or any combination thereof.
- the peptide is resistant to reduction or is stable in a reducing environment.
- the reduction or reducing environment comprises DDT or GSH.
- the peptide is stable at an elevated temperature.
- the peptide is capable of penetrating a cell membrane.
- the peptide exhibits an anti-cancer effect.
- the peptide comprises one or more chemical modifications.
- the chemical modification extends the half-life or modifies a pharmacokinetics of the peptide.
- the chemical modification is blocking the N-terminus of the peptide.
- the chemical modification is methylation, acetylation, or acylation.
- the chemical modification is: methylation of one or more lysine residues or analogue thereof; methylation of the N-terminus; or methylation of one or more lysine residue or analogue thereof and methylation of the N-terminus.
- the peptide is linked to an acyl adduct.
- the peptide is conjugated to, linked to, or fused with an active agent.
- the active agent is conjugated to, linked to, or fused with the peptide at an N-terminus or a C-terminus of the peptide.
- the active agent is an antibody, antibody fragment, Fc, or single chain Fv.
- the peptide is conjugated to, linked to, fused to, or is embedded in an Fc domain. In some aspects, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 active agents are linked to the peptide.
- the peptide is linked to the active agent via a cleavable linker or a pH sensitive linker.
- the peptide is linked to the active agent at an N-terminus, at the epsilon amine of an internal lysine residue, at the carboxylic acid of an aspartic acid or glutamic acid residue, or a C-terminus of the peptide by a linker.
- the composition further comprises a non-natural amino acid, wherein the non-natural amino acid is an insertion, appendage, or substitution for another amino acid.
- the peptide is linked to the active agent at the non-natural amino acid by a linker.
- the linker comprises an amide bond, an ester bond, a carbamate bond, a carbonate bond, a hydrazone bond, an oxime bond, a disulfide bond, a thioester bond, a thioether bond, or a carbon-nitrogen bond.
- the cleavable linker comprises a cleavage site for matrix metalloproteinases, thrombin, cathepsins, or beta-glucuronidase.
- the linker is a hydrolytically labile linker.
- the peptide is linked to the active agent via a noncleavable linker.
- the active agent is an anti-cancer agent.
- the active agent is an auristatin, MMAE, a maytansinoid, DM1, DM4, doxorubicin, a calicheamicin, a platinum compound, cisplatin, a taxane, paclitaxel, SN-38, a BACE inhibitor, a Bcl-xL inhibitor, WEHI-539, venetoclax, ABT-199, navitoclax, AT-101, obatoclax, a pyrrolobenzodiazepine or pyrrolobenzodiazepine dimer, or dolastatin.
- the composition further comprises a half-life modifying agent coupled to the peptide.
- the half-life modifying agent comprises a polymer, a polyethylene glycol (PEG), a hydroxyethyl starch, polyvinyl alcohol, a water soluble polymer, a zwitterionic water soluble polymer, a water soluble poly(amino acid), a water soluble polymer of proline, alanine and serine, a water soluble polymer containing glycine, glutamic acid, and serine, an Fc region, a fatty acid, palmitic acid, or a molecule that binds to albumin.
- PEG polyethylene glycol
- a hydroxyethyl starch polyvinyl alcohol
- a water soluble polymer a zwitterionic water soluble polymer
- a water soluble poly(amino acid) a water soluble poly(amino acid)
- proline a water soluble polymer of proline
- the composition further comprises a detectable agent coupled to the peptide.
- the detectable agent is conjugated to, linked to, or fused with the peptide at an N-terminus or a C-terminus of the peptide.
- 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 detectable agents are linked to the peptide.
- the peptide is linked to the detectable agent via a cleavable linker.
- the peptide is linked to the detectable agent at an N-terminus, at the epsilon amine of an internal lysine residue, or a C-terminus of the peptide by a linker.
- the composition further comprises a non-natural amino acid, wherein the non-natural amino acid is an insertion, appendage, or substitution for another amino acid.
- the peptide is linked to the detectable agent at the non-natural amino acid by a linker.
- the linker comprises an amide bond, an ester bond, a carbamate bond, a hydrazone bond, an oxime bond, or a carbon-nitrogen bond.
- the cleavable linker comprises a cleavage site for matrix metalloproteinases, thrombin, cathepsins, or beta-glucuronidase.
- the peptide is linked to the detectable agent via a noncleavable linker.
- the detectable agent is a fluorophore, a near-infrared dye, a contrast agent, a nanoparticle, a metal-containing nanoparticle, a metal chelate, an X-ray contrast agent, a PET agent, a radioisotope, or a radionuclide chelator.
- the detectable agent is a fluorescent dye.
- the present disclosure provides a pharmaceutical composition comprising any of the compositions described above, or a salt thereof, and a pharmaceutically acceptable carrier.
- the pharmaceutical composition is formulated for administration to a subject.
- the pharmaceutical composition is formulated for oral administration, intravenous administration, subcutaneous administration, intramuscular administration, or a combination thereof.
- the present disclosure provides a method of treating a condition in a subject in need thereof, the method comprising: administering to the subject any of the compositions described above or any of the pharmaceutical compositions described above.
- the composition is administered by inhalation, intranasally, orally, topically, intravenously, subcutaneously, intramuscularly administration, intraperitoneally, intratumoral, or a combination thereof.
- the composition is administered intravenously as a bolus, infusion, or prolonged infusion.
- the composition or pharmaceutical composition disrupts YAP interactions with TEAD. In some aspects, the composition or pharmaceutical composition prevents YAP from binding to TEAD. In other aspects, the composition or pharmaceutical composition competes with YAP for binding to TEAD. In some aspects, the composition or pharmaceutical composition binds to TEAD. In some aspects, the composition or pharmaceutical composition inhibits an oncogene in a HIPPO signaling pathway.
- the composition or pharmaceutical composition is internalized by a cell. In other aspects, the composition or pharmaceutical composition penetrates a cell membrane of a target cell. In some aspects, the condition is diabetes. In other aspects, the condition is a cancer or a tumor. In further aspects, the cancer is pancreatic cancer, liver cancer, colon cancer, ovarian cancer, brain cancer, or lung cancer.
- the cancer is associated with a mutation in the HIPPO pathway.
- the condition comprises unregulated cell growth or dysregulated HIPPO pathway.
- the composition or the pharmaceutical composition is administered multiple times a day, twice a day, once a day, twice a week, three times a week, once a week, once every two weeks, or once a month or once every three months.
- the composition is administered subcutaneously once a day, once a week, or once a month.
- a method for designing a peptide capable of binding to TEAD comprises: a) using a computer program to identify a peptide from a library of peptides with optimized stability and folding, wherein each peptide of the library of peptides comprises at least three disulfide cross-linkers; b) using a computer program to superimpose amino acid residues of a binding patch from a peptide:TEAD complex to determine a stable peptide that binds to TEAD after grafting the binding patch onto the peptide; and c) grafting the binding patch onto the peptide to produce the stable peptide.
- the method further comprising performing site saturation mutagenesis to obtain a mutated peptide with a higher binding affinity for TEAD than the stable peptide.
- the peptide from a library of peptides is between 20 and 55 amino acid residues in length.
- the method further comprises designing a peptide capable of cell penetration comprising: e) using a computer program to identify a peptide from a library of peptides with optimized stability and folding, wherein each peptide of the library of peptides comprises is capable of cell penetration; f) using a computer program to superimpose amino acid residues of a binding patch from the mutant peptide:TEAD complex to determine a new peptide that binds to TEAD after grafting the binding patch onto the peptide; and g) grafting the binding patch onto the mutant peptide to produce the new peptide.
- FIG. 1 illustrates validation and functional analysis of the produced biotinylated TEAD and Siderocalin-fused YAP.
- FIG. 1 A illustrates SDS-PAGE with a band near 55 kDa corresponding to a sample of Siderocalin-YAP.
- FIG. 1 B illustrates surface plasmon resonance (SPR) data showing that Siderocalin-fused YAP binds to biotinylated TEAD immobilized on an SPR chip with a dissociation constant (K D ) of 570 nM.
- SPR surface plasmon resonance
- FIG. 1 C illustrates that HEK-293 cells expressing surface-tethered YAP (50-171) is stained by Alexa Fluorophore (AF)-647 conjugated to Streptavidin (AF657-Streptavidin) bound to biotinylated TEAD, corresponding to the right peak.
- AF Fluorophore
- AF657-Streptavidin AF657-Streptavidin
- FIG. 2 illustrates how the surface display GFP FasL (SDGF) vector provides an effective mammalian display method for identifying and evaluating protein-protein interactions, such as peptide-TEAD binding and knotted peptide binding to another moiety or protein.
- SDGF surface display GFP FasL
- FIG. 2 A illustrates a schematic of the SDGF vector.
- Cytosolic, N-terminal GFP is connected to the extracellular domain of a peptide via a transmembrane domain of human FasL.
- a bovine rhodopsin C9 tag and/or a short linker can be used to connect the FasL transmembrane domain and the N-terminus of a peptide.
- Any peptide or a library of peptides including, but not limited to, knottin peptides, or any recombinant, engineered, or designed peptides, can be screened for binding to a protein of interest using this method.
- Elastase binding to a GFP-elafin fusion peptide is shown here as an example.
- the protein of interest such as elastase in the example, can be tagged or stained with a detectable moiety, such as a fluorescent label, that confers fluorescence or a detectable signal to the cell to indicate protein binding or protein-peptide interaction.
- FIG. 2 B illustrates flow cytometry histograms showing that HEK-293 suspensions cells expressing SDGF-elafin are stained by AF647-conjugated elastase (as shown by the right-most peak). Negative control experiments with cells expressing either SDGF-YAP (50-171) or SDGF-MACV glycoprotein are not stained by AF647 elastase (as shown by the overlapping left-most peaks).
- FIG. 3 illustrates screening a designed or engineered library of peptides for TEAD-binding.
- FIG. 3 A illustrates a schematic of the screening steps for evaluating SDGF peptide libraries for protein binding.
- FIG. 3 B illustrates flow cytometry plots showing the fluorescence of peptide construct expression (e.g., GFP-fused peptides or peptide library) on the x-axis and target or partner protein of interest bound (e.g., TEAD stained with AF647) to the peptides on the y-axis.
- Double-positive cells indicate peptide-expressing cells that are bound to the target protein or protein of interest, such as TEAD.
- HEK-293 cells were transduced with the SDGF TEAD-binder peptide library and stained with 200 nM AF647-Streptavidin-TEAD.
- Flow cytometry plots show unsorted cells, cells sorted after 1, 2, or 3 rounds of sorting.
- FIG. 3 C illustrates Illumina sequencing data plotting the abundance of each library member versus its abundance prior to the screening and sorting (“input”) after round 1, 2, 3, and 4.
- the x-axis indicates an enrichment score (log 2 ratio of relative abundance versus input abundance) and the y-axis shows log 2 P-value (determined using a Student's t-test). Data are shown from triplicate samples. Library members whose reads were abundant are represented as data points in larger circles. The area of the circle representing a given data point is proportional to the read abundance in the samples.
- FIG. 3 D illustrates flow cytometry plots showing construct expression (GFP) on the x-axis and TEAD (AF647) on the y-axis.
- Double-positive cells indicate peptide-expressing cells that are bound to TEAD.
- HEK-293 suspension cells were transfected with hits from the screen cloned into the SDGF vector and stained with 200 nm AF647-Streptavidin-TEAD.
- FIG. 4 illustrates the structures of peptides of SEQ ID NO: 1 and SEQ ID NO: 2 and the modeled TEAD interface with YAP overlaid with the structures of peptides of SEQ ID NO: 1 and SEQ ID NO: 2.
- FIG. 4 A illustrates that YAP and peptides of SEQ ID NO: 1 and SEQ ID NO: 2 are predicted to bind TEAD at the same site (Site 2).
- the YAP-TEAD structure (Protein Data Bank (PDB) ID: 3KYS) is available from the Research Collaboratory for Structural Bioinformatics (RCSB). Structures of peptides of SEQ ID NO: 1 and SEQ ID NO: 2 were modeled onto the TEAD structure.
- PDB Protein Data Bank
- RCSB Research Collaboratory for Structural Bioinformatics
- FIG. 4 B illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 2 versus TEAD binding to HEK-293 suspension cells transfected with SDGF-L23A variant of SEQ ID NO: 2 (lysine to alanine variant of SEQ ID NO: 2 at position 23).
- FIG. 4 C illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 2 versus TEAD binding to HEK-293 suspension cells transfected with SDGF-L26A variant of SEQ ID NO: 2 (lysine to alanine variant of SEQ ID NO: 2 at position 26).
- FIG. 4 D illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 2 versus TEAD binding to HEK-293 suspension cells transfected with SDGF-F27A variant of SEQ ID NO: 2 (phenylalanine to alanine variant of SEQ ID NO: 2 at position 27).
- FIG. 4 E illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 2 versus TEAD binding to HEK-293 suspension cells transfected with SDGF-6 ⁇ CS variant of SEQ ID NO: 2 (a variant of SEQ ID NO: 2 in which all 6 cysteines are mutated to serines).
- FIG. 4 F illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 4 (SDGF-E25A variant of SEQ ID NO: 1, which is a glutamic acid to alanine variant of SEQ ID NO: 1 at position 25).
- SDGF-E25A variant of SEQ ID NO: 1 which is a glutamic acid to alanine variant of SEQ ID NO: 1 at position 25.
- FIG. 4 G illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 6 (SDGF-M33A variant of SEQ ID NO: 1, which is a methionine to alanine variant of SEQ ID NO: 1 at position 33).
- SDGF-M33A variant of SEQ ID NO: 1 which is a methionine to alanine variant of SEQ ID NO: 1 at position 33.
- FIG. 4 H illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 5 (SDGF-L37A variant of SEQ ID NO: 1, which is a leucine to alanine variant of SEQ ID NO: 1 at position 37).
- SDGF-L37A variant of SEQ ID NO: 1 which is a leucine to alanine variant of SEQ ID NO: 1 at position 37.
- FIG. 4 I illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 7 (SDGF-F38A variant of SEQ ID NO: 1, which is a phenylalanine to alanine variant of SEQ ID NO: 1 at position 38).
- SDGF-F38A variant of SEQ ID NO: 1 which is a phenylalanine to alanine variant of SEQ ID NO: 1 at position 38.
- FIG. 4 J illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 184(SDGF-6 ⁇ CS variant of SEQ ID NO: 1, which is a variant of SEQ ID NO: 1 in which all 6 cysteines are mutated to serines).
- FIG. 5 illustrates binding of soluble TEAD-binding peptides and variants thereof to TEAD.
- Gels show peptides in reducing conditions in NuPAGE at one-tenth the final volume, in which DTT is at 50 mM.
- HPLC shows peptides in reducing conditions in Dulbecco's phosphate-buffered saline (DPBS) with a final DTT concentration of 40 mM.
- Non-reducing conditions are designated as “NR” and reducing conditions are designated as “R.”
- FIG. 5 A illustrates an SDS-PAGE gel of a peptide of SEQ ID NO: 1 treated with non-reducing conditions or reducing conditions.
- FIG. 5 B illustrates HPLC chromatograms showing peaks representing a peptide of SEQ ID NO: 1 in non-reducing (NR) conditions or in reducing (R) conditions with DTT.
- FIG. 5 C illustrates SPR binding assay data of a peptide of SEQ ID NO: 1 to biotinylated TEAD immobilized on an SPR chip with a dissociation constant (K D ) of 31 nM.
- FIG. 5 D illustrates an SDS-PAGE gel of a peptide of SEQ ID NO: 5 treated with non-reducing conditions or reducing conditions.
- FIG. 5 E illustrates HPLC chromatograms showing peaks representing a peptide of SEQ ID NO: 5 in non-reducing conditions or in reducing conditions with DTT.
- FIG. 5 F illustrates SPR binding assay data of a peptide of SEQ ID NO: 5 to biotinylated TEAD immobilized on an SPR chip with a dissociation constant (K D ) of 280 nM.
- FIG. 5 G illustrates an SDS-PAGE gel of a peptide of SEQ ID NO: 7 treated with non-reducing conditions or reducing conditions.
- FIG. 5 H illustrates HPLC chromatograms showing peaks representing a peptide of SEQ ID NO: 7 in non-reducing conditions or in reducing conditions with DTT.
- FIG. 5 I illustrates SPR binding assay data of a peptide of SEQ ID NO: 7 to biotinylated TEAD immobilized on an SPR chip with a dissociation constant (K D ) of 23 ⁇ M.
- FIG. 5 J illustrates an SDS-PAGE gel of a peptide of SEQ ID NO: 3 treated with non-reducing conditions or reducing conditions.
- FIG. 5 K illustrates HPLC chromatograms showing peaks representing a peptide of SEQ ID NO: 3 in non-reducing conditions or in reducing conditions with DTT.
- FIG. 5 L illustrates SPR binding assay data of a peptide of SEQ ID NO: 3 to biotinylated TEAD immobilized on an SPR chip with a dissociation constant (K D ) of 12 ⁇ M.
- FIG. 6 illustrates results from co-immunoprecipitation assays evaluating disruption of the YAP-TEAD interaction with a soluble peptide of SEQ ID NO: 1.
- FIG. 6 A illustrates a Silver stain (top panel) and a Western blot (lower panel) showing that FLAG-YAP was not pulled down with Myc-TEAD resin or beads in the presence of a peptide of SEQ ID NO: 1 or SEQ ID NO: 7.
- FIG. 6 B illustrates a Western blot showing a dilution series of a peptide of SEQ ID NO: 1 demonstrating dose-dependent inhibition of FLAG-YAP binding to Myc-TEAD resin or beads.
- FIG. 6 C illustrates quantified densitometry data plotted from FIG. 6 B .
- Error bars show standard deviation from quantification of signal in four lanes per sample in one experiment.
- Amount of FLAG-YAP pulled down by Myc-TEAD beads was normalized to the Myc-TEAD signal for each sample in the Western blot.
- FIG. 7 illustrates the results of a site-saturation mutagenesis screen of SEQ ID NO: 1 variants with improved binding activity to TEAD.
- Flow cytometry plots show the fluorescence of the peptide construct expression on the x-axis (GFP) and TEAD (AF647) on the y-axis.
- Double-positive cells indicate peptide-expressing cells that are bound to TEAD.
- Panels labeled “SSM01” indicate cells transduced with the full library of peptide variants.
- FIG. 7 A illustrates a flow cytometry plot showing HEK-293 cells expressing a peptide of SEQ ID NO: 1 alone.
- FIG. 7 B illustrates a flow cytometry plot showing HEK-293 cells expressing a peptide of SEQ ID NO: 1 incubated with AF647-streptavidin alone, in the absence of biotinylated-TEAD.
- FIG. 7 C illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 (site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants) incubated with TEAD before sorting.
- SSM01 site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants
- FIG. 7 D illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 (site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants) incubated with TEAD after one round of sorting.
- SSM01 site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants
- FIG. 7 E illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 (site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants) incubated with TEAD after two rounds of sorting.
- SSM01 site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants
- FIG. 7 F illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 (site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants) incubated with AF647-streptavidin alone, in the absence of biotinylated-TEAD after two rounds of sorting.
- SSM01 site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants
- FIG. 8 illustrates enrichment scores at each position for the variants of SEQ ID NO: 1 generated in the site-saturation (SSM) mutagenesis screen and a structural model of the binding interface between the peptide or variant peptide and TEAD.
- SSM site-saturation
- FIG. 8 A illustrates a matrix of variants of a peptide of SEQ ID NO: 1 generated in the SSM screen.
- the x-axis shows the sequence of a peptide of SEQ ID NO: 1 versus all substituted non-cysteine residues on the y-axis, after two rounds of sorting.
- the enrichment score (log 2 change in relative abundance after two rounds of sorting versus input abundance) is indicated on a greyscale. Positive or high enrichment scores (lighter shades of grey) correspond to residues that are more tolerant to substitutions.
- Negative or lower enrichment scores correspond to residues that are less tolerant to substitution, such as residues that are important to binding.
- amino acid residue position counting does not include the N-terminal GS.
- FIG. 8 B illustrates a model of the SEQ ID NO: 1-TEAD interface, in which shading intensity on a greyscale correlates to the average enrichment score at each residue or position.
- Positive or higher enrichment scores correspond to residues that are more tolerant to substitutions.
- Negative or lower enrichment scores correspond to residues that are less tolerant to substitution, such as residues that are important to binding. These residues are most important to retain in a peptide that is desired to block YAP-TEAD interactions; the residues more tolerant of substitution can be varied.
- Black indicates cysteine residues.
- amino acid residue position counting does not include the N-terminal GS.
- FIG. 9 illustrates that combinations of enriched mutations identified in a peptide of SEQ ID NO: 1 by SSM resulted in improved TEAD binding.
- FIG. 9 A illustrates a schematic of the staining protocols used to evaluate TEAD binding. Both the “Normal” and “Extra Wash” protocols used 20 nM of TEAD.
- FIG. 9 B illustrates flow cytometry plots showing HEK-293 suspension cells expressing SDGF-SEQ ID NO: 1, SDGF-SEQ ID NO: 9 (QIDKW variant of SEQ ID NO: 1), and YAP.
- Five-letter codes e.g. QIDKW represent variants of a peptide of SEQ ID NO: 1 at residues 15 (G or Q), 23 (Y or I), 25 (E or D), 28 (G or K), and 40 (P or W).
- FIG. 9 C illustrates quantification of the mean fluorescence intensity (MFI) of cells that fall in the “slice” gate indicated in FIG. 9 B .
- the x-axis indicates the variant that was tested and all MFI values were normalized to the MFI value for a peptide of SEQ ID NO: 1.
- Shading of groups of labels on the x-axis represents clustering of mutations found in the variants, e.g., XXDKW (left most group); XXDGW (middle group); XXDKP (right most group).
- FIG. 10 illustrates binding to TEAD by variants of a peptide of SEQ ID NO: 1 as soluble peptides.
- Non-reducing conditions are designated as “NR” and reducing conditions are designated as “R.”
- FIG. 10 A illustrates an SDS-PAGE of a soluble peptide of SEQ ID NO: 9 in non-reduced (NR) or reduced (R) conditions.
- FIG. 10 B illustrates an HPLC chromatogram of a peptide of SEQ ID NO: 9 in non-reduced or reduced conditions.
- FIG. 10 C illustrates SPR data showing binding of a peptide of SEQ ID NO: 9 to biotinylated TEAD immobilized on an SPR chip.
- SPR experiments for a peptide of SEQ ID NO: 9 were conducted by single cycle kinetic analysis and the K D was determined to be 368 ⁇ M.
- FIG. 10 D illustrates an SDS-PAGE of a soluble peptide of SEQ ID NO: 10 in non-reduced (NR) or reduced (R) conditions.
- FIG. 10 E illustrates an HPLC chromatogram of a peptide of SEQ ID NO: 10 in non-reduced or reduced conditions.
- FIG. 10 F illustrates SPR data showing binding of a peptide of SEQ ID NO: 10 to biotinylated TEAD immobilized on an SPR chip.
- SPR experiments for a peptide of SEQ ID NO: 10 were conducted by single cycle kinetic analysis and the K D was determined to be 372 ⁇ M.
- FIG. 10 G illustrates an SDS-PAGE of a soluble peptide of SEQ ID NO: 11 in non-reduced (NR) or reduced (R) conditions.
- FIG. 10 H illustrates an HPLC chromatogram of a peptide of SEQ ID NO: 11 in non-reduced or reduced conditions.
- FIG. 10 I illustrates SPR data showing binding of a peptide of SEQ ID NO: 11 to biotinylated TEAD immobilized on an SPR chip.
- SPR experiments for a peptide of SEQ ID NO: 11 were conducted by steady state analysis and the K D was determined to be 3.8 nM.
- FIG. 11 illustrates inhibition of YAP binding to TEAD with a soluble peptide of SEQ ID NO: 9 as compared to inhibition of YAP binding to TEAD with a soluble peptide of SEQ ID NO: 1.
- FIG. 11 A illustrates flow cytometry plots showing HEK-293 suspension cells transfected with SDGF-YAP and incubated with 0 nM, 10 nM, or 100 nM of a peptide of SEQ ID NO: 1, followed by incubation with 5 nM biotinylated TEAD, and 5 nM AF647-streptavidin.
- FIG. 11 B illustrates flow cytometry plots showing HEK-293 suspension cells transfected with SDGF-YAP and incubated with 0 nM, 10 nM, or 100 nM of a peptide of SEQ ID NO: 9, followed by incubation with 5 nM biotinylated TEAD, and 5 nM AF647-streptavidin.
- FIG. 11 C illustrates a dose response curve quantifying the MFI of cells falling within the “slice” gate (representative of YAP-TEAD binding) shown in FIG. 11 A and FIG. 11 B .
- Doses below 5 nM TEAD staining does not provide data relevant to IC50 or K i determination, as cells were stained with 5 nM TEAD.
- FIG. 11 D illustrates a flow cytometry plot of cells expressing SDGF-YAP that were incubated with 5 nM TEAD and then washed. Cells were immediately stained with AF647-streptavidin and analyzed for YAP-expressing cells that have bound TEAD.
- FIG. 11 E illustrates a flow cytometry plot of cells expressing SDGF-YAP that were incubated with 5 nM TEAD and then washed. Cells were incubated on ice for 1 hour, stained with AF647-streptavidin and analyzed for YAP-expressing cells that have bound TEAD.
- FIG. 11 F illustrates a flow cytometry plot of cells expressing SDGF-YAP that were incubated with 5 nM TEAD and then washed. Cells were incubated on ice for 1 hour with 100 nM of a peptide of SEQ ID NO: 1, stained with AF647-streptavidin and analyzed for YAP-expressing cells that have bound TEAD.
- FIG. 11 G illustrates a flow cytometry plot of cells expressing SDGF-YAP that were incubated with 5 nM TEAD and then washed. Cells were incubated on ice for 1 hour with 100 nM of a peptide of SEQ ID NO: 9, stained with AF647-streptavidin and analyzed for YAP-expressing cells that have bound TEAD.
- FIG. 12 illustrates stability of TEAD-binding peptides in the presence of reducing agents.
- FIG. 12 A illustrates HPLC chromatograms of a peptide of SEQ ID NO: 9 in non-reducing conditions or in 10 mM DTT reducing conditions.
- HPLC chromatogram Under the HPLC chromatogram is a total ion chromatogram showing the various peaks of SEQ ID NO: 9 after exposure to DTT.
- a representative mass spectrometry peak profile is shown under the total ion chromatogram.
- FIG. 12 B illustrates HPLC chromatograms of peptides of SEQ ID NO: 1 and SEQ ID NO: 9 with or without incubation in 10 mM glutathione (GSH).
- FIG. 13 illustrates binding to TEAD after cells expressing SDGF-SEQ ID NO: 9 are exposed to a reducing agent.
- FIG. 13 A illustrates a flow cytometry plot showing binding of HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 (GFP) incubated for 5 minutes in PBS, 10 mM DTT, or 10 mM glutathione (GSH) before staining with 20 nM biotinylated TEAD, followed by a wash and then incubation with 20 nM AF647-streptavidin.
- GFP SDGF-SEQ ID NO: 1
- FIG. 13 B illustrates a flow cytometry plot showing binding of HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 9 (GFP) incubated for 5 minutes in PBS, 10 mM DTT, or 10 mM glutathione (GSH) before staining with 20 nM biotinylated TEAD, followed by a wash and then incubation with 20 nM AF647-streptavidin.
- GFP SDGF-SEQ ID NO: 9
- FIG. 13 C illustrates quantification of the AF647 MFI of cells falling within the “slice” gate shown in FIG. 13 A and FIG. 13 B .
- FIG. 14 illustrates protease resistance of a peptide of SEQ ID NO: 9.
- FIG. 14 A illustrates HPLC chromatograms of a peptide of SEQ ID NO: 9 after incubation with 500 U trypsin (T), which was then quenched with trypsin inhibitor (I) and placed in non-reducing (NR) conditions or reducing (R) conditions with 10 mM DTT.
- FIG. 14 B illustrates a schematic of the SDPR vector, a variant of the SDGF vector shown in FIG. 2 A , but with all basic and aromatic residues within the stalk removed to prevent trypsin/chymotrypsin cleavage, and with a 6 ⁇ His tag (SEQ ID NO: 284) added to the C-terminus of the peptide.
- Elafin is shown as an example for illustrative purpose.
- FIG. 14 C illustrates a flow cytometry plot of HEK-293 suspension cells transfected with protease sensitive SDPR-SK peptide and 0 or 40 ⁇ g/ml trypsin for 20 minutes, and stained with an AF647 anti-6 ⁇ HIS antibody.
- FIG. 14 D illustrates a flow cytometry plot of HEK-293 suspension cells transfected with SDPR-SEQ ID NO: 9 peptide and 0 or 40 ⁇ g/ml trypsin for 20 minutes, and stained with an AF647 anti-6 ⁇ HIS antibody.
- FIG. 14 E illustrates a flow cytometry plot of HEK-293 suspension cells transfected with SDPR-SK peptide and 0 or 40 ⁇ g/ml chymotrypsin for 20 minutes, and stained with an AF647 anti-6 ⁇ HIS antibody.
- FIG. 14 F illustrates a flow cytometry plot of HEK-293 suspension cells transfected with protease sensitive SDPR-SEQ ID NO: 9 peptide and 0 or 40 ⁇ g/ml chymotrypsin for 20 minutes, and stained with an AF647 anti-6 ⁇ HIS antibody.
- FIG. 14 G illustrates quantification of flow cytometry data comparing SDPR-SK peptide transfected cells and SDPR-SEQ ID NO: 9 peptide transfected cells, both incubated with trypsin at various concentrations.
- FIG. 14 H illustrates quantification of flow cytometry data comparing SDPR-SK peptide transfected cells and SDPR-SEQ ID NO: 9 peptide transfected cells, both incubated with chymotrypsin at various concentrations.
- FIG. 15 shows the results of Surface Plasmon Resonance (SPR) experiments.
- FIG. 15 A shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 1 at various concentrations.
- FIG. 15 B illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics.
- FIG. 15 C shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 5 at various concentrations.
- FIG. 15 D illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics.
- FIG. 15 E shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 7 at various concentrations.
- FIG. 15 F illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics.
- FIG. 15 G shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 8 at various concentrations.
- FIG. 15 H illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics.
- FIG. 15 I shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 11 at various concentrations.
- FIG. 15 J illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics.
- FIG. 16 illustrates data from SPR experiments illustrating binding of peptides of the present disclosure to TEAD.
- FIG. 16 A illustrates binding of SEQ ID NO: 9 to TEAD using a single cycle kinetics protocol.
- FIG. 16 B illustrates binding of SEQ ID NO: 10 to TEAD using a single cycle kinetics protocol.
- FIG. 16 C illustrates binding of SEQ ID NO: 11 to TEAD using a steady-state kinetics protocol.
- FIG. 17 illustrates mammalian surface display screening for identifying TEAD-binding peptides.
- FIG. 17 A illustrates a scheme for the screening strategy using a surface display GFP FasL (SDGF) vector.
- FasL-TM is the transmembrane domain of the FasL protein.
- the screening strategy can start with a library of disulfide-stabilized peptides, for example, any one of SEQ ID NO: 289-SEQ ID NO: 304.
- FIG. 17 B illustrates the modeled TEAD interface for the YAP-TEAD structure from Protein Data Bank (PDB ID) 3KYS.
- FIG. 17 C illustrates the modeled TEAD interface for SEQ ID NO: 1 modeled with the TEAD structure from FIG. 17 A .
- FIG. 17 D illustrates the modeled TEAD interface for SEQ ID NO: 2 modeled with the TEAD structure from FIG. 17 A .
- FIG. 17 E illustrates the TEAD-binding abilities of 293F cells transfected with surface display GFP FasL (SDGF)-SEQ ID NO: 1 compared to cells displaying alanine substitution mutants at sites found at the modeled TEAD interface (SDGF-SEQ ID NO: 4, SDGF-SEQ ID NO: 6, SDGF-SEQ ID NO: 5, and SDGF-SEQ ID NO: 7).
- SDGF-SEQ ID NO: 4 The variant with all Cys converted to Ser (6CS) to eliminate disulfide bonds was also tested (SEQ ID NO: 184). Binding was assessed by quantifying Alexa647 levels in transfected cells using flow cytometry. Shown are the median ⁇ 95% confidence intervals, normalized to that of cells displaying the parent peptide.
- FIG. 17 F illustrates the TEAD-binding abilities of 293F cells transfected with surface display GFP FasL (SDGF)-SEQ ID NO: 2 compared to cells displaying alanine substitution mutants at sites found at the modeled TEAD interface (SDGF-SEQ ID NO: 39, SDGF-SEQ ID NO: 40, SDGF-SEQ ID NO: 41, and SDGF-SEQ ID NO: 42).
- SDGF-SEQ ID NO: 39, SDGF-SEQ ID NO: 40, SDGF-SEQ ID NO: 41, and SDGF-SEQ ID NO: 42 The variant with all Cys converted to Ser (6CS) to eliminate disulfide bonds were also tested (SEQ ID NO: 185). Binding was assessed by quantifying Alexa647 levels in transfected cells using flow cytometry. Shown are the median ⁇ 95% confidence intervals, normalized to that of cells displaying the parent peptide.
- FIG. 18 illustrates that SEQ ID NO: 9 significantly reduces YAP:TEAD dimers in the nucleus.
- FIG. 18 A illustrates the relative luminescence units of SEQ ID NO: 1 or SEQ ID NO: 9 expressed directly into the cytosol as part of an mCherry-T2a-peptide fusion construct, co-transfected with YAP and 8 ⁇ GTIIC (TEAD luciferase reporter). This was done in 24-well plate wells, in which 293 T cells were transfected with 50 ng FLAG-YAP, 300 ng 8 ⁇ GTIIC, and either 100 or 250 ng mCherry-T2a-peptide plasmids. *: P ⁇ 0.05, **: P ⁇ 0.005 vs. YAP only.
- FIG. 18 B illustrates the FLAG-tagged SEQ ID NO: 7, FLAG-tagged SEQ ID NO: 1, FLAG-tagged SEQ ID NO: 9, or FLAG-tagged SEQ ID NO: 177 in the mCherry-T2a-peptide construct SDS-PAGE gel mobility shift upon DTT reduction by Western blot (anti-FLAG M2 antibody). Shown are the bands corresponding to the size of the uncleaved fusion protein.
- SEQ ID NO: 177 is SEQ ID NO: 9-6 ⁇ CS, in which all six cysteines were mutated to serines, simulating non-oxidizable sulfhydryls.
- FIG. 18 C illustrates SEQ ID NO: 9-DyLight488 that was introduced to the cytosol/nucleus of HeLa cells using 5 ⁇ M dfTAT, which induces endosomal leakage.
- dfTAT was visible in the TRITC channel, while SEQ ID NO: 9-DyLight488 was seen in the FITC channel ( FIG. 18 D ).
- FIG. 18 D illustrates SEQ ID NO: 9-DyLight488 that was introduced to the cytosol/nucleus of HeLa cells using 5 ⁇ M dfTAT, which induces endosomal leakage.
- SEQ ID NO: 9-DyLight488 was seen in the FITC channel, while dfTAT was visible in the TRITC channel ( FIG. 18 C ).
- FIG. 18 E illustrates a proximity ligation assay (PLA) in HeLa cells.
- PLA proximity ligation assay
- FIG. 18 F illustrates a proximity ligation assay (PLA) in HeLa cells.
- PLA proximity ligation assay
- FIG. 18 G illustrates a representative image of a control proximity ligation assay (PLA) reaction with anti-YAP primary antibodies omitted in which some speckles were non-specific to YAP:TEAD dimers.
- PLA control proximity ligation assay
- FIG. 18 H illustrates a representative image of a control proximity ligation assay (PLA) reaction with anti-TEAD primary antibodies omitted in which some speckles were non-specific to YAP:TEAD dimers.
- PLA control proximity ligation assay
- FIG. 18 I illustrates a dot graph of automated counting of YAP:TEAD proximity ligation assay (PLA) speckles per nucleus of HeLa cells treated with 5 ⁇ M dfTAT and/or 5 ⁇ M TEAD-binding peptides. Each dot represents a single nucleus, with the bars representing the median ⁇ 95% confidence intervals. A line was drawn at the sum of the two antibody omission samples' average speckle counts, representing the approximate value attributable to non-specific speckles. ****: P ⁇ 0.0001 vs. any other sample. All P-values determined by two-tailed T-test.
- PPA YAP:TEAD proximity ligation assay
- FIG. 19 illustrates a site saturation mutagenesis (SSM) library of SEQ ID NO: 1 variants. This library contains improved TEAD binders.
- SSM site saturation mutagenesis
- FIG. 19 A illustrates the binding profile of SEQ ID NO: 1.
- SEQ ID NO: 1 binding was apparent but weak under a 20 nM TEAD concentration and 2-step staining binding conditions.
- FIG. 19 B illustrates the binding profile of unsorted site saturation mutagenesis (SSM) library stained with TEAD followed by streptavidin-Alexa647.
- SSM site saturation mutagenesis
- FIG. 19 C illustrates the binding profile of sorted once site saturation mutagenesis (SSM) library stained with TEAD followed by streptavidin-Alexa647.
- FIG. 19 D illustrates the binding profile of sorted twice site saturation mutagenesis (SSM) library stained with TEAD followed by streptavidin-Alexa647.
- FIG. 19 E illustrates the binding profile of the population in FIG. 19 D stained with streptavidin-Alexa647 only, without TEAD.
- FIG. 20 illustrates SEQ ID NO: 9 and variants of SEQ ID NO: 9 are stable in extreme heat.
- FIG. 20 A illustrates circular dichroism spectra of SEQ ID NO: 9, which demonstrates the structure is dominated by ⁇ -helical elements, and that this secondary structure signature is identical before (Pre) and after (Post) incubation at 95° C.
- FIG. 20 B illustrates circular dichroism spectra of SEQ ID NO: 10, which demonstrates the structure is dominated by ⁇ -helical elements, and that this secondary structure signature is identical before (Pre) and after (Post) incubation at 95° C.
- FIG. 20 C illustrates circular dichroism spectra of SEQ ID NO: 11, which demonstrates the structure is dominated by ⁇ -helical elements, and that this secondary structure signature is identical before (Pre) and after (Post) incubation at 95° C.
- FIG. 20 D illustrates a SYPRO Orange melting assay of peptides. Shown is the slope of the change in relative fluorescence units (dRFU/dtemp) during heating from 20° C. to 95° C. Human siderocalin (HuScn) demonstrated an expected melting temperature of 79° C., as interpreted by the peak of its RFU vs temperature slope. Conversely, no melting temperature could be determined for the three peptides tested (SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11).
- FIG. 21 illustrates biotinylated TEAD with streptavidin-Alexa647 stained cells expressing surface-displayed YAP.
- FIG. 21 A illustrates TEAD produced in Hi5 insect cells.
- FIG. 21 B illustrates a cartoon of the surface display GFP FasL (SDGF) vector comprising a bovine rhodopsin C9 tag, and the peptide.
- SDGF surface display GFP FasL
- FIG. 21 C illustrates a flow cytometry profile of a suspension of HEK-293 Freestyle (293F) cells transfected with surface display GFP FasL (SDGF)-control peptide stained with anti-C9-Alexa647.
- SDGF surface display GFP FasL
- FIG. 21 D illustrates 293F cells transfected with SDGF-YAP are stained by streptavidin-Alexa647 after co-incubation with biotinylated TEAD compared to after co-incubated with a control protein (biotinylated TfR ectodomain).
- FIG. 22 illustrates SEQ ID NO: 2 (TB2G1) soluble peptide has multiple disulfide connection patterns.
- the reversed-phase chromatography (RPC) traces of the non-reduced (NR) and 10 mM DTT-reduced (R) TB2G1 peptide indicate multiple species prior to reduction. Because they have the same mobility upon elimination of disulfide bonds, there is most likely only one peptide product and the different species are the peptide existing in different disulfide connection patterns.
- FIG. 23 illustrates the full anti-FLAG M2 Western blot from FIG. 18 B of the mCherry-T2a-FLAG-peptide constructs (FLAG-SEQ ID NO: 7, FLAG SEQ ID NO: 1, FLAG SEQ ID NO: 9, or FLAG SEQ ID NO: 184).
- 293T cells were transfected with 500 ng of construct.
- intact fusion but not cleaved, soluble peptides were found in 293T cell lysate.
- the prominent bands correspond to the expected size of the intact mCherry-T2a-peptide.
- the box shows the region where T2a-cleaved, FLAG-tagged peptides would be expected to run, based on SDS-PAGE of soluble, untagged peptides.
- NR non-reduced.
- DTT 5 mM DTT, added immediately before loading SDS-PAGE gel.
- UTF Untransfected 293T lysate.
- FIG. 24 illustrates a surface plasmon resonance (SPR) equilibrium analysis fit curves for TEAD-binding K D determination. This analytical method was used because the separate on- and off-rates of these peptides were faster than the SPR instrument could resolve.
- SPR surface plasmon resonance
- FIG. 24 A illustrates the K D of SEQ ID NO: 1 using surface plasmon resonance (SPR) equilibrium analysis.
- FIG. 24 B illustrates the K D of SEQ ID NO: 5 using surface plasmon resonance (SPR) equilibrium analysis.
- FIG. 24 C illustrates the K D of SEQ ID NO: 7 using surface plasmon resonance (SPR) equilibrium analysis.
- FIG. 25 illustrates SDS-PAGE gels of TEAD Binder-Cell Penetrating Peptide fusions (CPP fusions) and Tandem-Cysteine Dense Peptides (Tandem-CDPs) under non-reduced (NR) and reduced (R) conditions.
- the tested CPP fusions were SEQ ID NO: 96, SEQ ID NO: 95, SEQ ID NO: 85, SEQ ID NO: 97, SEQ ID NO: 105, SEQ ID NO: 111, SEQ ID NO: 100, SEQ ID NO: 94, SEQ ID NO: 109, SEQ ID NO: 98, and SEQ ID NO: 108.
- the tested Tandem-CDPs were SEQ ID NO: 134, SEQ ID NO: 124, SEQ ID NO: 117, SEQ ID NO: 125, SEQ ID NO: 132, SEQ ID NO: 119, SEQ ID NO: 141, SEQ ID NO: 130, and SEQ ID NO: 138.
- the CPP fusions and Tandem-CDPs were produced at small scale in 1 mL cultures and TEV-cleaved to separate the peptide (lower band(s) in FIG. 25 ) from the siderocalin carrier (middle band(s) in FIG. 25 ). Uncleaved fusion proteins appear as the top-most band(s).
- This figure illustrates use of a spacer of sequence GGGS (SEQ ID NO: 203) in SEQ ID NO: 134, SEQ ID NO: 125, and SEQ ID NO: 119.
- FIG. 26 illustrates SDS-PAGE gel, from left to right, of hadrucalcin (SEQ ID NO: 170), imperatoxin (SEQ ID NO: 169), opicalcin-2 (SEQ ID NO: 173), chlorotoxin (SEQ ID NO: 176), the TEAD Binder (SEQ ID NO: 9), CPP fusions of SEQ ID NO: 95 and SEQ ID NO: 96, and Tandem-CDPs of SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 124, SEQ ID NO: 125, and SEQ ID NO: 134.
- FIG. 27 illustrates microscopy images of HeLa cells evaluated for cell penetration with a Halo assay.
- the top left image shows the fluorescence of cells treated with a test solution with 1 ⁇ M HT (no protein).
- the top right image shows the fluorescence of cells treated with buffer only.
- the bottom left image shows the fluorescence of cells treated with 1 ⁇ M HT-SEQ ID NO: 9 (bottom left).
- the bottom right image shows the fluorescence of cells treated with 1 ⁇ M HT-SEQ ID NO: 124 (bottom right).
- the peptide of SEQ ID NO: 124 (bottom right) exhibited high cell penetration.
- FIG. 28 illustrates cell-by-cell quantitation of average fluorescence in the red channel of HeLa cells.
- Cells were incubated with no HaloTag (HT) (not shown in figure; used for calibration as 0 cell penetration score (CPS)), 1 ⁇ M HT (not shown in graph; used for calibration as 1 CPS), 1 ⁇ M HT-SEQ ID NO: 9 (a control TEAD binder), 1 ⁇ M SEQ ID NO: 94, 1 ⁇ M HT-SEQ ID NO: 95, 1 ⁇ M HT-SEQ ID NO: 96, 1 ⁇ M HT-SEQ ID NO: 119, 1 ⁇ M HT-SEQ ID NO: 124, 1 ⁇ M HT-SEQ ID NO: 125, or 1 ⁇ M HT-SEQ ID NO: 134.
- HT HaloTag
- CPS cell penetration score
- the HIPPO signaling pathway plays a critical role in contact inhibition, cell density regulation, cell proliferation, organ size and development (organogenesis), and tissue homeostasis, which are important in cancer development, tumor progression, and metastasis (Hong et al.
- the YAP and TAZ transcription co-activators key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 2012 September; 23(7):785-93, Santucci et al. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment. J Med Chem. 2015 Jun. 25; 58(12):4857-73.).
- This pathway is often dysregulated in many human cancers and other diseases associated with uncontrolled cell growth, including liver, pancreas, colon, ovarian, breast, brain, and lung cancers, melanoma, medulloblastoma, and diabetes (Types I and II), as its dysregulation can result in increased cell proliferation, reduced apoptosis and differentiation, tissue overgrowth, and tumorigenesis.
- the HIPPO pathway can be disregulated in osteosarcoma, hepatocellular carcinoma, malignant mesothelioma, schwannoma, meningioma, renal carcinoma, cholangiocarcinoma, bile duct hamartoma, soft tissue carcinoma, ovarian carcinoma, colonic adenoma, T cell acute lymphoblastic leukaemia, gastrointestinal hyperplasia, skin cancer, fibrosarcoma, pancreatic ductal metaplasia, squamous cell carcinoma, kaposis sarcoma, and HIV-induced non-Hodgkin's lymphoma.
- HIPPO pathway involves a core kinase cascade involving Mst1 or Mst2, which forms a complex with adaptor protein WW45 and phosphorylates kinases LATS1 and LATS2 and adaptor protein MOB.
- the LATS/MOB complex can then phosphorylate and repress transcriptional coactivators Yes-associated protein (YAP) and TAZ. Phosphorylation of YAP can promote YAP ubiquitination and subsequent degradation.
- YAP protein levels at multiple points including FERM domain proteins Merlin/NF2 and FRMD6, junctional proteins ZO-2 and AJUB, polarity complex proteins Crumbs, Angiomotin, Scribble, and KIBRA, and protein phosphatases PP2A and ASPP 1.
- Tight regulation of YAP is physiologically important, as YAP acts like an oncogene, and its overexpression is implicated in several human cancers. Increased YAP expression and nuclear localization are associated with tumor progression (Hong et al. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol.
- YAP is a transcription coactivator and is a key regulator of organ growth and cell proliferation in the HIPPO pathway. YAP interacts with several transcription factors that mediate biological functions of YAP in promoting cell growth, including ErbB4, Runx2, TEAD, and p73. TEAD is one of the most potent targets of YAP, as TEAD is required for YAP to stimulate gene expression and cell growth by activating various genes downstream from YAP. YAP binds to TEAD to mediate YAP-dependent gene induction. For example, interaction between YAP and TEAD can activate connective tissue growth factor (CTGF).
- CTGF connective tissue growth factor
- TEAD can be TEAD1, TEAD2, TEAD3, TEAD4, or a fragment, recombinant protein, homolog, or a variant thereof.
- the HIPPO pathway relies on the intranuclear interaction of the transcriptional coactivator YAP and the transcription factor TEAD (1-4). This pathway also plays a crucial role in recovery from injury; for example, its regulated repression allows hepatocytes to divide and replace tissue lost to a partial hepatectomy, after which its activation suppresses cell growth and prevents tissue overgrowth. Designing drugs that target cell growth signaling via protein-protein interactions has proven difficult because targeting protein-protein interactions requires efficient intracellular, and sometimes intranuclear, delivery.
- antibodies can be effective in targeting extracellular or cell surface epitopes, intracellular and intranuclear targets, such as the interaction between YAP and TEAD or TEAD and other proteins, are not amenable to antibody-based therapeutics because antibodies generally cannot penetrate the cell membrane to access cytosolic and nuclear target proteins.
- Finding therapeutic agents that can disrupt intracellular protein-protein interactions can be challenging, as such methods require high specificity or targeting, high affinity binders that can disrupt YAP-TEAD interactions, the ability to penetrate cells or the nucleus to act on the target proteins, and having low off-target adverse effects.
- high throughput screening campaigns with small molecule libraries failed to provide specific, high affinity binders capable of disrupting larger protein-protein interfaces, such as YAP-TEAD.
- peptides and methods of screening peptides for binding to a target protein of interest such as TEAD, and hence peptides that can disrupt YAP-TEAD interaction or TEAD interaction with other proteins in a cell.
- the same methods can also be applied to identify peptides that bind to any other target protein or receptor, or any protein of interest, such that peptide binding results in an inhibition or disruption in binding between the target protein of interest and its natural binders or substrates.
- target protein include, but not limited to, receptors, such as transferrin receptor (TfR), insulin receptor (InsR), leptin receptor (ObR), and apolipoprotein E3 (ApoE).
- peptides including, but not limited to, designed or engineered peptides, recombinant peptides, and small disulfide-knotted peptides (knottins or knotted peptides), that are large enough to interfere with protein-protein interactions, but small enough to access cellular compartments, such as the cytosol or the nucleus, or tissues, such as the middle of solid tumors, that are generally or often beyond the reach of antibodies.
- calcines activators of sarcoplasmic reticulum ryanodine receptors, and BLZ-100, a peptide-fluorophore conjugate or fusion that is capable of accumulating in a wide range of tumor types.
- the disclosure provides, in some embodiments, a protein design approach based on the 3D protein complex structure for identifying peptides capable of binding to TEAD and preventing YAP from binding.
- Xaa can indicate any amino acid.
- X can be asparagine (N), glutamine (Q), histidine (
- a position can be referred to as “position X,” wherein X is the position number within a sequence not counting, if present, the N-terminal GS.
- position 15 in SEQ ID NO: 1 refers to the “G” residue at position 15 within the sequence, wherein position 1 does not count the N-terminal “GS,” and is, thus, the first P residue.
- position 10 in SEQ ID NO: 2 refers to the “Q” residue within the sequence at position 10, wherein position 1 does not count the N-terminal “GS,” and is, thus, the first L residue.
- position 10 in SEQ ID NO: 43 refers to the “E” residue at position 10 within the sequence, wherein position 1 is the very first P residue and there is no N-terminal GS.
- a position can be referred to as “XY,” wherein X is the single-letter abbreviation for an amino acid and wherein Y is the position number within a sequence not counting, if present, the N-terminal GS.
- G15 refers to the “G” residue at position 15 within a sequence, not counting, if present, an N-terminal GS.
- Y23 refers to the “Y” residue at position 23 within a sequence, not counting, if present, an N-terminal GS.
- E25 refers to the “E” residue at position 25 within a sequence, not counting, if present, an N-terminal GS.
- a position can be referred to as “XYZ,” wherein X and Z are the single-letter abbreviation for an amino acid and wherein Y is the position number within a sequence not counting, if present, the N-terminal GS.
- L23A refers to a “L” residue at position 23 within a sequence (not counting, if present, an N-terminal GS), which has been substituted with a “A” residue.
- E25A refers to an “E” residue at position 25 within a sequence (not counting, if present, an N-terminal GS), which has been substituted with an “A” residue.
- F27A refers to an “F” residue at position 27 within a sequence (not counting, if present, an N-terminal GS), which has been substituted with an “A” residue.
- Some embodiments of the disclosure contemplate D-amino acid residues of any standard or non-standard amino acid or analogue thereof.
- an amino acid sequence is represented as a series of three-letter or one-letter amino acid abbreviations, the left-hand direction is the amino terminal direction and the right-hand direction is the carboxy terminal direction, in accordance with standard usage and convention.
- peptide sequences such as those listed in TABLE 1, capable of binding to TEAD or disrupting YAP-TEAD interaction, TEAD interaction with other proteins, or interaction between homologs, derivatives, or variants of YAP and TEAD.
- peptides disclosed herein can penetrate or enter target cells, such as cancerous or tumor cells, liver cells, pancreas cells, colon cells, ovarian cells, breast cells, and/or lung cells, or any combination thereof.
- peptides can penetrate a nucleus of a cell to modulate transcription activity of a gene.
- peptides described herein compete with YAP for binding to TEAD or displace YAP from binding to TEAD.
- peptides described herein bind to TEAD, or a variant, homolog, or derivative thereof.
- peptides described herein are capable of binding to TEAD and disrupting or inhibiting interaction between TEAD and other proteins or coactivators, such as TAZ.
- Compet or peptide competition for binding to TEAD or any target protein interest encompasses, but not limited to, steric hindrance, occupying binding sites of TEAD, non-covalent interactions, such as salt bridges or hydrophobic interactions, crosslinking, covalent interactions, sequestration of TEAD, binding to TEAD that prevents localization to the nucleus, and any combination thereof.
- peptides bind to TEAD with equal, similar, or greater affinity (lower dissociation constant K D ) as compared to YAP binding to TEAD.
- peptides described herein bind to TEAD with similar, same or equal, or lower dissociation constant as compared to YAP's dissociation constant.
- the peptide can have a K D of less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 1 nM, or less than 0.1 nM.
- one or more conserved residues at the YAP-TEAD interface are also present in the peptides described here.
- peptides bind to TEAD at residues found in the YAP-TEAD interface.
- a peptide that binds to TEAD comprises at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, or at least 99% homology as the binding interface or the sequence of a protein or co-factor known to bind TEAD.
- a peptide described herein binds to a protein of interest, which comprises at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, or at least 99% homology as TEAD, a fragment, homolog, or a variant thereof.
- peptides can bind to any of the four TEAD homologs, including TEAD1, TEAD2, TEAD3, TEAD4, or any combination thereof. In other embodiments, peptides are capable of binding to one, one or more, two, two or more, three, three or more, or all four TEAD homologs. In some embodiments, peptides of the present disclosure can prevent or disrupt binding between TEAD and any other protein or co-factor known to interact with TEAD. For example, in some embodiments, a peptide of the present disclosure can prevent or interfere with binding between TEAD and TAZ, thereby preventing or reducing oncogenic effects or transcription of a downstream oncogene. YAP and TAZ are two well-known TEAD-binding transcriptional cofactors.
- TAZ binding to TEAD is similar to YAP binding to TEAD, having similar protein-protein interface or protein binding interactions with TEAD that can be blocked by SEQ ID NO: 1 and its derivatives or variants (e.g. SEQ ID NO: 9; or any of SEQ ID NO: 1-SEQ ID NO: 84), and containing the leucine-X 1 -X 2 -leucine-phenylalanine (LX 1 X 2 LF, SEQ ID NO: 217), wherein X 1 and X 2 can be any amino acid, or containing the leucine-X 1 -X 2 -leucine-phenylalanine (LX 1 X 2 LF, SEQ ID NO: 217) motif, wherein X 1 and X 2 can be any amino acid.
- the X 1 X 2 in the LX 1 X 2 LF can be EA, as shown in SEQ ID NO: 2, or IC as shown in SEQ ID NO: 1.
- the X 1 X 2 in the LX 1 X 2 LF can also be EC, MC, VC, or FC.
- the LX 1 X 2 LF is present in both TAZ and YAP, wherein it is found in a helix comprising amino acids TD LEAL FNA (SEQ ID NO: 285).
- the X 1 X 2 in the LX 1 X 2 LF (SEQ ID NO: 217) motif can be EA, as shown in SEQ ID NO: 2, or IC as shown in SEQ ID NO: 1.
- the X 1 X 2 in the LX 1 X 2 LF (SEQ ID NO: 217) motif can also be EC, MC, VC, or FC.
- the LX 1 X 2 LF (SEQ ID NO: 217) motif is present in both TAZ and YAP, wherein the motif is found in a helix comprising amino acids TD LEAL FNA (SEQ ID NO: 285). TAZ is also implicated in many of the same cancers as YAP, but is not as well studied.
- peptides of the present disclosure can prevent or interfere with binding between TEAD and any TEAD-binding homolog or TEAD-binding moiety.
- a peptide that disrupts TEAD binding or interactions comprises a sequence of LX 1 X 2 LF (SEQ ID NO: 217), or variant thereof.
- a nucleic acid, vector, plasmid, or donor DNA comprises a sequence that encodes a peptide, or variant or fragment thereof, of the present disclosure.
- LX 1 X 2 LF (SEQ ID NO: 217) can be grafted onto peptide of a sequence of any one of SEQ ID NO: 1-SEQ ID NO: 84.
- the LX 1 X 2 LF (SEQ ID NO: 217) can be grafted onto the peptide at any position along the peptide.
- This position can be optimized to allow for the LX 1 X 2 LF (SEQ ID NO: 217) to be available for binding.
- it can be grafted into the peptide sequence at a position in the secondary structure that is at the surface of the peptide when folded.
- the position can be optimized according to higher binding affinity to TEAD and/or to better antagonist TEAD function.
- peptides inhibit binding between TEAD and YAP, or between YAP and any other protein. In some embodiments, peptides prevent TEAD from protein-protein interaction and/or prevent TEAD localization to a cell's nucleus. In some cases, peptides deactivate TEAD. In some embodiments, peptides can cause TEAD to be degraded, or prevent TEAD from localization to a cell's nucleus, or prevent TEAD from interacting with YAP or YAP-like proteins.
- peptides inhibit binding between TEAD and YAP, or between YAP and any other protein by binding to a certain amino acid residue or motif of amino acid residues in TEAD. In some embodiments, peptides prevent TEAD from protein-protein interaction and/or prevent TEAD localization to a cell's nucleus by binding to a certain amino acid residue or motif of amino acid residues in TEAD. In some cases, peptides deactivate TEAD by binding to a certain amino acid residue or motif of amino acid residues in TEAD.
- peptides can cause TEAD to be degraded, or prevent TEAD from localization to a cell's nucleus, or prevent TEAD from interacting with YAP or YAP-like proteins by binding to a certain amino acid residue or motif of amino acid residues in TEAD.
- a peptide can be selected for further testing or use based upon its ability to bind to the certain amino acid residue or motif of amino acid residues.
- the certain amino acid residue or motif of amino acid residues in TEAD can be identified an amino acid residue or sequence of amino acid residues that are involved in the binding of TEAD to YAP.
- a certain amino acid residue or motif of amino acid residues can be identified from a crystal structure of the YAP:TEAD complex.
- TEAD amino acid residues F314, K316, V318, Y346, F350, K353, V366, or any combination thereof can be target residues for TEAD binding to a peptide as disclosed herein based on the YAP:TEAD crystal structure modeled to bind to SEQ ID NO: 1.
- a peptide or a library of peptides is designed in silico without derivation from a naturally occurring knottin scaffold.
- a peptide or a library of peptides is designed in silico by derivation, grafting relevant or important protein-binding residues, or conserved residues, in the protein-binding interface, or structural modeling based on a naturally occurring peptide or protein known to bind to a protein or receptor of interest.
- a peptide with SEQ ID NO: 1 is used as a scaffold or base sequence for further modifications, including addition, deletion, or amino acid substitution.
- residues GS are added at the N-terminus of a peptide.
- peptides lack GS at the N-terminus.
- peptides undergo one or more post-translational modifications.
- a peptide that binds to TEAD comprises Ala at position 8, Asp at position 16, Ser at position 17, Met at position 23, Phe at position 38, or any combination thereof.
- a peptide comprises LX 1 X 2 FEXS (SEQ ID NO: 218), LX 1 X 2 FEXSXDPNVML (SEQ ID NO: 219), or LX 1 X 2 FEXSXDPNVMX 3 X 4 LF (SEQ ID NO: 220), wherein X 1 , X 2 , X 3 , and X 4 can be any amino acid.
- peptides of the present disclosure can comprise the amino acid sequence of leucine-X 1 -X 2 -leucine-phenylalanine (“LX 1 X 2 LF,” SEQ ID NO: 217), in which X 1 and X 2 are any amino acid residue, as shown in SEQ ID NO: 1 and SEQ ID NO: 2.
- peptides with the LX 1 X 2 LF (SEQ ID NO: 217) sequence display full TEAD binding.
- the X 1 X 2 in the LX 1 X 2 LF (SEQ ID NO: 217) sequence can be EA, as shown in SEQ ID NO: 2, or IC as shown in SEQ ID NO: 1.
- the X 1 X 2 in the LX 1 X 2 LF (SEQ ID NO: 217) sequence can also be EC, MC, VC, or FC.
- peptides of the present disclosure can comprise the amino acid sequence motif of leucine-X 1 -X 2 -leucine-phenylalanine (“LX 1 X 2 LF,” SEQ ID NO: 217), in which X 1 and X 2 are any amino acid residue, as shown in SEQ ID NO: 1 and SEQ ID NO: 2.
- peptides with the LX 1 X 2 LF (SEQ ID NO: 217) motif display full TEAD binding.
- the X 1 X 2 in the LX 1 X 2 LF (SEQ ID NO: 217) motif can be EA, as shown in SEQ ID NO: 2, or IC as shown in SEQ ID NO: 1.
- the X 1 X 2 in the LX 1 X 2 LF (SEQ ID NO: 217) motif can also be EC, MC, VC, or FC.
- a peptide of the present disclosure can comprise a sequence having cysteine residues at one or more of positions 11, 12, 13, 14, 19, 20, 21, 22, 36, 38, 39, 41.
- a peptide comprises Cys at positions 11, 12, 19, 20, 36, 39, or any combination thereof.
- a peptide can comprise a sequence having a cysteine residue at position 11.
- a peptide can comprise a sequence having a cysteine residue at position 12.
- a peptide can comprise a sequence having a cysteine residue at position 13.
- a peptide can comprise a sequence having a cysteine residue at position 14.
- a peptide can comprise a sequence having a cysteine residue at position 19. In certain embodiments, a peptide can comprise a sequence having a cysteine residue at position 20. In certain embodiments, a peptide can comprise a sequence having a cysteine residue at position 21. In certain embodiments, a peptide can comprise a sequence having a cysteine residue at position 22. In certain embodiments, a peptide can comprise a sequence having a cysteine residue at position 36. In certain embodiments, a peptide can comprise a sequence having a cysteine residue at position 38. In certain embodiments, a peptide can comprise a sequence having a cysteine residue at position 39.
- a peptide can comprise a sequence having a cysteine residue at position 41.
- the first cysteine residue in the sequence can be disulfide bonded with the 4th cysteine residue in the sequence
- the 2nd cysteine residue in the sequence can be disulfide bonded to the 5th cysteine residue in the sequence
- the 3rd cysteine residue in the sequence can be disulfide bonded to the 6th cysteine residue in the sequence.
- a peptide can comprise one disulfide bridge that passes through a ring formed by two other disulfide bridges, also known as a “two-and-through” structure system.
- the peptides disclosed herein can have one or more cysteines mutated to serine.
- SEQ ID NO: 9 can have one or more cysteines mutated to a serine, such as GSPDEYIERAKESSKKQDIQSSLRIFDESKDPNVMLISLFSW (SEQ ID NO: 177); GSPDEYIERAKESCKKQDIQSCLRIFDESKDPNVMLICLFCW (SEQ ID NO: 178); GSPDEYIERAKECSKKQDIQCCLRIFDESKDPNVMLICLFSW (SEQ ID NO: 179); GSPDEYIERAKECCKKQDIQCSLRIFDESKDPNVMLISLFCW (SEQ ID NO: 180); GSPDEYIERAKESSKKQDIQSCLRIFDESKDPNVMLICLFSW (SEQ ID NO: 181); GSPDEYIERAKECSKKQDIQCSLRIFDESKDPNVMLISLFSW (SEQ ID NO: 182); or GSPDEYIERAKESCKKQDIQSSLR
- SEQ ID NO: 51 can have one or more cysteines mutated to serines, such as PDEYIERAKESSKKQDIQSSLRIFDESKDPNVMLISLFSW (SEQ ID NO: 186); PDEYIERAKESCKKQDIQSCLRIFDESKDPNVMLICLFCW (SEQ ID NO: 187); PDEYIERAKECSKKQDIQCCLRIFDESKDPNVMLICLFSW (SEQ ID NO: 188); PDEYIERAKECCKKQDIQCSLRIFDESKDPNVMLISLFCW (SEQ ID NO: 189); PDEYIERAKESSKKQDIQSCLRIFDESKDPNVMLICLFSW (SEQ ID NO: 190); PDEYIERAKECSKKQDIQCSLRIFDESKDPNVMLISLFSW (SEQ ID NO: 191); or PDEYIERAKESCKKQDIQSSLRIFDESKDPNVMLISLFCW (SEQ ID NO: 192).
- SEQ ID NO: 1 can have one or more cysteines mutated to serines, such as GSPDEYIERAKESSKKGDIQSSLRYFEESGDPNVMLISLFSP (SEQ ID NO: 184). SEQ ID NO: 1 can have one or more cysteines mutated to serines, such as PDEYIERAKESSKKGDIQSSLRYFEESGDPNVMLISLFSP (SEQ ID NO: 193). SEQ ID NO: 2 can have one or more cysteines mutated to serines, such as GSLERLKKSSNQGLDSEEARWKSELEALFQGKNRETSLEES (SEQ ID NO: 185). SEQ ID NO: 2 can have one or more cysteines mutated to serines, such as LERLKKSSNQGLDSEEARWKSELEALFQGKNRETSLEES (SEQ ID NO: 194).
- peptides can comprise at least one or more tag peptide sequences for improved cell penetration.
- peptides can comprise at least one or multiple Arg residues or residues from Tat protein for improved cell penetration property.
- Additional tag peptide sequences can include CysTat (CYRKKRRQRRR; SEQ ID NO: 144), S19-TAT (PFVIGAGVLGALGTGIGGIGRKKRRQRRR; SEQ ID NO: 145), R8 (RRRRRRRR; SEQ ID NO: 146), pAntp (RQIKIWFQNRRMKWKK; SEQ ID NO: 147), Pas-TAT (FFLIPKGGRKKRRQRRR; SEQ ID NO: 148), Pas-R8 (FFLIPKGRRRRRRRR; SEQ ID NO: 149), PasFHV (FFLIPKGRRRRNRTRRNRRRVR; SEQ ID NO: 150), Pas-pAntP (FFLIPKGRQIKIWFQNRRMKWKK; SEQ ID NO
- the peptide can comprise an Arginine patch (Arg patch), for example, an RRRRRRRR (SEQ ID NO: 146), or a variant or fragment thereof, sequence can be appended to either the N-terminus or the C-terminus of a peptide.
- the Arg patch comprises two or more Arg residues, or Arg n wherein n is a whole number and can be 2, 3, 4, 5, 6, 7, 8, 9, or 10 (SEQ ID NO: 286).
- the peptide can comprise a Tat peptide (Tat proteins are reviewed in Gump et al. TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol Med.
- the Tat peptide can have a sequence of, for example, YGRKKRRQRRR (SEQ ID NO: 195), GRKKRRQRRR (SEQ ID NO: 143), or any modification, variant, or fragment thereof, can be appended to the N-terminus or C-terminus of any TEAD-binding peptide of the present disclosure.
- the Tat peptide sequence can be GRKKRRQRRRPQ (SEQ ID NO: 196), GRKKRRQRRR (SEQ ID NO: 143), or a fragment or variant thereof.
- the Tat peptide can be appended to the N-terminus of any TEAD-binding peptide of the present disclosure following an N-terminal GS dipeptide and preceding, for example, a GGGS (SEQ ID NO: 203) spacer.
- a cell-penetrating tag peptides such as any one of SEQ ID NO: 143-SEQ ID NO: 167, can be appended to either the N-terminus or C-terminus of any peptide disclosed herein using a peptide linker such as G x S y (SEQ ID NO: 283) peptide linker, wherein x and y can be any whole number, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10.
- a cell-penetrating peptide such as a Tat peptide or an Arg patch, or any other moiety
- a peptide linker such as G x S y peptide linker, wherein x and y can be any whole number, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10.
- the peptide linker comprises (GS) x (SEQ ID NO: 282), wherein x can be any whole number, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10.
- the peptide linker comprises GGSSG (SEQ ID NO: 204), GGGGG (SEQ ID NO: 205), GSGSGSGS (SEQ ID NO: 206), GSGG (SEQ ID NO: 207), GGGGS (SEQ ID NO: 208), GGGS (SEQ ID NO: 203), GGS (SEQ ID NO: 209), GGGSGGGSGGGS (SEQ ID NO: 210), or a variant or fragment thereof.
- KKYKPYVPVTTN SEQ ID NO: 211) from DkTx
- EPKSSDKTHT SEQ ID NO: 212
- the tag peptide can be appended to the peptide at any amino acid residue. In further embodiments, the tag peptide can be appended to the peptide at any amino acid residue without interfering with TEAD-binding activity. In some embodiments, the tag peptide is appended via conjugation, linking, or fusion techniques. In other embodiments, the Tat peptide can be appended to the peptide at any amino acid residue. In further embodiments, the Tat peptide can be appended to the peptide at any amino acid residue without interfering with TEAD-binding activity. In some embodiments, the Tat peptide is appended via conjugation, linking, or fusion techniques. Additional exemplary TEAD Binder-Cell Penetrating Peptide fusion (CPP fusion) sequences that can improve cell penetration are in TABLE 2.
- CPP fusion Additional exemplary TEAD Binder-Cell Penetrating Peptide fusion
- a peptide is conjugated to, linked to, or fused to one or more cell-penetrating peptides, such as arginine-rich, amphipathic and lysine-rich, and hydrophobic residues or peptides capable of penetrating plasma membrane or nucleus for in vivo delivery of a protein or macromolecular cargo.
- Conjugation or fusion can be direct or with a spacer in between (chemical or peptide-based).
- a spacer can be any peptide linker.
- a spacer can be GGGSGGGSGGGS (SEQ ID NO: 210), KKYKPYVPVTTN (SEQ ID NO: 211) from DkTx, EPKSSDKTHT (SEQ ID NO: 212) from human IgG3 or any variant or fragment thereof.
- Cell-penetrating peptides include, but are not limited to, short amphipathic or cationic short peptides with a positive net charge and are capable of penetrating cellular membrane and transferring a molecular or cargo either covalently or non-covalently attached to the peptides into a cell.
- Such cell-penetrating peptides can be synthesized or derived from known proteins, such as penetratin, Tat peptide, pVEC, or chimeric peptides, such as transportan, MPG, Pep-1, or synthetic peptides, such as polyarginines, MAP, and R 6 W 3 (SEQ ID NO: 287).
- proteins such as penetratin, Tat peptide, pVEC, or chimeric peptides, such as transportan, MPG, Pep-1, or synthetic peptides, such as polyarginines, MAP, and R 6 W 3 (SEQ ID NO: 287).
- peptides can comprise at least one or more cell penetrating peptide sequences for improved cell penetration.
- a cell penetrating peptide can include maurocaline (GDCLPHLKLCKENKDCCSKKCKRRGTNIEKRCR; SEQ ID NO: 168), imperatoxin (GDCLPHLKRCKADNDCCGKKCKRRGTNAEKRCR; SEQ ID NO: 169), hadrucalcin (SEKDCIKHLQRCRENKDCCSKKCSRRGTNPEKRCR; SEQ ID NO: 170), hemicalcin (GDCLPHLKLCKADKDCCSKKCKRRGTNPEKRCR; SEQ ID NO: 171), opicalcin-1 (GDCLPHLKRCKENNDCCSKKCKRRGTNPEKRCR; SEQ ID NO: 172), opicalcin-2 (GDCLPHLKRCKENNDCCSKKCKRRGANPEKRCR; SEQ ID NO: 173), midkine (62-104)
- the cell penetrating peptide can have at least 80%, 90%, 95%, or 99% sequence identity with any sequence of SEQ ID NO: 168-SEQ ID NO: 176.
- the cell penetrating peptide sequence can be appended to either the N-terminus or the C-terminus of a peptide.
- the cell penetrating peptide can be appended to the N-terminus of any TEAD-binding peptide of the present disclosure following an N-terminal GS dipeptide and preceding, for example, a GGGS (SEQ ID NO: 203) spacer.
- a cell-penetrating tag peptides such as any one of SEQ ID NO: 168-SEQ ID NO: 176, can be appended to either the N-terminus or C-terminus of any peptide disclosed herein using a peptide linker such as G x S y (SEQ ID NO: 283) peptide linker, wherein x and y can be any whole number, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10.
- the peptide linker comprises GGS (SEQ ID NO: 209), GGSSG (SEQ ID NO: 204), GGGGG (SEQ ID NO: 205), GSGSGSGS (SEQ ID NO: 206), GSGG (SEQ ID NO: 207), GGGGS (SEQ ID NO: 208), GGGS (SEQ ID NO: 203), GGGSGGGSGGGS (SEQ ID NO: 210), or a variant or fragment thereof.
- KKYKPYVPVTTN SEQ ID NO: 211) from DkTx
- EPKSSDKTHT SEQ ID NO: 212 from human IgG3 can be used as a peptide linker.
- the cell penetrating peptide can be appended to the peptide at any amino acid residue. In further embodiments, the cell penetrating peptide can be appended to the peptide at any amino acid residue without interfering with TEAD-binding activity. In some embodiments, the cell penetrating peptide is appended via conjugation, linking, or fusion techniques. In other embodiments, the cell penetrating peptide can be appended to the peptide at any amino acid residue. Additional exemplary cell penetrating Tandem-Cysteine Dense Peptide (Tandem-CDP) sequences that can improve cell penetration are in TABLE 3.
- Tandem-Cysteine Dense Peptide Tandem-Cysteine Dense Peptide
- nuclear localization signals can be couple to, conjugated to, linked to, or fused to a peptide described herein to promote nuclear localization.
- TEAD-binding peptides are conjugated to, linked to, or fused to a nuclear localization signal, such as a four-residue sequence of K-K/R-X-K/R (SEQ ID NO: 202), wherein X can be any amino acid, or a variant thereof.
- TEAD-binding peptides are conjugated to, linked to, or fused to a nuclear localization signal as described in Lange et al, J Biol Chem. 2007 Feb.
- a peptide described herein is conjugated to, linked to, or fused to a nuclear localization signal comprising KxRy (SEQ ID NO: 288), wherein x and y independently can be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, such as KKRR (SEQ ID NO: 199), KKKRR (SEQ ID NO: 200), or KKKK (SEQ ID NO: 201).
- cell penetrating moieties can also be linked to, conjugated to, linked to, or fused to the peptides described herein, including, but not limited to, polycations, polyorganic acids, endosomal releasing polymers, poly(2-propylacrylic acid), poly(2-ethylacrylic acid), or any combination thereof.
- TAT or dfTAT can be conjugated to, linked to, or fused to a peptide described herein, allowing the linked, conjugate, or fusion peptide or protein to use the endocytic pathway as a route of in vivo delivery or a way to penetrate a cell or nucleus.
- dfTAT can facilitate cytosolic delivery of TEAD-binding peptides.
- Co-delivery of dfTAT with TEAD-binding peptide can facilitate cytosolic uptake of TEAD-binding peptide into a cell.
- Efficient cell penetration of the peptides as described herein can interact with TEAD to downregulate or suppress genes, such as oncogenes, driven by YAP/TAZ-TEAD transcriptional activation.
- cell penetration can be increased by using high dosage of a peptide described here, such as up to 10 ⁇ M, or 10 ⁇ M or more of the peptide.
- an Arg patch can be fused, conjugated to, linked to, or co-delivered with a peptide. Up 10 ⁇ M, or 10 ⁇ M or more Arg patch may be co-delivered with a peptide to facilitate cell penetration.
- Protein transfection agents can also be used to increase cell penetration of a peptide.
- direct cytosolic expression of a peptide can be used.
- physical disruption methods such as electroporation can be used to improve delivery of a peptide into a cell.
- cell penetrance of a peptide described herein can be improved.
- the binding interface of a peptide described herein can be grafted on a scaffold that is naturally cell-penetrant, such as a calcine.
- calcines can be imperatoxin-A, maurocalcine, hemicalcin, opiclacin 1, opicalcin 2, and hadrucalcin.
- the scaffold can comprise at least 60%, 70%, 80%, 90%, 95%, or 98% with any one of SEQ ID NO: 168-SEQ ID NO: 176.
- the cell penetrance peptide can be calcines, modified calcines, derivatizes of calcines, or fragments thereof, which can be used to increase cell penetration.
- Modified calcines, derivatives of calcines, or fragments can be screened for cell penetration activity such as activation of sarcoplasmic reticulum ryanodine receptors, activity on ryanodine-sensitive Ca 2+ channels RyR1, Ryr2, or both, or as a selective agonist of the foregoing.
- modified calcines can include substitution, addition or reduction of Lysine residues, or other charged residues, within a native calcine in order to modify activity and optimize such calcine cell-penetration activity or activity on the RyR1 or RyR2 receptors.
- the six amino acid portion of helix 3 (MLICLF; SEQ ID NO: 221), which can be a major component of SEQ ID NO: 9 binding to TEAD, can be transplanted onto a calcine or modified calcine scaffold to produce a bi-functional peptide that retains the cell penetration of the calcine with the novel SEQ ID NO: 9 TEAD binding function.
- a peptide as described herein can have improved cell penetrating capabilities using cis-acting elements, including inclusion of K/R-rich sequences like TAT or octa-arginine (SEQ ID NO: 146), intra-helical arginine patches, or fusion to larger fragments of proteins identified in cell penetration screening like penetratin or melittin.
- K/R-rich sequences like TAT or octa-arginine (SEQ ID NO: 146)
- intra-helical arginine patches or fusion to larger fragments of proteins identified in cell penetration screening like penetratin or melittin.
- peptides can penetrate into a target cell or a nucleus of a target cell.
- target cells include cancerous cells, tumors, and other cell types wherein the HIPPO pathway is dysregulated.
- the target cell can be a human cell, a mammalian cell, a human or mammalian cell line, a cancer cell line, a cell extracted from a subject, in vivo, or in vitro.
- the peptide can contain only one lysine residue, or no lysine residues. In some instances, some or all of the lysine residues in the peptide are replaced with arginine residues. In some instances, some or all of the methionine residues in the peptide are replaced by leucine or isoleucine. Some or all of the tryptophan residues in the peptide can be replaced by phenylalanine or tyrosine. In some instances, some or all of the asparagine residues in the peptide are replaced by glutamine. In some embodiments, some or all of the aspartic acid residues can be replaced by glutamic acid residues.
- the N-terminus of the peptide is blocked, such as by an acetyl group.
- the C-terminus of the peptide is blocked, such as by an amide group.
- the peptide is modified by methylation on free amines. For example, full methylation can be accomplished through the use of reductive methylation with formaldehyde and sodium cyanoborohydride.
- GS can be added as the first two N-terminal amino acids, as shown in SEQ ID NO: 1-SEQ ID NO: 42, or such N-terminal amino acids (GS) can be absent as shown in SEQ ID NO: 43-SEQ ID NO: 84, or can be substituted by any other one or two amino acids.
- GS is used as a linker or used to couple to a linker to make a protein conjugate or fusion.
- the linker comprises a G x S y (SEQ ID NO: 283) peptide, wherein x and y independently can be any whole number, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10.
- the peptide linker comprises (GS) x (SEQ ID NO: 282), wherein x can be any whole number, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10.
- the peptide linker comprises GGSSG (SEQ ID NO: 204), GGGGG (SEQ ID NO: 205), GSGSGSGS (SEQ ID NO: 206), GGGGS (SEQ ID NO: 208), GGGS (SEQ ID NO: 203), or a variant or fragment thereof.
- the C-terminal Arg residues of a peptide is modified to another residue such as Ala, Asn, Asp, Gln, Glu, Gly, His, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val.
- the C-terminal Arg residue of a peptide can be modified to Ile.
- the C-terminal Arg residue of a peptide can be modified to any non-natural amino acid. This modification can prevent clipping of the C-terminal residue during expression, synthesis, processing, storage, in vitro, or in vivo including during treatment, while still allowing maintenance of a key hydrogen bond.
- a key hydrogen bond can be the hydrogen bond formed during the initial folding nucleation and is critical for forming the initial hairpin.
- the peptide comprises the sequence of any one of SEQ ID NO: 1-SEQ ID NO: 84.
- a peptide can be a fragment comprising a contiguous fragment of any one of SEQ ID NO: 1-SEQ ID NO: 84 that is at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46 at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, at least 65, at least 66,
- the peptide sequence is flanked by additional amino acids.
- additional amino acids can, for example, confer a desired in vivo charge, isoelectric point, chemical conjugation site, stability, or physiologic property to a peptide.
- peptides capable of disrupting YAP-TEAD interact comprise no more than 60 amino acids in length, or no more than 50, no more than 45, no more than 40, no more than 35, no more than 30, no more than 25, no more than 20, no more than 15, or no more than 10 amino acids in length.
- peptide sequences comprise primarily beta-sheets and/or alpha-helix structures.
- designed or engineered TEAD-binding peptides of the present disclosure are small, compact mini-proteins stabilized by intra-chain disulfide bonds (mediated by cysteines) and a well-packed hydrophobic core.
- engineered TEAD-binding peptides have structures comprising helical bundles with at least one disulfide bridge between each of the alpha helices, thereby stabilizing the peptides.
- the engineered TEAD-binding peptides comprise structures with three alpha helices and three intra-chain disulfide bonds, one between each of the three alpha helices in the bundle.
- one alpha helix in the bundle comprising at least two helical turns, can present the leucine-X 1 -X 2 -leucine-phenylalanine (LX 1 X 2 LF, SEQ ID NO: 217) motif on the surface of the folded structure of the engineered TEAD-binding peptide, wherein X 1 and X 2 can be any amino acid.
- the LX 1 X 2 LF (SEQ ID NO: 217) motif is a key binding motif found in the YAP sequence and is at the core of the binding interface between YAP and TEAD.
- peptides can be conjugated to, linked to, or fused to a carrier or a molecule with targeting or homing function for a cell of interest or a target cell. In other embodiments, peptides can be conjugated to, linked to, or fused to a molecule that extends half-life or modifies the pharmacodynamic and/or pharmacokinetic properties of the peptides, or any combination thereof.
- a peptide comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 positively charged residues, such as Arg or Lys, or any combination thereof.
- one or more lysine residues in the peptide are replaced with arginine residues.
- peptides comprise one or more Arg patches.
- an Arg patch is positioned in the N-terminus of a peptide.
- an Arg patch is positioned in the C-terminus of a peptide.
- an Arg patch comprises 8 consecutive Arg residues (SEQ ID NO: 146). In some cases, 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, or 10 or more Arg or Lys residues are solvent exposed on a peptide. In some embodiments, an Arg patch can be two or more consecutive Arg residues. In some embodiments, an Arg patch comprises one or more Arg substituted with Lys.
- the peptides of the present disclosure can further comprise neutral amino acid residues.
- the peptide has 35 or fewer neutral amino acid residues.
- the peptide has 81 or fewer neutral amino acid residues, 70 or fewer neutral amino acid residues, 60 or fewer neutral amino acid residues, 50 or fewer neutral amino acid residues, 40 or fewer neutral amino acid residues, 36 or fewer neutral amino acid residues, 33 or fewer neutral amino acid residues, 30 or fewer neutral amino acid residues, 25 or fewer neutral amino acid residues, or 10 or fewer neutral amino acid residues.
- the peptides of the present disclosure can further comprise negative amino acid residues.
- the peptide has 6 or fewer negative amino acid residues, 5 or fewer negative amino acid residues, 4 or fewer negative amino acid residues, 3 or fewer negative amino acid residues, 2 or fewer negative amino acid residues, or 1 or fewer negative amino acid residues.
- negative amino acid residues can be selected from any negatively charged amino acid residues, in some embodiments, the negative amino acid residues are either E, or D, or a combination of both E and D.
- a peptide comprises no Cys or disulfides. In some cases, a peptide comprises 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more Cys or disulfides. In other embodiments, 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more Cys residues have been replaced with Ser residues. In some embodiments, 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more Cys residues have been replaced with Thr residues.
- the methionine residues in the peptide are replaced by leucine or isoleucine.
- some or all of the tryptophan residues in the peptide are replaced by phenylalanine or tyrosine.
- some or all of the asparagine residues in the peptide are replaced by glutamine.
- the N-terminus of the peptide is blocked, such as by an acetyl group.
- the C-terminus of the peptide is blocked, such as by an amide group.
- the peptide is modified by methylation on free amines.
- full methylation may be accomplished through the use of reductive methylation with formaldehyde and sodium cyanoborohydride.
- the C-terminal Arg residues of a peptide is modified to another residue such as Ala, Asn, Asp, Gln, Glu, Gly, His, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val.
- the C-terminal Arg residue of a peptide can be modified to Ile.
- the C-terminal Arg residue of a peptide can be modified to any non-natural amino acid.
- This modification can prevent clipping of the C-terminal residue during expression, synthesis, processing, storage, in vitro, or in vivo including during treatment, while still allowing maintenance of a key hydrogen bond.
- a key hydrogen bond can be the hydrogen bond formed during the initial folding nucleation and is critical for forming the initial hairpin.
- the NMR solution structures of related structural homologs can be used to inform mutational strategies that may improve the folding, stability, manufacturability, while maintaining a particular biological function. They can be used to predict the 3D pharmacophore of a group of structurally homologous scaffolds, as wells as to predict possible graft regions of related proteins to create chimeras with improved properties. For example, this strategy was used to identify critical amino acid positions and loops that may be used to design peptides with improved cell penetrating properties, high affinity for either TEAD or YAP, high expression, high stability in vivo, or any combination thereof.
- a peptide capable of disrupting YAP-TEAD interaction comprises a sequence with at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of the exemplary peptide sequences listed in TABLE 1, or a fragment thereof. Two or more peptides can share a degree of sequence identity or homology and share similar properties in vivo.
- a peptide can share a degree of sequence identity or homology with any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84.
- one or more peptides of the disclosure can have up to about 20% pairwise sequence identity or homology, up to about 25% pairwise sequence identity or homology, up to about 30% pairwise sequence identity or homology, up to about 35% pairwise sequence identity or homology, up to about 40% pairwise sequence identity or homology, up to about 45% pairwise sequence identity or homology, up to about 50% pairwise sequence identity or homology, up to about 55% pairwise sequence identity or homology, up to about 60% pairwise sequence identity or homology, up to about 65% pairwise sequence identity or homology, up to about 70% pairwise sequence identity or homology, up to about 75% pairwise sequence identity or homology, up to about 80% pairwise sequence identity or homology, up to about 85% pairwise sequence identity or homology, up to about 90% pairwise sequence identity or homology, up to about 95% pairwise sequence identity
- one or more peptides of the disclosure can have at least about 20% pairwise sequence identity or homology, at least about 25% pairwise sequence identity or homology, at least about 30% pairwise sequence identity or homology, at least about 35% pairwise sequence identity or homology, at least about 40% pairwise sequence identity or homology, at least about 45% pairwise sequence identity or homology, at least about 50% pairwise sequence identity or homology, at least about 55% pairwise sequence identity or homology, at least about 60% pairwise sequence identity or homology, at least about 65% pairwise sequence identity or homology, at least about 70% pairwise sequence identity or homology, at least about 75% pairwise sequence identity or homology, at least about 80% pairwise sequence identity or homology, at least about 85% pairwise sequence identity or homology, at least about 90% pairwise sequence identity or homology, at least about 95% pairwise sequence identity or homology, at least about 96% pairwise sequence identity or homology, at least about 97% pairwise sequence identity or homology, at least about 98% pairwise sequence identity or homology,
- Various methods and software programs can be used to determine the homology between two or more peptides, such as NCBI BLAST, Clustal W, MAFFT, Clustal Omega, AlignMe, Praline, or another suitable method or algorithm. Pairwise sequence alignment is used to identify regions of similarity that may indicate functional, structural and/or evolutionary relationships between two biological sequences (protein or nucleic acid), By contrast, multiple sequence alignment (MSA) is the alignment of three or more biological sequences. From the output of MSA applications, homology can be inferred and the evolutionary relationship between the sequences assessed.
- MSA multiple sequence alignment
- sequence homology and “sequence identity” and “percent (%) sequence identity” and “percent (%) sequence homology” have been used interchangeably to mean the sequence relatedness or variation, as appropriate, to a reference polynucleotide or amino acid sequence.
- the peptide is any one of SEQ ID NO: 1-SEQ ID NO: 84 or a functional fragment thereof.
- the peptide of the disclosure further comprises a peptide with 99%, 95%, 90%, 85%, or 80% sequence identity or homology to any one of SEQ ID NO: 1-SEQ ID NO: 84 or fragment thereof.
- the peptide can be a peptide that is homologous to any one of SEQ ID NO: 1-SEQ ID NO: 84 or a functional fragment thereof.
- the term “homologous” is used herein to denote peptides having at least 70%, at least 80%, at least 90%, at least 95%, or greater than 95% sequence identity or homology to a sequence of any one of SEQ ID NO: 1-SEQ ID NO: 84 or a functional fragment thereof.
- variant nucleic acid molecules that encode a peptide of any one of SEQ ID NO: 1-SEQ ID NO: 84 can be identified by either a determination of the sequence identity or homology of the encoded peptide amino acid sequence with the amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 84, or by a nucleic acid hybridization assay.
- Such peptide variants of any one of SEQ ID NO: 1-SEQ ID NO: 84 can be characterized as nucleic acid molecules (1) that remain hybridized with a nucleic acid molecule having the nucleotide sequence of any one of SEQ ID NO: 1-SEQ ID NO: 84 (or its complement) under highly stringent washing conditions, in which the wash stringency is equivalent to 0.1 ⁇ -0.2 ⁇ SSC with 0.1% SDS at 50-65° C., and (2) that encode a peptide having at least 70%, at least 80%, at least 90%, at least 95% or greater than 95% sequence identity or homology to the amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 84.
- TEAD binding peptides as described herein contain no disulfides or Cys. In other embodiments, TEAD binding peptides comprise one or more Cys, or one or more disulfide bond. In some embodiments, the TEAD binding peptides are derived from knotted or knottin peptides. In some embodiments, such knotted peptides can bind TEAD, thereby preventing TEAD interactions, such as YAP-TEAD interactions. In some embodiments, a peptide that disrupts TEAD binding interactions comprises one or more properties of some knottin peptides, such as stability, resistance to proteolysis, resistance to reducing conditions, and/or ability to cross the blood brain barrier.
- knotted peptides can be conjugated to, linked to, or fused to TEAD binding peptides, such as those described in TABLE 1, to provide homing or targeting function to a target cell, such as a cancer cell, pancreatic cell, liver cell, colon cell, ovarian cell, breast cell, lung cell, or any combination thereof.
- a target cell such as a cancer cell, pancreatic cell, liver cell, colon cell, ovarian cell, breast cell, lung cell, or any combination thereof.
- such knotted peptides selectively target or home to a cancer cell, such as a breast cancer, liver cancer, colon cancer, brain cancer, or tumor cell.
- knotted peptides can home to or target an unhealthy or diseased cell or a cancer cell across the blood brain barrier.
- knotted peptides are conjugated to, linked to, or fused to TEAD binding peptides and are capable of localizing TEAD binding peptides across the blood brain barrier to deliver TEAD binding peptides to target cells in the central nervous system.
- targeting or homing peptides or knotted peptides can be used to deliver a cytotoxic agent to the target cell or target TEAD in a target cell for degradation or inactivation, such as targeting TEAD for ubiquitination or other post-translation modification that targets TEAD for degradation or inactivation.
- Knottins are a class of peptides, usually ranging from about 11 to about 81 amino acids in length that are often folded into a compact structure. Knottins are typically assembled into a complex tertiary structure that is characterized by a number of intramolecular disulfide crosslinks and may contain beta strands, alpha helices, and other secondary structures. The presence of the disulfide bonds gives knottins remarkable environmental stability, allowing them to withstand extremes of temperature and pH and to resist the proteolytic enzymes of the blood stream. The presence of a disulfide knot may provide resistance to reduction by reducing agents.
- knottins also allows them to bind to targets without paying the “entropic penalty” that a floppy peptide accrues upon binding a target.
- binding is adversely affected by the loss of entropy that occurs when a peptide binds a target to form a complex. Therefore, “entropic penalty” is the adverse effect on binding, and the greater the entropic loss that occurs upon this binding, the greater the “entropic penalty.”
- unbound molecules that are flexible lose more entropy when forming a complex than molecules that are rigidly structured, because of the loss of flexibility when bound up in a complex.
- rigidity in the unbound molecule also generally increases specificity by limiting the number of complexes that molecule can form.
- knotted peptides can bind targets with antibody-like affinity, or with nanomolar or picomolar affinity.
- a wider examination of the sequence structure and sequence identity or homology of knottins reveals that they have arisen by convergent evolution in all kinds of animals and plants. In animals, they are often found in venoms, for example, the venoms of spiders and scorpions and have been implicated in the modulation of ion channels.
- the knottin proteins of plants can inhibit the proteolytic enzymes of animals or have antimicrobial activity, suggesting that knottins can function in the native defense of plants.
- knotted peptides that comprise or are derived from these knotted peptides (or knottins).
- knottins or knottins.
- the term “knotted peptide” is considered to be interchangeable with the terms “knottin” and “peptide.”
- the peptides of the present disclosure comprise cysteine amino acid residues.
- the peptide has at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 cysteine amino acid residues.
- the peptide has at least 8 cysteine amino acid residues.
- the peptide has at least 10 cysteine amino acid residues, at least 12 cysteine amino acid residues, at least 14 cysteine amino acid residues or at least 16 cysteine amino acid residues.
- a knotted peptide can comprise disulfide bridges.
- a knotted peptide can be a peptide wherein 5% or more of the residues are cysteines forming intramolecular disulfide bonds.
- a disulfide-linked peptide can be a drug scaffold.
- the disulfide bridges form a knot.
- a disulfide bridge can be formed between cysteine residues, for example, between cysteines 1 and 4, 2 and 5, or, 3 and 6. In some cases, one disulfide bridge passes through a loop formed by the other two disulfide bridges, for example, to form the knot. In other cases, the disulfide bridges can be formed between any two cysteine residues.
- the present disclosure further includes peptide scaffolds that, e.g., can be used as a starting point for generating additional peptides.
- these scaffolds can be derived from a variety of knotted peptides (or knottins).
- knotted peptides are assembled into a complex tertiary structure that is characterized by a number of intramolecular disulfide crosslinks, and optionally contain beta strands and other secondary structures such as an alpha helix.
- knotted peptides include, in some embodiments, small disulfide-rich proteins characterized by a disulfide through disulfide knot. This knot can be, e.g., obtained when one disulfide bridge crosses the macrocycle formed by two other disulfides and the interconnecting backbone.
- the knotted peptides can include growth factor cysteine knots or inhibitor cysteine knots.
- Other possible peptide structures include peptide having two parallel helices linked by two disulfide bridges without ⁇ -sheets (e.g., hefutoxin).
- a knotted peptide can comprise at least one amino acid residue in an L configuration.
- a knotted peptide can comprise at least one amino acid residue in a D configuration.
- a knotted peptide is 15-40 amino acid residues long.
- a knotted peptide is 11-57 amino acid residues long.
- a knotted peptide is 11-81 amino acid residues long.
- a knotted peptide is at least 20 amino acid residues long.
- Knotted peptides or peptides can be derived from a class of proteins known to be present or associated with toxins or venoms. In some cases, the peptide can be derived from toxins or venoms associated with scorpions or spiders. The peptide can be derived from venoms and toxins of spiders and scorpions of various genus and species.
- the peptide can be derived from a venom or toxin of the Leiurus quinquestriatus hebraeus, Buthus occitanus tunetanus, Hottentotta judaicus, Mesobuthus eupeus, Buthus occitanus israelis, Hadrurus gertschi, Androctonus australis, Centruroides noxius, Heteroticians laoticus, Opistophthalmus carinatus, Haplopelma schmidti, Isometrus maculatus, Haplopelma huwenum, Haplopelma hainanum, Haplopelma schmidti, Agelenopsis aperta, Haydronyche versuta, Selenocosmia huwena, Heteropoda venatoria, Grammostola rosea, Omithoctonus huwena, Hadronyche versuta, Atrax
- Percent sequence identity or homology is determined by conventional methods. See, for example, Altschul et al., Bull. Math. Bio. 48:603 (1986), and Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1992). Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the “BLOSUM62” scoring matrix of Henikoff and Henikoff (Id.). The sequence identity or homology is then calculated as: ([Total number of identical matches]/[length of the longer sequence plus the number of gaps introduced into the longer sequence in order to align the two sequences])(100).
- the “FASTA” similarity search algorithm of Pearson and Lipman is a suitable protein alignment method for examining the level of sequence identity or homology shared by an amino acid sequence of a peptide disclosed herein and the amino acid sequence of a peptide variant.
- the FASTA algorithm is described by Pearson and Lipman, Proc. Nat'l Acad. Sci. USA 85:2444 (1988), and by Pearson, Meth. Enzymol. 183:63 (1990).
- the ten regions with the highest density of identities are then rescored by comparing the similarity of all paired amino acids using an amino acid substitution matrix, and the ends of the regions are “trimmed” to include only those residues that contribute to the highest score.
- the trimmed initial regions are examined to determine whether the regions can be joined to form an approximate alignment with gaps.
- the highest scoring regions of the two amino acid sequences are aligned using a modification of the Needleman-Wunsch-Sellers algorithm (Needleman and Wunsch, J. Mol. Biol. 48:444 (1970); Sellers, Siam J. Appl. Math. 26:787 (1974)), which allows for amino acid insertions and deletions.
- FASTA can also be used to determine the sequence identity or homology of nucleic acid molecules using a ratio as disclosed above.
- the ktup value can range between one to six, preferably from three to six, most preferably three, with other parameters set as described above.
- ⁇ amino acids that are a “conservative amino acid substitution” are illustrated by a substitution among amino acids within each of the following groups: (1) glycine, alanine, valine, leucine, and isoleucine, (2) phenylalanine, tyrosine, and tryptophan, (3) serine and threonine, (4) aspartate and glutamate, (5) glutamine and asparagine, and (6) lysine, arginine and histidine.
- the BLOSUM62 table is an amino acid substitution matrix derived from about 2,000 local multiple alignments of protein sequence segments, representing highly conserved regions of more than 500 groups of related proteins (Henikoff and Henikoff, Proc. Nat'l Acad. Sci.
- the BLOSUM62 substitution frequencies can be used to define conservative amino acid substitutions that may be introduced into the amino acid sequences of the present invention.
- conservative amino acid substitution preferably refers to a substitution represented by a BLOSUM62 value of greater than ⁇ 1.
- an amino acid substitution is conservative if the substitution is characterized by a BLOSUM62 value of 0, 1, 2, or 3.
- preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 1 (e.g., 1, 2 or 3), while more preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 2 (e.g., 2 or 3).
- Determination of amino acid residues that are within regions or domains that are critical to maintaining structural integrity can be determined. Within these regions one can determine specific residues that can be more or less tolerant of change and maintain the overall tertiary structure of the molecule.
- Methods for analyzing sequence structure include, but are not limited to, alignment of multiple sequences with high amino acid or nucleotide identity or homology and computer analysis using available software (e.g., the Insight II® viewer and homology modeling tools; MSI, San Diego, Calif.), secondary structure propensities, binary patterns, complementary packing and buried polar interactions (Barton, G. J., Current Opin. Struct. Biol. 5:372-6 (1995) and Cordes, M. H. et al., Current Opin. Struct. Biol. 6:3-10 (1996)).
- modifications to molecules or identifying specific fragments determination of structure can typically be accompanied by evaluating activity of modified molecules.
- peptides can have a net charge, for example, of ⁇ 5, ⁇ 4, ⁇ 3, ⁇ 2, ⁇ 1, 0, +1, +2, +3, +4, or +5.
- the net charge is zero, the peptide can be uncharged or zwitterionic.
- the peptide contains one or more disulfide bonds and has a positive net charge at physiological pH where the net charge can be +0.5 or less than +0.5, +1 or less than +1, +1.5 or less than +1.5, +2 or less than +2, +2.5 or less than +2.5, +3 or less than +3, +3.5 or less than +3.5, +4 or less than +4, +4.5 or less than +4.5, +5 or less than +5, +5.5 or less than +5.5, +6 or less than +6, +6.5 or less than +6.5, +7 or less than +7, +7.5 or less than +7.5, +8 or less than +8, +8.5 or less than +8.5, +9 or less than +9.5, +10 or less than +10.
- the peptide has a negative net charge at physiological pH where the net charge can be ⁇ 0.5 or less than ⁇ 0.5, ⁇ 1 or less than ⁇ 1, ⁇ 1.5 or less than ⁇ 1.5, ⁇ 2 or less than ⁇ 2, ⁇ 2.5 or less than ⁇ 2.5, ⁇ 3 or less than ⁇ 3, ⁇ 3.5 or less than ⁇ 3.5, ⁇ 4 or less than ⁇ 4, ⁇ 4.5 or less than ⁇ 4.5, ⁇ 5 or less than ⁇ 5, ⁇ 5.5 or less than ⁇ 5.5, ⁇ 6 or less than ⁇ 6, ⁇ 6.5 or less than ⁇ 6.5, ⁇ 7 or less than ⁇ 7, ⁇ 7.5 or less than ⁇ 7.5, ⁇ 8 or less than ⁇ 8, ⁇ 8.5 or less than ⁇ 8.5, ⁇ 9 or less than ⁇ 9.5, ⁇ 10 or less than ⁇ 10.
- peptides of the present disclosure can have an isoelectric point (pI) value from 3 and 10. In other embodiments, peptides of the present disclosure can have a pI value from 4.3 and 8.9. In some embodiments, peptides of the present disclosure can have a pI value from 3-4. In some embodiments, peptides of the present disclosure can have a pI value from 3-5. In some embodiments, peptides of the present disclosure can have a pI value from 3-6. In some embodiments, peptides of the present disclosure can have a pI value from 3-7. In some embodiments, peptides of the present disclosure can have a pI value from 3-8.
- pI isoelectric point
- peptides of the present disclosure can have a pI value from 3-9. In some embodiments, peptides of the present disclosure can have a pI value from 4-5. In some embodiments, peptides of the present disclosure can have a pI value from 4-6. In some embodiments, peptides of the present disclosure can have a pI value from 4-7. In some embodiments, peptides of the present disclosure can have a pI value from 4-8. In some embodiments, peptides of the present disclosure can have a pI value from 4-9. In some embodiments, peptides of the present disclosure can have a pI value from 4-10.
- peptides of the present disclosure can have a pI value from 5-6. In some embodiments, peptides of the present disclosure can have a pI value from 5-7. In some embodiments, peptides of the present disclosure can have a pI value from 5-8. In some embodiments, peptides of the present disclosure can have a pI value from 5-9. In some embodiments, peptides of the present disclosure can have a pI value from 5-10. In some embodiments, peptides of the present disclosure can have a pI value from 6-7. In some embodiments, peptides of the present disclosure can have a pI value from 6-8.
- peptides of the present disclosure can have a pI value from 6-9. In some embodiments, peptides of the present disclosure can have a pI value from 6-10. In some embodiments, peptides of the present disclosure can have a pI value from 7-8. In some embodiments, peptides of the present disclosure can have a pI value from 7-9. In some embodiments, peptides of the present disclosure can have a pI value from 7-10. In some embodiments, peptides of the present disclosure can have a pI value from 8-9. In some embodiments, peptides of the present disclosure can have a pI value from 8-10. In some embodiments, peptides of the present disclosure can have a pI value from 9-10.
- the engineering of one or more mutations within a peptide yields a peptide with an altered isoelectric point, charge, surface charge, or rheology at physiological pH.
- Such engineering of a mutation to a peptide derived from a scorpion or spider can change the net charge of the complex, for example, by decreasing the net charge by 1, 2, 3, 4, or 5, or by increasing the net charge by 1, 2, 3, 4, or 5.
- the engineered mutation can facilitate the ability of the peptide to penetrate a cell, an endosome, or the nucleus.
- Suitable amino acid modifications for improving the rheology and potency of a peptide can include conservative or non-conservative mutations.
- a peptide can comprise at most 1 amino acid mutation, at most 2 amino acid mutations, at most 3 amino acid mutations, at most 4 amino acid mutations, at most 5 amino acid mutations, at most 6 amino acid mutations, at most 7 amino acid mutations, at most 8 amino acid mutations, at most 9 amino acid mutations, at most 10 amino acid mutations, or another suitable number as compared to the sequence of the venom or toxin component that the peptide is derived from.
- a peptide, or a functional fragment thereof comprises at least 1 amino acid mutation, at least 2 amino acid mutations, at least 3 amino acid mutations, at least 4 amino acid mutations, at least 5 amino acid mutations, at least 6 amino acid mutations, at least 7 amino acid mutations, at least 8 amino acid mutations, at least 9 amino acid mutations, at least 10 amino acid mutations, or another suitable number as compared to the sequence of the venom or toxin component that the peptide is derived from.
- mutations can be engineered within a peptide to provide a peptide that has a desired charge or stability at physiological pH.
- the NMR solution structures, the x-ray crystal structures, as well as the primary structure sequence alignment of related structural homologs or in silico design can be used to inform mutational strategies that can improve the folding, stability, and/or manufacturability, while maintaining a particular biological function.
- the general strategy for producing homologs or in silico designed peptides or proteins can include identification of a charged surface patch or conserved residues of a protein, mutation of critical amino acid positions and loops, and testing of sequences.
- This strategy can be used to design peptides with improved properties or to correct deleterious mutations that complicate folding and manufacturability. These key amino acid positions and loops can be retained while other residues in the peptide sequences can be mutated to improve, change, remove, or otherwise modify function, such as binding or ability to penetrate a cell, endosome, or nucleus in a cell, homing, or another activity of the peptide.
- the present disclosure also encompasses multimers of the various peptides described herein.
- multimers include dimers, trimers, tetramers, pentamers, hexamers, heptamers, and so on.
- a multimer may be a homomer formed from a plurality of identical subunits or a heteromer formed from a plurality of different subunits.
- a peptide of the present disclosure is arranged in a multimeric structure with at least one other peptide, or two, three, four, five, six, seven, eight, nine, ten, or more other peptides.
- the peptides of a multimeric structure each have the same sequence. In alternative embodiments, some or all of the peptides of a multimeric structure have different sequences.
- the present disclosure further includes peptide scaffolds that, e.g., can be used as a starting point for generating additional peptides.
- these scaffolds can be derived from a variety of knotted peptides or knottins.
- Suitable peptides for scaffolds can include, but are not limited to, chlorotoxin, brazzein, circulin, stecrisp, hanatoxin, midkine, hefutoxin, potato carboxypeptidase inhibitor, bubble protein, attractin, ⁇ -GI, ⁇ -GID, ⁇ -PIIIA, ⁇ -MVIIA, ⁇ -CVID, ⁇ -MrIA, ⁇ -TIA, conantokin G, conantokin G, conantokin G, conantokin G, GsMTx4, margatoxin, shK, toxin K, chymotrypsin inhibitor (CTI), and EGF epiregulin core.
- the peptide sequence is flanked by additional amino acids.
- One or more additional amino acids can, for example, confer a desired in vivo charge, isoelectric point, chemical conjugation site, stability, or physiologic property to a peptide.
- a peptide can be chemically modified one or more of a variety of ways.
- the peptide can be mutated to add function, delete function, or modify the in vivo behavior.
- peptides of the presenting disclosure may be chemically modified with a molecule that would lead to proteasomal degradation of TEAD (e.g., ubiquitin ligase engaging conjugate or fusion or cereblon-binding molecule).
- TEAD e.g., ubiquitin ligase engaging conjugate or fusion or cereblon-binding molecule.
- One or more loops between the disulfide linkages can be modified or replaced to include active elements from other peptides (such as described in Moore and Cochran, Methods in Enzymology, 503, p. 223-251, 2012).
- Amino acids can also be mutated, such as to increase half-life, modify, add or delete binding behavior in vivo, add new targeting function, modify surface charge and hydrophobicity, or allow conjugation sites.
- N-methylation is one example of methylation that can occur in a peptide of the disclosure.
- the peptide is modified by methylation on free amines.
- full methylation may be accomplished through the use of reductive methylation with formaldehyde and sodium cyanoborohydride.
- a chemical modification can, for instance, extend the half-life of a peptide or change the biodistribution or pharmacokinetic profile.
- a chemical modification can comprise a polymer, a polyether, polyethylene glycol, a biopolymer, a polyamino acid, a fatty acid, a dendrimer, an Fc region, a simple saturated carbon chain such as palmitate or myristolate, or albumin.
- a polyamino acid can include, for example, a poly amino acid sequence with repeated single amino acids (e.g., poly glycine), and a poly amino acid sequence with mixed poly amino acid sequences (e.g, gly-ala-gly-ala) that may or may not follow a pattern, or any combination of the foregoing.
- the peptides of the present disclosure can be modified such that the modification increases the stability and/or the half-life of the peptides.
- the attachment of a hydrophobic moiety, such as to the N-terminus, the C-terminus, or an internal amino acid, can be used to extend half-life of a peptide of the present disclosure.
- the peptides can also be modified to increase or decrease the gut permeability or cellular permeability of the peptide.
- the peptide of the present disclosure can include post-translational modifications (e.g., methylation and/or amidation and/or glycosylation), which can affect, e.g., serum half-life.
- simple carbon chains can be conjugated to, linked to, the fusion proteins or peptides.
- the simple carbon chains can render the fusion proteins or peptides easily separable from the unconjugated material.
- methods that can be used to separate the fusion proteins or peptides from the unconjugated material include, but are not limited to, solvent extraction and reverse phase chromatography.
- Lipophilic moieties can extend half-life through reversible binding to serum albumin.
- Conjugated moieties can, e.g., be lipophilic moieties that extend half-life of the peptides through reversible binding to serum albumin.
- the lipophilic moiety can be cholesterol or a cholesterol derivative including cholestenes, cholestanes, cholestadienes and oxysterols.
- the peptides can be conjugated to, linked to, myristic acid (tetradecanoic acid) or a derivative thereof.
- the peptides of the present disclosure can be coupled (e.g., conjugated, linked, or fused) to a half-life modifying agent.
- half-life modifying agents can include, but is not limited to: a polymer, a polyethylene glycol (PEG), a hydroxyethyl starch, polyvinyl alcohol, a water soluble polymer, a zwitterionic water soluble polymer, a water soluble poly(amino acid), a water soluble polymer of proline, alanine and serine, a water soluble polymer containing glycine, glutamic acid, and serine, an Fc region, a fatty acid, palmitic acid, or a molecule that binds to albumin.
- PEG polyethylene glycol
- a hydroxyethyl starch polyvinyl alcohol
- a water soluble polymer a zwitterionic water soluble polymer
- a water soluble poly(amino acid) a water soluble poly(amino acid)
- proline a water soluble polymer of proline
- alanine and serine a water soluble polymer
- conjugation of the peptide to a near infrared dye, such as Cy5.5, or to an albumin binder such as Albu-tag can extend serum half-life of any peptide as described herein.
- immunogenicity is reduced by using minimal non-human protein sequences to extend serum half-life of the peptide.
- the first two N-terminal amino acids (GS) of SEQ ID NO: 1-SEQ ID NO: 84 serve as a spacer or linker in order to facilitate conjugation or fusion to another molecule, as well as to facilitate cleavage of the peptide from such conjugated to, linked to, or fused molecules.
- the fusion proteins or peptides of the present disclosure can be conjugated to, linked to, or fused to other moieties that, e.g., can modify or effect changes to the properties of the peptides.
- the peptides of the present disclosure can themselves be used to inhibit YAP binding to TEAD. In other embodiments, peptides of the present disclosure can also be used to deliver another active agent. Peptides according to the present disclosure can be conjugated to, linked to, or fused to an agent for use in the treatment of tumors and cancers. For example, in certain embodiments, the peptides described herein are fused to another molecule, such as an active agent that provides an additional functional capability. A peptide can be fused with an active agent through expression of a vector containing the sequence of the peptide with the sequence of the active agent. In various embodiments, the sequence of the peptide and the sequence of the active agent can be expressed from the same Open Reading Frame (ORF).
- ORF Open Reading Frame
- sequence of the peptide and the sequence of the active agent can comprise a contiguous sequence.
- the peptide and the active agent can each retain similar functional capabilities in the fusion peptide compared with their functional capabilities when expressed separately.
- examples of active agents can include other peptides.
- the peptides described herein are attached to another molecule, such as an active agent that provides a functional capability.
- TEAD-binding peptides can direct the active agent into the cell.
- TEAD-binding peptides can direct the active agent into the nucleus.
- the active agent has intrinsic tumor-homing properties or the active agent can be engineering to have tumor-homing properties.
- 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 active agents can be linked to a peptide.
- Multiple active agents can be attached by methods such as conjugating to multiple lysine residues and/or the N-terminus, or by linking the multiple active agents to a scaffold, such as a polymer or dendrimer and then attaching that agent-scaffold to the peptide (such as described in Yurkovetskiy, A. V., Cancer Res 75(16): 3365-72 (2015)).
- active agents include but are not limited to: a peptide, an oligopeptide, a polypeptide, a peptidomimetic, a polynucleotide, a polyribonucleotide, a DNA, a cDNA, a ssDNA, a RNA, a dsRNA, a micro RNA, an oligonucleotide, an antibody, a single chain variable fragment (scFv), an antibody fragment, an aptamer, a cytokine, an interferon, a hormone, an enzyme, a growth factor, a checkpoint inhibitor, a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA4 inhibitor, a CD antigen, a chemokine, a neurotransmitter, an ion channel inhibitor, an ion channel activator, a G-protein coupled receptor inhibitor, a G-protein coupled receptor activator, a chemical agent, a radiosensitizer, a radioprotect
- the peptide is covalently or non-covalently linked to an active agent, e.g., directly or via a linker.
- cytotoxic molecules that can be used include auristatins, MMAE, MMAF, dolostatin, auristatin F, monomethylaurstatin D, DM1, DM4, maytansinoids, maytansine, calicheamicins, N-acetyl- ⁇ -calicheamicin, pyrrolobenzodiazepines, PBD dimers, doxorubicin, vinca alkaloids (4-deacetylvinblastine), duocarmycins, cyclic octapeptide analogs of mushroom amatoxins, epothilones, and anthracylines, CC-1065, taxanes, paclitaxel, cabazitaxel, docetaxel, SN-38, irinotecan, vincristine, vinblastine, platinum compounds,
- the peptide conjugated to, linked to, or fused to an active agent as described herein can exhibit better penetration of solid tumors due to its smaller size.
- the peptide conjugated to, linked to, or fused to an active agent as described herein can carry different or higher doses of active agents as compared to antibody-drug conjugates.
- the peptide conjugated to, linked to, or fused to an active agent as described herein can have better site specific delivery of defined drug ratio as compared to antibody-drug conjugates.
- the peptide can be amenable to solvation in organic solvents (in addition to water), which can allow more synthetic routes for solvation and conjugation of a drug (which often has low aqueous solubility) and higher conjugation yields, higher ratios of drug conjugated to, linked to, or fused to peptide (versus an antibody), and/or reduce aggregate/high molecular weight species formation during conjugation.
- a unique amino acid residue(s) can be introduced into the peptide via a residue that is not otherwise present in the short sequence or via inclusion of a non-natural amino acid, allowing site specific conjugation to the peptide.
- the peptides or fusion peptides of the present disclosure can also be conjugated to, linked to, or fused to other moieties that can serve other roles, such as providing an affinity handle (e.g., biotin) for retrieval of the peptides from tissues or fluids.
- an affinity handle e.g., biotin
- peptides or fusion peptides of the present disclosure can also be conjugated to, linked to, or fused to biotin.
- biotin can also act as an affinity handle for retrieval of peptides or fusion peptides from tissues or other locations.
- fluorescent biotin conjugates that can act both as a detectable label and an affinity handle can be used.
- Non limiting examples of commercially available fluorescent biotin conjugates can include Atto 425-Biotin, Atto 488-Biotin, Atto 520-Biotin, Atto-550 Biotin, Atto 565-Biotin, Atto 590-Biotin, Atto 610-Biotin, Atto 620-Biotin, Atto 655-Biotin, Atto 680-Biotin, Atto 700-Biotin, Atto 725-Biotin, Atto 740-Biotin, fluorescein biotin, biotin-4-fluorescein, biotin-(5-fluorescein) conjugate, and biotin-B-phycoerythrin, Alexa fluor 488 biocytin, Alexa flour 546, Alexa Fluor 549, lucifer yellow cadaverine biotin-X, Lucifer yellow biocytin, Oregon green 488 biocytin, biotin-rhodamine and tetramethylrho
- the conjugates can include chemiluminescent compounds, colloidal metals, luminescent compounds, enzymes, radioisotopes, and paramagnetic labels.
- the peptide described herein can also be attached to another molecule.
- the peptide sequence also can be attached to another active agent (e.g., small molecule, peptide, polypeptide, polynucleotide, antibody, aptamer, cytokine, growth factor, neurotransmitter, an active fragment or modification of any of the preceding agents, fluorophore, radioisotope, radionuclide chelator, acyl adduct, chemical linker, or sugar).
- the peptide can be conjugated to, linked to, or fused with, or covalently or non-covalently linked to an active agent.
- a peptide sequence derived from a toxin or venom knottin protein can be present on, conjugated to, linked to, or fused with a particular peptide.
- a peptide can be incorporated into a biomolecule by various techniques.
- a peptide can be incorporated by a chemical transformation, such as the formation of a covalent bond, such as an amide bond.
- a peptide can be incorporated, for example, by solid phase or solution phase peptide synthesis.
- a peptide can be incorporated by preparing a nucleic acid sequence encoding the biomolecule, wherein the nucleic acid sequence includes a subsequence that encodes the peptide. The subsequence can be in addition to the sequence that encodes the biomolecule, or can substitute for a subsequence of the sequence that encodes the biomolecule.
- a peptide can be conjugated to, linked to, or fused to an agent used in imaging, research, therapeutics, theranostics, pharmaceuticals, chemotherapy, chelation therapy, targeted drug delivery, and radiotherapy.
- a peptide is conjugated to, linked to, or fused with detectable agents, such as a fluorophore, a near-infrared dye, a contrast agent, a nanoparticle, a metal-containing nanoparticle, a metal chelate, an X-ray contrast agent, a PET agent, a metal, a radioisotope, a dye, radionuclide chelator, or another suitable material that can be used in imaging.
- detectable agents such as a fluorophore, a near-infrared dye, a contrast agent, a nanoparticle, a metal-containing nanoparticle, a metal chelate, an X-ray contrast agent, a PET agent, a metal, a radioisotope, a dye, radion
- 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 detectable agents can be linked to a peptide.
- radioisotopes include alpha emitters, beta emitters, positron emitters, and gamma emitters.
- the metal or radioisotope is selected from the group consisting of actinium, americium, bismuth, cadmium, cesium, cobalt, europium, gadolinium, iridium, lead, lutetium, manganese, palladium, polonium, radium, ruthenium, samarium, strontium, technetium, thallium, and yttrium.
- the metal is actinium, bismuth, lead, radium, strontium, samarium, or yttrium.
- the radioisotope is actinium-225 or lead-212.
- the near-infrared dyes are not easily quenched by biological tissues and fluids.
- the fluorophore is a fluorescent agent emitting electromagnetic radiation at a wavelength between 650 nm and 4000 nm, such emissions being used to detect such agent.
- Non-limiting examples of fluorescent dyes that could be used as a conjugating molecule in the present disclosure include DyLight-680, DyLight-750, VivoTag-750, DyLight-800, IRDye-800, VivoTag-680, Cy5.5, or indocyanine green (ICG).
- near infrared dyes often include cyanine dyes (e.g., Cy7, Cy5.5, and Cy5).
- fluorescent dyes for use as a conjugating molecule in the present disclosure include acradine orange or yellow, Alexa Fluors (e.g., Alexa Fluor 790, 750, 700, 680, 660, and 647) and any derivative thereof, 7-actinomycin D, 8-anilinonaphthalene-1-sulfonic acid, ATTO dye and any derivative thereof, auramine-rhodamine stain and any derivative thereof, bensantrhone, bimane, 9-10-bis(phenylethynyl)anthracene, 5,12-bis(phenylethynyl)naththacene, bisbenzimide, brainbow, calcein, carbodyfluorescein and any derivative thereof, 1-chloro-9,10-bis(phenylethynyl)anthracene and any derivative thereof, DAPI, DiOC6, DyLight Fluors and any derivative thereof, epicocconone, ethidium bromide,
- Suitable fluorescent dyes include, but are not limited to, fluorescein and fluorescein dyes (e.g., fluorescein isothiocyanine or FITC, naphthofluorescein, 4′,5′-dichloro-2′,7′-dimethoxyfluorescein, 6-carboxyfluorescein or FAM, etc.), carbocyanine, merocyanine, styryl dyes, oxonol dyes, phycoerythrin, erythrosin, eosin, rhodamine dyes (e.g., carboxytetramethyl-rhodamine or TAMRA, carboxyrhodamine 6G, carboxy-X-rhodamine (ROX), lissamine rhodamine B, rhodamine 6G, rhodamine Green, rhodamine Red, tetramethylrhodamine (TMR), etc.), cou
- radioisotopes include alpha emitters, beta emitters, positron emitters, and gamma emitters.
- the metal or radioisotope is selected from the group consisting of actinium, americium, bismuth, cadmium, cesium, cobalt, europium, gadolinium, iridium, lead, lutetium, manganese, palladium, polonium, radium, ruthenium, samarium, strontium, technetium, thallium, and yttrium.
- the metal is actinium, bismuth, lead, radium, strontium, samarium, or yttrium.
- the radioisotope is actinium-225 or lead-212.
- Peptides can be conjugated to, linked to, or fused to a radiosensitizer or photosensitizer.
- radiosensitizers include but are not limited to: ABT-263, ABT-199, WEHI-539, paclitaxel, carboplatin, cisplatin, oxaliplatin, gemcitabine, etanidazole, misonidazole, tirapazamine, and nucleic acid base derivatives (e.g., halogenated purines or pyrimidines, such as 5-fluorodeoxyuridine).
- photosensitizers can include but are not limited to: fluorescent molecules or beads that generate heat when illuminated, nanoparticles, porphyrins and porphyrin derivatives (e.g., chlorins, bacteriochlorins, isobacteriochlorins, phthalocyanines, and naphthalocyanines), metalloporphyrins, metallophthalocyanines, angelicins, chalcogenapyrrillium dyes, chlorophylls, coumarins, flavins and related compounds such as alloxazine and riboflavin, fullerenes, pheophorbides, pyropheophorbides, cyanines (e.g., merocyanine 540), pheophytins, sapphyrins, texaphyrins, purpurins, porphycenes, phenothiaziniums, methylene blue derivatives, naphthalimides, nile blue derivatives, a
- this approach can allow for highly specific targeting of diseased cells (e.g., cancer cells) using both a therapeutic agent (e.g., drug) and electromagnetic energy (e.g., radiation or light) concurrently.
- a therapeutic agent e.g., drug
- electromagnetic energy e.g., radiation or light
- the peptide is conjugated to, linked to, fused with, or covalently or non-covalently linked to the agent, e.g., directly or via a linker.
- Exemplary linkers suitable for use with the embodiments herein are discussed in further detail below.
- Peptides according to the present disclosure can be attached to another moiety (e.g., an active agent or an detectable agent), such as a small molecule, a second peptide, a protein, an antibody, an antibody fragment, an aptamer, polypeptide, polynucleotide, a fluorophore, a radioisotope, a radionuclide chelator, a polymer, a biopolymer, a fatty acid, an acyl adduct, a chemical linker, or sugar or other active agent or detectable agent described herein through a linker, or directly in the absence of a linker.
- an active agent or an detectable agent such as a small molecule, a second peptide, a protein, an antibody, an antibody fragment, an aptamer, polypeptide, polynucleotide, a fluorophore, a radioisotope, a radionuclide chelator, a polymer, a biopol
- an active agent or an detectable agent can be conjugated to, linked to, or fused to the N-terminus or the C-terminus of a peptide to create an active agent or detectable agent fusion peptide.
- the link can be made by a peptide fusion via reductive alkylation.
- a cleavable linker is used for in vivo delivery of the peptide, such as a linker that can be cleaved or degraded upon entry in a cell, endosome, or a nucleus.
- in vivo delivery of a peptide requires a small linker that does not interfere with penetration of a cell or localization to a nucleus of a cell.
- a linker can also be used to covalently attach a peptide as described herein to another moiety or molecule having a separate function, such a targeting, cytotoxic, therapeutic, homing, imaging, or diagnostic functions.
- Direct attachment can be through covalent attachment of a peptide to a region of the other molecule.
- an active agent or a detectable agent can be conjugated to, linked to, or fused to the N-terminus or the C-terminus of a peptide to create an active agent or detectable agent fusion peptide.
- the peptide can be attached at the N-terminus, an internal lysine, glutamic acid, or aspartic acid residue, or the C-terminus to a terminus of the amino acid sequence of the other molecule by a linker. If the attachment is at an internal lysine residue, the other molecule can be linked to the peptide at the epsilon amine of the internal lysine residue.
- the peptide can be attached to the other molecule by a side chain, such as the side chain of a lysine, serine, threonine, cysteine, tyrosine, aspartic acid, a non-natural amino acid residue, or glutamic acid residue.
- a side chain such as the side chain of a lysine, serine, threonine, cysteine, tyrosine, aspartic acid, a non-natural amino acid residue, or glutamic acid residue.
- a linker can be an amide bond, an ester bond, an ether bond, a carbamate bond, a carbonate bond, a carbon-nitrogen bond, a triazole, a macrocycle, an oxime bond, a thioester bond, a thioether bond a hydrazone bond, a carbon-carbon single, double, or triple bond, a disulfide bond, a two carbon bridge between two cysteines, a three carbon bridge between two cysteines, or a thioether bond.
- the peptide can comprise a non-natural amino acid, wherein the non-natural amino acid can be an insertion, appendage, or substitution for another amino acid, and the peptide can be linked to the active agent at the non-natural amino acid by a linker.
- similar regions of the disclosed peptide(s) itself can be used to link other molecules.
- an amino acid side chain such as the side chain of a lysine, serine, threonine, cysteine, tyrosine, aspartic acid, a non-natural amino acid residue, or glutamic acid residue
- an amide bond, an ester bond, an ether bond, a carbamate bond, a carbon-nitrogen bond, a triazole, a macrocycle, an oxime bond, a hydrazone bond, a carbon-carbon single, double, or triple bond, a disulfide bond, a thioether bond, or other linker as described herein can be used to link other molecules.
- Attachment via a linker involves incorporation of a linker moiety between the other molecule and the peptide.
- the peptide and the other molecule can both be covalently attached to the linker.
- the linker can be cleavable, non-cleavable, self-immolating, hydrophilic, or hydrophobic.
- the linker has at least two functional groups, one bonded to the other molecule, and one bonded to the peptide, and a linking portion between the two functional groups.
- Non-limiting examples of the functional groups for attachment can include functional groups capable of forming, for example, an amide bond, an ester bond, an ether bond, a carbonate bond, a carbamate bond, a carbon-nitrogen bond, a triazole, a macrocycle, an oxime bond, a hydrazone bond, a carbon-carbon single, double, or triple bond, a disulfide bond or a thioether bond.
- Non-limiting examples of functional groups capable of forming such bonds include amino groups; carboxyl groups; aldehyde groups; azide groups; alkyne and alkene groups; ketones; hydrazides; hydrazines; acid halides such as acid fluorides, chlorides, bromides, and iodides; acid anhydrides, including symmetrical, mixed, and cyclic anhydrides; carbonates; carbonyl functionalities bonded to leaving groups such as cyano, succinimidyl, and N-hydroxysuccinimidyl; maleimides; linkers containing maleimide groups that are designed to hydrolyze; maleimidocaproyl; MCC ([N-maleimidomethyl]cyclohexane-1-carboxylate); N-ethylmaleimide; maleimide alkane; mc-vc-PABC; DUBA (DuocarmycinhydroxyBenzamide-Azaindole linker); SMCC Succinimidyl-4-(N
- Non-limiting examples of the linking portion can include alkylene, alkenylene, alkynylene, polyether, such as polyethylene glycol (PEG), polyester, polyamide, polyamino acids, polypeptides, cleavable peptides, Val-Cit, Phe-Lys, Val-Lys, Val-Ala, other peptide linkers as given in Doronina et al., 2008, linkers cleavable by beta glucuronidase, linkers cleavable by a cathepsin or by cathepsin B, D, E, H, L, S, C, K, O, F, V, X, or W, Val-Cit-p-aminobenzyloxycarbonyl, glucuronide-MABC, aminobenzylcarbamates, D-amino acids, and polyamine, any of which being unsubstituted or substituted with any number of substituents, such as halogens, hydroxyl groups,
- linkers include:
- each n is independently 0 to about 1,000; 1 to about 1,000; 0 to about 500; 1 to about 500; 0 to about 250; 1 to about 250; 0 to about 200; 1 to about 200; 0 to about 150; 1 to about 150; 0 to about 100; 1 to about 100; 0 to about 50; 1 to about 50; 0 to about 40; 1 to about 40; 0 to about 30; 1 to about 30; 0 to about 25; 1 to about 25; 0 to about 20; 1 to about 20; 0 to about 15; 1 to about 15; 0 to about 10; 1 to about 10; 0 to about 5; or 1 to about 5.
- each n is independently 0, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41, about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, or about 50.
- m is 1 to about 1,000; 1 to about 500; 1 to about 250; 1 to about 200; 1 to about 150; 1 to about 100; 1 to about 50; 1 to about 40; 1 to about 30; 1 to about 25; 1 to about 20; 1 to about 15; 1 to about 10; or 1 to about 5.
- m is 0, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41, about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, or about 50, or any linker as disclosed in Jain, N., Pharm Res. 32(11): 3526-40 (2015) or Ducry, L., Antibody Drug Conjugates (2013).
- a linker can be a succinic linker, and a drug can be attached to a peptide via an ester bond or an amide bond with two methylene carbons in between.
- a linker can be any linker with both a hydroxyl group and a carboxylic acid, such as hydroxy hexanoic acid or lactic acid.
- the linker can release the active agent in an unmodified form.
- the active agent can be released with chemical modification.
- catabolism can release the active agent still linked to parts of the linker and/or peptide.
- the linker can be a noncleavable linker or a cleavable linker.
- the noncleavable linker can slowly release the conjugated moiety by an exchange of the conjugated moiety onto the free thiols on serum albumin.
- the use of a cleavable linker can permit release of the conjugated moiety (e.g., a therapeutic agent) from the peptide, e.g., after administration to a subject in need thereof.
- the use of a cleavable linker can permit the release of the conjugated therapeutic from the peptide.
- the linker is enzyme cleavable, e.g., a valine-citrulline linker.
- the linker contains a self-immolating portion.
- the linker includes one or more cleavage sites for a specific protease, such as a cleavage site for matrix metalloproteases (MMPs), thrombin, cathepsins, peptidases, or beta-glucuronidase.
- MMPs matrix metalloproteases
- thrombin cleavage site for matrix metalloproteases
- cathepsins peptidases
- beta-glucuronidase beta-glucuronidase
- the linker is cleavable by other mechanisms, such as via pH, reduction, or hydrolysis.
- the rate of hydrolysis or reduction of the linker can be fine-tuned or modified depending on an application.
- the rate of hydrolysis of linkers with unhindered esters can be faster compared to the hydrolysis of linkers with bulky groups next to an ester carbonyl.
- a bulky group can be a methyl group, an ethyl group, a phenyl group, a ring, or an isopropyl group, or any group that provides steric bulk.
- the steric bulk can be provided by the drug itself, such as by ketorolac when conjugated, linked, or fused via its carboxylic acid.
- the rate of hydrolysis of the linker can be tuned according to the residency time of the conjugate or fusion in the target location.
- the linker when a peptide is cleared from a tumor, or the brain, relatively quickly, the linker can be tuned to rapidly hydrolyze. When a peptide has a longer residence time in the target location, a slower hydrolysis rate would allow for extended delivery of an active agent. “Programmed hydrolysis in designing paclitaxel prodrug for nanocarrier assembly” Sci Rep 2015, 5, 12023 Fu et al., provides an example of modified hydrolysis rates.
- a peptide of the present disclosure can be stable in various biological or physiological conditions, such as the pH or reducing environments inside a cell, in the cytosol, in a cell nucleus, or endosome.
- any peptide of SEQ ID NO: 1-SEQ ID NO: 84 can exhibit resistance to reducing agents, proteases, oxidative conditions, or acidic conditions.
- biologic molecules can provide therapeutic functions, but such therapeutic functions are decreased or impeded by instability caused by the in vivo environment.
- biologic molecules such as peptides and proteins
- the GI tract can contain a region of low pH (e.g.
- protease-rich environment that can degrade peptides and proteins.
- Proteolytic activity in other areas of the body such as the mouth, eye, lung, intranasal cavity, joint, skin, vaginal tract, mucous membranes, and serum, can also be an obstacle to the delivery of functionally active peptides and polypeptides.
- the half-life of peptides in serum can be very short, in part due to proteases, such that the peptide can be degraded too quickly to have a lasting therapeutic effect when administering reasonable dosing regimens.
- proteolytic activity in cellular compartments such as lysosomes and reduction activity in lysosomes and the cytosol can degrade peptides and proteins such that they may be unable to provide a therapeutic function on intracellular targets. Therefore, peptides that are resistant to reducing agents, proteases, and low pH may be able to provide enhanced therapeutic effects or enhance the therapeutic efficacy of co-formulated or conjugated, linked, or fused active agents in vivo.
- oral delivery of drugs can be desirable in order to target certain areas of the body (e.g., disease in the GI tract such as colon cancer, irritable bowel disorder, infections, metabolic disorders, and constipation) despite the obstacles to the delivery of functionally active peptides and polypeptides presented by this method of administration.
- oral delivery of drugs can increase compliance by providing a dosage form that is more convenient for patients to take as compared to parenteral delivery.
- Oral delivery can be useful in treatment regimens that have a large therapeutic window. Therefore, peptides that are resistant to reducing agents, proteases, and low pH can allow for oral delivery of peptides without nullifying their therapeutic function.
- Peptides of this disclosure can contain one or more cysteines, which can participate in disulfide bridges that can be integral to preserving the folded state of the peptide. Exposure of peptides to biological environments with reducing agents can result in unfolding of the peptide and loss of functionality and bioactivity.
- glutathione GSH
- a peptide can become reduced during trafficking of a peptide across the gastrointestinal epithelium after oral administration. A peptide can become reduced upon exposure to various parts of the GI tract.
- the GI tract can be a reducing environment, which can inhibit the ability of therapeutic molecules with disulfide bonds to have optimal therapeutic efficacy, due to reduction of the disulfide bonds.
- a peptide can also be reduced upon entry into a cell, such as after internalization by endosomes or lysosomes or into the cytosol, or other cellular compartments.
- Reduction of the disulfide bonds and unfolding of the peptide can lead to loss of functionality or affect key pharmacokinetic parameters such as bioavailability, peak plasma concentration, bioactivity, and half-life. Reduction of the disulfide bonds can also lead to loss of functionality due to increased susceptibility of the peptide to subsequent degradation by proteases, resulting in rapid loss of intact peptide after administration.
- a peptide that is resistant to reduction can remain intact and can impart a functional activity for a longer period of time in various compartments of the body and in cells, as compared to a peptide that is more readily reduced.
- the peptides of this disclosure can be analyzed for the characteristic of resistance to reducing agents to identify stable peptides.
- the peptides of this disclosure can remain intact after being exposed to different molarities of reducing agents such as 0.00001 M-0.0001 M, 0.0001 M-0.001 M, 0.001 M-0.01 M, 0.01 M-0.05 M, 0.05 M-0.1 M, for 15 minutes or more.
- the reducing agent used to determine peptide stability can be dithiothreitol (DTT), Tris(2-carboxyethyl)phosphine HCl (TCEP), 2-Mercaptoethanol, (reduced) glutathione (GSH), or any combination thereof.
- peptides are completely resistant to GSH reducing conditions and are partially resistant to degradation in DTT reducing conditions. In some embodiments, peptides described herein can withstand or are resistant to degradation in physiological reducing conditions.
- proteases also referred to as peptidases or proteinases, are enzymes that can degrade peptides and proteins by breaking bonds between adjacent amino acids. Families of proteases with specificity for targeting specific amino acids can include serine proteases, cysteine proteases, threonine proteases, aspartic proteases, glutamic proteases, and asparagine proteases. Additionally, metalloproteases, matrix metalloproteases, elastase, carboxypeptidases, Cytochrome P450 enzymes, and cathepsins can also digest peptides and proteins.
- Proteases can be present at high concentration in blood, in mucous membranes, lungs, skin, the GI tract, the mouth, nose, eye, and in compartments of the cell. Misregulation of proteases can also be present in various diseases such as rheumatoid arthritis and other immune disorders. Degradation by proteases can reduce bioavailability, biodistribution, half-life, and bioactivity of therapeutic molecules such that they are unable to perform their therapeutic function. In some embodiments, peptides that are resistant to proteases can better provide therapeutic activity at reasonably tolerated concentrations in vivo.
- peptides of this disclosure can resist degradation by any class of protease.
- peptides of this disclosure resist degradation by pepsin (which can be found in the stomach), trypsin (which can be found in the duodenum), serum proteases, or any combination thereof.
- the proteases used to determine peptide stability can be pepsin, trypsin, chymotrypsin, or any combination thereof.
- peptides of this disclosure can resist degradation by lung proteases (e.g., serine, cysteinyl, and aspartyl proteases, metalloproteases, neutrophil elastase, alpha-1 antitrypsin, secretory leucoprotease inhibitor, and elafin), or any combination thereof.
- lung proteases e.g., serine, cysteinyl, and aspartyl proteases, metalloproteases, neutrophil elastase, alpha-1 antitrypsin, secretory leucoprotease inhibitor, and elafin
- Peptides of this disclosure can be administered in biological environments that are acidic.
- peptides can experience acidic environmental conditions in the gastric fluids of the stomach and gastrointestinal (GI) tract.
- the pH of the stomach can range from about 1-4 and the pH of the GI tract ranges from acidic to normal physiological pH descending from the upper GI tract to the colon.
- the vagina, late endosomes, and lysosomes can also have acidic pH values, such as less than pH 7. These acidic conditions can lead to denaturation of peptides and proteins into unfolded states. Unfolding of peptides and proteins can lead to increased susceptibility to subsequent digestion by other enzymes as well as loss of biological activity of the peptide.
- the peptides of this disclosure can resist denaturation and degradation in acidic conditions and in buffers, which simulate acidic conditions.
- peptides of this disclosure can resist denaturation or degradation in buffer with a pH less than 1, a pH less than 2, a pH less than 3, a pH less than 4, a pH less than 5, a pH less than 6, a pH less than 7, or a pH less than 8.
- peptides of this disclosure remain intact at a pH of 1-3.
- the peptides of this disclosure can be resistant to denaturation or degradation in simulated gastric fluid (pH 1-2).
- low pH solutions such as simulated gastric fluid can be used to determine peptide stability.
- the peptides described herein are resistant to degradation in vivo, in the serum of a subject, or inside a cell.
- the peptides are stable at physiological pH ranges, such as about pH 7, about pH 7.5, between about pH 5 to 7.5, between about 6.5 to 7.5, between about pH 5 to 8, or between about pH 5 to 7.
- the peptides described herein are stable in acidic conditions, such as less than or equal to about pH 5, less than or equal to about pH 3, or within a range from about 3 to about 5.
- the peptides are stable in conditions of an endosome or lysosome, or inside a nucleus.
- Peptides of this disclosure can be administered in biological environments with high temperatures.
- peptides can experience high temperatures in the body.
- Body temperature can range from 36° C. to 40° C.
- High temperatures can lead to denaturation of peptides and proteins into unfolded states. Unfolding of peptides and proteins can lead to increased susceptibility to subsequent digestion by other enzymes as well as loss of biological activity of the peptide.
- a peptide of this disclosure can remain intact at temperatures from 25° C. to 100° C. High temperatures can lead to faster degradation of peptides. Stability at a higher temperature can allow for storage of the peptide in tropical environments or areas where access to refrigeration is limited.
- 5%-100% of the peptide can remain intact after exposure to 25° C. for 6 months to 5 years. 5%-100% of a peptide can remain intact after exposure to 70° C. for 15 minutes to 1 hour. 5%-100% of a peptide can remain intact after exposure to 100° C. for 15 minutes to 1 hour. In other embodiments, at least 5%-10%, at least 10%-20%, at least 20%-30%, at least 30%-40%, at least 40%-50%, at least 50%-60%, at least 60%-70%, at least 70%-80%, at least 80%-90%, or at least 90%-100% of the peptide remains intact after exposure to 25° C. for at least 6 months to 5 years.
- At least 5%-10%, at least 10%-20%, at least 20%-30%, at least 30%-40%, at least 40%-50%, at least 50%-60%, at least 60%-70%, at least 70%-80%, at least 80%-90%, or at least 90%-100% of the peptide remains intact after exposure to 70° C. for 15 minutes to 1 hour.
- sequences from the peptide library generated from computational design can be synthesized using expression vectors or solid phase or solution phase peptide synthesis methods.
- TEAD-binding peptides, or peptides, and Siderocalin-YAP can be cloned into a secreted, soluble protein production/expression vector and purified, as per Bannesayake et al., 2011.
- Purification methods include, but are not limited to, affinity purification columns, ion exchange (cation and/or anion columns), reversed-phase, hydrophobic interaction, and size exchange columns.
- SDS-PAGE followed by Coomassie staining and reverse phase HPLC can be used to analyze a sample of the purified protein. Protein concentrations were determined by UV spectral absorption and/or amino acid analysis.
- surface display vectors can be used to clone and express recombinant peptides as described herein.
- Peptides can be cloned or expressed with a modified coding sequence and without an IRES-GFP.
- the coding sequence of the vector comprises: GFP; the transmembrane domain of the single pass Type II transmembrane protein FASLG (human Fas ligand); a poly-GGGS spacer (SEQ ID NO: 203); a 9-residue bovine rhodopsin antigen; a poly-GGGS spacer (SEQ ID NO: 203); a TEV-cleavage site, including a GS-linker; the displayed peptide; and for SDPR only, a 6 ⁇ His tag (SEQ ID NO: 284).
- the entire construct in some embodiments, can be cloned with lentiviral LTRs, and introduced to cells by transient transfection or transduction.
- Peptide sequences can be inserted between unique BamHI and NotI cut sites for SDGF vector, or between unique BamHI and AgeI cut sites for SDPR.
- SDGF vascular endothelial growth factor
- SDPR construct a number of standard cloning strategies can be used to insert a desired coding sequence, including restriction digestion (BamHI and NotI, NEB; T4 DNA Ligase, Invitrogen), In-Fusion (Clontech), or Gibson Assembly (NEB), with all transformations using Stellar chemically competent cells (Clontech), or electrocompetent cells (NEB 10-beta cells), transformed by electroporation.
- restriction digestion BamHI and NotI, NEB; T4 DNA Ligase, Invitrogen
- In-Fusion Clontech
- Gibson Assembly NEB
- DNA can be PCR-amplified using exemplary primers such as: SDGF Forward primer: TGTACTTCCAGGGAGGATCC (SEQ ID NO: 213); SDGF Reverse primer: AATGGTGATGAGCGGCC (SEQ ID NO: 214); SDPR Forward primer: CCAGCAGGAGGTGGAAGCG (SEQ ID NO: 215); SDPR Reverse primer: ATGATGGTGATGATGGTGAGATCCTC (SEQ ID NO: 216).
- SDGF Forward primer TGTACTTCCAGGGAGGATCC (SEQ ID NO: 213)
- SDGF Reverse primer AATGGTGATGAGCGGCC (SEQ ID NO: 214)
- SDPR Forward primer CCAGCAGGAGGTGGAAGCG (SEQ ID NO: 215)
- SDPR Reverse primer ATGATGGTGATGATGGTGAGATCCTC (SEQ ID NO: 216).
- Validation of peptides or single candidates for binding to TEAD can be validated using a suspension of HEK-293 cells.
- cells are transfected with 2.5 ⁇ g SDGF vector comprising a putative or candidate peptide and 3.5 ⁇ g polyethyleneimine to 2E6 cells in 1 mL media, in a 24-well suspension tissue culture dish. After incubation of cells, all pooled screening can be performed in 293T cells transduced with lentivirus (VSV-G coated, produced by standard methods in 293T cells), delivering the SDGF construct, at an MOI of approximately 1, or up to 5.
- lentivirus VSV-G coated, produced by standard methods in 293T cells
- Transduced or transfected suspension HEK-293 cells can be pelleted (500 ⁇ g, 5 min) and resuspended at up to 8E6 cells/mL in Flow Buffer (PBS with 0.5% BSA and 2 mM EDTA) containing DAPI and target protein, with or without Alexa Fluor 647-conjugated streptavidin (ThermoFisher) in equimolar quantity to the target protein. All staining incubations took place at 4 C for 30 mins with mild agitation. For the low stringency protocol (initial assay validation and pooled screening), 200 nM target protein can be used, and streptavidin can be pre-mixed with target protein.
- Flow Buffer PBS with 0.5% BSA and 2 mM EDTA
- Alexa Fluor 647-conjugated streptavidin ThermoFisher
- Cells can be incubated, diluted 10-fold with Flow Buffer, pelleted (500 ⁇ g, 5 min), and resuspended in fresh Flow Buffer (up to 6.5E6 cells/mL) before flow cytometry.
- SSM maturation only 20 nM target protein can be used, and cells can be incubated with target protein alone, diluted 10-fold with Flow Buffer, pelleted, and then resuspended with 20 nM streptavidin. Cells were incubated again, diluted 10-fold with Flow Buffer, pelleted (500 ⁇ g, 5 min), and resuspended in fresh Flow Buffer (up to 6.5E6 cells/mL) before flow cytometry.
- the high stringency protocol is identical to the medium stringency protocol, except that an additional Flow Buffer-only wash step is included immediately after target protein staining.
- flow sorting is performed on a Beckton-Dickinson Aria II, while analysis is performed on a combination of Beckton-Dickson LSR II and Acea NovoCyte flow cytometers. Data analysis can be performed on FlowJo (FlowJo, LLC) and Excel (Microsoft).
- SDPR protease resistance testing can be used with sequencing-grade enzymes, including Trypsin and Chymotrypsin. Trypsin and trypsin inhibitor can be used for HPLC analysis.
- screens for enrichment or depletion of variants affecting TEAD binding can be assessed by Illumina sequencing.
- Illumina sequencing method involves collecting cell pellets (1.5E6, 3 technical replicates) resuspended in 50 ⁇ L Terra Direct PCR Mix (from Clontech) and amplified for 16 cycles using the original cloning primers. Up to four aliquots can be diluted 16-fold into 60 ⁇ L Phusion DNA Polymerase reactions and amplified using distinct Illumina primers, containing adaptor sequences for flow cell adherence. Forward primers can include a 6 bp barcode for multiplexing.
- Illumina HiSeq 2500 in rapid mode can be used to run samples, which Bowtie2 software can be used for mapping, and Excel (Microsoft) and MATLAB (MathWorks) used for data analysis.
- in vitro assays are used to analyze candidate peptides for ability to inhibit or interfere with YAP-TEAD interaction, or ability to bind to TEAD and thereby sequester TEAD from interaction with YAP.
- biotinylated, His-Avi-TEAD(194-411) can be expressed in Hi5 insect cells using the BacMagic system (EMD Millipore), as per manufacturer protocols.
- the transgene can be cloned into the pIEX-BAC3 vector and then cotransfected with BacMagic-3 DNA (100 ⁇ g vector, 1 ⁇ L BacMagic-3) using calfectin II into Sf9 cells in a 12-well dish.
- Baculovirus encoding His-Avi-TEAD can be amplified in Sf9 cells, and viral supernatant (5 mL) can be used to transduce 2.5E8 Hi5 cells in 250 mL Express Five media supplemented with L-glutamine. Transduced cells can be grown for 72 hrs (expanding to 500 mL) at 27° C. and 140 RPM before collecting the cell pellets for analysis.
- cells can be pelleted (2000 ⁇ g, 10 min) and resuspended in I-PER buffer (Invitrogen) containing protease inhibitor cocktail (ThermoFisher), benzonase at 1:10,000 (Millipore), 0.5 mM TCEP, and 20 mM imidazole. Lysate can be clarified (10,000 ⁇ g, 30 min), using nickel NTA resin to purify GST-TEAD. Protein can be buffer exchanged (Zeba spin columns, 5 mL capacity) into thrombin cleavage buffer (25 mM Tris pH 8.4, 150 mM NaCl, 0.1% Triton X100, 10% glycerol, 2.5 mM CaCl2)).
- TEAD can be re-purified on nickel resin and then by FPLC on a Superdex 200 10/300 GL size exclusion chromatography (SEC) column (GE Healthsciences).
- SEC running buffer can contain 10 mM phosphate buffer pH 7.2, 50 mM NaCl, 0.5 mM TCEP.
- Purified TEAD can be biotinylated using the BirA-500 kit (Avidity) as per manufacturer's protocol, followed by a final buffer exchange into PBS containing 5% glycerol, and storage in small aliquots at ⁇ 80° C.
- screening peptides or a library of peptides involves labeling of a protein of interest or a protein partner with a fluorophore or any other detectable moiety, such that detection of a signal from the fluorophore or detectable moiety is indicative of binding to the peptide.
- a fluorophore that can be used is Alexa Fluor 647 NHS Ester (Life Technologies), which can be used to label a protein of interest or a protein partner, such as TEAD or YAP, as per manufacturer's protocol. Saturation is approximately 1 fluorophore per molecule, as determined by spectrometry.
- TEAD binding can be assessed using surface plasmon resonance.
- YAP is unstable and precipitates if cleaved from siderocalin, such that it is used as a fusion protein for SPR validation of TEAD-binding. All other peptides are TEV-cleavable and can be analyzed as independent, soluble proteins.
- biotinylated TEAD is injected over a flow cell at a specified rate to capture ⁇ 300 resonance units (RUs).
- a reference surface is generated by capturing a molar equivalent of biotinylated human transferrin receptor ectodomain.
- serial two-fold dilutions can be prepared in running buffer at concentration ranges that cover the span of each peptide's dissociation constant (K D ).
- Duplicate samples, interspersed with multiple buffer blanks, can be randomly injected for further testing. Regeneration can be accomplished with buffer flow alone. Double-referenced data can fit with either a 1:1 affinity or kinetics binding model using BIAevaluation 2.0.4 software (GE Healthcare).
- Two samples, SEQ ID NO: 9 and SEQ ID NO: 10 (with GS at the N-terminus), or SEQ ID NO: 51 and SEQ ID NO: 52 (without GS at the N-terminus), can be performed using a single cycle kinetics protocol in the T100 Control 2.0.4 software.
- Serial 3-fold dilutions (3.6 nM to 0.044 nM) of these peptides can be prepared in running buffer and injected at increasing concentration order with 7 minutes of injection time and 15 minutes dissociation.
- Two buffer blank cycles for referencing can be run prior to analyte injection and one buffer blank cycle followed which allowed time for complete analyte dissociation prior to the next analyte injection.
- Double-referenced data were fit with the 1:1 binding model for single cycle kinetics using BIAevaluation 2.0.4 software (GE Healthcare). Figures were made in Prism 7 (GraphPad) for Mac OS X version 7.0a.
- 293T cells can be transfected with either Myc-tagged TEAD expression plasmid pRK5-Myc-TEAD1 or the FLAG-tagged YAP expression plasmid pFLAG-YAP1. After 2 days of growth, cells are lysed with RIPA buffer (ThermoFisher), and lysates are used as follows: 125 ⁇ L aliquots of anti-Myc agarose resin (Sigma) can be prepared and used to pull down Myc-TEAD from Myc-TEAD-transfected cell lysate.
- RIPA buffer ThermoFisher
- TEAD-bound beads are then incubated for 30 min at 4 C with 50 ⁇ L FLAG-YAP-transfected cell lysate, which is pre-mixed with competitive TEAD-binding peptides, in a final volume of 100 ⁇ L. Resin is then washed twice with 500 ⁇ L PBS, and then resuspended in 20 ⁇ L 2 ⁇ LDS sample buffer. Beads are then boiled before analyzing the sample using SDS-PAGE and either silver stain or Western Blot using anti-FLAG M2, Sigma, at 1:2000 and/or anti-Myc tag antibody, Abcam, at 1:2000; LiCor secondary antibodies at 1:10,000.
- peptides or peptides, with varying affinity for TEAD.
- Peptides that bind TEAD make TEAD unavailable for binding to YAP, thus inhibiting the YAP-TEAD interaction.
- the input topology parameters used for scaffold construction can be as follows: minimum and maximum sequence length: 30 and 41 residues, respectively; secondary structure types: helix, helix, helix; secondary structure length ranges: 6-18 residues; turn lengths: 2-4 residues; number of disulfides: 3; disulfide topology: H1-H2, H1-H3, and H2-H3.
- minimum and maximum sequence length 30 and 41 residues, respectively
- secondary structure types helix, helix, helix
- secondary structure length ranges 6-18 residues
- turn lengths 2-4 residues
- number of disulfides 3
- disulfide topology H1-H2, H1-H3, and H2-H3.
- helix and turn lengths can be sampled randomly from the corresponding length ranges, fixing the secondary structure of the design, which can then be used to select backbone fragments for a low-resolution fragment assembly simulation.
- the protein backbone can be scanned for residue pairs that could be linked by disulfide connections using a library of N—Ca-C backbone transforms derived from disulfide bonds in the protein structure database.
- Backbones with matching residue pairs that satisfied the disulfide topology constraints can be used to initiate an all-atom sequence design simulation consisting of two cycles of alternating fixed-backbone sequence design and fixed-sequence structure relaxation.
- Final designs can be filtered for packing (sasapack score ⁇ 0.5), satisfaction of buried polar groups (using a 1.0 A probe radius), and sorted by energy per residue.
- the top 10% of the filtered designs can be assessed for sequence-structure compatibility by an in silico refolding test in which the design sequence can be used to initiate 3000 independent structure prediction simulations. Success can be measured by assessing the fraction of low-energy structure prediction models within 2 ⁇ C ⁇ -RMSD of the design model.
- the crystal structure of the YAP-TEAD complex (PDB ID 3KYS) can be examined to identify binding patches on TEAD and corresponding backbone elements on YAP to serve as templates for interface design.
- the following backbone residue segments can be selected as superposition targets for orienting design scaffolds: 3KYS/B/53-55, 3KYS/B/55-57, 3KYS/B/64-68, 3KYS/B/64-69, 3KYS/B/86-89, 3KYS/B/94-96 (given as: PDB ID/chain/residue numbers).
- design simulations can be conducted targeting each YAP backbone segment selected for superposition.
- Each design simulation can consist of the following steps: (1) superimposing the scaffold backbone onto the YAP backbone segment using a scaffold backbone element with matching secondary structure, (2) random small perturbations to generate diversity and relieve backbone clashes, (3) all-atom sequence design alternating between fixed-backbone sequence selection and fixed-sequence structure relaxation.
- Final interface designs were filtered for satisfaction of polar groups (using a 1.0 A probe radius), interface surface complementarity (sc score>0.5), and interface quality (predicted binding energy per 100 ⁇ of buried SASA ⁇ 1.1), and sorted by predicted binding energy.
- Top-scoring designs can be assessed by an in silico redocking test in which the redesigned scaffold peptide can be removed from TEAD, randomly reoriented, and redocked onto the TEAD protein structure. Success can be measured as the fraction of low-energy redocking simulations that reached a final state close to the designed interface conformation.
- Protein secondary structures can be assessed using Circular Dichrosim (CD).
- CD spectra can be measured with a Jasco J-720W spectropolarimeter using a 1.0 mm path length cell.
- Samples can be analyzed at wavelength ranges of 260-190 nM.
- Data can be expressed in terms of relative ellipticity [ ⁇ ]; (mdeg).
- samples can be subjected to incremental increase in temperature at a ramp of 2° C./min from 20° C. to 95° C. Stability and protein unfolding were monitored at 220 and 215 for ⁇ -helix and ⁇ -sheet secondary structures, respectively.
- Data can be expressed in terms of relative ellipticity [ ⁇ ], reported in mdeg.
- Protein melting temperature (Tm) determination can be performed by monitoring protein unfolding using SYPRO Orange dye (Molecular Probes).
- SYPRO Orange dye Molecular Probes
- 0.1 mg/mL protein sample in 20 ⁇ L total volume PBS buffer can be mixed with 2 ⁇ L of 10 ⁇ SYPRO Orange dye.
- Dye intercalation into the hydrophobic protein core following protein unfolding was assayed using the C1000 Touch Thermal Cycler with CFX96 Deep Well Real-Time System (BioRad). Samples were heated from 20° C. to 95° C. with stepwise increments of 0.5° C. per minute and a 5 see hold step for every point, followed by fluorescence reading. Tm were calculated by analyzing the derivatives of Relative florescence Units (RFU).
- REU Relative florescence Units
- Peptides FLAG-tagged or not, can be cloned into a mammalian expression vector consisting of a CMV promoter, then a monocistronic mCherry-T2a-peptide sequence. These can be transfected, along with (where indicated) pFLAG-YAP1 and 8 ⁇ GTIIC-luciferase (Addgene plasmid #34615) into 293T cells. 24 hrs post-transfection, cells can be either harvested for luminescence (ONE-Glo, Promega) or Western blot (anti-FLAG M2, Sigma).
- Peptides as disclosed herein can be fluoresceinated with DyLight 488 NHS-ester (ThermoFisher), with final dye:peptide labeling ratios between 0.8 and 1.4 as assessed by A280 and A488 on a Nanodrop spectrometer (Thermo Scientific).
- DyLight 488 NHS-ester ThermoFisher
- N-drop spectrometer Thermo Scientific
- 293T and HeLa cells can be plated in a 96-well plate in DMEM with 10% FBS, 1 ⁇ penicillin/streptomycin (Pen/Strep) and grown overnight to ⁇ 50% confluence.
- Cells can be gently washed 3 times with PBS containing 1 mM CaCl 2 ) and 0.5 mM MgCl 2 , then 2 times in serum-free DMEM.
- Wells 50 ⁇ L total) received either 5 ⁇ M (final) peptide in PBS, or PBS alone, and can also receive either 5 ⁇ M (final) dfTAT reagent in PBS, or PBS alone, before a 60 minute incubation at 37° C. and 5% CO 2 in a humidified tissue culture incubator. After incubation, cells can be gently washed 3 times in PBS, which can be followed by fixation at 4° C. for 10 minutes with 4% formaldehyde in PBS.
- TEAD-binding peptides can use any peptide as disclosed herein, and can be a 1:1 mix of unaltered peptide and peptide reacted with DyLight 488 NHS-ester, as above.
- HeLa cells can be seeded in an 8-well chamber slide (Nunc Lab-Tek II) in DMEM+10% FBS and 1 ⁇ Pen/Strep, and can be grown overnight, reaching ⁇ 50% confluence. Cells can be gently washed 3 times with PBS containing 1 mM CaCl 2 and 0.5 mM MgCl 2 , then 2 times in serum-free DMEM.
- Wells (120 ⁇ L total) can receive either 5 ⁇ M (final) peptide in PBS, or PBS alone, and can also receive either 5 ⁇ M (final) dfTAT reagent in PBS, or PBS alone, before a 90 minute incubation at 37° C. and 5% CO 2 in a humidified tissue culture incubator. After incubation, cells can be gently washed 3 times in PBS, followed by fixation at 4° C. for 10 minutes with 4% formaldehyde in PBS. Fixed samples can be washed 3 times with cold PBS, then can be permeabilized at room temperature for 10 minutes with 0.25% Triton X-100 in PBS. Samples can be rinsed three more times in PBS prior to proximity ligation assay (PLA).
- PPA proximity ligation assay
- PLA can be performed using the Duolink In Situ Fluorescence (Far Red) kit according to manufacturer's instructions, using supplied buffers without substitution and at recommended volumes for 1 cm 2 samples. All incubations can take place at 37° C. in a humidified chamber. Samples can be blocked for 30 minutes, which can be followed by incubation for 1 hour with primary antibodies against human YAP (1:100 rabbit anti-YAP1, AbCam catalog number ab52771) and/or human TEAD (1:200 mouse anti-TEF-1, BD Biosciences catalog number 610923). Samples can be washed twice (well dividers can be removed after these washes, and further washes can take place in a Coplin jar), and then ligation can be performed for 30 minutes.
- Far Red Duolink In Situ Fluorescence
- samples can be washed twice prior to the 100 minute amplification reaction.
- the slide can then be washed, briefly dried, and mounted with supplied mounting media and a coverslip.
- Imaging can take place on a DeltaVision Elite (GE) with a 40 ⁇ objective, and complete Z-stacks can be acquired and deconvolved.
- UV and Cy5.5 filtered images can be Z-projected (maximum intensity), and can be processed using a custom macro to identify nuclear boundaries (UV channel) and speckles (Cy5.5 channel).
- Overlap and speckle counting can be automated used the Biovoxxel toolbox (Brocher, 2015) with the Speckle Inspector tool. Plots, confidence intervals, and significance calculations can be produced in Prism 7 (GraphPad).
- Various expression vector/host systems can be utilized for the recombinant expression of peptides described herein.
- Non-limiting examples of such systems include microorganisms such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing a nucleic acid sequence encoding peptides or peptide fusion proteins/chimeric proteins described herein, yeast transformed with recombinant yeast expression vectors containing the aforementioned nucleic acid sequence, insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the aforementioned nucleic acid sequence, plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus (CaMV), tobacco mosaic virus (TMV)), or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing the aforementioned nucleic acid sequence, or animal cell systems infected with re
- a host cell can be adapted to express one or more peptides described herein.
- the host cells can be prokaryotic, eukaryotic, or insect cells.
- host cells are capable of modulating the expression of the inserted sequences, or modifying and processing the gene or protein product in the specific fashion desired. For example, expression from certain promoters can be elevated in the presence of certain inducers (e.g., zinc and cadmium ions for metallothionine promoters).
- inducers e.g., zinc and cadmium ions for metallothionine promoters.
- modifications e.g., phosphorylation
- processing e.g., cleavage
- Host cells can have characteristic and specific mechanisms for the post-translational processing and modification of a peptide.
- the host cells used to express the peptides secrete minimal amounts of proteolytic enzymes.
- organisms can be treated prior to purification to preserve and/or release a target polypeptide.
- the cells are fixed using a fixing agent.
- the cells are lysed.
- the cellular material can be treated in a manner that does not disrupt a significant proportion of cells, but which removes proteins from the surface of the cellular material, and/or from the interstices between cells.
- cellular material can be soaked in a liquid buffer, or, in the case of plant material, can be subjected to a vacuum, in order to remove proteins located in the intercellular spaces and/or in the plant cell wall. If the cellular material is a microorganism, proteins can be extracted from the microorganism culture medium.
- the peptides can be packed in inclusion bodies.
- the inclusion bodies can further be separated from the cellular components in the medium.
- the cells are not disrupted.
- a cellular or viral peptide that is presented by a cell or virus can be used for the attachment and/or purification of intact cells or viral particles.
- peptides can also be synthesized in a cell-free system prior to extraction using a variety of known techniques employed in protein and peptide synthesis.
- a host cell produces a peptide that has an attachment point for a drug.
- An attachment point could comprise a lysine residue, an N-terminus, a cysteine residue, a cysteine disulfide bond, a glutamic acid or aspartic acid residue, a C-terminus, or a non-natural amino acid.
- the peptide could also be produced synthetically, such as by solid-phase peptide synthesis, or solution-phase peptide synthesis. Peptide synthesis can be performed by fluorenylmethyloxycarbonyl (Fmoc) chemistry or by butyloxycarbonyl (Boc) chemistry.
- the peptide could be folded (formation of disulfide bonds) during synthesis or after synthesis or both.
- Peptide fragments could be produced synthetically or recombinantly. Peptide fragments can be then be joined together enzymatically or synthetically.
- the peptides of the present disclosure can be prepared by conventional solid phase chemical synthesis techniques, for example according to the Fmoc solid phase peptide synthesis method (“Fmoc solid phase peptide synthesis, a practical approach,” edited by W. C. Chan and P. D. White, Oxford University Press, 2000).
- the peptides of this disclosure can be more stable during manufacturing.
- peptides of this disclosure can be more stable during recombinant expression and purification, resulting in lower rates of degradation by proteases that are present in the manufacturing process, a higher purity of peptide, a higher yield of peptide, or any combination thereof.
- the peptides can also be more stable to degradation at high temperatures and low temperatures during manufacturing, storage, and distribution.
- peptides of this disclosure can be stable at 25° C.
- peptides of this disclosure can be stable at 70° C. or higher than 70° C.
- peptides of this disclosure can be stable at 100° C. or higher than 100° C.
- a pharmaceutical composition of the disclosure can be a combination of any peptide as described herein with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, antioxidants, solubilizers, buffers, osmolytes, salts, surfactants, amino acids, encapsulating agents, bulking agents, cryoprotectants, and/or excipients.
- the pharmaceutical composition facilitates administration of a peptide described herein to an organism.
- the pharmaceutical composition comprises factors that extend half-life of the peptide and/or help the peptide to penetrate the target cells.
- compositions can be administered in therapeutically-effective amounts as pharmaceutical compositions by various forms and routes including, for example, intravenous, subcutaneous, intramuscular, rectal, aerosol, parenteral, ophthalmic, pulmonary, transdermal, vaginal, optic, nasal, oral, sublingual, inhalation, dermal, intrathecal, intratumoral, intranasal, and topical administration.
- a pharmaceutical composition can be administered in a local or systemic manner, for example, via injection of the peptide described herein directly into an organ, optionally in a depot.
- Parenteral injections can be formulated for bolus injection or continuous infusion.
- the pharmaceutical compositions can be in a form suitable for parenteral injection as a sterile suspension, solution or emulsion in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- Pharmaceutical formulations for parenteral administration include aqueous solutions of a peptide described herein in water-soluble form.
- Suspensions of peptide-antibody complexes described herein can be prepared as oily injection suspensions.
- Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
- Aqueous injection suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
- the suspension can also contain suitable stabilizers or agents which increase the solubility and/or reduce the aggregation of such peptide-antibody complexes described herein to allow for the preparation of highly concentrated solutions.
- Formulations or approaches to increase cell penetration or a peptide as describe herein can include, but not limited to, using high dosage of a peptide as described herein, such as up to 10 ⁇ M; conjugating or fusing a Tat peptide or a cell-penetrating peptide, or a variant or derivative thereof to a peptide; co-delivering a Tat peptide or a cell-penetrating peptide, or a variant or derivative thereof with a peptide; conjugating or fusing an Arg patch to a peptide; or co-delivering a peptide with an Arg patch peptide, such as up to 10 ⁇ M.
- protein transfection agents direct cytosolic expression of the peptide, or electrophoration of the peptide can be used to increase cell penetration.
- other excipients can be formulated with a peptide in order to increase the cell penetration of the peptide, such as those approaches described in “Protein and Peptide Drug Delivery: Oral Approaches” Indian J. Pharm. Sci., Shaji and Patole, v70(3) 269-277, 2008. Any combination of these formulations or approaches can be used to increase cell penetration of a peptide as described herein.
- the peptide described herein can be lyophilized or in powder form for re-constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- a purified peptide is administered intravenously.
- a peptide described herein can be administered to a subject, home, target, migrate to, or be directed to cancerous cell, a tumor, or a cell with dysregulated HIPPO pathway.
- a peptide can be conjugated to, linked to, or fused to another peptide that provides a targeting function to a specific target cell type in the central nervous system or across the blood brain barrier.
- a peptide of the disclosure can be applied directly to an organ, or an organ tissue or cells, such as brain or brain tissue or cells, during a surgical procedure.
- the recombinant peptide described herein can be administered topically and can be formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams, and ointments.
- Such pharmaceutical compositions can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
- therapeutically-effective amounts of a peptide described herein can be administered in pharmaceutical compositions to a subject suffering from a condition that affects the immune system.
- the subject is a mammal such as a human or a primate.
- a therapeutically-effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compounds used, and other factors.
- a peptide is cloned into a viral or non-viral expression vector.
- Such expression vector can be packaged in a viral particle, a virion, or a non-viral carrier or delivery mechanism, which is administered to patients in the form of gene therapy.
- patient cells are extracted and modified to express a peptide capable of inhibiting YAP-TEAD interaction ex vivo before the modified cells are returned back to the patient in the form of a cell-based therapy, such that the modified cells will express the peptide once transplanted back in the patient.
- compositions can be formulated using one or more physiologically-acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compounds into preparations that can be used pharmaceutically. Formulation can be modified depending upon the route of administration chosen.
- Pharmaceutical compositions comprising a peptide described herein can be manufactured, for example, by expressing the peptide in a recombinant system, purifying the peptide, lyophilizing the peptide, mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or compression processes.
- the pharmaceutical compositions can include at least one pharmaceutically acceptable carrier, diluent, or excipient and compounds described herein as free-base or pharmaceutically-acceptable salt form.
- Methods for the preparation of peptide described herein comprising the compounds described herein include formulating peptide described herein with one or more inert, pharmaceutically-acceptable excipients or carriers to form a solid, semi-solid, or liquid composition.
- Solid compositions include, for example, powders, tablets, dispersible granules, capsules, cachets, and suppositories. These compositions can also contain minor amounts of nontoxic, auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and other pharmaceutically-acceptable additives.
- Non-limiting examples of pharmaceutically-acceptable excipients can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. 1975; Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999), each of which is incorporated by reference in its entirety.
- compositions can also include permeation or absorption enhancers (Aungst et al. AAPS J. 14(1):10-8. (2012) and Moroz et al. Adv Drug Deliv Rev 101:108-21. (2016)).
- Permeation enhancers can facilitate uptake of molecules from the GI tract into systemic circulation.
- Permeation enhancers can include salts of medium chain fatty acids, sodium caprate, sodium caprylate, N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC), N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), hydrophilic aromatic alcohols such as phenoxyethanol, benzyl alcohol, and phenyl alcohol, chitosan, alkyl glycosides, dodecyl-2-N,N-dimethylamino propionate (DDAIPP), chelators of divalent cations including EDTA, EGTA, and citric acid, sodium alkyl sulfate, sodium salicylate, lecithin-based, or bile salt-derived agents such as deoxycholates,
- SNAC N-(8-[2-hydroxybenzoyl]amino)caprylic acid
- 5-CNAC N-(5-chlorosalicyloyl)-8
- Compositions can also include protease inhibitors including soy bean trypsin inhibitor, aprotinin, sodium glycocholate, camostat mesilate, vacitracin, or cyclopentadecalactone,
- protease inhibitors including soy bean trypsin inhibitor, aprotinin, sodium glycocholate, camostat mesilate, vacitracin, or cyclopentadecalactone
- the method includes administering an effective amount of a peptide as described herein to a subject in need thereof.
- the method includes administering an effective amount of a peptide as described herein to a subject in need thereof.
- an effective amount refers to a sufficient amount of an agent or a compound being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.
- Compositions containing such agents or compounds can be administered for prophylactic, enhancing, and/or therapeutic treatments.
- An appropriate “effective” amount in any individual case may be determined using techniques, such as a dose escalation study.
- the methods, compositions, and kits of this disclosure may comprise a method to prevent, treat, arrest, reverse, or ameliorate the symptoms of a condition.
- the treatment may comprise treating a subject (e.g., an individual, a domestic animal, a wild animal, or a lab animal afflicted with a disease or condition) with a peptide of the disclosure.
- the disease may be a cancer or tumor.
- the peptide may contact the tumor or cancerous cells.
- the subject may be a human.
- Subjects can be humans; non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like.
- a subject can be of any age.
- Subjects can be, for example, elderly adults, adults, adolescents, pre-adolescents, children, toddlers, infants, and fetuses in utero.
- Treatment may be provided to the subject before clinical onset of disease. Treatment may be provided to the subject after clinical onset of disease. Treatment may be provided to the subject after 1 day, 1 week, 6 months, 12 months, or 2 years or more after clinical onset of the disease. Treatment may be provided to the subject for more than 1 day, 1 week, 1 month, 6 months, 12 months, 2 years or more after clinical onset of disease. Treatment may be provided to the subject for less than 1 day, 1 week, 1 month, 6 months, 12 months, or 2 years after clinical onset of the disease. Treatment may also include treating a human in a clinical trial.
- a treatment can comprise administering to a subject a pharmaceutical composition, such as one or more of the pharmaceutical compositions described throughout the disclosure.
- a treatment can comprise a once daily dosing.
- a treatment can comprise delivering a peptide of the disclosure to a subject, either intravenously, subcutaneously, intramuscularly, by inhalation, dermally, topically, by intra-articular injection, orally, sublingually, intrathecally, transdermally, intranasally, via a peritoneal route, directly into a tumor, e.g., injection directly into a tumor, directly into the brain, e.g., via and intracerebral ventricle route, or directly onto a joint, e.g., via topical, intra-articular injection route.
- a treatment can comprise administering a peptide-active agent complex to a subject, either intravenously, subcutaneously, intramuscularly, by inhalation, by intra-articular injection, dermally, topically, orally, intrathecally, transdermally, intransally, parenterally, orally, via a peritoneal route, nasally, sublingually, or directly onto cancerous tissues.
- Disruption of the YAP-TEAD interaction can have implications in a number of diseases, condition, or disorders associated to dysregulated cell growth, cell proliferation, angiogenesis, organogenesis, tumor progression, and/or metastasis.
- Compositions comprising any one of the peptides that bind TEAD, or a pharmaceutical composition thereof, can be used in a method of treating a cancer, tumor progression, and/or dysregulated cell growth.
- Exemplary diseases, disorder, or condition include: multiple myeloma, plastic anemia, myelodysplasia, and related bone marrow failure syndromes, myeloproliferative diseases, acute and chronic myeloid leukemia, malignancies of lymphoid cells, hematologic malignancies, plasma cell disorders, skeletal muscle disorder, myopathy, muscular dystrophy (e.g., Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumoeral muscular dystrophy, Myotonia congentia, and myotonic dystrophy), and chronic obstructive pulmonary disorder.
- multiple myeloma plastic anemia, myelodysplasia, and related bone marrow failure syndromes
- myeloproliferative diseases acute and chronic myeloid leukemia
- malignancies of lymphoid cells hematologic malignancies
- plasma cell disorders e.g., skeletal muscle disorder
- compositions/peptides disclosed herein are used to treat dysregulated cell growth, cancer, tumor, and/or metastasis associated with any of the following cell, tissue, or organ types: brain, lung, liver, spleen, kidney, lymph node, small intestine, blood cell, pancreatic, colon, stomach, cervix, breast, endometrial, prostate, testicle, ovarian, skin, head and neck, esophageal, oral tissue, and bone marrow.
- compositions/peptides disclosed herein are used to treat nay of the following: osteosarcoma, hepatocellular carcinoma, malignant mesothelioma, schwannoma, meningioma, renal carcinoma, cholangiocarcinoma, bile duct hamartoma, soft tissue carcinoma, ovarian carcinoma, colonic adenoma, T cell acute lymphoblastic leukaemia, gastrointestinal hyperplasia, fibrosarcoma, pancreatic ductal metaplasia, squamous cell carcinoma, kaposis sarcoma, and HIV-induced non-Hodgkin's lymphoma.
- the peptides of this disclosure can be used to access and treat these disorders due to their enhanced stability in various biological environments, including low pH, protease-rich environments, acidic environments, reducing environments, or environments with varying temperatures.
- compositions comprise any one of the peptides disclosed herein that modulates one or more factors of the HIPPO pathway, and is used to treat a condition or disease associated with a dysregulated HIPPO pathway.
- peptides described herein can be provided as a kit.
- peptide conjugates described herein can be provided as a kit.
- a kit comprises amino acids encoding a peptide described herein, a vector, a host organism, and an instruction manual.
- a kit includes written instructions on the use or administration of the peptides.
- the peptide sequence was reverse-translated into DNA, synthesized, and cloned in-frame with siderocalin using standard molecular biology techniques (M. R. Green, Joseph Sambrook. Molecular Cloning. 2012 Cold Spring Harbor Press).
- the resulting construct was packaged into a lentivirus, transduced into HEK-293 cells, expanded, isolated by immobilized metal affinity chromatography (IMAC), cleaved with tobacco etch virus protease, and purified to homogeneity by reverse-phase chromatography. Following purification, each peptide was lyophilized and stored frozen.
- IMAC immobilized metal affinity chromatography
- FIG. 1 illustrates validation and functional analysis of the produced biotinylated TEAD and Siderocalin-fused YAP.
- FIG. 1 A illustrates and SDS-PAGE with a band near 55 kDa indicating presence of the Siderocalin-YAP.
- FIG. 1 B illustrates surface plasmon resonance (SPR) data showing that Siderocalin-fused YAP binds biotinylated TEAD immobilized on an SPR chip with a dissociation constant (K D ) of 570 nM.
- FIG. 1 C illustrates that HEK-293 cells expressing surface-tethered YAP (50-171) is stained by Alexa Fluorophore (AF)-647 conjugated to Streptavidin (AF657-Streptavidin) bound to biotinylated TEAD.
- AF-647 Alexa Fluorophore
- Streptavidin AF657-Streptavidin
- FIG. 2 illustrates that the surface display GFP FasL (SDGF) vector is an effective mammalian display vector for peptide expression and evaluation of knottin peptide binding to another moiety.
- FIG. 2 A illustrates a schematic of the SDGF vector.
- Cytosolic, N-terminal GFP is connected to the extracellular domain via the transmembrane domain of human FasL.
- a bovine rhodopsin C9 tag follows, separated by a short linker from the C-terminal knottin (elafin is shown here as a representative example, however any peptide can be used).
- Specific binding partners elastase to elafin is shown here as a representative example, however any peptide or library of peptides can be used
- FIG. 2 B illustrates flow cytometry histograms showing that HEK-293 suspensions cells expressing SDGF-elafin are stained by AF647-conjugated elastase. Negative control experiments with cells expressing either SDGF-YAP (50-171) or SDGF-MACV glycoprotein are not stained by AF647 elastase.
- FIG. 17 further illustrates the method of using mammalian surface display screening for identifying TEAD-binding peptides.
- FIG. 17 A shows a detailed scheme for the screening strategy using a surface display GFP FasL (SDGF) vector.
- FasL-TM is the transmembrane domain of the FasL protein.
- the designed peptides are cloned as a pool into SDGF, which are then made into lentivirus.
- 293F cells are transduced with this library at a multiplicity of infection of 1, and after three days of growth, the pool of transduced cells are incubated with Alexa647-labeled TEAD.
- a percentage of the highest-staining APC-positive cells, from GFP and APC double-positive cells, are sorted and expanded. At every expansion, a portion of the cells are collected, and at the end, the enriched peptides are identified by sequencing.
- FIG. 3 illustrates screening a designed library for TEAD-binding peptides.
- FIG. 3 A illustrates a schematic of the screening steps for SDGF peptide libraries.
- FIG. 3 B illustrates flow cytometry plots showing the fluorescence of peptide construct expression (GFP) on the x-axis and TEAD (AF647) on the y-axis. Double-positive cells (upper right hand quadrant) indicate peptide-expressing cells that are bound to TEAD.
- HEK-293 cells were transduced with the SDGF TEAD-binder library and stained with 200 nM AF547-Streptavidin-TEAD.
- Flow cytometry plots show unsorted cells, cells sorted after 1, 2, or 3 rounds of screening.
- FIG. 3 C illustrates Illumina sequencing data plotting the abundance of each library member versus its abundance prior to the screening and sorting (“input”) after round 1, 2, 3, and 4.
- the x-axis indicates an enrichment score (log 2 ratio of relative abundance versus input abundance) and the y-axis shows log 2 P-value (determined using a Student's t-test). Data are shown from triplicate samples.
- TEAD-binding peptides were identified by selecting an enrichment score >5 and applying abundance and statistical significance filters. Enriched hits began appearing after two rounds of sorting.
- FIG. 3 D illustrates flow cytometry plots showing peptide construct expression (GFP) on the x-axis and TEAD (AF647) on the y-axis.
- Double-positive cells indicate peptide-expressing cells that are bound to TEAD.
- HEK-293 suspension cells were transfected with hits from the screen cloned into the SDGF vector and stained with 200 nm AF647-Streptavidin-TEAD.
- Peptides of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 expressed by HEK-293 cells displayed binding to TEAD, as demonstrated by cells that fall into the GFP+AF647+ region of the flow cytometry plots.
- FIG. 17 E illustrates the TEAD-binding abilities of 293F cells transfected with surface display GFP FasL (SDGF)-SEQ ID NO: 1 compared to cells displaying alanine substitution mutants at sites found at the modeled TEAD interface (SDGF-SEQ ID NO: 4, SDGF-SEQ ID NO: 6, SDGF-SEQ ID NO: 5, and SDGF-SEQ ID NO: 7).
- SDGF-SEQ ID NO: 4 The variant with all Cys converted to Ser (6CS) to eliminate disulfide bonds was also tested (SEQ ID NO: 184). Binding was assessed by quantifying Alexa647 levels in transfected cells using flow cytometry. Shown are the median ⁇ 95% confidence intervals, normalized to that of cells displaying the parent peptide.
- FIG. 17 E illustrates the TEAD-binding abilities of 293F cells transfected with surface display GFP FasL (SDGF)-SEQ ID NO: 1 compared to cells displaying alanine substitution mutants at sites found at
- 17 F illustrates the TEAD-binding abilities of 293F cells transfected with surface display GFP FasL (SDGF)-SEQ ID NO: 2 compared to cells displaying alanine substitution mutants at sites found at the modeled TEAD interface (SDGF-SEQ ID NO: 39, SDGF-SEQ ID NO: 40, SDGF-SEQ ID NO: 41, and SDGF-SEQ ID NO: 42).
- SDGF-SEQ ID NO: 39, SDGF-SEQ ID NO: 40, SDGF-SEQ ID NO: 41, and SDGF-SEQ ID NO: 42 The variant with all Cys converted to Ser (6CS) to eliminate disulfide bonds were also tested (SEQ ID NO: 185). Binding was assessed by quantifying Alexa647 levels in transfected cells using flow cytometry. Shown are the median ⁇ 95% confidence intervals, normalized to that of cells displaying the parent peptide.
- FIG. 4 illustrates peptides of SEQ ID NO: 1 and SEQ ID NO: 2 and the modeled TEAD interface with YAP and binding of TEAD to variants of SEQ ID NO: 1 and SEQ ID NO: 2.
- FIG. 4 A illustrates that YAP and peptides of SEQ ID NO: 1 and SEQ ID NO: 2 are predicted to bind TEAD at the same site (Site 2).
- the YAP-TEAD structure protein data bank (PDB) ID: 3KYS) is from the Research Collaboratory for Structural Bioinformatics (RCSB) PDB.
- SEQ ID NO: 1 and SEQ ID NO: 2 were modeled bound to the TEAD structure from RCSB 3KYS.
- FIG. 4 B illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 2 versus TEAD binding to HEK-293 suspension cells transfected with SDGF-L23A variant of SEQ ID NO: 2 (lysine to alanine variant of SEQ ID NO: 2 at position 23).
- Position L23 of SEQ ID NO: 2 analogous to the L65 residue of YAP, when mutated to alanine resulted in loss of binding to TEAD.
- FIG. 4 C illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 2 versus TEAD binding to HEK-293 suspension cells transfected with SDGF-L26A variant of SEQ ID NO: 2 (lysine to alanine variant of SEQ ID NO: 2 at position 26).
- Position L26 of SEQ ID NO: 2 analogous to the L68 residue of YAP, when mutated to alanine resulted in loss of binding to TEAD.
- FIG. 4 D illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 2 versus TEAD binding to HEK-293 suspension cells transfected with SDGF-F27A variant of SEQ ID NO: 2 (phenylalanine to alanine variant of SEQ ID NO: 2 at position 27).
- Position F27 of SEQ ID NO: 2 analogous to the F69 residue of YAP, when mutated to alanine resulted in loss of binding to TEAD.
- FIG. 4 E illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 2 versus TEAD binding to HEK-293 suspension cells transfected with SDGF-6 ⁇ CS variant of SEQ ID NO: 2 (a variant of SEQ ID NO: 2 in which all 6 cysteines are mutated to serines). Mutation of cysteines to serines resulted in loss of binding to TEAD.
- 4 F illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 4 (SDGF-E25A variant of SEQ ID NO: 1, which is a glutamic acid to alanine variant of SEQ ID NO: 1 at position 25). Position E25 of SEQ ID NO: 1, when mutated to alanine, resulted in loss of binding to TEAD.
- SDGF-E25A variant of SEQ ID NO: 1 which is a glutamic acid to alanine variant of SEQ ID NO: 1 at position 25.
- FIG. 4 G illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 6 (SDGF-M33A variant of SEQ ID NO: 1, which is a methionine to alanine variant of SEQ ID NO: 1 at position 33).
- SDGF-M33A variant of SEQ ID NO: 1 which is a methionine to alanine variant of SEQ ID NO: 1 at position 33.
- Position M33 of SEQ ID NO: 2 when mutated to alanine, resulted in loss of binding to TEAD.
- FIG. 4 H illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 5 (SDGF-L37A variant of SEQ ID NO: 1, which is a leucine to alanine variant of SEQ ID NO: 1 at position 37).
- SDGF-L37A variant of SEQ ID NO: 1 which is a leucine to alanine variant of SEQ ID NO: 1 at position 37.
- Position L37 of SEQ ID NO: 1 analogous to the L68 residue of YAP, when mutated to alanine, resulted in a marginal loss of binding to TEAD.
- FIG. 4 I illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 7 (SDGF-F38A variant of SEQ ID NO: 1, which is a phenylalanine to alanine variant of SEQ ID NO: 1 at position 38).
- SDGF-F38A variant of SEQ ID NO: 1 which is a phenylalanine to alanine variant of SEQ ID NO: 1 at position 38.
- Position F38 of SEQ ID NO: 1 analogous to the F69 residue of YAP, when mutated to alanine, resulted in loss of binding to TEAD.
- 4 J illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 184 (SDGF-6 ⁇ CS variant of SEQ ID NO: 1, which is a variant of SEQ ID NO: 1 in which all 6 cysteines are mutated to serines). Mutation of cysteines to serines resulted in loss of binding to TEAD.
- Soluble TEAD-binding peptides made using methods of EXAMPLE 1 and then were evaluated for binding by incubation of a dilution series varying from 150 ⁇ M to 44 ⁇ M (concentration range was varied depending on the TEAD-binding peptide being tested) of TEAD-binding peptides with 2 ⁇ g/mL TEAD, capturing ⁇ 300 resonance units (RUs) of protein for surface plasmon resonance (SPR, Biacore) experiments.
- FIG. 5 illustrates binding of soluble TEAD-binding peptides and variants to TEAD. Gels show peptides in reducing conditions in NuPAGE at one-tenth the final volume, in which DTT is at 50 mM.
- HPLC shows peptides in reducing conditions in Dulbecco's phosphate-buffered saline (DPBS) with a final DTT concentration of 40 mM.
- Non-reducing conditions are designated as “NR” and reducing conditions are designated as “R.”
- FIG. 5 A illustrates an SDS-PAGE gel of a peptide of SEQ ID NO: 1 in non-reducing conditions and reducing conditions.
- FIG. 5 B illustrates HPLC chromatograms showing peaks representing a peptide of SEQ ID NO: 1 in non-reducing conditions and in reducing conditions with DTT.
- FIG. 5 C illustrates SPR binding assay data of a peptide of SEQ ID NO: 1 to biotinylated TEAD immobilized on an SPR chip with a dissociation constant (K D ) of 31 nM.
- FIG. 5 D illustrates an SDS-PAGE gel of a peptide of SEQ ID NO: 5 in non-reducing conditions and reducing conditions.
- FIG. 5 E illustrates HPLC chromatograms showing peaks representing a peptide of SEQ ID NO: 5 in non-reducing conditions and in reducing conditions with DTT.
- FIG. 5 F illustrates SPR binding assay data of a peptide of SEQ ID NO: 5 to biotinylated TEAD immobilized on an SPR chip with a dissociation constant (K D ) of 280 nM.
- FIG. 5 G illustrates an SDS-PAGE gel of a peptide of SEQ ID NO: 7 in non-reducing conditions and reducing conditions.
- FIG. 5 H illustrates HPLC chromatograms showing peaks representing a peptide of SEQ ID NO: 7 in non-reducing conditions and in reducing conditions with DTT.
- FIG. 5 I illustrates SPR binding assay data of a peptide of SEQ ID NO: 7 to biotinylated TEAD immobilized on an SPR chip with a dissociation constant (K D ) of 23 ⁇ M.
- FIG. 5 J illustrates an SDS-PAGE gel of a peptide of SEQ ID NO: 3 in non-reducing conditions and reducing conditions.
- FIG. 5 K illustrates HPLC chromatograms showing peaks representing a peptide of SEQ ID NO: 3 in non-reducing conditions and in reducing conditions with DTT.
- FIG. 5 L illustrates SPR binding assay data of a peptide of SEQ ID NO: 3 to biotinylated TEAD immobilized on an SPR chip with a dissociation constant (K D ) of 12 ⁇ M.
- a peptide of SEQ ID NO: 5 had reduced affinity for TEAD as compared to a peptide of SEQ ID NO: 1.
- a peptide of SEQ ID NO: 7 also had reduced affinity for TEAD as compared to a peptide of SEQ ID NO: 1.
- a peptide of SEQ ID NO: 5 had reduced binding to TEAD as compared to a peptide of SEQ ID NO: 1.
- a peptide of SEQ ID NO: 3 also showed lower binding affinity for TEAD as compared to a peptide of SEQ ID NO: 1. Since the peptide of SEQ ID NO: 3 was not designed for binding to TEAD, it is possible that the lower affinity for binding to TEAD was a result of poor folding of the peptide.
- This example describes disruption of YAP-TEAD binding by a peptide of this disclosure.
- a peptide of SEQ ID NO: 1 was evaluated for disruption of YAP binding to TEAD by co-immunoprecipitation.
- Two separate populations of HEK-293T suspension cells were transfected with either Myc-TEAD or FLAG-YAP and cells were lysed.
- Myc-TEAD lysate was incubated with anti-Myc resin to generated TEAD bound resin, which was subsequently incubated for 30 minutes with the YAP lysate and peptides of SEQ ID NO: 1 or SEQ ID NO: 7.
- Beads were washed and analyzed by a silver stain or a Western blot.
- FIG. 6 A illustrates a Silver stain and Western blot showing that FLAG-YAP was not pulled down with Myc-TEAD resins in the presence of a peptide of SEQ ID NO: 1, but was pulled down with the Myc-TEAD resins in the presence of a peptide of SEQ ID NO: 7.
- FIG. 6 A illustrates a Silver stain and Western blot showing that FLAG-YAP was not pulled down with Myc-TEAD resins in the presence of a peptide of SEQ ID NO: 1, but was pulled down with the Myc-TEAD resins in the presence of a peptide of SEQ ID NO: 7.
- FIG. 6 B illustrates a Western blot showing a dilution series of a peptide of SEQ ID NO: 1 demonstrating dose-dependent inhibition of FLAG-YAP binding to Myc-TEAD resins.
- FIG. 6 C illustrates quantified densitometry data plotted from FIG. 6 B . Error bars show standard deviation from quantification of signal in four lanes per sample in one experiment. FLAG-YAP signal was normalized to Myc-TEAD signal by taking the ratio of each of the four blot lanes of YAP signal (not shown) to the TEAD signal.
- SSM site saturation mutagenesis
- TEAD binding of mammalian cells expressing peptides of the SSM library was performed as described in EXAMPLE 4 and EXAMPLE 5, but with a higher stringency protocol.
- the higher stringency protocol included a lower concentration of TEAD (20 nM) and staining in two separate steps—first with biotinylated TEAD followed by AF647-streptavidin. After four rounds of sorting, nearly the entire cell population expressing variants displayed improved binding to TEAD.
- FIG. 7 illustrates the results of a site-saturation mutagenesis screen in SEQ ID NO: 1 variants with improved binding activity to TEAD.
- FIG. 7 A illustrates a flow cytometry plot showing HEK-293 cells expressing a peptide of SEQ ID NO: 1 alone.
- FIG. 7 B illustrates a flow cytometry plot showing HEK-293 cells expressing a peptide of SEQ ID NO: 1 incubated with AF647-streptavidin alone, in the absence of biotinylated-TEAD.
- FIG. 7 C illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 (site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants) incubated with TEAD before sorting.
- SSM01 site-saturation mutagenesis
- FIG. 7 D illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 (site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants) incubated with TEAD after 1 round of sorting.
- FIG. 7 E illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 (site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants) incubated with TEAD after 2 rounds of sorting.
- FIG. 7 F illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 (site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants) incubated with AF647-streptavidin alone, in the absence of biotinylated-TEAD after two rounds of sorting. Results showed that after two rounds of sorting, double positive cells (upper right hand quadrant) were enriched, indicating enhanced inhibition of YAP-TEAD binding.
- FIG. 19 also illustrates the results of a site-saturation mutagenesis screen in SEQ ID NO: 1 variants with improved binding activity to TEAD.
- FIG. 19 A illustrates a flow cytometry plot showing HEK-293 cells expressing a peptide of SEQ ID NO: 1 alone. SEQ ID NO: 1 binding was apparent but weak under a 20 nM TEAD concentration and 2-step staining binding conditions.
- FIG. 19 A illustrates a flow cytometry plot showing HEK-293 cells expressing a peptide of SEQ ID NO: 1 alone. SEQ ID NO: 1 binding was apparent but weak under a 20 nM TEAD concentration and 2-step staining binding conditions.
- FIG. 19 B illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 (site-saturation mutagenesis “SSM” library containing the original peptide of SEQ ID NO: 1) incubated with TEAD before sorting.
- FIG. 19 C illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 incubated with TEAD after 1 round of sorting.
- FIG. 19 D illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 incubated with TEAD after 2 rounds of sorting.
- FIG. 8 illustrates enrichment scores at each position for the variants of SEQ ID NO: 1 generated in the site-saturation (SSM) mutagenesis screen and a structural model of the binding interface between the peptide or variant peptide and TEAD.
- FIG. 8 A illustrates a matrix of variants of a peptide of SEQ ID NO: 1 generated in the SSM screen.
- the x-axis shows the sequence of a peptide of SEQ ID NO: 1
- the y-axis shows each amino acid substitution tested at each position (all non-cysteine residues).
- the level of enrichment for each single point mutation is indicated in the matrix table after two rounds of sorting.
- the enrichment score (log 2 change in relative abundance after two rounds of sorting versus input abundance) is indicated on a greyscale and as numerical values.
- Positive or high enrichment scores correspond to residues that are more tolerant to substitutions. Examples of residues that are more tolerant of substitutions include residues corresponding to positions 15, 23, and 40 in SEQ ID NO: 1.
- Negative or lower enrichment scores correspond to residues that are less tolerant to substitution, such as residues that are important to binding.
- TABLE 4 and TABLE 5 below illustrate another representation of FIG. 8 A , showing the SSM screen for improved variants of SEQ ID NO: 1, which provided insight into the structure and tolerance to mutation at each position of the peptide.
- each amino acid residue of SEQ ID NO: 1 sequence is shown in the columns, with all the substituted non-Cys residues shown in the rows, after two rounds of sorting.
- Grey shading indicates either the native amino acid at the position or an unchanged Cys.
- the level of enrichment for each single point mutation is indicated as a numerical score in the TABLE 4 and TABLE 5.
- TABLE 4 shows amino acid residues at positions 1-20 of SEQ ID NO: 1.
- TABLE 5 shows amino acid residues at positions 21-40 of SEQ ID NO: 1.
- G15 and G28 (present in the interhelix loop) mutations to hydrophilic amino acid residues displayed a higher enrichment score indicating better binding. This is likely due to improved folding kinetics or improved solubility.
- a mutation at E25 to aspartate lead better binding, and this was the most enriched variant after four rounds of screening.
- Mutations at Y23 were overall beneficial for improving binding, with the exception of mutations to aromatic residues. This may likely be due to the fact that the Y23 residue is in part shielded from solvent and in part exposed to solvent. Thus, substitutions to smaller aliphatic residues may improve interhelix interactions and substitutions to hydrophilic residues may improve solubility.
- FIG. 8 B illustrates a model of the SEQ ID NO: 1-TEAD interface, in which shading intensity on a greyscale indicates the average enrichment score at each residue. Positive or high enrichment scores (lighter shades of grey) correspond to residues that are more tolerant to substitutions. Negative or lower enrichment scores (darker shades of grey) correspond to residues that are less tolerant to substitution, such as residues that are important to binding. Black indicates cysteine residues.
- This example describes TEAD binding of SSM-generated variant TEAD-binding peptides made in EXAMPLE 8.
- SSM screening generated many beneficial mutations, from which we selected five especially beneficial mutations to a peptide of SEQ ID NO: 1 including G15Q, Y23I, E25D, G28K, and P40W.
- Variants of SEQ ID NO: 1 with these mutations were made in which ten triple mutants were made including all combinations in which three of the five mutations described above, five quadruple mutants were made including all combinations in which four of the five mutations described above, and the quintuple mutant.
- the TEAD binding assays described in EXAMPLE 4 and EXAMPLE 5 tested at the same stringency as was used in EXAMPLE 8.
- TEAD binding assays were also described in which an extra wash step was introduced between incubation with biotinylated TEAD and incubation with the AF647-streptavidin. Altered binding due to an additional wash step informed us about the kinetics of a candidate peptide's binding, specifically the k off value, to TEAD.
- FIG. 9 illustrates that combinations of enriched mutations identified in a peptide of SEQ ID NO: 1 by SSM result in improved TEAD binding.
- FIG. 9 A illustrates a schematic of the staining protocols used to evaluate TEAD binding. Both the “Normal” and “Extra Wash” protocols use 20 nM of TEAD.
- FIG. 9 B illustrates flow cytometry plots showing HEK-293 suspension cells expressing SDGF-SEQ ID NO: 1, SDGF-SEQ ID NO: 9 (QIDKW variant of SEQ ID NO: 1), and YAP. Five-letter codes (e.g.
- QIDKW represent variants of a peptide of SEQ ID NO: 1 at residues 15 (G or Q), 23 (Y or I), 25 (E or D), 28 (G or K), and 40 (P or W).
- FIG. 9 C illustrates quantification of the mean fluorescence intensity (MFI) of cells that fall in the “slice” gate indicated in FIG. 9 B .
- the x-axis indicates the variant that was tested and all MFI values are normalized to the MFI value for a peptide of SEQ ID NO: 1.
- Shaded groups are clusters with particular combinations of mutations: XXDKW; XXDGW; XXDKP.
- the quintuple variant “QIDKW” performed the best, but only marginally better than those variants in which three or four mutations were made and contained at least E25D, G28K, and P40W.
- E25D is a conservative mutation, or, in other words, a biochemically similar mutation (i.e., glutamic acid and aspartic acid are residues with negatively charged side chains), at a salt bridge modeled to be formed with K152 on TEAD.
- Residue G28 of a peptide of SEQ ID NO: 1, whether or not mutated to K, does not appear to directly bind TEAD as predicted by the computational model.
- FIG. 10 illustrates binding to TEAD by variants of a peptide of SEQ ID NO: 1 as soluble peptides.
- Non-reducing conditions are designated as “NR” and reducing conditions are designated as “R.”
- FIG. 10 A illustrates an SDS-PAGE of a soluble peptide of SEQ ID NO: 9 in non-reduced (NR) and reduced (R) conditions.
- FIG. 10 B illustrates an HPLC chromatogram of a peptide of SEQ ID NO: 9 in non-reduced or reduced conditions.
- FIG. 10 E illustrates early peaks ( ⁇ 3 mins) seen on the reduced (R) peptide HPLC chromatograms.
- FIG. 10 C illustrates SPR data showing binding of a peptide of SEQ ID NO: 9 to biotinylated TEAD immobilized on an SPR chip.
- FIG. 10 D illustrates an SDS-PAGE of a soluble peptide of SEQ ID NO: 10 in non-reduced (NR) or reduced (R) conditions.
- FIG. 10 E illustrates an HPLC chromatogram of a peptide of SEQ ID NO: 10 in non-reduced or reduced conditions.
- FIG. 10 F illustrates SPR data showing binding of a peptide of SEQ ID NO: 10 to biotinylated TEAD immobilized on an SPR chip.
- FIG. 10 G illustrates an SDS-PAGE of a soluble peptide of SEQ ID NO: 11 in non-reduced (NR) and reduced (R) conditions.
- FIG. 10 H illustrates an HPLC chromatogram of a peptide of SEQ ID NO: 11 in non-reduced or reduced conditions.
- FIG. 10 I illustrates SPR data showing binding of a peptide of SEQ ID NO: 11 to biotinylated TEAD immobilized on an SPR chip.
- This example describes competitive binding of peptides of this disclosure to TEAD, or disruption of TEAD binding to surface-displayed YAP.
- HEK-293 suspension cells expressing SDGF-YAP were first incubated with either a peptide of SEQ ID NO: 1 or SEQ ID NO: 9. The cell culture was next stained with 5 nM of biotinylated TEAD as shown in FIG. 11 .
- FIG. 11 illustrates inhibition of YAP binding to TEAD with a soluble peptide of SEQ ID NO: 9 as compared to inhibition of YAP binding to TEAD with a soluble peptide of SEQ ID NO: 1.
- FIG. 11 A illustrates flow cytometry plots showing HEK-293 suspension cells transfected with SDGF-YAP and incubated with 0 nM, 10 nM, or 100 nM of a peptide of SEQ ID NO: 1, followed by incubation with 5 nM biotinylated TEAD, and 5 nM AF647-streptavidin.
- FIG. 11 A illustrates flow cytometry plots showing HEK-293 suspension cells transfected with SDGF-YAP and incubated with 0 nM, 10 nM, or 100 nM of a peptide of SEQ ID NO: 1, followed by incubation with 5 nM biotinylated TEAD, and 5 nM AF647-stre
- FIG. 11 B illustrates flow cytometry plots showing HEK-293 suspension cells transfected with SDGF-YAP and incubated with 0 nM, 10 nM, or 100 nM of a peptide of SEQ ID NO: 9, followed by incubation with 5 nM biotinylated TEAD, and 5 nM AF647-streptavidin.
- FIG. 11 C illustrates a dose response curve quantifying the MFI of cells falling within the “slice” gate shown in FIG. 11 A and FIG. 11 B . Doses below 5 nM TEAD staining does not provide data relevant to IC50 or K i determination, as cells were stained with 5 nM TEAD.
- FIG. 11 B illustrates flow cytometry plots showing HEK-293 suspension cells transfected with SDGF-YAP and incubated with 0 nM, 10 nM, or 100 nM of a peptide of SEQ ID NO: 9, followed by incubation with 5 n
- FIG. 11 D illustrates a flow cytometry plot of cells expressing SDGF-YAP that were incubated with 5 nM TEAD and then washed. Cells were immediately stained with AF647-streptavidin and analyzed for YAP-expressing cells that have bound TEAD.
- FIG. 11 E illustrates a flow cytometry plot of cells expressing SDGF-YAP that were incubated with 5 nM TEAD and then washed. Cells were incubated on ice for 1 hour, stained with AF647-streptavidin and analyzed for YAP-expressing cells that have bound TEAD.
- FIG. 11 D illustrates a flow cytometry plot of cells expressing SDGF-YAP that were incubated with 5 nM TEAD and then washed. Cells were incubated on ice for 1 hour, stained with AF647-streptavidin and analyzed for YAP-expressing cells that have bound TEAD.
- FIG. 11 F illustrates a flow cytometry plot of cells expressing SDGF-YAP that were incubated with 5 nM TEAD and then washed. Cells were incubated on ice for 1 hour with 100 nM of a peptide of SEQ ID NO: 1, stained with AF647-streptavidin and analyzed for YAP-expressing cells that have bound TEAD.
- FIG. 11 G illustrates a flow cytometry plot of cells expressing SDGF-YAP that were incubated with 5 nM TEAD and then washed. Cells were incubated on ice for 1 hour with 100 nM of a peptide of SEQ ID NO: 9, stained with AF647-streptavidin and analyzed for YAP-expressing cells that have bound TEAD.
- This example describes stability of peptides under reducing conditions. Peptides that target TEAD in the nucleus are exposed to reducing conditions in the cytosolic compartment of cells. Thus, it is advantageous for peptides of this disclosure to display stability in reducing conditions. Stability of peptides of this disclosure was tested in 10 mM DTT and 10 mM GSH. GSH is a more physiologically relevant reducing agent for testing peptide stability in intracellular conditions. As shown in FIG.
- FIG. 12 illustrates stability of TEAD-binding peptides to reducing agents.
- FIG. 12 A illustrates HPLC chromatograms of a peptide of SEQ ID NO: 9 in non-reducing conditions and in 10 mM DTT reducing conditions. A representative mass spectrometry peak profile is shown in the inset.
- FIG. 12 B illustrates HPLC chromatograms of peptides of SEQ ID NO: 1 and SEQ ID NO: 9 in with or without incubation in 10 mM glutathione (GSH).
- GSH mM glutathione
- FIG. 13 illustrates binding to TEAD after cells expressing SDGF-SEQ ID NO: 9 are exposed to a reducing agent.
- FIG. 13 A illustrates a flow cytometry plot showing binding of HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 (GFP) incubated for 5 minutes in PBS, 10 mM DTT, or 10 mM glutathione (GSH) before staining with 20 nM biotinylated TEAD and 20 nM AF647-streptavidin.
- FIG. 13 A illustrates a flow cytometry plot showing binding of HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 (GFP) incubated for 5 minutes in PBS, 10 mM DTT, or 10 mM glutathione (GSH) before staining with 20 nM biotinylated TEAD and 20 nM AF647-streptavidin.
- FIG. 13 B illustrates a flow cytometry plot showing binding of HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 9 (GFP) incubated for 5 minutes in PBS, 10 mM DTT, or 10 mM glutathione (GSH) before staining with 20 nM biotinylated TEAD and 20 nM AF647-streptavidin.
- FIG. 13 C illustrates quantification of the AF647 MFI of cells falling within the “slice” gate shown in FIG. 13 A and FIG. 13 B .
- the results of the binding assay indicated that cells displaying a peptide of SEQ ID NO: 1 showed partial loss in binding to TEAD after DTT treatment and no loss in binding to TEAD after GSH treatment.
- the results of the binding assay also indicated that cells displaying a peptide of SEQ ID NO: 9 showed no loss in binding to TEAD regardless of whether DTT or GSH was used as the reducing agent.
- This example illustrates stability of peptides of this disclosure to proteases.
- Tumor environments generally contain a high amount of proteases.
- resistance to proteolysis reduces the likelihood that a peptide will be degraded and then displayed to the immune system by MHC.
- resistance to proteolysis can increase peptide half-life in serum after administration prior to trafficking to a tumor.
- Soluble peptides were exposed to 500 U/mL porcine trypsin and analyzed by HPLC. Protease resistance was also assessed by using SDPR-displaying peptides.
- the SDPR vector is similar to the SDGF vector, but contains a C-terminal 6 ⁇ His tag (SEQ ID NO: 284) and all basic or aromatic amino acid residues on the stalk removed. Protease resistance is then tested by incubation of cells displaying peptides with trypsin or chymotrypsin, followed by incubation in 10 mM DTT, and staining with an anti-6 ⁇ His fluorophore-labeled antibody. If peptides are uncleaved, they retain the His tag and are stained with by the antibody. A control protease-sensitive knottin peptide (SK) was used as a positive control. Cells displaying peptides were treated with up to 40 ⁇ g/ml trypsin or chymotrypsin.
- FIG. 14 illustrates protease resistance of a peptide of SEQ ID NO: 9.
- FIG. 14 A illustrates HPLC chromatograms of a peptide of SEQ ID NO: 9 after incubation with 500U trypsin (T), which was then quenched with trypsin inhibitor (I) and placed in non-reducing (NR) conditions or reducing (R) conditions with 10 mM DTT. The products were then run on HPLC. The chromatograms appear similar (though not identical) to those seen in experiments lacking trypsin.
- FIG. 14 B illustrates a schematic of the SDPR vector, a variant of the SDGF vector shown in FIG.
- the modified surface display vector was designed to be capable of assessment of protease or reduction resistance, which can be accomplished by staining for anti-6 ⁇ His.
- cells expressing the constructs can be incubated with a protease, such as trypsin or chymotrypsin, followed by treatment with a reducing agent.
- any linearized peptide product or degradation product resulting from reduction and/or proteolysis by treatment with a protease can be detected or analyzed by staining against the 6 ⁇ His tag (SEQ ID NO: 284).
- a peptide can become linearized in the presence of a reducing agent, which can make it more susceptible to proteolysis, or a reduction-resistant peptide can be cleaved by a protease.
- the presence of a single cleavage event in the peptide backbone can result in a linearized, displayed peptide, which can lose the 6 ⁇ His tag (SEQ ID NO: 284) on the C-terminus, causing cells with such peptides to lose staining against 6 ⁇ His (SEQ ID NO: 284).
- FIG. 14 C , FIG. 14 D , FIG. 14 E , and FIG. 14 F illustrate the flow cytometry analyses of HEK-293 suspension cells transfected with either a protease sensitive knottin peptide SK cloned into the SDPR construct (SDPR-SK) or SEQ ID NO: 9 cloned into the SDPR construct, and treated with 0 or 40 ⁇ g/ml trypsin or chymotrypsin for 20 minutes, and then stained with an AF647 anti-6 ⁇ HIS antibody. Loss of anti-6 ⁇ HIS signal is indicative of peptide destabilization or degradation.
- SDPR-SK protease sensitive knottin peptide SK cloned into the SDPR construct
- SEQ ID NO: 9 cloned into the SDPR construct
- FIG. 14 C illustrates a flow cytometry plot of HEK-293 suspension cells transfected with protease sensitive SDPR-SK peptide and then treated with 0 or 40 ⁇ g/ml trypsin for 20 minutes, and stained with an AF647 anti-6 ⁇ HIS antibody.
- a knottin previously characterized as protease-sensitive (SK) displayed a loss of staining after treatment with trypsin or chymotrypsin (visualized as a reduction in APC signal when cells are stained with Alexa647-conjugated anti-6 ⁇ His antibody.
- FIG. 14 D illustrates a flow cytometry plot of HEK-293 suspension cells transfected with SDPR-SEQ ID NO: 9 peptide and then treated with 0 or 40 ⁇ g/ml trypsin for 20 minutes, and stained with an AF647 anti-6 ⁇ HIS antibody.
- FIG. 14 E illustrates a flow cytometry plot of HEK-293 suspension cells transfected with protease sensitive SDPR-SK peptide and then treated with 0 or 40 ⁇ g/ml chymotrypsin for 20 minutes, and stained with an AF647 anti-6 ⁇ HIS antibody.
- FIG. 14 E illustrates a flow cytometry plot of HEK-293 suspension cells transfected with protease sensitive SDPR-SK peptide and then treated with 0 or 40 ⁇ g/ml chymotrypsin for 20 minutes, and stained with an AF647 anti-6 ⁇ HIS antibody.
- FIG. 14 F illustrates a flow cytometry plot of HEK-293 suspension cells transfected with SDPR-SEQ ID NO: 9 peptide and then treated with 0 or 40 ⁇ g/ml chymotrypsin for 20 minutes, and stained with an AF647 anti-6 ⁇ HIS antibody.
- FIG. 14 G illustrates quantification of flow cytometry data comparing SDPR-SK peptide transfected cells and SDPR-SEQ ID NO: 9 peptide transfected cells, both treated with trypsin at various concentrations.
- FIG. 14 H illustrates quantification of flow cytometry data comparing SDPR-SK peptide transfected cells and SDPR-SEQ ID NO: 9 peptide transfected cells, both treated with chymotrypsin at various concentrations. The results of exposure to protease indicated that a peptide of SEQ ID NO: 9 was partially resistant to cleavage by proteases.
- This example describes the radiolabeling of peptides.
- Several peptides were radiolabeled by reductive methylation with 14 C formaldehyde and sodium cyanoborohydride with standard techniques (such as those described in Jentoft et al. J Biol Chem. 254(11):4359-65. 1979).
- the sequences were engineered to have the amino acids, “G” and “S” at the N terminus. See Methods in Enzymology V91:1983 p. 570 and JBC 254(11):1979 p. 4359.
- An excess of formaldehyde was used to drive complete methylation (dimethylation of every free amine).
- the labeled peptides were isolated via solid-phase extraction on Strata-X columns (Phenomenex 8B-S100-AAK), rinsed with water with 5% methanol, and recovered in methanol with 2% formic acid. Solvent was subsequently removed in a blowdown evaporator with gentle heat and a stream of nitrogen gas.
- This example describes the dye labeling of peptides.
- a peptide of the disclosure is expressed recombinantly or chemically synthesized, and then the N-terminus of the peptide is conjugated to, linked to, or fused to a detectable agent via an NHS ester using DCC or EDC to produce a peptide-detectable agent conjugate.
- the detectable agent is the fluorophore dye is a cyanine dye, such as Cy5.5 or an Alexa fluorophore, such as Alexa647.
- the peptide detectable agent conjugates are administered to a subject.
- the subject can be a human or a non-human animal. After administration, the peptide detectable agent conjugates home to the kidneys.
- the subject, or a biopsy from the subject, is imaged to visualize localization of the peptide detectable agent conjugates to the kidney.
- diagnosis of renal disorders is based on the visualization of the peptide detectable agent conjugates in kidneys after administration.
- a peptide of the present disclosure is recombinantly expressed or chemically synthesized and used directly.
- the peptide is administrated in a pharmaceutical composition to a subject in need thereof as a therapeutic for cancer.
- the peptide is selected from any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84.
- the peptide can be SEQ ID NO: 9.
- One or more peptides are administered to a subject.
- the subject can be a human or an animal.
- the pharmaceutical composition is administered intravenously, subcutaneously, intramuscularly, orally, or injected directly into the tumor microenvironment.
- the peptides disrupt YAP-TEAD interactions and TAZ-TEAD interactions by binding to TEAD, and precluding subsequent binding by YAP or TAZ.
- the peptides disrupt YAP-TEAD and TAZ-TEAD interactions by competing with bound YAP or TAZ, resulting in YAP or TAZ dissociation from TEAD and peptide binding to TEAD.
- the administered peptides which disrupt YAP-TEAD and TAZ-TEAD interactions, treat a cancer condition in the subject.
- the cancer condition may be breast cancer, liver cancer, colon cancer, or brain cancer.
- the same method can also be adapted for or used to treat diabetes Type I and II.
- Peptides of the present disclosure can be directed to the tumor microenvironment (e.g., immune infiltrates or a cancerous cell) by delivery mediated by gene therapy-modified cells.
- a gene therapy composition comprising a viral vector that selectively infects or targets cancer cells and carrying a gene encoding a peptide of the present disclosure can be administered to a subject to selectively express the peptide in cancer cells or a tumor.
- cells expressing the peptide of the present disclosure are modified ex vivo using gene therapy, followed by transplanting the modified cells back into the subject.
- the subject is a human or an animal. After transplantation, the modified cells migrate to a tumor microenvironment or cancer cells to disrupt TEAD binding in vivo.
- the pharmaceutical composition is administered intravenously, subcutaneously, or orally.
- FIGS. 18 A and 18 B illustrate an example of SEQ ID NO: 1 and SEQ ID NO: 9 expression in target cells.
- FIG. 18 A illustrates the relative luminescence units of SEQ ID NO: 1 or SEQ ID NO: 9 expressed directly into the cytosol as part of an mCherry-T2a-peptide fusion construct, co-transfected with YAP and 8 ⁇ GTIIC (TEAD luciferase reporter). This was done in 24-well plate wells, in which 293F cells were transfected with 50 ng FLAG-YAP, 300 ng 8 ⁇ GTIIC, and either 100 or 250 ng mCherry-T2a-peptide plasmids. *: P ⁇ 0.05, **: P ⁇ 0.005 vs.
- FIG. 18 B illustrates the FLAG-tagged SEQ ID NO: 7, FLAG-tagged SEQ ID NO: 1, FLAG-tagged SEQ ID NO: 9, or FLAG-tagged SEQ ID NO: 184 in the mCherry-T2a-peptide construct SDS-PAGE gel mobility shift upon DTT reduction by Western blot (anti-FLAG M2 antibody). Shown are the bands corresponding to the size of the uncleaved fusion protein.
- SEQ ID NO: 184 is SEQ ID NO: 9-6 ⁇ CS, in which all six cysteines were mutated to serines, simulating non-oxidizable sulfhydryls.
- the peptide Upon expression of the peptide, the peptide disrupts YAP/TAZ interactions with TEAD by binding to TEAD and precluding subsequent binding by YAP or TAZ, which downregulates oncogenes.
- the peptide disrupts YAP-TEAD and TAZ-TEAD interactions by competing with bound YAP or TAZ, resulting in YAP/TAZ dissociation from TEAD.
- the administered gene therapy encoding the peptide, which disrupts YAP/TAZ-TEAD interactions, is used to treat a cancer condition in the subject.
- the cancer condition may be breast cancer, liver cancer, colon cancer, or brain cancer.
- the gene therapy can also be used to treat diabetes Type I and II using gene therapy vectors that selectively target pancreatic cells.
- This example illustrates surface plasmon resonance (SPR) analysis of peptide binding interactions.
- SPR surface plasmon resonance
- Various peptides of the present disclosure were analyzed for binding affinity to TEAD. Briefly, binding affinity was analyzed by SPR experiments, which were performed at 25° C. on a Biacore T100 instrument (GE Healthcare) with Series S SA chips.
- HBS-EP+ (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% surfactant P20) was used as a running buffer in the experiments with 0.1 mg/mL bovine serum albumin (BSA).
- BSA bovine serum albumin
- Biotinylated TEAD was injected over a flow cell at a concentration of 2 ⁇ g/mL and at a rate of 10 ⁇ L/min to capture TEAD corresponding to ⁇ 300 resonance units (RUs) on the SPR chip.
- a reference surface was generated by capturing a molar equivalent of biotinylated human transferrin receptor ectodomain.
- serial two-fold dilutions of the peptides were prepared in the running buffer described above at concentration ranges which widely spanned and covered each peptide's K D .
- Serial three-fold dilutions (3.6 nM to 0.044 nM) of peptides of SEQ ID NO: 9 and SEQ ID NO: 10 were prepared in running buffer and injected at a rate of 50 ⁇ L/minute in increasing concentration order with 7 mins of injection time and 15 minutes dissociation time.
- Two buffer only blank cycles for referencing were run prior to peptide injection and one buffer only blank cycle followed which allowed time for complete peptide dissociation prior to the injection of the next peptide.
- Double-referenced data were fit with the 1:1 binding model for single cycle kinetics using BIAevaluation 2.0.4 software (GE Healthcare).
- TABLE 6 illustrates the SPR method conditions for assessing peptide binding to captured biotinylated TEAD.
- FIG. 15 shows the results of SPR experiments.
- FIG. 15 A shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 1 at various concentrations.
- FIG. 15 B illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics.
- FIG. 15 C shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 5 at various concentrations.
- FIG. 15 D illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics.
- FIG. 15 E shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 7 at various concentrations.
- FIG. 15 F illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics.
- FIG. 15 G shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 8 at various concentrations.
- FIG. 15 H illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics.
- FIG. 15 I shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 11 at various concentrations.
- FIG. 15 J illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics.
- FIG. 16 illustrates data from SPR experiments illustrating binding of peptides of the present disclosure to TEAD.
- FIG. 16 A illustrates binding of SEQ ID NO: 9 to TEAD using a single cycle kinetics protocol.
- FIG. 16 B illustrates binding of SEQ ID NO: 10 to TEAD using a single cycle kinetics protocol.
- FIG. 16 C illustrates binding of SEQ ID NO: 11 to TEAD using a steady-state kinetics protocol.
- a TEAD-binding peptide of the present disclosure is recombinantly expressed as a fusion to a cell penetrating peptide moiety.
- the TEAD-binding peptide is selected from any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84.
- the cell penetrating peptide moiety is one or multiple Arg residues, such as an RRRRRRRR (SEQ ID NO: 146) sequence conjugated to, linked to, or fused at the N-terminus, or a Tat peptide with the sequence YGRKKRRQRRR (SEQ ID NO: 195) that is conjugated to, linked to, or fused to the N-terminus of any TEAD-binding peptide of the present disclosure.
- the cell penetrating peptide moiety is selected from maurocaline, imperatoxin, hadrucalcin, hemicalcin, oplicalin-1, opicalcin-2, midkine (62-104), MCoTI-II, or chlorotoxin, which is fused to the N-terminus of any TEAD-binding peptide of the present disclosure.
- the cell penetrating peptide moiety is selected from TAT (SEQ ID NO: 143), CysTAT (SEQ ID NO: 144), S19-TAT (SEQ ID NO: 145), R8 (SEQ ID NO: 146), pAntp (SEQ ID NO: 147), Pas-TAT (SEQ ID NO: 148), Pas-R8 (SEQ ID NO: 149), Pas-FHV (SEQ ID NO: 150), Pas-pAntP (SEQ ID NO: 151), F2R4 (SEQ ID NO: 152), B55 (SEQ ID NO: 153), azurin (SEQ ID NO: 154), IMT-P8 (SEQ ID NO: 155), BR2 (SEQ ID NO: 156), OMOTAGI (SEQ ID NO: 157), OMOTAG2 (SEQ ID NO: 158), pVEC (SEQ ID NO: 159), SynB3 (SEQ ID NO: 160), DPV10
- the cell penetrating peptide moiety is fused to the N-terminus of any TEAD-binding peptide of the present disclosure by a linker.
- the linker is selected from GGGSGGGSGGGS (SEQ ID NO: 210), KKYKPYVPVTTN (SEQ ID NO: 211) (linker from DkTx), or EPKSSDKTHT (SEQ ID NO: 212) (linker from human IgG3), any linker of SEQ ID NO: 203-SEQ ID NO: 212, or any other linker.
- the TEAD-binding peptide, the cell penetrating peptide moiety, and, optionally, the linker are joined by other means.
- the other means includes, but is not limited to, chemical conjugation at any location, fusion of the cell penetrating peptide moiety and/or the linker to the C-terminus of the TEAD-binding peptide, co-formulation with liposomes, or other methods.
- Cell-penetrating peptide fusions or conjugates are administered to a subject in need thereof.
- the subject is a human or animal and has a disease, such as cancer or diabetes (Type I or Type II).
- a disease such as cancer or diabetes (Type I or Type II).
- cell-penetrating peptide fusions traverse cellular membranes to access intracellular compartments and subsequently bind TEAD, preventing YAP association with TEAD.
- a TEAD-binding peptide of the present disclosure is recombinantly expressed or chemically synthesized.
- the peptide is selected from any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84.
- TEAD-binding peptides are conjugated to, linked to, or fused to a nuclear localization signal, such as a four-residue sequence of K-K/R-X-K/R (SEQ ID NO: 202), wherein X can be any amino acid, or a variant thereof (Lange et al, J Biol Chem. 2007 Feb. 23; 282(8):5101-5).
- Peptide fusions are administered to a subject in need thereof.
- the subject is a human or animal and has a disease, such as cancer or diabetes (Type I or Type II).
- peptide fusions traffick to the nucleus, where they efficiently prevent YAP association with TEAD.
- a TEAD-binding peptide of the present disclosure is recombinantly expressed or chemically synthesized.
- the peptide is selected from any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84.
- TEAD-binding peptides are conjugated to, linked to, or fused to a dfTAT and/or co-delivered with dfTAT.
- a nuclear localization signal such as a four-residue sequence of K-K/R-X-K/R (SEQ ID NO: 202), wherein X can be any amino acid, or a variant thereof (Lange et al, J Biol Chem.
- Peptide fusions are administered to a subject in need thereof.
- the subject is a human or animal and has a disease, such as cancer or diabetes (Type I or Type II).
- peptide fusions are expressed in the cytosol and interact with TEAD in the cytosol and nucleus to disrupt TEAD binding to transcription coactivators, such as YAP or TAZ.
- SEQ ID NO: 9 was co-administered with dfTAT, a small dimeric peptide that facilitates endosomal escape of cargoes up to 150 kDa without noticeable effects on viability or gene expression profiles.
- dfTAT a small dimeric peptide that facilitates endosomal escape of cargoes up to 150 kDa without noticeable effects on viability or gene expression profiles.
- SEQ ID NO: 9 conjugated to DyLight 488 for visualization co-incubation of HeLa cells with both SEQ ID NO: 9 and dfTAT yielded accumulation of SEQ ID NO: 9 in cells in a disperse pattern. More specifically, FIGS. 18 - 18 I show that SEQ ID NO: 9 significantly reduces YAP:TEAD dimers in the nucleus.
- SEQ ID NO: 9-DyLight488 was introduced to the cytosol/nucleus of HeLa cells using 5 ⁇ M dfTAT, which induces endosomal leakage.
- dfTAT was visible in the TRITC channel ( FIG. 18 C ), while SEQ ID NO: 9-DyLight488 was seen in the FITC channel ( FIG. 18 D ).
- Proximity ligation assay (PLA) in HeLa cells was performed using primary antibodies against YAP and TEAD, in which speckles (APC channel) overlapping DAPI-stained nuclei (UV channel) were produced.
- FIG. 18 E shows a representative image of cells treated with 5 ⁇ M dfTAT only.
- FIG. 18 F shows a representative image of cells treated with 5 ⁇ M dfTAT and 5 ⁇ M SEQ ID NO: 9.
- FIG. 18 G shows a representative image of a control proximity ligation assay (PLA) reaction with anti-YAP primary antibodies omitted in which some speckles were non-specific to YAP:TEAD dimers.
- FIG. 18 H shows a representative image of a control PLA reaction with anti-TEAD primary antibodies omitted in which some speckles were non-specific to YAP:TEAD dimers.
- PLA proximity ligation assay
- 18 I illustrates a dot graph of automated counting of YAP:TEAD PLA speckles per nucleus of HeLa cells that were treated with 5 ⁇ M dfTAT and/or 5 ⁇ M TEAD-binding peptides. Each dot represents a single nucleus, with the bars representing the median ⁇ 95% confidence intervals. A line was drawn at the sum of the two antibody omission samples' average speckle counts, representing the approximate value attributable to non-specific speckles. ****: P ⁇ 0.0001 vs. any other sample. All P-values were determined by two-tailed T-test.
- the speckles per nucleus were significantly reduced in cells that were treated with the peptide of SEQ ID NO: 9 combined with dfTAT, which is supportive that the treatment may have reduced the interactions of YAP and TEAD in the nucleus of the treated cells.
- a peptide of the present disclosure is recombinantly expressed or chemically synthesized and used directly.
- the peptide is administrated in a pharmaceutical composition to a subject in need thereof as a therapeutic for cancer.
- the peptide is selected from any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84.
- One or more peptides are administered to a subject along with a treatment regimen of standard small molecule or chemotherapy, such as cisplatin, methotrexate, docetaxel, and etoposide, among others.
- the subject is a human or an animal.
- the pharmaceutical composition is administered intravenously, subcutaneously, intramuscularly, orally, or injected directly into the tumor microenvironment.
- the peptides disrupt YAP-TEAD interactions by binding to TEAD, and precluding subsequent binding by YAP.
- the administered peptides with standard small molecule therapy treats a cancer condition in the subject.
- the cancer condition may be breast cancer, liver cancer, colon cancer, or brain cancer.
- Biopsies are taken from a subject in need thereof and are analyzed for mutations in the YAP/TAZ-TEAD pathway, such as mutations that result in YAP overexpression.
- a peptide of the present disclosure is recombinantly expressed or chemically synthesized and used directly.
- the peptide is administrated in a pharmaceutical composition to a subject in need thereof as a therapeutic for cancer.
- the peptide is selected from any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84.
- One or more peptides are administered to a subject.
- the subject is a human.
- the pharmaceutical composition is administered intravenously, subcutaneously, intramuscularly, orally, or injected directly into the tumor microenvironment.
- the peptides disrupt YAP/TAZ-TEAD interactions by binding to TEAD, and precluding subsequent binding by YAP or TAZ.
- the cancer condition may be breast cancer, liver cancer, colon cancer, or brain cancer.
- a peptide of the present disclosure is mutated using Site Saturation Mutagenesis (SSM) or any random mutagenesis method to decrease the off rate and/or increase the on rate, thereby increasing or improving the binding affinity.
- the peptide is selected from any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84.
- any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84 is mutated or grafted to comprise LX 1 X 2 LF (SEQ ID NO: 217) sequence or motif to improve binding/antagonist activity on TEAD.
- the LX 1 X 2 LF (SEQ ID NO: 217) is mutated or grafted on the peptide at any position along the sequence which allows for improve binding/antagonist activity on TEAD.
- the example illustrates a method for the computational design of a peptide library of scaffold peptides with three disulfide cross-links that bind to TEAD.
- Initial candidates were identified either by searching for specific peptide properties or through peptide design.
- the Rosetta software package was used for peptide design to identify de novo scaffold construction: candidate scaffold peptides with three disulfide cross-links were constructed by de novo fold design, optimizing only for folding and stability without regard to binding functionality.
- the input topology parameters used for scaffold construction were as follows: minimum and maximum sequence length: 30 and 41 residues, respectively; secondary structure types: helix, helix, helix; secondary structure length ranges: 6-18 residues; turn lengths: 2-4 residues; number of disulfides: 3; disulfide topology: H1-H2, H1-H3, and H2-H3.
- Several hundred thousand independent design simulations were performed to build a large library of candidate scaffolds, which was then be filtered by sequence-structure compatibility, packing, satisfaction of polar groups, and disulfide score.
- backbone residue segments were selected as superposition targets for orienting design scaffolds: 3KYS/B/53-55, 3KYS/B/55-57, 3KYS/B/64-68, 3KYS/B/64-69, 3KYS/B/86-89, 3KYS/B/94-96 (given as: PDB ID/chain/residue numbers).
- 150 design simulations were conducted targeting each YAP backbone segment selected for superposition.
- Each design simulation consisted of the following steps: (1) superimposing the scaffold backbone onto the YAP backbone segment using a scaffold backbone element with matching secondary structure, (2) random small perturbations to generate diversity and relieve backbone clashes, and (3) all-atom sequence design alternating between fixed-backbone sequence selection and fixed-sequence structure relaxation.
- Final interface designs were filtered for satisfaction of polar groups (using a 1.0 A probe radius), interface surface complementarity (sc score>0.5), and interface quality (predicted binding energy per 100 ⁇ of buried SASA ⁇ 1.1), and sorted by predicted binding energy.
- Top-scoring designs were assessed by an in silico redocking test in which the redesigned scaffold peptide was removed from TEAD, randomly reoriented, and redocked onto the TEAD protein structure.
- FIG. 17 B illustrates the modeled TEAD interface for the YAP-TEAD structure from Protein Data Bank (PDB ID) 3KYS.
- FIG. 17 C illustrates the modeled TEAD interface for SEQ ID NO: 1 modeled with the TEAD structure from FIG. 17 A .
- FIG. 17 D illustrates the modeled TEAD interface for SEQ ID NO: 2 modeled with the TEAD structure from FIG. 17 A .
- This example illustrates methods for improving cell penetrance of a peptide.
- a peptide whose binding partner is located within a cell needs to enter/penetrate a cell in order to exert its activity.
- One method to overcome this is to graft a binding interface of a designed peptide identified by the methods in EXAMPLE 24 onto a cell penetrating peptide scaffold.
- a naturally cell-penetrant peptide is used as the scaffold, such as a calcine or a modified cell-penetrant peptide (such as a modified calcine or calcine derivative).
- Some peptides that are used include, but are not limited to, imperatoxin, maurocalcine, hemicalcin, opiclacin 1, opicalcin 2, midkine (62-104), MCoTI-II, chlorotoxin, and hadrucalcin.
- Such scaffolds used are also modified derivatives of the foregoing calcines as described herein.
- the six amino acid portion of helix 3 (MLICLF; SEQ ID NO: 221), a major component of SEQ ID NO: 9 binding to TEAD, is transplanted onto a calcine scaffold and a bi-functional peptide that retains the cell penetration of the calcine with the novel SEQ ID NO: 9 TEAD binding function is produced.
- This method is used to improve the cell penetrance of any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84.
- cis-acting elements including inclusion of K/R-rich sequences like TAT or octa-arginine (SEQ ID NO: 146), intra-helical arginine patches, or fusion to larger fragments of proteins identified in cell penetration screening like penetratin or melittin are used to improve cell penetrance of a peptide.
- This method is used to improve the cell penetrance of any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84.
- site saturation mutagenesis is used to improve the binding of a calcine based-TEAD binding peptide.
- peptides that are not calcines but that have similar surface charge distributions to calcines are designed, containing a TEAD binding pharmacophore.
- selenocysteine is substituted for some or all cysteine residues in the peptides to result in bridges that are more stable to cytosolic reducing conditions than disulfide bonds.
- activity on ryanoride receptors is mutated out of the peptide.
- the example illustrates a method for the computational design of a peptide library of scaffold cell penetrating peptides.
- Initial candidates are identified either by searching for specific peptide properties (such as cell penetration) or through peptide design.
- the Rosetta software package is used for peptide design to identify de novo scaffold construction: candidate cell-penetrating scaffold peptides with are constructed by de novo fold design, optimizing only for folding and stability without regard to binding functionality.
- Promising peptides identified by de novo scaffold construction, as well as known cell-penetrating peptides of 30-50 residues in length are then used as scaffolds for interface design targeting the SEQ ID NO: 9 footprint on TEAD.
- Interface side chains of the scaffold peptide redesign sequence are targeted in the second stage preserving the core amino acids and disulfide-forming residues. Additionally, the crystal structure of the SEQ ID NO: 9-TEAD complex is examined to identify binding patches on TEAD. Corresponding backbone elements on SEQ ID NO: 9 are observed and are selected to serve as templates for the interface design of the peptide in order to retain binding to TEAD. From this, specific backbone residue segments are selected as superposition targets for orienting design scaffolds. For each peptide scaffold, multiple design simulations are conducted targeting each SEQ ID NO: 9 backbone segment selected for superposition.
- Top-scoring designs are assessed by an in silico redocking test in which the redesigned scaffold peptide was removed from TEAD, randomly reoriented, and redocked onto the TEAD protein structure. Success is measured as the fraction of low-energy redocking simulations that reached a final state close to the designed interface conformation. Cell-penetrating peptides that bind to TEAD are identified.
- CD Circular Dichrosim
- FIG. 20 A illustrates that the CD spectra of SEQ ID NO: 9 demonstrated that the structure was dominated by ⁇ -helical elements, and that this secondary structure signature was identical before (Pre) and after (Post) incubation at 95° C.
- the inset shows relative ellipticity at 220 nm during heating from 20° C. to 95° C.
- FIG. 20 B illustrates that the circular dichroism spectra of SEQ ID NO: 10 demonstrated the structure is dominated by ⁇ -helical elements, and that this secondary structure signature was identical before (Pre) and after (Post) incubation at 95° C.
- This inset also shows relative ellipticity at 220 nm during heating from 20° C. to 95° C.
- FIG. 20 C illustrates that the circular dichroism spectra of SEQ ID NO: 11 demonstrated the structure was dominated by ⁇ -helical elements, and that this secondary structure signature was identical before (Pre) and after (Post) incubation at 95° C.
- the inset shows relative ellipticity at 220 nm during heating from 20° C. to 95° C.
- Tm protein melting temperature determination was performed by monitoring protein unfolding using SYPRO Orange dye (Molecular Probes).
- SYPRO Orange dye Molecular Probes
- 0.1 mg/mL protein sample in 20 ⁇ L total volume PBS buffer were mixed with 2 ⁇ L of 10 ⁇ SYPRO Orange dye.
- Dye intercalation into the hydrophobic protein core following protein unfolding was assayed using the C1000 Touch Thermal Cycler with CFX96 Deep Well Real-Time System (BioRad). Samples were heated from 20° C. to 95° C. with stepwise increments of 0.5° C. per minute and a 5 see hold step for every point, followed by fluorescence reading.
- Tm was calculated by analyzing the derivatives of Relative florescence Units (RFU).
- 20 D illustrates this SYPRO Orange melting assay of peptides.
- Human siderocalin Human siderocalin (HuScn) demonstrated an expected melting temperature of 79° C., as interpreted by the peak of its RFU vs. temperature slope. Conversely, no melting temperature could be determined for the three peptides tested (SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11).
- the SYPRO Orange thermal shift assay showed no evidence of protein unfolding, and therefore, SEQ ID NO: 9 and its point variants were shown to be stable at high temperatures.
- a TEAD-binding peptide of the present disclosure is recombinantly expressed or chemically synthesized.
- the peptide is selected from any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84.
- TEAD-binding peptides are conjugated to maurocaline (SEQ ID NO: 168), imperatoxin (SEQ ID NO: 169), hadrucalcin (SEQ ID NO: 170), hemicalcin (SEQ ID NO: 171), oplicalin-1 (SEQ ID NO: 172), opicalcin-2 (SEQ ID NO: 173), midkine (62-104) (SEQ ID NO: 174), MCoTI-II (SEQ ID NO: 175), chlorotoxin (SEQ ID NO: 176), DRI-TAT31 (rrrqrrkkrgy, wherein the lowercase notation indicates D-amino acids; SEQ ID NO: 280), cyclic heptapeptide cyclo (cF ⁇ R 4 ) (F ⁇ RRRRQ, where (1 is 1-2-naphthylalanine, the entire moiety is cyclized, and Gln serves as a conjugation handle and can be substituted for
- the peptide is linked to the cell penetrating moeity by a linker, in which amine coupling is used to attach the linker/functional group to amines on a TEAD-binding peptide of the present disclosure.
- a linker in which amine coupling is used to attach the linker/functional group to amines on a TEAD-binding peptide of the present disclosure.
- Any or all Lys residues of a TEAD-binding peptide of the present disclosure may be mutated to Arg to homogenize chemical conjugation and/or enhance cell penetration.
- peptide conjugates are tested for functional impairment of TEAD signaling in 293T cells transfected with a luciferase reporter responsive to YAP:TEAD signaling (8 ⁇ GTIIC), and for inhibition of YAP:TEAD dimerization in HeLa cells by proximity ligation assay (PLA). Liposomal formulation of successful peptide conjugates is investigated. Additionally, in some peptide conjugates, a disulfide bridge, a furin cleavage site (RX[K/R]R), and/or a cathepsin cleavage site is introduced into the linker.
- RX[K/R]R furin cleavage site
- cathepsin cleavage site is introduced into the linker.
- a peptide conjugate is administered to a subject in need thereof.
- the subject is a human or animal and has a disease, such as cancer or diabetes (Type I or Type II).
- target cells are penetrated by peptide conjugates and interact with TEAD to disrupt TEAD binding to transcription coactivators, such as YAP or TAZ.
- This example shows a method of extending the serum half life of a peptide as disclosed herein.
- a peptide of any one of SEQ ID NO: 1-SEQ ID NO: 142 and SEQ ID NO: 222-SEQ ID NO: 279 is modified in order to increase its serum half life.
- Conjugation of the peptide to a near infrared dye, such as Cy5.5 is used to extend serum half life of the peptide conjugate.
- conjugation of the peptide to an albumin binder, such as Albu-tag is used to extend serum half-life.
- serum half-life is extended as a result of reduced immunogenicity by using minimal non-human protein sequences.
- This example describes small scale and large scale production of TEAD Binder-Cell Penetrating Peptide fusions (CPP fusions) and Tandem-Cysteine Dense Peptides (Tandem-CDPs).
- CPP fusions and Tandem-CDPs were cloned in a Daedalus vector, which is a lentivector that drives secretion of siderocalin-tagged proteins.
- the siderocalin produced by this vector is 6 ⁇ His-tagged (SEQ ID NO: 284) and contains the linker that has a TEV cleavage site, leaving only “GS” behind on the peptide's N-terminus after cleavage.
- VSV-G pseudotyped lentivirus was then produced through standard methods. Suspension 293F cells were transduced with the VSV-G pseudotyped lentivirus and were grown in FreeStyle (ThermoFisher) expression media. For small scale production, 1 ⁇ 10 6 cells were then transduced in 1 mL with 100 ⁇ L viral supernatant and shaken at 1,000 rpm until harvest ( ⁇ 7 days). 3 mM valproic acid was added after 5 days.
- FIG. 25 illustrates SDS-PAGE gels of CPP fusions and Tandem-CDPs under non-reduced (NR) and reduced (R) conditions.
- the tested CPP fusions were SEQ ID NO: 96, SEQ ID NO: 95, SEQ ID NO: 85, SEQ ID NO: 97, SEQ ID NO: 105, SEQ ID NO: 111, SEQ ID NO: 100, SEQ ID NO: 94, SEQ ID NO: 109, SEQ ID NO: 99, and SEQ ID NO: 108.
- the tested Tandem-CDPs were SEQ ID NO: 134, SEQ ID NO: 124, SEQ ID NO: 117, SEQ ID NO: 125, SEQ ID NO: 132, SEQ ID NO: 119, SEQ ID NO: 141, SEQ ID NO: 130, and SEQ ID NO: 138.
- the CPP fusions and Tandem-CDPs were produced at small scale in 1 mL cultures and TEV-cleaved to separate the peptide (lower band(s) in FIG. 25 ) from the siderocalin carrier (middle band(s) in FIG. 25 ). Uncleaved fusion proteins appear as the top-most band (s).
- Molecular weight markers (MWMs) are shown in kiloDalton (kDa) in the lane immediately to the right of the (non-reduced) NR and (reduced) R lanes for each sequence.
- FIG. 26 illustrates non-reduced SDS-PAGE gels of CPP fusions and Tandem-CDPs. From left to right, FIG. 26 shows four controls including hadrucalcin (SEQ ID NO: 170), imperatoxin (SEQ ID NO: 169), opicalcin-2 (SEQ ID NO: 173), and chlorotoxin (SEQ ID NO: 176) were tested.
- FIG. 26 additionally shows the TEAD Binder of (SEQ ID NO: 9), CPP fusions of SEQ ID NO: 95 and SEQ ID NO: 96, and Tandem-CDPs of SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 124, SEQ ID NO: 125, and SEQ ID NO: 134.
- Molecular weight markers are shown in kiloDalton (kDa) in the left most lane.
- This example shows the use of a chloroalkane penetration assay (CAPA) to determine cell penetration and cytosolic access of the Tandem CDP of SEQ ID NO: 124.
- CUA chloroalkane penetration assay
- HeLa cells expressing the HaloEnzyme (a modified bacterial haloalkane dehalogenase, further modified to target to the cytosol-facing side of the outer mitochondrial membrane) were grown in 24 well dishes until ⁇ 60% confluent. Cells were rinsed with PBS and then incubated with solutions comprising no HaloTag (HT) or 1 ⁇ M HT, or with 1 ⁇ M HT-SEQ ID NO: 176, HT-SEQ ID NO: 9, HT-SEQ ID NO: 232, or HT-SEQ ID NO: 124 in Opti-MEM serum free buffer for 4 hours.
- HaloEnzyme a modified bacterial haloalkane dehalogenase, further modified to target to the cytosol-facing side of the outer mitochondrial membrane
- FIG. 27 illustrates microscopy images of HeLa cells evaluated for cell penetration with a Halo assay.
- the top left image shows the fluorescence of cells treated with a test solution with 1 ⁇ M HT (no protein).
- the top right image shows the fluorescence of cells treated with buffer only.
- the bottom left image shows the fluorescence of cells treated with 1 ⁇ M HT-SEQ ID NO: 9 (bottom left).
- the bottom right image shows the fluorescence of cells treated with 1 ⁇ M HT-SEQ ID NO: 124 (bottom right).
- the peptide of SEQ ID NO: 124 (bottom right) exhibited high cell penetration.
- FIG. 28 illustrates cell-by-cell quantitation of average fluorescence in the red channel of cells in a CAPA.
- Cells were incubated with no HaloTag (HT) (not shown in figure; used for calibration as 0 cell penetration score (CPS) indicating no cell penetration), 1 ⁇ M HT (not shown in graph; used for calibration as 1 CPS indicating total cell penetration), 1 ⁇ M HT-SEQ ID NO: 9 (a control TEAD binder), 1 ⁇ M SEQ ID NO: 94, 1 ⁇ M HT-SEQ ID NO: 95, 1 ⁇ M HT-SEQ ID NO: 96, 1 ⁇ M HT-SEQ ID NO: 119, 1 ⁇ M HT-SEQ ID NO: 124, 1 ⁇ M HT-SEQ ID NO: 125, or 1 ⁇ M HT-SEQ ID NO: 134.
- HT HaloTag
- CPS cell penetration score
- a high CPS (the inverse of the cells' fluorescence, calibrated to the no HT (0 CPS) and 1 ⁇ M HT (1 CPS) controls) indicated that the intracellular HaloEnzyme was occupied by HT, and thus, the tested HT-ligand-labeled peptide comprised a peptide that was cell penetrating.
- a low CPS indicated that the intracellular HaloEnzyme was unoccupied allowing for accumulation of HT-TAMRA in cells, and that, therefore, the tested HT-ligand-labeled peptide was not cell penetrating.
- a CPS above the original TEAD binder (SEQ ID NO: 9) suggests an improvement in cell penetration.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biotechnology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- This application is a Continuation Application of U.S. application Ser. No. 16/478,672, filed Jul. 17, 2019, which is a U.S. National Phase Application under 35 U.S.C. § 371 of International Application No. PCT/US2018/014203, filed Jan. 18, 2018, which claims the benefit of U.S. Provisional Patent Application No. 62/447,864, filed Jan. 18, 2017, and U.S. Provisional Patent Application No. 62/510,719, filed May 24, 2017, the disclosures of which are incorporated herein in their entireties.
- The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jan. 17, 2018, is named 44189-718_601_SL.txt and is 177,067 bytes in size.
- Cancer is a leading cause of death worldwide, with more than 90% of all cancer-related deaths caused by metastasis. The HIPPO signaling pathway is important for cell growth, cell contact inhibition, and organogenesis. If the HIPPO pathway is disrupted, oncogenes can be left unchecked, causing overexpression of downstream genes that favor cell proliferation, tumor progression, and metastasis. As such, there is need for inhibitors of the HIPPO pathway with high affinity and specificity so that unchecked oncogenes can be suppressed. Such HIPPO pathway modulators, including inhibitors, can be used to prevent or treat cancers, tumor progression, metastasis, or other disease or condition associated with a dysregulated HIPPO pathway.
- The present disclosure provides compositions and methods for disrupting TEAD interactions.
- This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This summary is not intended to identify key features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.
- In various aspects, the present disclosure provides a composition, comprising a non-naturally occurring, synthetic, or engineered peptide capable of binding to TEAD, or a variant, homolog, or analog thereof. In some aspects, the peptide binds to TEAD and disrupts TEAD interactions. In some aspects, the TEAD interactions comprise TEAD interaction with TAZ, YAP, or any combination thereof.
- In some aspects, the peptide disrupts or inhibits one or more components of a HIPPO signaling pathway. In other aspects, the peptide modulates one or more components of a HIPPO signaling pathway. In some aspects, the peptide suppresses an oncogene in a HIPPO signaling pathways.
- In some aspects, the peptide comprises from 1 to 10 contiguous amino acids from YAP peptide. In further aspects, the from 1 to 10 contiguous amino acids are selected from one or more of amino acid residues: 53-55, 55-57, 64-68, 64-69, 86-89, or 94-96 of the B chain of PDB 3KYS. In some aspects, the from 1 to 10 contiguous amino acids is grafted onto a peptide comprising three disulfide cross-linkers. In various aspects, the peptide comprising three disulfide cross-linkers is a knottin. In some aspects, the from 1 to 10 contiguous amino acids is grafted onto a cell-penetrating peptide. In further aspects, the cell-penetrating peptide is maurocalcin, imperatoxin, hadrucalcin, hemicalcin, opicalcin-1, opicalcin-2, midkine (62-104), MCoTI-II, or chlorotoxin. In various aspects, the cell-penetrating peptide comprises at least 60%, 70%, 80%, 90%, 95%, or 100% sequence identity with any one of SEQ ID NO: 168-SEQ ID NO: 176.
- In some aspects, the peptide comprises a sequence of any one of SEQ ID NO: 1-SEQ ID NO: 42, or a variant or fragment thereof. In further aspects, the peptide comprises a sequence that has at least 80% sequence identity with any one of SEQ ID NO: 1-SEQ ID NO: 42, or a variant or a fragment thereof. In still further aspects, the peptide comprises a sequence that has at least 85%, at least 90%, or at least 95% sequence identity with any one of SEQ ID NO: 1-SEQ ID NO: 42 or a variant or a fragment thereof.
- In some aspects, the peptide comprises a sequence of any one of SEQ ID NO: 43-SEQ ID NO: 84, or a variant or a fragment thereof. In further aspects, the peptide comprises a sequence that has at least 80% sequence identity with any one of SEQ ID NO: 45-SEQ ID NO: 84, or a variant or a fragment thereof. In still further aspects, the peptide comprises a sequence that has at least 85%, at least 90%, or at least 95% sequence identity with any one of SEQ ID NO: 43-SEQ ID NO: 84 or a variant or a fragment thereof. In some aspects, the peptide is a knotted peptide or is derived from a knotted peptide.
- In other aspects, the peptide competes with YAP or TAZ for binding to TEAD. In some aspects the peptide sequesters TEAD or prevents another protein from binding to TEAD. In further aspects, the peptide has equal or greater affinity or specificity for TEAD as compared to that of YAP or TAZ. In some aspects, the peptide has equal or lower dissociation constant for TEAD as compared to that of YAP or TAZ. In further aspects, the peptide has a KD of less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 1 nM, or less than 0.1 nM.
- In some aspects, the peptide can penetrate or localize into a target cell. In other aspects, the peptide penetrates or localizes into a target cell by formulation with, fusion to, or conjugation to a cell-penetrating moiety. In some aspects, the cell-penetrating moiety comprises polycations, polyorganic acids, endosomal releasing polymers, poly(2-propylacrylic acid), poly(2-ethylacrylic acid), Tat peptide, Arg patch, a knotted peptide, CysTAT, S19-TAT, R8 (SEQ ID NO: 146), pAntp, Pas-TAT, Pas-R8 (SEQ ID NO: 149), Pas-FHV, Pas-pAntP, F2R4 (SEQ ID NO: 152), B55, aurin, IMT-P8, BR2, OMOTAG1, OMOTAG2, pVEC, SynB3, DPV1047, C105Y, Transpotan, MTS, hLF, PFVYLI (SEQ ID NO: 166), maurocalcine, imperatoxin, hadrucalin, hemicalcin, opicalcin-1, opicalcin-2, midkin(62-104), MCoTI-II, chlorotoxin, DRI-TAT, cFΦR4 (SEQ ID NO: 281), myristate, yBBR, or a fragment or variant thereof, or any combination thereof. In further aspects, the cell-penetrating moiety comprises at least 80%, 90%, 95%, 98%, or 100% sequence identity with any sequence of SEQ ID NO: 143-SEQ ID NO: 176. I other aspects, the peptide fusion to the cell-penetrating moiety comprises at least 80%, 90%, 95%, 98%, or 100% sequence identity with SEQ ID NO: 85-SEQ ID NO: 142 or SEQ ID NO: 222-SEQ ID NO: 279.
- In other aspects, the peptide can localize into a target cell's nucleus. In further aspects, the peptide localizes into the target cell's nucleus by formulation with, fusion to, or conjugation to a nuclear localization signal peptide or moiety. In some aspects, the peptide is further conjugated to, linked to, or fused to a moiety or a second peptide that targets, homes, or selectively penetrates a cancer cell. In some aspects, the moiety or a second peptide is a knotted peptide or variant or fragment thereof. In further aspects, the knotted peptide targets or homes the peptide across the blood brain barrier.
- In some aspects, the peptide is conjugated to, linked to, or fused to a moiety that targets TEAD inactivation or degradation. In some aspects, the moiety that targets TEAD inactivation or degradation results in post-translational modification of TEAD. In some aspects, the post-translational modification of TEAD comprises ubiquitination.
- In other aspects, the target cell is a cell with a dysregulated HIPPO pathway. In some aspects, the target cell is a cell with uncontrolled or dysregulated cell growth. In some aspects, the target cell is a cancerous cell or a tumor cell. In other aspects, the target cell is a pancreatic cell, liver cell, colon cell, ovarian cell, breast cell, lung cell, brain cell, or any combination thereof.
- In some aspects, the peptide comprises a disulfide through disulfide knot. In some aspects, the peptide comprises a plurality of disulfide bridges formed between cysteine residues. In some aspects, the peptide comprises three or more disulfide bridges formed between cysteine residues, wherein one of the disulfide bridges passes through a loop formed by two other disulfide bridges. In other aspects, the peptide comprises no disulfide bond or a disulfide knot.
- In some aspects, at least one amino acid residue of the peptide is in an L configuration or, wherein at least one amino acid residue is in a D configuration. In some aspects, the peptide comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 positively charged residues.
- In other aspects, the peptide comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 consecutive positively charged residues. In some aspects, the positively charged residues are Arg, Lys, or any combination thereof.
- In still other aspects, the peptide comprises an Arg patch. In some aspects, the peptide comprises two or more consecutive Arg residues at the N-terminus. In some aspects, the peptide comprises a Tat peptide, or a fragment thereof. In some aspects, the Tat peptide comprises a sequence YGRKKRRQRRR (SEQ ID NO: 195), GRKKRRQRRR (SEQ ID NO: 143), or a fragment or variant thereof.
- In some aspects, the Tat peptide is appended to the N-terminus or C-terminus of the peptide using a linker having a sequence of (GS)x (SEQ ID NO: 282) or GxSy (SEQ ID NO: 283), wherein x and y is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In other aspects, the Tat peptide is appended to any residue of the peptide. In still other aspects, the Tat peptide is appended to any residue of the peptide without interfering with TEAD-binding activity.
- In some aspects, the peptide comprises at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, or at least 16 cysteine residues. In other aspects, the peptide comprises one, two, three, four, five, or six Cys residues.
- In some aspects, the peptide comprises, is mutated to comprise, or is grafted to comprise LX1X2LF (SEQ ID NO: 217), wherein X1 and X2 is any amino acid. In further aspects, X1 and X2 in the LX1X2LF (SEQ ID NO: 217) comprises EA, IC, EC, MC, VC, or FC. In some aspects, the peptide comprises, is mutated to comprise, or is grafted to comprise a LX1X2LF (SEQ ID NO: 217) motif, wherein X1 and X2 is any amino acid. In further aspects, X1 and X2 in the LX1X2LF (SEQ ID NO: 217) motif comprises EA, IC, EC, MC, VC, or FC. In some aspects, the peptide comprises a mutation at positions: L23, L26, and F27. In other aspects, the peptide comprises a mutation at positions: G15, Y23, E25, G28, and P40. In still other aspects, the peptide comprises a mutation at positions: G15, Y23, and P40.
- In still other aspects, the peptide comprises a mutation at position P40. In some aspects, the peptide comprises one or more mutations selected from the group consisting of: G15Q, Y23I, E25D, G28K, and P40W. In some aspects, the peptide comprises E25D, G28K, and P40W.
- In some aspects, the peptide comprises one or more regions of negatively charged residues. In some aspects, the peptide comprises one or more regions of positively charged residues. In some aspects, the peptide sequence comprises at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58 residues, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, at least 65, at least 66, at least 67, at least 68, at least 69, at least 70, at least 71, at least 72, at least 73, at least 74, at least 75, at least 76, at least 77, at least 78, at least 79, at least 80, or at least 81 residues.
- In some aspects, the peptide comprises or is derived from the group consisting of: chlorotoxins, brazzeins, circulins, stecrisps, hanatoxins, midkines, hefutoxins, potato carboxypeptidase inhibitors, bubble proteins, attractins, α-GI, α-GID, μ-pIIIA, ω-MVIIA, ω-CVID, χ-MrIA, ρ-TIA, conantokin G, contulakin G, GsMTx4, margatoxins, shK, toxin K, chymotrypsin inhibitors (CTI), EGF epiregulin core, hainantoxins, theraphotoxins, hexatoxins, opicalcins, imperatoxins, defensins, and insectotoxins.
- In some aspects, the peptide comprises or is derived from a human protein or peptide. In some aspects, the peptide is arranged in a multimeric structure with at least one other peptide. In further aspects, the multimeric structure comprises a dimer, trimer, tetramer, pentamer, hexamer, or heptamer.
- In some aspects, the peptide comprises an isoelectric point within a range from about 3.0 to about 10.0. In other aspects, the peptide comprises an isoelectric point within a range from about 4.5 to about 8.9. In some aspects, the peptide comprises a non-uniform charge distribution. In some aspects, the peptide is stable at physiological or intracellular pH values. In other aspects, the peptide is stable at pH of about 7 or 7.5. In still other aspects, the peptide is stable at pH of about 6.5 to 7.5.
- In still other aspects, the peptide is stable at pH values less than or equal to about 5.0, less than or equal to about 3.0, or within a range from about 3.0 to about 5.0. In other aspects, the peptide is stable at pH values within a range from about 5.0 to about 7.0. In some aspects, the peptide comprises a hydrophobic core.
- In some aspects, the peptide is resistant to protease degradation. In further aspects, the protease is any one of pepsin, trypsin, chymotrypsin, serum proteases, intracellular proteases, or any combination thereof. In other aspects, the peptide is resistant to reduction or is stable in a reducing environment.
- In further aspects, the reduction or reducing environment comprises DDT or GSH. In some aspects, the peptide is stable at an elevated temperature. In some aspects, the peptide is capable of penetrating a cell membrane. In some aspects, the peptide exhibits an anti-cancer effect. In some aspects, the peptide comprises one or more chemical modifications. In further aspects, the chemical modification extends the half-life or modifies a pharmacokinetics of the peptide. In some aspects, the chemical modification is blocking the N-terminus of the peptide. In some aspects, the chemical modification is methylation, acetylation, or acylation.
- In some aspects, the chemical modification is: methylation of one or more lysine residues or analogue thereof; methylation of the N-terminus; or methylation of one or more lysine residue or analogue thereof and methylation of the N-terminus. In other aspects, the peptide is linked to an acyl adduct.
- In some aspects, the peptide is conjugated to, linked to, or fused with an active agent. In further aspects, the active agent is conjugated to, linked to, or fused with the peptide at an N-terminus or a C-terminus of the peptide. In some aspects, the active agent is an antibody, antibody fragment, Fc, or single chain Fv. In other aspects, the peptide is conjugated to, linked to, fused to, or is embedded in an Fc domain. In some aspects, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 active agents are linked to the peptide.
- In further aspects, the peptide is linked to the active agent via a cleavable linker or a pH sensitive linker. In some aspects, the peptide is linked to the active agent at an N-terminus, at the epsilon amine of an internal lysine residue, at the carboxylic acid of an aspartic acid or glutamic acid residue, or a C-terminus of the peptide by a linker. In other aspects, the composition further comprises a non-natural amino acid, wherein the non-natural amino acid is an insertion, appendage, or substitution for another amino acid.
- In other aspects, the peptide is linked to the active agent at the non-natural amino acid by a linker. In some aspects, the linker comprises an amide bond, an ester bond, a carbamate bond, a carbonate bond, a hydrazone bond, an oxime bond, a disulfide bond, a thioester bond, a thioether bond, or a carbon-nitrogen bond. In some aspects, the cleavable linker comprises a cleavage site for matrix metalloproteinases, thrombin, cathepsins, or beta-glucuronidase. In other aspects, the linker is a hydrolytically labile linker.
- In still other aspects, the peptide is linked to the active agent via a noncleavable linker. In some aspects, the active agent is an anti-cancer agent. In further aspects, the active agent is an auristatin, MMAE, a maytansinoid, DM1, DM4, doxorubicin, a calicheamicin, a platinum compound, cisplatin, a taxane, paclitaxel, SN-38, a BACE inhibitor, a Bcl-xL inhibitor, WEHI-539, venetoclax, ABT-199, navitoclax, AT-101, obatoclax, a pyrrolobenzodiazepine or pyrrolobenzodiazepine dimer, or dolastatin.
- In other aspects, the composition further comprises a half-life modifying agent coupled to the peptide. In some aspects, the half-life modifying agent comprises a polymer, a polyethylene glycol (PEG), a hydroxyethyl starch, polyvinyl alcohol, a water soluble polymer, a zwitterionic water soluble polymer, a water soluble poly(amino acid), a water soluble polymer of proline, alanine and serine, a water soluble polymer containing glycine, glutamic acid, and serine, an Fc region, a fatty acid, palmitic acid, or a molecule that binds to albumin.
- In some aspects, the composition further comprises a detectable agent coupled to the peptide. In some aspects, the detectable agent is conjugated to, linked to, or fused with the peptide at an N-terminus or a C-terminus of the peptide. In some aspects, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 detectable agents are linked to the peptide. In some aspects, the peptide is linked to the detectable agent via a cleavable linker. In other aspects, the peptide is linked to the detectable agent at an N-terminus, at the epsilon amine of an internal lysine residue, or a C-terminus of the peptide by a linker. In some aspects, the composition further comprises a non-natural amino acid, wherein the non-natural amino acid is an insertion, appendage, or substitution for another amino acid.
- In other aspects, the peptide is linked to the detectable agent at the non-natural amino acid by a linker. In some aspects, the linker comprises an amide bond, an ester bond, a carbamate bond, a hydrazone bond, an oxime bond, or a carbon-nitrogen bond. In some aspects, the cleavable linker comprises a cleavage site for matrix metalloproteinases, thrombin, cathepsins, or beta-glucuronidase.
- In still other aspects, the peptide is linked to the detectable agent via a noncleavable linker. In some aspects, the detectable agent is a fluorophore, a near-infrared dye, a contrast agent, a nanoparticle, a metal-containing nanoparticle, a metal chelate, an X-ray contrast agent, a PET agent, a radioisotope, or a radionuclide chelator. In some aspects, the detectable agent is a fluorescent dye.
- In various aspects, the present disclosure provides a pharmaceutical composition comprising any of the compositions described above, or a salt thereof, and a pharmaceutically acceptable carrier. In some aspects, the pharmaceutical composition is formulated for administration to a subject. In some aspects, the pharmaceutical composition is formulated for oral administration, intravenous administration, subcutaneous administration, intramuscular administration, or a combination thereof.
- In various aspects, the present disclosure provides a method of treating a condition in a subject in need thereof, the method comprising: administering to the subject any of the compositions described above or any of the pharmaceutical compositions described above. In some aspects, the composition is administered by inhalation, intranasally, orally, topically, intravenously, subcutaneously, intramuscularly administration, intraperitoneally, intratumoral, or a combination thereof. In other aspects, the composition is administered intravenously as a bolus, infusion, or prolonged infusion.
- In some aspects, the composition or pharmaceutical composition disrupts YAP interactions with TEAD. In some aspects, the composition or pharmaceutical composition prevents YAP from binding to TEAD. In other aspects, the composition or pharmaceutical composition competes with YAP for binding to TEAD. In some aspects, the composition or pharmaceutical composition binds to TEAD. In some aspects, the composition or pharmaceutical composition inhibits an oncogene in a HIPPO signaling pathway.
- In some aspects, the composition or pharmaceutical composition is internalized by a cell. In other aspects, the composition or pharmaceutical composition penetrates a cell membrane of a target cell. In some aspects, the condition is diabetes. In other aspects, the condition is a cancer or a tumor. In further aspects, the cancer is pancreatic cancer, liver cancer, colon cancer, ovarian cancer, brain cancer, or lung cancer.
- In some aspects, the cancer is associated with a mutation in the HIPPO pathway. In some aspects, the condition comprises unregulated cell growth or dysregulated HIPPO pathway. In some aspects, the composition or the pharmaceutical composition is administered multiple times a day, twice a day, once a day, twice a week, three times a week, once a week, once every two weeks, or once a month or once every three months. In other aspects, the composition is administered subcutaneously once a day, once a week, or once a month.
- In some aspects, a method for designing a peptide capable of binding to TEAD comprises: a) using a computer program to identify a peptide from a library of peptides with optimized stability and folding, wherein each peptide of the library of peptides comprises at least three disulfide cross-linkers; b) using a computer program to superimpose amino acid residues of a binding patch from a peptide:TEAD complex to determine a stable peptide that binds to TEAD after grafting the binding patch onto the peptide; and c) grafting the binding patch onto the peptide to produce the stable peptide. In some aspects, the method further comprising performing site saturation mutagenesis to obtain a mutated peptide with a higher binding affinity for TEAD than the stable peptide. In other aspects, the peptide from a library of peptides is between 20 and 55 amino acid residues in length. In additional aspects, the method further comprises designing a peptide capable of cell penetration comprising: e) using a computer program to identify a peptide from a library of peptides with optimized stability and folding, wherein each peptide of the library of peptides comprises is capable of cell penetration; f) using a computer program to superimpose amino acid residues of a binding patch from the mutant peptide:TEAD complex to determine a new peptide that binds to TEAD after grafting the binding patch onto the peptide; and g) grafting the binding patch onto the mutant peptide to produce the new peptide.
- All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
- The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
-
FIG. 1 illustrates validation and functional analysis of the produced biotinylated TEAD and Siderocalin-fused YAP. -
FIG. 1A illustrates SDS-PAGE with a band near 55 kDa corresponding to a sample of Siderocalin-YAP. -
FIG. 1B illustrates surface plasmon resonance (SPR) data showing that Siderocalin-fused YAP binds to biotinylated TEAD immobilized on an SPR chip with a dissociation constant (KD) of 570 nM. -
FIG. 1C illustrates that HEK-293 cells expressing surface-tethered YAP (50-171) is stained by Alexa Fluorophore (AF)-647 conjugated to Streptavidin (AF657-Streptavidin) bound to biotinylated TEAD, corresponding to the right peak. Cells expressing the Machupo virus (MACV) glycoprotein, a specific ligand for human transferrin receptor, are not stained by AF-647, indicating that TEAD does not bind MACV, corresponding to the left peak. -
FIG. 2 illustrates how the surface display GFP FasL (SDGF) vector provides an effective mammalian display method for identifying and evaluating protein-protein interactions, such as peptide-TEAD binding and knotted peptide binding to another moiety or protein. -
FIG. 2A illustrates a schematic of the SDGF vector. Cytosolic, N-terminal GFP is connected to the extracellular domain of a peptide via a transmembrane domain of human FasL. A bovine rhodopsin C9 tag and/or a short linker can be used to connect the FasL transmembrane domain and the N-terminus of a peptide. Any peptide or a library of peptides, including, but not limited to, knottin peptides, or any recombinant, engineered, or designed peptides, can be screened for binding to a protein of interest using this method. Elastase binding to a GFP-elafin fusion peptide is shown here as an example. The protein of interest, such as elastase in the example, can be tagged or stained with a detectable moiety, such as a fluorescent label, that confers fluorescence or a detectable signal to the cell to indicate protein binding or protein-peptide interaction. -
FIG. 2B illustrates flow cytometry histograms showing that HEK-293 suspensions cells expressing SDGF-elafin are stained by AF647-conjugated elastase (as shown by the right-most peak). Negative control experiments with cells expressing either SDGF-YAP (50-171) or SDGF-MACV glycoprotein are not stained by AF647 elastase (as shown by the overlapping left-most peaks). -
FIG. 3 illustrates screening a designed or engineered library of peptides for TEAD-binding. -
FIG. 3A illustrates a schematic of the screening steps for evaluating SDGF peptide libraries for protein binding. -
FIG. 3B illustrates flow cytometry plots showing the fluorescence of peptide construct expression (e.g., GFP-fused peptides or peptide library) on the x-axis and target or partner protein of interest bound (e.g., TEAD stained with AF647) to the peptides on the y-axis. Double-positive cells (upper right hand quadrant) indicate peptide-expressing cells that are bound to the target protein or protein of interest, such as TEAD. HEK-293 cells were transduced with the SDGF TEAD-binder peptide library and stained with 200 nM AF647-Streptavidin-TEAD. Flow cytometry plots show unsorted cells, cells sorted after 1, 2, or 3 rounds of sorting. -
FIG. 3C illustrates Illumina sequencing data plotting the abundance of each library member versus its abundance prior to the screening and sorting (“input”) afterround -
FIG. 3D illustrates flow cytometry plots showing construct expression (GFP) on the x-axis and TEAD (AF647) on the y-axis. Double-positive cells (upper right hand quadrant) indicate peptide-expressing cells that are bound to TEAD. HEK-293 suspension cells were transfected with hits from the screen cloned into the SDGF vector and stained with 200 nm AF647-Streptavidin-TEAD. Peptides tested included peptides of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3. -
FIG. 4 illustrates the structures of peptides of SEQ ID NO: 1 and SEQ ID NO: 2 and the modeled TEAD interface with YAP overlaid with the structures of peptides of SEQ ID NO: 1 and SEQ ID NO: 2. -
FIG. 4A illustrates that YAP and peptides of SEQ ID NO: 1 and SEQ ID NO: 2 are predicted to bind TEAD at the same site (Site 2). The YAP-TEAD structure (Protein Data Bank (PDB) ID: 3KYS) is available from the Research Collaboratory for Structural Bioinformatics (RCSB). Structures of peptides of SEQ ID NO: 1 and SEQ ID NO: 2 were modeled onto the TEAD structure. -
FIG. 4B illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 2 versus TEAD binding to HEK-293 suspension cells transfected with SDGF-L23A variant of SEQ ID NO: 2 (lysine to alanine variant of SEQ ID NO: 2 at position 23). -
FIG. 4C illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 2 versus TEAD binding to HEK-293 suspension cells transfected with SDGF-L26A variant of SEQ ID NO: 2 (lysine to alanine variant of SEQ ID NO: 2 at position 26). -
FIG. 4D illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 2 versus TEAD binding to HEK-293 suspension cells transfected with SDGF-F27A variant of SEQ ID NO: 2 (phenylalanine to alanine variant of SEQ ID NO: 2 at position 27). -
FIG. 4E illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 2 versus TEAD binding to HEK-293 suspension cells transfected with SDGF-6×CS variant of SEQ ID NO: 2 (a variant of SEQ ID NO: 2 in which all 6 cysteines are mutated to serines). -
FIG. 4F illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 4 (SDGF-E25A variant of SEQ ID NO: 1, which is a glutamic acid to alanine variant of SEQ ID NO: 1 at position 25). -
FIG. 4G illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 6 (SDGF-M33A variant of SEQ ID NO: 1, which is a methionine to alanine variant of SEQ ID NO: 1 at position 33). -
FIG. 4H illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 5 (SDGF-L37A variant of SEQ ID NO: 1, which is a leucine to alanine variant of SEQ ID NO: 1 at position 37). -
FIG. 4I illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 7 (SDGF-F38A variant of SEQ ID NO: 1, which is a phenylalanine to alanine variant of SEQ ID NO: 1 at position 38). -
FIG. 4J illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 184(SDGF-6×CS variant of SEQ ID NO: 1, which is a variant of SEQ ID NO: 1 in which all 6 cysteines are mutated to serines). -
FIG. 5 illustrates binding of soluble TEAD-binding peptides and variants thereof to TEAD. Gels show peptides in reducing conditions in NuPAGE at one-tenth the final volume, in which DTT is at 50 mM. HPLC shows peptides in reducing conditions in Dulbecco's phosphate-buffered saline (DPBS) with a final DTT concentration of 40 mM. Non-reducing conditions are designated as “NR” and reducing conditions are designated as “R.” -
FIG. 5A illustrates an SDS-PAGE gel of a peptide of SEQ ID NO: 1 treated with non-reducing conditions or reducing conditions. -
FIG. 5B illustrates HPLC chromatograms showing peaks representing a peptide of SEQ ID NO: 1 in non-reducing (NR) conditions or in reducing (R) conditions with DTT. -
FIG. 5C illustrates SPR binding assay data of a peptide of SEQ ID NO: 1 to biotinylated TEAD immobilized on an SPR chip with a dissociation constant (KD) of 31 nM. -
FIG. 5D illustrates an SDS-PAGE gel of a peptide of SEQ ID NO: 5 treated with non-reducing conditions or reducing conditions. -
FIG. 5E illustrates HPLC chromatograms showing peaks representing a peptide of SEQ ID NO: 5 in non-reducing conditions or in reducing conditions with DTT. -
FIG. 5F illustrates SPR binding assay data of a peptide of SEQ ID NO: 5 to biotinylated TEAD immobilized on an SPR chip with a dissociation constant (KD) of 280 nM. -
FIG. 5G illustrates an SDS-PAGE gel of a peptide of SEQ ID NO: 7 treated with non-reducing conditions or reducing conditions. -
FIG. 5H illustrates HPLC chromatograms showing peaks representing a peptide of SEQ ID NO: 7 in non-reducing conditions or in reducing conditions with DTT. -
FIG. 5I illustrates SPR binding assay data of a peptide of SEQ ID NO: 7 to biotinylated TEAD immobilized on an SPR chip with a dissociation constant (KD) of 23 μM. -
FIG. 5J illustrates an SDS-PAGE gel of a peptide of SEQ ID NO: 3 treated with non-reducing conditions or reducing conditions. -
FIG. 5K illustrates HPLC chromatograms showing peaks representing a peptide of SEQ ID NO: 3 in non-reducing conditions or in reducing conditions with DTT. -
FIG. 5L illustrates SPR binding assay data of a peptide of SEQ ID NO: 3 to biotinylated TEAD immobilized on an SPR chip with a dissociation constant (KD) of 12 μM. -
FIG. 6 illustrates results from co-immunoprecipitation assays evaluating disruption of the YAP-TEAD interaction with a soluble peptide of SEQ ID NO: 1. -
FIG. 6A illustrates a Silver stain (top panel) and a Western blot (lower panel) showing that FLAG-YAP was not pulled down with Myc-TEAD resin or beads in the presence of a peptide of SEQ ID NO: 1 or SEQ ID NO: 7. -
FIG. 6B illustrates a Western blot showing a dilution series of a peptide of SEQ ID NO: 1 demonstrating dose-dependent inhibition of FLAG-YAP binding to Myc-TEAD resin or beads. -
FIG. 6C illustrates quantified densitometry data plotted fromFIG. 6B . Error bars show standard deviation from quantification of signal in four lanes per sample in one experiment. Amount of FLAG-YAP pulled down by Myc-TEAD beads was normalized to the Myc-TEAD signal for each sample in the Western blot. -
FIG. 7 illustrates the results of a site-saturation mutagenesis screen of SEQ ID NO: 1 variants with improved binding activity to TEAD. Flow cytometry plots show the fluorescence of the peptide construct expression on the x-axis (GFP) and TEAD (AF647) on the y-axis. Double-positive cells (upper right hand quadrant) indicate peptide-expressing cells that are bound to TEAD. Panels labeled “SSM01” indicate cells transduced with the full library of peptide variants. -
FIG. 7A illustrates a flow cytometry plot showing HEK-293 cells expressing a peptide of SEQ ID NO: 1 alone. -
FIG. 7B illustrates a flow cytometry plot showing HEK-293 cells expressing a peptide of SEQ ID NO: 1 incubated with AF647-streptavidin alone, in the absence of biotinylated-TEAD. -
FIG. 7C illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 (site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants) incubated with TEAD before sorting. -
FIG. 7D illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 (site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants) incubated with TEAD after one round of sorting. -
FIG. 7E illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 (site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants) incubated with TEAD after two rounds of sorting. -
FIG. 7F illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 (site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants) incubated with AF647-streptavidin alone, in the absence of biotinylated-TEAD after two rounds of sorting. -
FIG. 8 illustrates enrichment scores at each position for the variants of SEQ ID NO: 1 generated in the site-saturation (SSM) mutagenesis screen and a structural model of the binding interface between the peptide or variant peptide and TEAD. -
FIG. 8A illustrates a matrix of variants of a peptide of SEQ ID NO: 1 generated in the SSM screen. The x-axis shows the sequence of a peptide of SEQ ID NO: 1 versus all substituted non-cysteine residues on the y-axis, after two rounds of sorting. The enrichment score (log 2 change in relative abundance after two rounds of sorting versus input abundance) is indicated on a greyscale. Positive or high enrichment scores (lighter shades of grey) correspond to residues that are more tolerant to substitutions. Negative or lower enrichment scores (darker shades of grey) correspond to residues that are less tolerant to substitution, such as residues that are important to binding. As disclosed herein, amino acid residue position counting does not include the N-terminal GS. -
FIG. 8B illustrates a model of the SEQ ID NO: 1-TEAD interface, in which shading intensity on a greyscale correlates to the average enrichment score at each residue or position. Positive or higher enrichment scores (lighter shades of grey) correspond to residues that are more tolerant to substitutions. Negative or lower enrichment scores (darker shades of grey) correspond to residues that are less tolerant to substitution, such as residues that are important to binding. These residues are most important to retain in a peptide that is desired to block YAP-TEAD interactions; the residues more tolerant of substitution can be varied. Black indicates cysteine residues. As disclosed herein, amino acid residue position counting does not include the N-terminal GS. -
FIG. 9 illustrates that combinations of enriched mutations identified in a peptide of SEQ ID NO: 1 by SSM resulted in improved TEAD binding. -
FIG. 9A illustrates a schematic of the staining protocols used to evaluate TEAD binding. Both the “Normal” and “Extra Wash” protocols used 20 nM of TEAD. -
FIG. 9B illustrates flow cytometry plots showing HEK-293 suspension cells expressing SDGF-SEQ ID NO: 1, SDGF-SEQ ID NO: 9 (QIDKW variant of SEQ ID NO: 1), and YAP. Five-letter codes (e.g. QIDKW) represent variants of a peptide of SEQ ID NO: 1 at residues 15 (G or Q), 23 (Y or I), 25 (E or D), 28 (G or K), and 40 (P or W). -
FIG. 9C illustrates quantification of the mean fluorescence intensity (MFI) of cells that fall in the “slice” gate indicated inFIG. 9B . The x-axis indicates the variant that was tested and all MFI values were normalized to the MFI value for a peptide of SEQ ID NO: 1. Shading of groups of labels on the x-axis represents clustering of mutations found in the variants, e.g., XXDKW (left most group); XXDGW (middle group); XXDKP (right most group). -
FIG. 10 illustrates binding to TEAD by variants of a peptide of SEQ ID NO: 1 as soluble peptides. Non-reducing conditions are designated as “NR” and reducing conditions are designated as “R.” -
FIG. 10A illustrates an SDS-PAGE of a soluble peptide of SEQ ID NO: 9 in non-reduced (NR) or reduced (R) conditions. -
FIG. 10B illustrates an HPLC chromatogram of a peptide of SEQ ID NO: 9 in non-reduced or reduced conditions. -
FIG. 10C illustrates SPR data showing binding of a peptide of SEQ ID NO: 9 to biotinylated TEAD immobilized on an SPR chip. SPR experiments for a peptide of SEQ ID NO: 9 were conducted by single cycle kinetic analysis and the KD was determined to be 368 μM. -
FIG. 10D illustrates an SDS-PAGE of a soluble peptide of SEQ ID NO: 10 in non-reduced (NR) or reduced (R) conditions. -
FIG. 10E illustrates an HPLC chromatogram of a peptide of SEQ ID NO: 10 in non-reduced or reduced conditions. -
FIG. 10F illustrates SPR data showing binding of a peptide of SEQ ID NO: 10 to biotinylated TEAD immobilized on an SPR chip. SPR experiments for a peptide of SEQ ID NO: 10 were conducted by single cycle kinetic analysis and the KD was determined to be 372 μM. -
FIG. 10G illustrates an SDS-PAGE of a soluble peptide of SEQ ID NO: 11 in non-reduced (NR) or reduced (R) conditions. -
FIG. 10H illustrates an HPLC chromatogram of a peptide of SEQ ID NO: 11 in non-reduced or reduced conditions. -
FIG. 10I illustrates SPR data showing binding of a peptide of SEQ ID NO: 11 to biotinylated TEAD immobilized on an SPR chip. SPR experiments for a peptide of SEQ ID NO: 11 were conducted by steady state analysis and the KD was determined to be 3.8 nM. -
FIG. 11 illustrates inhibition of YAP binding to TEAD with a soluble peptide of SEQ ID NO: 9 as compared to inhibition of YAP binding to TEAD with a soluble peptide of SEQ ID NO: 1. -
FIG. 11A illustrates flow cytometry plots showing HEK-293 suspension cells transfected with SDGF-YAP and incubated with 0 nM, 10 nM, or 100 nM of a peptide of SEQ ID NO: 1, followed by incubation with 5 nM biotinylated TEAD, and 5 nM AF647-streptavidin. -
FIG. 11B illustrates flow cytometry plots showing HEK-293 suspension cells transfected with SDGF-YAP and incubated with 0 nM, 10 nM, or 100 nM of a peptide of SEQ ID NO: 9, followed by incubation with 5 nM biotinylated TEAD, and 5 nM AF647-streptavidin. -
FIG. 11C illustrates a dose response curve quantifying the MFI of cells falling within the “slice” gate (representative of YAP-TEAD binding) shown inFIG. 11A andFIG. 11B . Doses below 5 nM TEAD staining does not provide data relevant to IC50 or Ki determination, as cells were stained with 5 nM TEAD. -
FIG. 11D illustrates a flow cytometry plot of cells expressing SDGF-YAP that were incubated with 5 nM TEAD and then washed. Cells were immediately stained with AF647-streptavidin and analyzed for YAP-expressing cells that have bound TEAD. -
FIG. 11E illustrates a flow cytometry plot of cells expressing SDGF-YAP that were incubated with 5 nM TEAD and then washed. Cells were incubated on ice for 1 hour, stained with AF647-streptavidin and analyzed for YAP-expressing cells that have bound TEAD. -
FIG. 11F illustrates a flow cytometry plot of cells expressing SDGF-YAP that were incubated with 5 nM TEAD and then washed. Cells were incubated on ice for 1 hour with 100 nM of a peptide of SEQ ID NO: 1, stained with AF647-streptavidin and analyzed for YAP-expressing cells that have bound TEAD. -
FIG. 11G illustrates a flow cytometry plot of cells expressing SDGF-YAP that were incubated with 5 nM TEAD and then washed. Cells were incubated on ice for 1 hour with 100 nM of a peptide of SEQ ID NO: 9, stained with AF647-streptavidin and analyzed for YAP-expressing cells that have bound TEAD. -
FIG. 12 illustrates stability of TEAD-binding peptides in the presence of reducing agents. -
FIG. 12A illustrates HPLC chromatograms of a peptide of SEQ ID NO: 9 in non-reducing conditions or in 10 mM DTT reducing conditions. Under the HPLC chromatogram is a total ion chromatogram showing the various peaks of SEQ ID NO: 9 after exposure to DTT. A representative mass spectrometry peak profile is shown under the total ion chromatogram. -
FIG. 12B illustrates HPLC chromatograms of peptides of SEQ ID NO: 1 and SEQ ID NO: 9 with or without incubation in 10 mM glutathione (GSH). -
FIG. 13 illustrates binding to TEAD after cells expressing SDGF-SEQ ID NO: 9 are exposed to a reducing agent. -
FIG. 13A illustrates a flow cytometry plot showing binding of HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 (GFP) incubated for 5 minutes in PBS, 10 mM DTT, or 10 mM glutathione (GSH) before staining with 20 nM biotinylated TEAD, followed by a wash and then incubation with 20 nM AF647-streptavidin. -
FIG. 13B illustrates a flow cytometry plot showing binding of HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 9 (GFP) incubated for 5 minutes in PBS, 10 mM DTT, or 10 mM glutathione (GSH) before staining with 20 nM biotinylated TEAD, followed by a wash and then incubation with 20 nM AF647-streptavidin. -
FIG. 13C illustrates quantification of the AF647 MFI of cells falling within the “slice” gate shown inFIG. 13A andFIG. 13B . -
FIG. 14 illustrates protease resistance of a peptide of SEQ ID NO: 9. -
FIG. 14A illustrates HPLC chromatograms of a peptide of SEQ ID NO: 9 after incubation with 500 U trypsin (T), which was then quenched with trypsin inhibitor (I) and placed in non-reducing (NR) conditions or reducing (R) conditions with 10 mM DTT. -
FIG. 14B illustrates a schematic of the SDPR vector, a variant of the SDGF vector shown inFIG. 2A , but with all basic and aromatic residues within the stalk removed to prevent trypsin/chymotrypsin cleavage, and with a 6×His tag (SEQ ID NO: 284) added to the C-terminus of the peptide. Elafin is shown as an example for illustrative purpose. -
FIG. 14C illustrates a flow cytometry plot of HEK-293 suspension cells transfected with protease sensitive SDPR-SK peptide and 0 or 40 μg/ml trypsin for 20 minutes, and stained with an AF647 anti-6×HIS antibody. -
FIG. 14D illustrates a flow cytometry plot of HEK-293 suspension cells transfected with SDPR-SEQ ID NO: 9 peptide and 0 or 40 μg/ml trypsin for 20 minutes, and stained with an AF647 anti-6×HIS antibody. -
FIG. 14E illustrates a flow cytometry plot of HEK-293 suspension cells transfected with SDPR-SK peptide and 0 or 40 μg/ml chymotrypsin for 20 minutes, and stained with an AF647 anti-6×HIS antibody. -
FIG. 14F illustrates a flow cytometry plot of HEK-293 suspension cells transfected with protease sensitive SDPR-SEQ ID NO: 9 peptide and 0 or 40 μg/ml chymotrypsin for 20 minutes, and stained with an AF647 anti-6×HIS antibody. -
FIG. 14G illustrates quantification of flow cytometry data comparing SDPR-SK peptide transfected cells and SDPR-SEQ ID NO: 9 peptide transfected cells, both incubated with trypsin at various concentrations. -
FIG. 14H illustrates quantification of flow cytometry data comparing SDPR-SK peptide transfected cells and SDPR-SEQ ID NO: 9 peptide transfected cells, both incubated with chymotrypsin at various concentrations. -
FIG. 15 shows the results of Surface Plasmon Resonance (SPR) experiments. -
FIG. 15A shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 1 at various concentrations. -
FIG. 15B illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics. -
FIG. 15C shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 5 at various concentrations. -
FIG. 15D illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics. -
FIG. 15E shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 7 at various concentrations. -
FIG. 15F illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics. -
FIG. 15G shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 8 at various concentrations. -
FIG. 15H illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics. -
FIG. 15I shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 11 at various concentrations. -
FIG. 15J illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics. -
FIG. 16 illustrates data from SPR experiments illustrating binding of peptides of the present disclosure to TEAD. -
FIG. 16A illustrates binding of SEQ ID NO: 9 to TEAD using a single cycle kinetics protocol. -
FIG. 16B illustrates binding of SEQ ID NO: 10 to TEAD using a single cycle kinetics protocol. -
FIG. 16C illustrates binding of SEQ ID NO: 11 to TEAD using a steady-state kinetics protocol. -
FIG. 17 illustrates mammalian surface display screening for identifying TEAD-binding peptides. -
FIG. 17A illustrates a scheme for the screening strategy using a surface display GFP FasL (SDGF) vector. In the vector, FasL-TM is the transmembrane domain of the FasL protein. This figure illustrates that the screening strategy can start with a library of disulfide-stabilized peptides, for example, any one of SEQ ID NO: 289-SEQ ID NO: 304. -
FIG. 17B illustrates the modeled TEAD interface for the YAP-TEAD structure from Protein Data Bank (PDB ID) 3KYS. -
FIG. 17C illustrates the modeled TEAD interface for SEQ ID NO: 1 modeled with the TEAD structure fromFIG. 17A . -
FIG. 17D illustrates the modeled TEAD interface for SEQ ID NO: 2 modeled with the TEAD structure fromFIG. 17A . -
FIG. 17E illustrates the TEAD-binding abilities of 293F cells transfected with surface display GFP FasL (SDGF)-SEQ ID NO: 1 compared to cells displaying alanine substitution mutants at sites found at the modeled TEAD interface (SDGF-SEQ ID NO: 4, SDGF-SEQ ID NO: 6, SDGF-SEQ ID NO: 5, and SDGF-SEQ ID NO: 7). The variant with all Cys converted to Ser (6CS) to eliminate disulfide bonds was also tested (SEQ ID NO: 184). Binding was assessed by quantifying Alexa647 levels in transfected cells using flow cytometry. Shown are the median ±95% confidence intervals, normalized to that of cells displaying the parent peptide. -
FIG. 17F illustrates the TEAD-binding abilities of 293F cells transfected with surface display GFP FasL (SDGF)-SEQ ID NO: 2 compared to cells displaying alanine substitution mutants at sites found at the modeled TEAD interface (SDGF-SEQ ID NO: 39, SDGF-SEQ ID NO: 40, SDGF-SEQ ID NO: 41, and SDGF-SEQ ID NO: 42). The variant with all Cys converted to Ser (6CS) to eliminate disulfide bonds were also tested (SEQ ID NO: 185). Binding was assessed by quantifying Alexa647 levels in transfected cells using flow cytometry. Shown are the median ±95% confidence intervals, normalized to that of cells displaying the parent peptide. -
FIG. 18 illustrates that SEQ ID NO: 9 significantly reduces YAP:TEAD dimers in the nucleus. -
FIG. 18A illustrates the relative luminescence units of SEQ ID NO: 1 or SEQ ID NO: 9 expressed directly into the cytosol as part of an mCherry-T2a-peptide fusion construct, co-transfected with YAP and 8×GTIIC (TEAD luciferase reporter). This was done in 24-well plate wells, in which 293 T cells were transfected with 50 ng FLAG-YAP, 300 ng 8×GTIIC, and either 100 or 250 ng mCherry-T2a-peptide plasmids. *: P<0.05, **: P<0.005 vs. YAP only. -
FIG. 18B illustrates the FLAG-tagged SEQ ID NO: 7, FLAG-tagged SEQ ID NO: 1, FLAG-tagged SEQ ID NO: 9, or FLAG-tagged SEQ ID NO: 177 in the mCherry-T2a-peptide construct SDS-PAGE gel mobility shift upon DTT reduction by Western blot (anti-FLAG M2 antibody). Shown are the bands corresponding to the size of the uncleaved fusion protein. SEQ ID NO: 177 is SEQ ID NO: 9-6×CS, in which all six cysteines were mutated to serines, simulating non-oxidizable sulfhydryls. -
FIG. 18C illustrates SEQ ID NO: 9-DyLight488 that was introduced to the cytosol/nucleus of HeLa cells using 5 μM dfTAT, which induces endosomal leakage. dfTAT was visible in the TRITC channel, while SEQ ID NO: 9-DyLight488 was seen in the FITC channel (FIG. 18D ). -
FIG. 18D illustrates SEQ ID NO: 9-DyLight488 that was introduced to the cytosol/nucleus of HeLa cells using 5 μM dfTAT, which induces endosomal leakage. SEQ ID NO: 9-DyLight488 was seen in the FITC channel, while dfTAT was visible in the TRITC channel (FIG. 18C ). -
FIG. 18E illustrates a proximity ligation assay (PLA) in HeLa cells. Using primary antibodies against YAP and TEAD, speckles (APC channel) overlapping DAPI-stained nuclei (UV channel) were produced. Shown is a representative image of cells treated with 5 μM dfTAT only. -
FIG. 18F illustrates a proximity ligation assay (PLA) in HeLa cells. Using primary antibodies against YAP and TEAD, speckles (APC channel) overlapping DAPI-stained nuclei (UV channel) were produced. Shown is a representative image of cells treated with 5 μM dfTAT and 5 μM SEQ ID NO: 9. -
FIG. 18G illustrates a representative image of a control proximity ligation assay (PLA) reaction with anti-YAP primary antibodies omitted in which some speckles were non-specific to YAP:TEAD dimers. -
FIG. 18H illustrates a representative image of a control proximity ligation assay (PLA) reaction with anti-TEAD primary antibodies omitted in which some speckles were non-specific to YAP:TEAD dimers. -
FIG. 18I illustrates a dot graph of automated counting of YAP:TEAD proximity ligation assay (PLA) speckles per nucleus of HeLa cells treated with 5 μM dfTAT and/or 5 μM TEAD-binding peptides. Each dot represents a single nucleus, with the bars representing the median ±95% confidence intervals. A line was drawn at the sum of the two antibody omission samples' average speckle counts, representing the approximate value attributable to non-specific speckles. ****: P<0.0001 vs. any other sample. All P-values determined by two-tailed T-test. -
FIG. 19 illustrates a site saturation mutagenesis (SSM) library of SEQ ID NO: 1 variants. This library contains improved TEAD binders. -
FIG. 19A illustrates the binding profile of SEQ ID NO: 1. SEQ ID NO: 1 binding was apparent but weak under a 20 nM TEAD concentration and 2-step staining binding conditions. -
FIG. 19B illustrates the binding profile of unsorted site saturation mutagenesis (SSM) library stained with TEAD followed by streptavidin-Alexa647. -
FIG. 19C illustrates the binding profile of sorted once site saturation mutagenesis (SSM) library stained with TEAD followed by streptavidin-Alexa647. -
FIG. 19D illustrates the binding profile of sorted twice site saturation mutagenesis (SSM) library stained with TEAD followed by streptavidin-Alexa647. -
FIG. 19E illustrates the binding profile of the population inFIG. 19D stained with streptavidin-Alexa647 only, without TEAD. -
FIG. 20 illustrates SEQ ID NO: 9 and variants of SEQ ID NO: 9 are stable in extreme heat. -
FIG. 20A illustrates circular dichroism spectra of SEQ ID NO: 9, which demonstrates the structure is dominated by α-helical elements, and that this secondary structure signature is identical before (Pre) and after (Post) incubation at 95° C. Inset: relative ellipticity at 220 nm during heating from 20° C. to 95° C. -
FIG. 20B illustrates circular dichroism spectra of SEQ ID NO: 10, which demonstrates the structure is dominated by α-helical elements, and that this secondary structure signature is identical before (Pre) and after (Post) incubation at 95° C. Inset: relative ellipticity at 220 nm during heating from 20° C. to 95° C. -
FIG. 20C illustrates circular dichroism spectra of SEQ ID NO: 11, which demonstrates the structure is dominated by α-helical elements, and that this secondary structure signature is identical before (Pre) and after (Post) incubation at 95° C. Inset: relative ellipticity at 220 nm during heating from 20° C. to 95° C. -
FIG. 20D illustrates a SYPRO Orange melting assay of peptides. Shown is the slope of the change in relative fluorescence units (dRFU/dtemp) during heating from 20° C. to 95° C. Human siderocalin (HuScn) demonstrated an expected melting temperature of 79° C., as interpreted by the peak of its RFU vs temperature slope. Conversely, no melting temperature could be determined for the three peptides tested (SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11). -
FIG. 21 illustrates biotinylated TEAD with streptavidin-Alexa647 stained cells expressing surface-displayed YAP. -
FIG. 21A illustrates TEAD produced in Hi5 insect cells. -
FIG. 21B illustrates a cartoon of the surface display GFP FasL (SDGF) vector comprising a bovine rhodopsin C9 tag, and the peptide. -
FIG. 21C illustrates a flow cytometry profile of a suspension of HEK-293 Freestyle (293F) cells transfected with surface display GFP FasL (SDGF)-control peptide stained with anti-C9-Alexa647. -
FIG. 21D illustrates 293F cells transfected with SDGF-YAP are stained by streptavidin-Alexa647 after co-incubation with biotinylated TEAD compared to after co-incubated with a control protein (biotinylated TfR ectodomain). -
FIG. 22 illustrates SEQ ID NO: 2 (TB2G1) soluble peptide has multiple disulfide connection patterns. The reversed-phase chromatography (RPC) traces of the non-reduced (NR) and 10 mM DTT-reduced (R) TB2G1 peptide indicate multiple species prior to reduction. Because they have the same mobility upon elimination of disulfide bonds, there is most likely only one peptide product and the different species are the peptide existing in different disulfide connection patterns. -
FIG. 23 illustrates the full anti-FLAG M2 Western blot fromFIG. 18B of the mCherry-T2a-FLAG-peptide constructs (FLAG-SEQ ID NO: 7, FLAG SEQ ID NO: 1, FLAG SEQ ID NO: 9, or FLAG SEQ ID NO: 184). 293T cells were transfected with 500 ng of construct. As indicated by the Western blot, intact fusion but not cleaved, soluble peptides were found in 293T cell lysate. The prominent bands correspond to the expected size of the intact mCherry-T2a-peptide. The box shows the region where T2a-cleaved, FLAG-tagged peptides would be expected to run, based on SDS-PAGE of soluble, untagged peptides. NR: non-reduced. DTT: 5 mM DTT, added immediately before loading SDS-PAGE gel. UTF: Untransfected 293T lysate. -
FIG. 24 illustrates a surface plasmon resonance (SPR) equilibrium analysis fit curves for TEAD-binding KD determination. This analytical method was used because the separate on- and off-rates of these peptides were faster than the SPR instrument could resolve. -
FIG. 24A illustrates the KD of SEQ ID NO: 1 using surface plasmon resonance (SPR) equilibrium analysis. -
FIG. 24B illustrates the KD of SEQ ID NO: 5 using surface plasmon resonance (SPR) equilibrium analysis. -
FIG. 24C illustrates the KD of SEQ ID NO: 7 using surface plasmon resonance (SPR) equilibrium analysis. -
FIG. 25 illustrates SDS-PAGE gels of TEAD Binder-Cell Penetrating Peptide fusions (CPP fusions) and Tandem-Cysteine Dense Peptides (Tandem-CDPs) under non-reduced (NR) and reduced (R) conditions. The tested CPP fusions were SEQ ID NO: 96, SEQ ID NO: 95, SEQ ID NO: 85, SEQ ID NO: 97, SEQ ID NO: 105, SEQ ID NO: 111, SEQ ID NO: 100, SEQ ID NO: 94, SEQ ID NO: 109, SEQ ID NO: 98, and SEQ ID NO: 108. The tested Tandem-CDPs were SEQ ID NO: 134, SEQ ID NO: 124, SEQ ID NO: 117, SEQ ID NO: 125, SEQ ID NO: 132, SEQ ID NO: 119, SEQ ID NO: 141, SEQ ID NO: 130, and SEQ ID NO: 138. The CPP fusions and Tandem-CDPs were produced at small scale in 1 mL cultures and TEV-cleaved to separate the peptide (lower band(s) inFIG. 25 ) from the siderocalin carrier (middle band(s) inFIG. 25 ). Uncleaved fusion proteins appear as the top-most band(s). This figure illustrates use of a spacer of sequence GGGS (SEQ ID NO: 203) in SEQ ID NO: 134, SEQ ID NO: 125, and SEQ ID NO: 119. -
FIG. 26 illustrates SDS-PAGE gel, from left to right, of hadrucalcin (SEQ ID NO: 170), imperatoxin (SEQ ID NO: 169), opicalcin-2 (SEQ ID NO: 173), chlorotoxin (SEQ ID NO: 176), the TEAD Binder (SEQ ID NO: 9), CPP fusions of SEQ ID NO: 95 and SEQ ID NO: 96, and Tandem-CDPs of SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 124, SEQ ID NO: 125, and SEQ ID NO: 134. -
FIG. 27 illustrates microscopy images of HeLa cells evaluated for cell penetration with a Halo assay. The top left image shows the fluorescence of cells treated with a test solution with 1 μM HT (no protein). The top right image shows the fluorescence of cells treated with buffer only. The bottom left image shows the fluorescence of cells treated with 1 μM HT-SEQ ID NO: 9 (bottom left). The bottom right image shows the fluorescence of cells treated with 1 μM HT-SEQ ID NO: 124 (bottom right). The peptide of SEQ ID NO: 124 (bottom right) exhibited high cell penetration. -
FIG. 28 illustrates cell-by-cell quantitation of average fluorescence in the red channel of HeLa cells. Cells were incubated with no HaloTag (HT) (not shown in figure; used for calibration as 0 cell penetration score (CPS)), 1 μM HT (not shown in graph; used for calibration as 1 CPS), 1 μM HT-SEQ ID NO: 9 (a control TEAD binder), 1 μM SEQ ID NO: 94, 1 μM HT-SEQ ID NO: 95, 1 μM HT-SEQ ID NO: 96, 1 μM HT-SEQ ID NO: 119, 1 μM HT-SEQ ID NO: 124, 1 μM HT-SEQ ID NO: 125, or 1 μM HT-SEQ ID NO: 134. - The HIPPO signaling pathway plays a critical role in contact inhibition, cell density regulation, cell proliferation, organ size and development (organogenesis), and tissue homeostasis, which are important in cancer development, tumor progression, and metastasis (Hong et al. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 2012 September; 23(7):785-93, Santucci et al. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment. J Med Chem. 2015 Jun. 25; 58(12):4857-73.). This pathway is often dysregulated in many human cancers and other diseases associated with uncontrolled cell growth, including liver, pancreas, colon, ovarian, breast, brain, and lung cancers, melanoma, medulloblastoma, and diabetes (Types I and II), as its dysregulation can result in increased cell proliferation, reduced apoptosis and differentiation, tissue overgrowth, and tumorigenesis. For example, the HIPPO pathway can be disregulated in osteosarcoma, hepatocellular carcinoma, malignant mesothelioma, schwannoma, meningioma, renal carcinoma, cholangiocarcinoma, bile duct hamartoma, soft tissue carcinoma, ovarian carcinoma, colonic adenoma, T cell acute lymphoblastic leukaemia, gastrointestinal hyperplasia, skin cancer, fibrosarcoma, pancreatic ductal metaplasia, squamous cell carcinoma, kaposis sarcoma, and HIV-induced non-Hodgkin's lymphoma.
- Components of the HIPPO pathway are evolutionarily conserved in vertebrates and mammals. In mammals, the HIPPO pathway involves a core kinase cascade involving Mst1 or Mst2, which forms a complex with adaptor protein WW45 and phosphorylates kinases LATS1 and LATS2 and adaptor protein MOB. The LATS/MOB complex can then phosphorylate and repress transcriptional coactivators Yes-associated protein (YAP) and TAZ. Phosphorylation of YAP can promote YAP ubiquitination and subsequent degradation. Various other proteins and complexes regulate YAP protein levels at multiple points, including FERM domain proteins Merlin/NF2 and FRMD6, junctional proteins ZO-2 and AJUB, polarity complex proteins Crumbs, Angiomotin, Scribble, and KIBRA, and protein phosphatases PP2A and
ASPP 1. Tight regulation of YAP is physiologically important, as YAP acts like an oncogene, and its overexpression is implicated in several human cancers. Increased YAP expression and nuclear localization are associated with tumor progression (Hong et al. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 2012 September; 23(7):785-93, Santucci et al. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment. J Med Chem. 2015 Jun. 25; 58(12):4857-73). - YAP is a transcription coactivator and is a key regulator of organ growth and cell proliferation in the HIPPO pathway. YAP interacts with several transcription factors that mediate biological functions of YAP in promoting cell growth, including ErbB4, Runx2, TEAD, and p73. TEAD is one of the most potent targets of YAP, as TEAD is required for YAP to stimulate gene expression and cell growth by activating various genes downstream from YAP. YAP binds to TEAD to mediate YAP-dependent gene induction. For example, interaction between YAP and TEAD can activate connective tissue growth factor (CTGF). Inhibitors that can disrupt the interaction between YAP and TEAD provide a powerful approach to preventing and/or treating cancers or other diseases associated with dysregulation of the HIPPO pathway and/or cell growth, such as diabetes (Type I or Type II). (Hong et al. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 2012 September; 23(7):785-93, Santucci et al. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment. J Med Chem. 2015 Jun. 25; 58(12):4857-73). As described herein, TEAD can be TEAD1, TEAD2, TEAD3, TEAD4, or a fragment, recombinant protein, homolog, or a variant thereof.
- The HIPPO pathway relies on the intranuclear interaction of the transcriptional coactivator YAP and the transcription factor TEAD (1-4). This pathway also plays a crucial role in recovery from injury; for example, its regulated repression allows hepatocytes to divide and replace tissue lost to a partial hepatectomy, after which its activation suppresses cell growth and prevents tissue overgrowth. Designing drugs that target cell growth signaling via protein-protein interactions has proven difficult because targeting protein-protein interactions requires efficient intracellular, and sometimes intranuclear, delivery. While antibodies can be effective in targeting extracellular or cell surface epitopes, intracellular and intranuclear targets, such as the interaction between YAP and TEAD or TEAD and other proteins, are not amenable to antibody-based therapeutics because antibodies generally cannot penetrate the cell membrane to access cytosolic and nuclear target proteins.
- Finding therapeutic agents that can disrupt intracellular protein-protein interactions can be challenging, as such methods require high specificity or targeting, high affinity binders that can disrupt YAP-TEAD interactions, the ability to penetrate cells or the nucleus to act on the target proteins, and having low off-target adverse effects. With few exceptions, high throughput screening campaigns with small molecule libraries failed to provide specific, high affinity binders capable of disrupting larger protein-protein interfaces, such as YAP-TEAD.
- Described herein are peptides and methods of screening peptides for binding to a target protein of interest, such as TEAD, and hence peptides that can disrupt YAP-TEAD interaction or TEAD interaction with other proteins in a cell. The same methods can also be applied to identify peptides that bind to any other target protein or receptor, or any protein of interest, such that peptide binding results in an inhibition or disruption in binding between the target protein of interest and its natural binders or substrates. Examples of target protein include, but not limited to, receptors, such as transferrin receptor (TfR), insulin receptor (InsR), leptin receptor (ObR), and apolipoprotein E3 (ApoE).
- Described herein are peptides, including, but not limited to, designed or engineered peptides, recombinant peptides, and small disulfide-knotted peptides (knottins or knotted peptides), that are large enough to interfere with protein-protein interactions, but small enough to access cellular compartments, such as the cytosol or the nucleus, or tissues, such as the middle of solid tumors, that are generally or often beyond the reach of antibodies. Examples include the calcines, activators of sarcoplasmic reticulum ryanodine receptors, and BLZ-100, a peptide-fluorophore conjugate or fusion that is capable of accumulating in a wide range of tumor types. Because the YAP-TEAD interface is structurally well-characterized (Li et al., 2010; RCSB Protein Data Bank ID: 3KYS, crystal structure of human YAP and TEAD complex), the disclosure provides, in some embodiments, a protein design approach based on the 3D protein complex structure for identifying peptides capable of binding to TEAD and preventing YAP from binding.
- Additional aspects and advantages of the present disclosure will become apparent to those skilled in this art from the following detailed description, wherein illustrative embodiments of the present disclosure are shown and described. As will be realized, the present disclosure is capable of other and different embodiments, and its several details are capable of modifications in various respects, all without departing from the disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.
- As used herein, the abbreviations for the natural L-enantiomeric amino acids are conventional and are as follows: alanine (A, Ala); arginine (R, Arg); asparagine (N, Asn); aspartic acid (D, Asp); cysteine (C, Cys); glutamic acid (E, Glu); glutamine (Q, Gln); glycine (G, Gly); histidine (H, His); isoleucine (I, Ile); leucine (L, Leu); lysine (K, Lys); methionine (M, Met); phenylalanine (F, Phe); proline (P, Pro); serine (S, Ser); threonine (T, Thr); tryptophan (W, Trp); tyrosine (Y, Tyr); valine (V, Val). Typically, Xaa can indicate any amino acid. In some embodiments, X can be asparagine (N), glutamine (Q), histidine (H), lysine (K), or arginine (R).
- The present disclosure refers to amino acid residues and positions of amino acid residues within a sequence. As referred to herein, a position can be referred to as “position X,” wherein X is the position number within a sequence not counting, if present, the N-terminal GS. For example,
position 15 in SEQ ID NO: 1 (GSPDEYIERAKECCKKGDIQCCLRYFEESGDPNVMLICLFCP) refers to the “G” residue atposition 15 within the sequence, whereinposition 1 does not count the N-terminal “GS,” and is, thus, the first P residue. As another example,position 10 in SEQ ID NO: 2 (GSLERLKKCCNQGLDCEEARWKCELEALFQGKNRETCLEEC) refers to the “Q” residue within the sequence atposition 10, whereinposition 1 does not count the N-terminal “GS,” and is, thus, the first L residue. As yet another example,position 10 in SEQ ID NO: 43 (PDEYIERAKECCKKGDIQCCLRYFEESGDPNVMLICLFCP) refers to the “E” residue atposition 10 within the sequence, whereinposition 1 is the very first P residue and there is no N-terminal GS. As also referred to herein, a position can be referred to as “XY,” wherein X is the single-letter abbreviation for an amino acid and wherein Y is the position number within a sequence not counting, if present, the N-terminal GS. For example, G15 refers to the “G” residue atposition 15 within a sequence, not counting, if present, an N-terminal GS. As another example, Y23 refers to the “Y” residue at position 23 within a sequence, not counting, if present, an N-terminal GS. As yet another example, E25 refers to the “E” residue atposition 25 within a sequence, not counting, if present, an N-terminal GS. As also referred to herein, a position can be referred to as “XYZ,” wherein X and Z are the single-letter abbreviation for an amino acid and wherein Y is the position number within a sequence not counting, if present, the N-terminal GS. For example, L23A refers to a “L” residue at position 23 within a sequence (not counting, if present, an N-terminal GS), which has been substituted with a “A” residue. As another example, E25A refers to an “E” residue atposition 25 within a sequence (not counting, if present, an N-terminal GS), which has been substituted with an “A” residue. As yet another example, F27A refers to an “F” residue atposition 27 within a sequence (not counting, if present, an N-terminal GS), which has been substituted with an “A” residue. - Some embodiments of the disclosure contemplate D-amino acid residues of any standard or non-standard amino acid or analogue thereof. When an amino acid sequence is represented as a series of three-letter or one-letter amino acid abbreviations, the left-hand direction is the amino terminal direction and the right-hand direction is the carboxy terminal direction, in accordance with standard usage and convention.
- Disclosed herein are peptide sequences, such as those listed in TABLE 1, capable of binding to TEAD or disrupting YAP-TEAD interaction, TEAD interaction with other proteins, or interaction between homologs, derivatives, or variants of YAP and TEAD. In some embodiments, peptides disclosed herein can penetrate or enter target cells, such as cancerous or tumor cells, liver cells, pancreas cells, colon cells, ovarian cells, breast cells, and/or lung cells, or any combination thereof.
- In some embodiments, peptides can penetrate a nucleus of a cell to modulate transcription activity of a gene. In other embodiments, peptides described herein compete with YAP for binding to TEAD or displace YAP from binding to TEAD. In some embodiments, peptides described herein bind to TEAD, or a variant, homolog, or derivative thereof. In other embodiments, peptides described herein are capable of binding to TEAD and disrupting or inhibiting interaction between TEAD and other proteins or coactivators, such as TAZ. As described herein, “compete” or peptide competition for binding to TEAD or any target protein interest encompasses, but not limited to, steric hindrance, occupying binding sites of TEAD, non-covalent interactions, such as salt bridges or hydrophobic interactions, crosslinking, covalent interactions, sequestration of TEAD, binding to TEAD that prevents localization to the nucleus, and any combination thereof.
- In some embodiments, peptides bind to TEAD with equal, similar, or greater affinity (lower dissociation constant KD) as compared to YAP binding to TEAD. In some embodiments, peptides described herein bind to TEAD with similar, same or equal, or lower dissociation constant as compared to YAP's dissociation constant. In some embodiments, the peptide can have a KD of less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 1 nM, or less than 0.1 nM. In other embodiments, one or more conserved residues at the YAP-TEAD interface are also present in the peptides described here.
- In some embodiments, peptides bind to TEAD at residues found in the YAP-TEAD interface. In some embodiments, a peptide that binds to TEAD comprises at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, or at least 99% homology as the binding interface or the sequence of a protein or co-factor known to bind TEAD. In other embodiments, a peptide described herein binds to a protein of interest, which comprises at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, or at least 99% homology as TEAD, a fragment, homolog, or a variant thereof.
- In some embodiments, peptides can bind to any of the four TEAD homologs, including TEAD1, TEAD2, TEAD3, TEAD4, or any combination thereof. In other embodiments, peptides are capable of binding to one, one or more, two, two or more, three, three or more, or all four TEAD homologs. In some embodiments, peptides of the present disclosure can prevent or disrupt binding between TEAD and any other protein or co-factor known to interact with TEAD. For example, in some embodiments, a peptide of the present disclosure can prevent or interfere with binding between TEAD and TAZ, thereby preventing or reducing oncogenic effects or transcription of a downstream oncogene. YAP and TAZ are two well-known TEAD-binding transcriptional cofactors. TAZ binding to TEAD is similar to YAP binding to TEAD, having similar protein-protein interface or protein binding interactions with TEAD that can be blocked by SEQ ID NO: 1 and its derivatives or variants (e.g. SEQ ID NO: 9; or any of SEQ ID NO: 1-SEQ ID NO: 84), and containing the leucine-X1-X2-leucine-phenylalanine (LX1X2LF, SEQ ID NO: 217), wherein X1 and X2 can be any amino acid, or containing the leucine-X1-X2-leucine-phenylalanine (LX1X2LF, SEQ ID NO: 217) motif, wherein X1 and X2 can be any amino acid. In some embodiments, the X1X2 in the LX1X2LF (SEQ ID NO: 217) can be EA, as shown in SEQ ID NO: 2, or IC as shown in SEQ ID NO: 1. In other embodiments, the X1X2 in the LX1X2LF (SEQ ID NO: 217) can also be EC, MC, VC, or FC. The LX1X2LF (SEQ ID NO: 217) is present in both TAZ and YAP, wherein it is found in a helix comprising amino acids TDLEALFNA (SEQ ID NO: 285). In some embodiments, the X1X2 in the LX1X2LF (SEQ ID NO: 217) motif can be EA, as shown in SEQ ID NO: 2, or IC as shown in SEQ ID NO: 1. In other embodiments, the X1X2 in the LX1X2LF (SEQ ID NO: 217) motif can also be EC, MC, VC, or FC. The LX1X2LF (SEQ ID NO: 217) motif is present in both TAZ and YAP, wherein the motif is found in a helix comprising amino acids TDLEALFNA (SEQ ID NO: 285). TAZ is also implicated in many of the same cancers as YAP, but is not as well studied. (Hong et al. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 2012 September; 23(7):785-93, Santucci et al. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment. J Med Chem. 2015 Jun. 25; 58(12):4857-73). In some embodiments, peptides of the present disclosure can prevent or interfere with binding between TEAD and any TEAD-binding homolog or TEAD-binding moiety. In some embodiments, a peptide that disrupts TEAD binding or interactions comprises a sequence of LX1X2LF (SEQ ID NO: 217), or variant thereof. In other embodiments, a nucleic acid, vector, plasmid, or donor DNA comprises a sequence that encodes a peptide, or variant or fragment thereof, of the present disclosure. In further embodiments, LX1X2LF (SEQ ID NO: 217) can be grafted onto peptide of a sequence of any one of SEQ ID NO: 1-SEQ ID NO: 84. The LX1X2LF (SEQ ID NO: 217) can be grafted onto the peptide at any position along the peptide. This position can be optimized to allow for the LX1X2LF (SEQ ID NO: 217) to be available for binding. For example, it can be grafted into the peptide sequence at a position in the secondary structure that is at the surface of the peptide when folded. Alternatively, the position can be optimized according to higher binding affinity to TEAD and/or to better antagonist TEAD function.
- In some embodiments, peptides inhibit binding between TEAD and YAP, or between YAP and any other protein. In some embodiments, peptides prevent TEAD from protein-protein interaction and/or prevent TEAD localization to a cell's nucleus. In some cases, peptides deactivate TEAD. In some embodiments, peptides can cause TEAD to be degraded, or prevent TEAD from localization to a cell's nucleus, or prevent TEAD from interacting with YAP or YAP-like proteins.
- In some embodiments, peptides inhibit binding between TEAD and YAP, or between YAP and any other protein by binding to a certain amino acid residue or motif of amino acid residues in TEAD. In some embodiments, peptides prevent TEAD from protein-protein interaction and/or prevent TEAD localization to a cell's nucleus by binding to a certain amino acid residue or motif of amino acid residues in TEAD. In some cases, peptides deactivate TEAD by binding to a certain amino acid residue or motif of amino acid residues in TEAD. In some embodiments, peptides can cause TEAD to be degraded, or prevent TEAD from localization to a cell's nucleus, or prevent TEAD from interacting with YAP or YAP-like proteins by binding to a certain amino acid residue or motif of amino acid residues in TEAD. Furthermore, a peptide can be selected for further testing or use based upon its ability to bind to the certain amino acid residue or motif of amino acid residues.
- The certain amino acid residue or motif of amino acid residues in TEAD can be identified an amino acid residue or sequence of amino acid residues that are involved in the binding of TEAD to YAP. A certain amino acid residue or motif of amino acid residues can be identified from a crystal structure of the YAP:TEAD complex. For example, TEAD amino acid residues F314, K316, V318, Y346, F350, K353, V366, or any combination thereof can be target residues for TEAD binding to a peptide as disclosed herein based on the YAP:TEAD crystal structure modeled to bind to SEQ ID NO: 1.
- In some embodiments, a peptide or a library of peptides is designed in silico without derivation from a naturally occurring knottin scaffold. In other embodiments, a peptide or a library of peptides is designed in silico by derivation, grafting relevant or important protein-binding residues, or conserved residues, in the protein-binding interface, or structural modeling based on a naturally occurring peptide or protein known to bind to a protein or receptor of interest.
- In some embodiments, a peptide with SEQ ID NO: 1 is used as a scaffold or base sequence for further modifications, including addition, deletion, or amino acid substitution. In some embodiments, residues GS are added at the N-terminus of a peptide. In some cases, peptides lack GS at the N-terminus. In some instances, peptides undergo one or more post-translational modifications.
- TABLE 1 lists exemplary peptide sequences according to the present disclosure.
-
TABLE 1 Exemplary Peptide Sequences SEQ ID NO Amino Acid Sequence SEQ ID GSPDEYIERAKECCKKGDIQCCLRYFEESGDPNVMLICLFCP NO: 1 SEQ ID GSLERLKKCCNQGLDCEEARWKCELEALFQGKNRETCLEEC NO: 2 SEQ ID GSFGLYDNQCATSDACSAICKYWTGSGQGKCQNNQCRCY NO: 3 SEQ ID GSPDEYIERAKECCKKGDIQCCLRYFAESGDPNVMLICLFCP NO: 4 SEQ ID GSPDEYIERAKECCKKGDIQCCLRYFEESGDPNVMLICAFCP NO: 5 SEQ ID GSPDEYIERAKECCKKGDIQCCLRYFEESGDPNVALICLFCP NO: 6 SEQ ID GSPDEYIERAKECCKKGDIQCCLRYFEESGDPNVMLICLACP NO: 7 SEQ ID GSPDEYIERARRCCRRGDIQCCLRYFEESGDPNVMLICLFCP NO: 8 SEQ ID GSPDEYIERAKECCKKQDIQCCLRIFDESKDPNVMLICLFCW NO: 9 SEQ ID GSPDEYIERAKECCKKQDIQCCLRIFDESGDPNVMLICLFCW NO: 10 SEQ ID GSPDEYIERAKECCKKQDIQCCLRIFDESKDPNVMLICLFCP NO: 11 SEQ ID GSPDEYIERAKECCKKGDIQCCLRIFDESKDPNVMLICLFCW NO: 12 SEQ ID GSPDEYIERAKECCKKQDIQCCLRYFDESKDPNVMLICLFCW NO: 13 SEQ ID GSPDEYIERAKECCKKQDIQCCLRIFEESKDPNVMLICLFCW NO: 14 SEQ ID GSPDEYIERAKECCKKGDIQCCLRYFDESKDPNVMLICLFCW NO: 15 SEQ ID GSPDEYIERAKECCKKGDIQCCLRIFEESKDPNVMLICLFCW NO: 16 SEQ ID GSPDEYIERAKECCKKGDIQCCLRIFDESGDPNVMLICLFCW NO: 17 SEQ ID GSPDEYIERAKECCKKGDIQCCLRIFDESKDPNVMLICLFCP NO: 18 SEQ ID GSPDEYIERAKECCKKQDIQCCLRYFEESKDPNVMLICLFCW NO: 19 SEQ ID GSPDEYIERAKECCKKQDIQCCLRYFDESGDPNVMLICLFCW NO: 20 SEQ ID GSPDEYIERAKECCKKQDIQCCLRYFDESKDPNVMLICLFCP NO: 21 SEQ ID GSPDEYIERAKECCKKQDIQCCLRIFEESGDPNVMLICLFCW NO: 22 SEQ ID GSPDEYIERAKECCKKQDIQCCLRIFEESKDPNVMLICLFCP NO: 23 SEQ ID GSPDEYIERAKECCKKQDIQCCLRIFDESGDPNVMLICLFCP NO: 24 SEQ ID GSPDRYIERAKRCCKRQDIQCCLRIFDESKDPNVMLICLFCW NO: 25 SEQ ID GSPDRYIREAKRCCRKQDIQCCLRIFDESKDPNVMLICLFCW NO: 26 SEQ ID GSPDRYIERAKRCCRRQDIQCCLRIFDESKDPNVMLICLFCW NO: 27 SEQ ID GSPDRYIREARRCCRKQDIQCCLRIFDESKDPNVMLICLFCW NO: 28 SEQ ID GSPDRYIRRAKRCCRKQDIQCCLRIFDESKDPNVMLICLFCW NO: 29 SEQ ID GSPDRYIRRAKRCCKRQDIQCCLRIFDESKDPNVMLICLFCW NO: 30 SEQ ID GSPDRYIRRAKRCCRRQDIQCCLRIFDESKDPNVMLICLFCW NO: 31 SEQ ID GSPDRYIERAKRCCKRQDIQCCLRIFDESGDPNVMLICLFCW NO: 32 SEQ ID GSPDRYIREAKRCCRKQDIQCCLRIFDESGDPNVMLICLFCW NO: 33 SEQ ID GSPDRYIERAKRCCRRQDIQCCLRIFDESGDPNVMLICLFCW NO: 34 SEQ ID GSPDRYIREARRCCRKQDIQCCLRIFDESGDPNVMLICLFCW NO: 35 SEQ ID GSPDRYIRRAKRCCRKQDIQCCLRIFDESGDPNVMLICLFCW NO: 36 SEQ ID GSPDRYIRRAKRCCKRQDIQCCLRIFDESGDPNVMLICLFCW NO: 37 SEQ ID GSPDRYIRRAKRCCRRQDIQCCLRIFDESGDPNVMLICLFCW NO: 38 SEQ ID GSLERLKKCCNQGLDCEEARAKCELEALFQGKNRETCLEEC NO: 39 SEQ ID GSLERLKKCCNQGLDCEEARWKCEAEALFQGKNRETCLEEC NO: 40 SEQ ID GSLERLKKCCNQGLDCEEARWKCELEAAFQGKNRETCLEEC NO: 41 SEQ ID GSLERLKKCCNQGLDCEEARWKCELEALAQGKNRETCLEEC NO: 42 SEQ ID PDEYIERAKECCKKGDIQCCLRYFEESGDPNVML1CLFCP NO: 43 SEQ ID LERLKKCCNQGLDCEEARWKCELEALFQGKNRETCLEEC NO: 44 SEQ ID FGLYDNQCATSDACSAICKYWTGSGQGKCQNNQCRCY NO: 45 SEQ ID PDEYIERAKECCKKGDIQCCLRYFAESGDPNVMLICLFCP NO: 46 SEQ ID PDEYIERAKECCKKGDIQCCLRYFEESGDPNVMLICAFCP NO: 47 SEQ ID PDEYIERAKECCKKGDIQCCLRYFEESGDPNVALICLFCP NO: 48 SEQ ID PDEYIERAKECCKKGDIQCCLRYFEESGDPNVMLICLACP NO: 49 SEQ ID PDEYIERARRCCRRGDIQCCLRYFEESGDPNVMLICLFCP NO: 50 SEQ ID PDEYIERAKECCKKQDIQCCLRIFDESKDPNVMLICLFCW NO: 51 SEQ ID PDEYIERAKECCKKQDIQCCLRIFDESGDPNVMLICLFCW NO: 52 SEQ ID PDEYIERAKECCKKQDIQCCLRIFDESKDPNVMLICLFCP NO: 53 SEQ ID PDEYIERAKECCKKGDIQCCLRIFDESKDPNVMLICLFCW NO: 54 SEQ ID PDEYIERAKECCKKQDIQCCLRYFDESKDPNVMLICLFCW NO: 55 SEQ ID PDEYIERAKECCKKQDIQCCLRIFEESKDPNVMLICLFCW NO: 56 SEQ ID PDEYIERAKECCKKGDIQCCLRYFDESKDPNVMLICLFCW NO: 57 SEQ ID PDEYIERAKECCKKGDIQCCLRIFEESKDPNVMLICLFCW NO: 58 SEQ ID PDEYIERAKECCKKGDIQCCLRIFDESGDPNVMLICLFCW NO: 59 SEQ ID PDEYIERAKECCKKGDIQCCLRIFDESKDPNVMLICLFCP NO: 60 SEQ ID PDEYIERAKECCKKQDIQCCLRYFEESKDPNVMLICLFCW NO: 61 SEQ ID PDEYIERAKECCKKQDIQCCLRYFDESGDPNVMLICLFCW NO: 62 SEQ ID PDEYIERAKECCKKQDIQCCLRYFDESKDPNVMLICLFCP NO: 63 SEQ ID PDEYIERAKECCKKQDIQCCLRIFEESGDPNVMLICLFCW NO: 64 SEQ ID PDEYIERAKECCKKQDIQCCLRIFEESKDPNVMLICLFCP NO: 65 SEQ ID PDEYIERAKECCKKQDIQCCLRIFDESGDPNVMLICLFCP NO: 66 SEQ ID PDRYIERAKRCCKRQDIQCCLRIFDESKDPNVMLICLFCW NO: 67 SEQ ID PDRYIREAKRCCRKQDIQCCLRIFDESKDPNVMLICLFCW NO: 68 SEQ ID PDRYIERAKRCCRRQDIQCCLRIFDESKDPNVMLICLFCW NO: 69 SEQ ID PDRYIREARRCCRKQDIQCCLRIFDESKDPNVMLICLFCW NO: 70 SEQ ID PDRYIRRAKRCCRKQDIQCCLRIFDESKDPNVMLICLFCW NO: 71 SEQ ID PDRYIRRAKRCCKRQDIQCCLRIFDESKDPNVMLICLFCW NO: 72 SEQ ID PDRYIRRAKRCCRRQDIQCCLRIFDESKDPNVMLICLFCW NO: 73 SEQ ID PDRYIERAKRCCKRQDIQCCLRIFDESGDPNVMLICLFCW NO: 74 SEQ ID PDRYIREAKRCCRKQDIQCCLRIFDESGDPNVMLICLFCW NO: 75 SEQ ID PDRYIERAKRCCRRQDIQCCLRIFDESGDPNVMLICLFCW NO: 76 SEQ ID PDRYIREARRCCRKQDIQCCLRIFDESGDPNVMLICLFCW NO: 77 SEQ ID PDRYIRRAKRCCRKQDIQCCLRIFDESGDPNVMLICLFCW NO: 78 SEQ ID PDRYIRRAKRCCKRQDIQCCLRIFDESGDPNVMLICLFCW NO: 79 SEQ ID PDRYIRRAKRCCRRQDIQCCLRIFDESGDPNVMLICLFCW NO: 80 SEQ ID LERLKKCCNQGLDCEEARAKCELEALFQGKNRETCLEEC NO: 81 SEQ ID LERLKKCCNQGLDCEEARWKCEAEALFQGKNRETCLEEC NO: 82 SEQ ID LERLKKCCNQGLDCEEARWKCELEAAFQGKNRETCLEEC NO: 83 SEQ ID LERLKKCCNQGLDCEEARWKCELEALAQGKNRETCLEEC NO: 84 - In some embodiments, a peptide that binds to TEAD comprises Ala at
position 8, Asp atposition 16, Ser atposition 17, Met at position 23, Phe at position 38, or any combination thereof. - See
FIG. 8 for exemplary important residues. In some embodiments, a peptide comprises LX1X2FEXS (SEQ ID NO: 218), LX1X2FEXSXDPNVML (SEQ ID NO: 219), or LX1X2FEXSXDPNVMX3X4LF (SEQ ID NO: 220), wherein X1, X2, X3, and X4 can be any amino acid. - In some embodiments, peptides of the present disclosure can comprise the amino acid sequence of leucine-X1-X2-leucine-phenylalanine (“LX1X2LF,” SEQ ID NO: 217), in which X1 and X2 are any amino acid residue, as shown in SEQ ID NO: 1 and SEQ ID NO: 2. In some embodiments, peptides with the LX1X2LF (SEQ ID NO: 217) sequence display full TEAD binding.
- In some embodiments, the X1X2 in the LX1X2LF (SEQ ID NO: 217) sequence can be EA, as shown in SEQ ID NO: 2, or IC as shown in SEQ ID NO: 1. In other embodiments, the X1X2 in the LX1X2LF (SEQ ID NO: 217) sequence can also be EC, MC, VC, or FC. In some embodiments, peptides of the present disclosure can comprise the amino acid sequence motif of leucine-X1-X2-leucine-phenylalanine (“LX1X2LF,” SEQ ID NO: 217), in which X1 and X2 are any amino acid residue, as shown in SEQ ID NO: 1 and SEQ ID NO: 2. In some embodiments, peptides with the LX1X2LF (SEQ ID NO: 217) motif display full TEAD binding. In some embodiments, the X1X2 in the LX1X2LF (SEQ ID NO: 217) motif can be EA, as shown in SEQ ID NO: 2, or IC as shown in SEQ ID NO: 1. In other embodiments, the X1X2 in the LX1X2LF (SEQ ID NO: 217) motif can also be EC, MC, VC, or FC.
- In some embodiments, a peptide of the present disclosure can comprise a sequence having cysteine residues at one or more of
positions positions position 11. In certain embodiments, a peptide can comprise a sequence having a cysteine residue atposition 12. In certain embodiments, a peptide can comprise a sequence having a cysteine residue atposition 13. In certain embodiments, a peptide can comprise a sequence having a cysteine residue atposition 14. In certain embodiments, a peptide can comprise a sequence having a cysteine residue atposition 19. In certain embodiments, a peptide can comprise a sequence having a cysteine residue atposition 20. In certain embodiments, a peptide can comprise a sequence having a cysteine residue atposition 21. In certain embodiments, a peptide can comprise a sequence having a cysteine residue atposition 22. In certain embodiments, a peptide can comprise a sequence having a cysteine residue at position 36. In certain embodiments, a peptide can comprise a sequence having a cysteine residue at position 38. In certain embodiments, a peptide can comprise a sequence having a cysteine residue at position 39. In certain embodiments, a peptide can comprise a sequence having a cysteine residue atposition 41. In some embodiments, the first cysteine residue in the sequence can be disulfide bonded with the 4th cysteine residue in the sequence, the 2nd cysteine residue in the sequence can be disulfide bonded to the 5th cysteine residue in the sequence, and the 3rd cysteine residue in the sequence can be disulfide bonded to the 6th cysteine residue in the sequence. Optionally, a peptide can comprise one disulfide bridge that passes through a ring formed by two other disulfide bridges, also known as a “two-and-through” structure system. In some embodiments, the peptides disclosed herein can have one or more cysteines mutated to serine. For example, SEQ ID NO: 9 can have one or more cysteines mutated to a serine, such as GSPDEYIERAKESSKKQDIQSSLRIFDESKDPNVMLISLFSW (SEQ ID NO: 177); GSPDEYIERAKESCKKQDIQSCLRIFDESKDPNVMLICLFCW (SEQ ID NO: 178); GSPDEYIERAKECSKKQDIQCCLRIFDESKDPNVMLICLFSW (SEQ ID NO: 179); GSPDEYIERAKECCKKQDIQCSLRIFDESKDPNVMLISLFCW (SEQ ID NO: 180); GSPDEYIERAKESSKKQDIQSCLRIFDESKDPNVMLICLFSW (SEQ ID NO: 181); GSPDEYIERAKECSKKQDIQCSLRIFDESKDPNVMLISLFSW (SEQ ID NO: 182); or GSPDEYIERAKESCKKQDIQSSLRIFDESKDPNVMLISLFCW (SEQ ID NO: 183). SEQ ID NO: 51 can have one or more cysteines mutated to serines, such as PDEYIERAKESSKKQDIQSSLRIFDESKDPNVMLISLFSW (SEQ ID NO: 186); PDEYIERAKESCKKQDIQSCLRIFDESKDPNVMLICLFCW (SEQ ID NO: 187); PDEYIERAKECSKKQDIQCCLRIFDESKDPNVMLICLFSW (SEQ ID NO: 188); PDEYIERAKECCKKQDIQCSLRIFDESKDPNVMLISLFCW (SEQ ID NO: 189); PDEYIERAKESSKKQDIQSCLRIFDESKDPNVMLICLFSW (SEQ ID NO: 190); PDEYIERAKECSKKQDIQCSLRIFDESKDPNVMLISLFSW (SEQ ID NO: 191); or PDEYIERAKESCKKQDIQSSLRIFDESKDPNVMLISLFCW (SEQ ID NO: 192). SEQ ID NO: 1 can have one or more cysteines mutated to serines, such as GSPDEYIERAKESSKKGDIQSSLRYFEESGDPNVMLISLFSP (SEQ ID NO: 184). SEQ ID NO: 1 can have one or more cysteines mutated to serines, such as PDEYIERAKESSKKGDIQSSLRYFEESGDPNVMLISLFSP (SEQ ID NO: 193). SEQ ID NO: 2 can have one or more cysteines mutated to serines, such as GSLERLKKSSNQGLDSEEARWKSELEALFQGKNRETSLEES (SEQ ID NO: 185). SEQ ID NO: 2 can have one or more cysteines mutated to serines, such as LERLKKSSNQGLDSEEARWKSELEALFQGKNRETSLEES (SEQ ID NO: 194). - In some embodiments, peptides can comprise at least one or more tag peptide sequences for improved cell penetration. For example, peptides can comprise at least one or multiple Arg residues or residues from Tat protein for improved cell penetration property. Additional tag peptide sequences can include CysTat (CYRKKRRQRRR; SEQ ID NO: 144), S19-TAT (PFVIGAGVLGALGTGIGGIGRKKRRQRRR; SEQ ID NO: 145), R8 (RRRRRRRR; SEQ ID NO: 146), pAntp (RQIKIWFQNRRMKWKK; SEQ ID NO: 147), Pas-TAT (FFLIPKGGRKKRRQRRR; SEQ ID NO: 148), Pas-R8 (FFLIPKGRRRRRRRR; SEQ ID NO: 149), PasFHV (FFLIPKGRRRRNRTRRNRRRVR; SEQ ID NO: 150), Pas-pAntP (FFLIPKGRQIKIWFQNRRMKWKK; SEQ ID NO: 151), F2R4 (FFRRRR; SEQ ID NO: 152), B55 (KAVLGATKIDLPVDINDPYDLGLLLRHLRHHSNLLANIGDPAVREQVLSAMQEEE; SEQ ID NO: 153), auzurin (LSTAADMQGVVTDGMASGLDKDYLKPDD; SEQ ID NO: 154), IMT-P8 (RRWRRWNRFNRRRCR; SEQ ID NO: 155), BR2 (RAGLQFPVGRLLRRLLR; SEQ ID NO: 156), OMOTAGI (KRAHHNALERKRR; SEQ ID NO: 157), OMOTAG2 (RRMKANARERNRM; SEQ ID NO: 158), pVEC (LLIILRRRIRKQAHAHSK; SEQ ID NO: 159), SynB3 (RRLSYSRRRF; SEQ ID NO: 160), DPV1047 (VKRGLKLRHVRPRVTRMDV; SEQ ID NO: 161), CY105Y (CSIPPEVKFNKPFVYLI; SEQ ID NO: 162), Transpotan (GWTLNSAGYLLGKINLKALAALAKKIL; SEQ ID NO: 163), MTS (KGEGAAVLLPVLLAAPG; SEQ ID NO: 164), hLF (KCFQWQRNMRKVRGPPVSCIKR; SEQ ID NO: 165), PFVYLI (PFVYLI; SEQ ID NO: 166), and yBBR (VLDSLEFIASKL, SEQ ID NO: 167). For example, in some embodiments, the peptide can comprise an Arginine patch (Arg patch), for example, an RRRRRRRR (SEQ ID NO: 146), or a variant or fragment thereof, sequence can be appended to either the N-terminus or the C-terminus of a peptide. In some embodiments, the Arg patch comprises two or more Arg residues, or Argn wherein n is a whole number and can be 2, 3, 4, 5, 6, 7, 8, 9, or 10 (SEQ ID NO: 286). In other embodiments, the peptide can comprise a Tat peptide (Tat proteins are reviewed in Gump et al. TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol Med. 2007 October; 13(10):443-8 and Harada et al. Antitumor protein therapy; application of the protein transduction domain to the development of a protein drug for cancer treatment. Breast Cancer. 2006; 13(1):16-26). The Tat peptide can have a sequence of, for example, YGRKKRRQRRR (SEQ ID NO: 195), GRKKRRQRRR (SEQ ID NO: 143), or any modification, variant, or fragment thereof, can be appended to the N-terminus or C-terminus of any TEAD-binding peptide of the present disclosure. In some embodiments, the Tat peptide sequence can be GRKKRRQRRRPQ (SEQ ID NO: 196), GRKKRRQRRR (SEQ ID NO: 143), or a fragment or variant thereof. In some embodiments, the Tat peptide can be appended to the N-terminus of any TEAD-binding peptide of the present disclosure following an N-terminal GS dipeptide and preceding, for example, a GGGS (SEQ ID NO: 203) spacer. In some embodiments, a cell-penetrating tag peptides, such as any one of SEQ ID NO: 143-SEQ ID NO: 167, can be appended to either the N-terminus or C-terminus of any peptide disclosed herein using a peptide linker such as GxSy (SEQ ID NO: 283) peptide linker, wherein x and y can be any whole number, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. In other embodiments, a cell-penetrating peptide, such as a Tat peptide or an Arg patch, or any other moiety, can be appended to either the N-terminus or C-terminus of any peptide disclosed herein using a peptide linker such as GxSy peptide linker, wherein x and y can be any whole number, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. In some embodiments, the peptide linker comprises (GS)x (SEQ ID NO: 282), wherein x can be any whole number, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. In some embodiments, the peptide linker comprises GGSSG (SEQ ID NO: 204), GGGGG (SEQ ID NO: 205), GSGSGSGS (SEQ ID NO: 206), GSGG (SEQ ID NO: 207), GGGGS (SEQ ID NO: 208), GGGS (SEQ ID NO: 203), GGS (SEQ ID NO: 209), GGGSGGGSGGGS (SEQ ID NO: 210), or a variant or fragment thereof. Additionally, KKYKPYVPVTTN (SEQ ID NO: 211) from DkTx, and EPKSSDKTHT (SEQ ID NO: 212) from human IgG3 can be used as a peptide linker. In other embodiments, the tag peptide can be appended to the peptide at any amino acid residue. In further embodiments, the tag peptide can be appended to the peptide at any amino acid residue without interfering with TEAD-binding activity. In some embodiments, the tag peptide is appended via conjugation, linking, or fusion techniques. In other embodiments, the Tat peptide can be appended to the peptide at any amino acid residue. In further embodiments, the Tat peptide can be appended to the peptide at any amino acid residue without interfering with TEAD-binding activity. In some embodiments, the Tat peptide is appended via conjugation, linking, or fusion techniques. Additional exemplary TEAD Binder-Cell Penetrating Peptide fusion (CPP fusion) sequences that can improve cell penetration are in TABLE 2.
-
TABLE 2 Exemplary TEAD Binder-Cell Penetrating Peptide Fusion Sequences Fusion SEQ ID NO: Sequence GS-Tat-SEQ SEQ ID NO: 85 GSGRKKRRQRRRGGSPDEYIERAKECCKKQDIQCCLRIFDES ID NO: 9 KDPNVMLICLFCW GS-CysTat- SEQ ID NO: 86 GSCYRKKRRQRRRGGSPDEYIERAKECCKKQDIQCCLRIFDE SEQ ID NO: 9 SKDPNVMLICLFCW GS-S19-Tat- SEQ ID NO: 87 GSPFVIGAGVLGALGTGIGGIGRKKRRQRRRGGSPDEYIERA SEQ ID NO: 9 KECCKKQDIQCCLRIFDESKDPNVMLICLFCW GS-Pas-Tat- SEQ ID NO: 88 GSFFLIPKGGRKKRRQRRRGGSPDEYIERAKECCKKQDIQCC SEQ ID NO: 9 LRIFDESKDPNVMLICLFCW GS-R8-SEQ ID SEQ ID NO: 89 GSRRRRRRRRGGSPDEYIERAKECCKKQDIQCCLRIFDESKD NO: 9 PNVMLICLFCW GS-Pas-R8- SEQ ID NO: 90 GSFFLIPKGRRRRRRRRGGSPDEYIERAKECCKKQDIQCCLRI SEQ ID NO: 9 FDESKDPNVMLICLFCW GS-pAntp-SEQ SEQ ID NO: 91 GSRQIKIWFQNRRMKWKKGGSPDEYIERAKECCKKQDIQCC ID NO: 9 LRIFDESKDPNVMLICLFCW GS-Pas-pAntp- SEQ ID NO: 92 GSFFLIPKGRQIKIWFQNRRMKWKKGGSPDEYIERAKECCK SEQ ID NO: 9 KQDIQCCLRIFDESKDPNVMLICLFCW GS-Pas-FHV- SEQ ID NO: 93 GSFFLIPKGRRRRNRTRRNRRRVRGGSPDEYIERAKECCKKQ SEQ ID NO: 9 DIQCCLRIFDESKDPNVMLICLFCW GS-MCa(1-9)- SEQ ID NO: 94 GSGDALPHLKLGGSPDEYIERAKECCKKQDIQCCLRIFDESK SEQ ID NO: 9 DPNVMLICLFCW GS-Imp(1-9)- SEQ ID NO: 95 GSGDALPHLKRGGSPDEYIERAKECCKKQDIQCCLRIFDESK SEQ ID NO: 9 DPNVMLICLFCW GS-Had(1-ll)- SEQ ID NO: 96 GSSEKDAIKHLQRGGSPDEYIERAKECCKKQDIQCCLRIFDE SEQ ID NO: 9 SKDPNVMLICLFCW GS-Had(3-ll)- SEQ ID NO: 97 GSKDAIKHLQRGGSPDEYIERAKECCKKQDIQCCLRIFDESK SEQ ID NO: 9 DPNVMLICLFCW GS-yBBR-SEQ SEQ ID NO: 98 GSVLDSLEFIASKLGGSPDEYIERAKECCKKQDIQCCLRIFDE ID NO: 9 SKDPNVMLICLFCW GS-Q15(F2R4) SEQ ID NO: 99 GSPDEYIERAKECCKKFFRRRRDIQCCLRIFDESKDPNVMLIC -SEQ ID NO: 9 LFCW GS-B55-SEQ SEQ ID NO: 100 GSKAVLGATKIDLPVDINDPYDLGLLLRHLRHHSNLLANIG ID NO: 9 DPAVREQVLSAMQEEEGGSPDEYIERAKECCKKQDIQCCLR IFDESKDPNVMLICLFCW GS-azu-SEQ SEQ ID NO: 101 GSLSTAADMQGVVTDGMASGLDKDYLKPDDGGSPDEYIER ID NO: 9 AKECCKKQDIQCCLRIFDESKDPNVMLICLFCW GS-IMT-P8- SEQ ID NO: 102 GSRRWRRWNRFNRRRCRGGSPDEYIERAKECCKKQDIQCC SEQ ID NO: 9 LRIFDESKDPNVMLICLFCW GS-BR2-SEQ SEQ ID NO: 103 GSRAGLQFPVGRLLRRLLRGGSPDEYIERAKECCKKQDIQC ID NO: 9 CLRIFDESKDPNVMLICLFCW GS- SEQ ID NO: 104 GSKRAHHNALERKRRGGSPDEYIERAKECCKKQDIQCCLRI OMOTAG1- FDESKDPNVMLICLFCW SEQ ID NO: 9 GS- SEQ ID NO: 105 GSRRMKANARERNRMGGSPDEYIERAKECCKKQDIQCCLRI OMOTAG2- FDESKDPNVMLICLFCW SEQ ID NO: 9 GS-pVEC-SEQ SEQ ID NO: 106 GSLLIILRRRIRKQAHAHSKGGSPDEYIERAKECCKKQDIQC ID NO: 9 CLRIFDESKDPNVMLICLFCW GS-SynB3- SEQ ID NO: 107 GSRRLSYSRRRFGGSPDEYIERAKECCKKQDIQCCLRIFDES SEQ ID NO: 9 KDPNVMLICLFCW GS-DPV1047- SEQ ID NO: 108 GSVKRGLKLRHVRPRVTRMDVGGSPDEYIERAKECCKKQDI SEQ ID NO: 9 QCCLRIFDESKDPNVMLICLFCW GS-C105Y- SEQ ID NO: 109 GSCSIPPEVKFNKPFVYLIGGSPDEYIERAKECCKKQDIQCCL SEQ ID NO: 9 RIFDESKDPNVMLICLFCW GS- SEQ ID NO: 110 GSGWTLNSAGYLLGKINLKALAALAKKILGGSPDEYIERAK Transportan- ECCKKQDIQCCLRIFDESKDPNVMLICLFCW SEQ ID NO: 9 GS-MTS-SEQ SEQ ID NO: 111 GSKGEGAAVLLPVLLAAPGGGSPDEYIERAKECCKKQDIQC ID NO: 9 CLRIFDESKDPNVMLICLFCW GS-hLF-SEQ SEQ ID NO: 112 GSKCFQWQRNMRKVRGPPVSCIKRGGSPDEYIERAKECCKK ID NO: 9 QDIQCCLRIFDESKDPNVMLICLFCW GS-PFVY1- SEQ ID NO: 113 GSPFVYLIGGSPDEYIERAKECCKKQDIQCCLRIFDESKDPNV SEQ ID NO: 9 MLICLFCW GS-R8-SEQ ID SEQ ID NO: 114 GSRRRRRRRRGGGSPDEYIERAKECCKKGDIQCCLRYFEES NO: 1 GDPNVMLICLFCP GS-Tat-SEQ SEQ ID NO: 115 GSYGRKKRRQRRRGGGSPDEYIERAKECCKKGDIQCCLRYF ID NO: 1 EESGDPNVMLICLFCP Tat-SEQ ID SEQ ID NO: 222 GRKKRRQRRRGGSPDEYIERAKECCKKQDIQCCLRIFDESK NO: 9 DPNVMLICLFCW CysTat-SEQ SEQ ID NO: 223 CYRKKRRQRRRGGSPDEYIERAKECCKKQDIQCCLRIFDESK ID NO: 9 DPNVMLICLFCW S19-Tat-SEQ SEQ ID NO: 224 PFVIGAGVLGALGTGIGGIGRKKRRQRRRGGSPDEYIERAKE ID NO: 9 CCKKQDIQCCLRIFDESKDPNVMLICLFCW Pas-Tat-SEQ SEQ ID NO: 225 FFLIPKGGRKKRRQRRRGGSPDEYIERAKECCKKQDIQCCLR ID NO: 9 IFDESKDPNVMLICLFCW R8-SEQ ID SEQ ID NO: 226 RRRRRRRRGGSPDEYIERAKECCKKQDIQCCLRIFDESKDPN NO: 9 VMLICLFCW Pas-R8-SEQ SEQ ID NO: 227 FFLIPKGRRRRRRRRGGSPDEYIERAKECCKKQDIQCCLRIFD ID NO: 9 ESKDPNVMLICLFCW pAntp-SEQ ID SEQ ID NO: 228 RQIKIWFQNRRMKWKKGGSPDEYIERAKECCKKQDIQCCLR NO: 9 IFDESKDPNVMLICLFCW Pas-pAntp- SEQ ID NO: 229 GSFFLIPKGRQIKIWFQNRRMKWKKGGSPDEYIERAKECCK SEQ ID NO: 9 KQDIQCCLRIFDESKDPNVMLICLFCW Pas-FHV-SEQ SEQ ID NO: 230 FFLIPKGRRRRNRTRRNRRRVRGGSPDEYIERAKECCKKQDI ID NO: 9 QCCLRIFDESKDPNVMLICLFCW MCa(1-9)- SEQ ID NO: 231 GDALPHLKLGGSPDEYIERAKECCKKQDIQCCLRIFDESKDP SEQ ID NO: 9 NVMLICLFCW Imp(1-9)-SEQ SEQ ID NO: 232 GDALPHLKRGGSPDEYIERAKECCKKQDIQCCLRIFDESKDP ID NO: 9 NVMLICLFCW Had(1-ll)- SEQ ID NO: 233 SEKDAIKHLQRGGSPDEYIERAKECCKKQDIQCCLRIFDESK SEQ ID NO: 9 DPNVMLICLFCW Had(3-ll)- SEQ ID NO: 234 KDAIKHLQRGGSPDEYIERAKECCKKQDIQCCLRIFDESKDP SEQ ID NO: 9 NVMLICLFCW yBBR-SEQ ID SEQ ID NO: 235 VLDSLEFIASKLGGSPDEYIERAKECCKKQDIQCCLRIFDESK NO: 9 DPNVMLICLFCW Q15(F2R4)- SEQ ID NO: 236 PDEYIERAKECCKKFFRRRRDIQCCLRIFDESKDPNVMLICLF SEQ ID NO: 9 CW B55-SEQ ID SEQ ID NO: 237 KAVLGATKIDLPVDINDPYDLGLLLRHLRHHSNLLANIGDP NO: 9 AVREQVLSAMQEEEGGSPDEYIERAKECCKKQDIQCCLRIF DESKDPNVMLICLFCW azu-SEQ ID SEQ ID NO: 238 LSTAADMQGVVTDGMASGLDKDYLKPDDGGSPDEYIERAK NO: 9 ECCKKQDIQCCLRIFDESKDPNVMLICLFCW IMT-P8-SEQ SEQ ID NO: 239 RRWRRWNRFNRRRCRGGSPDEYIERAKECCKKQDIQCCLRI ID NO: 9 FDESKDPNVMLICLFCW BR2-SEQ ID SEQ ID NO: 240 RAGLQFPVGRLLRRLLRGGSPDEYIERAKECCKKQDIQCCL NO: 9 RIFDESKDPNVMLICLFCW OMOTAG1- SEQ ID NO: 241 KRAHHNALERKRRGGSPDEYIERAKECCKKQDIQCCLRIFD SEQ ID NO: 9 ESKDPNVMLICLFCW OMOTAG2- SEQ ID NO: 242 RRMKANARERNRMGGSPDEYIERAKECCKKQDIQCCLRIFD SEQ ID NO: 9 ESKDPNVMLICLFCW pVEC-SEQ ID SEQ ID NO: 243 LLIILRRRIRKQAHAHSKGGSPDEYIERAKECCKKQDIQCCL NO: 9 RIFDESKDPNVMLICLFCW SynB3-SEQ ID SEQ ID NO: 244 RRLSYSRRRFGGSPDEYIERAKECCKKQDIQCCLRIFDESKD NO: 9 PNVMLICLFCW DPV1047-SEQ SEQ ID NO: 245 VKRGLKLRHVRPRVTRMDVGGSPDEYIERAKECCKKQDIQ ID NO: 9 CCLRIFDESKDPNVMLICLFCW C105Y-SEQ SEQ ID NO: 246 CSIPPEVKFNKPFVYLIGGSPDEYIERAKECCKKQDIQCCLRI ID NO: 9 FDESKDPNVMLICLFCW Transportan- SEQ ID NO: 247 GWTLNSAGYLLGKINLKALAALAKKILGGSPDEYIERAKEC SEQ ID NO: 9 CKKQDIQCCLRIFDESKDPNVMLICLFCW MTS-SEQ ID SEQ ID NO: 248 KGEGAAVLLPVLLAAPGGGSPDEYIERAKECCKKQDIQCCL NO: 9 RIFDESKDPNVMLICLFCW hLF-SEQ ID SEQ ID NO: 249 KCFQWQRNMRKVRGPPVSCIKRGGSPDEYIERAKECCKKQ NO: 9 DIQCCLRIFDESKDPNVMLICLFCW PFVY1-SEQ SEQ ID NO: 250 PFVYLIGGSPDEYIERAKECCKKQDIQCCLRIFDESKDPNVM ID NO: 9 LICLFCW R8-SEQ ID SEQ ID NO: 251 RRRRRRRRGGGSPDEYIERAKECCKKGDIQCCLRYFEESGD NO: 1 PNVMLICLFCP Tat-SEQ ID SEQ ID NO: 252 YGRKKRRQRRRGGGSPDEYIERAKECCKKGDIQCCLRYFEE NO: 1 SGDPNVMLICLFCP - In some embodiments, a peptide is conjugated to, linked to, or fused to one or more cell-penetrating peptides, such as arginine-rich, amphipathic and lysine-rich, and hydrophobic residues or peptides capable of penetrating plasma membrane or nucleus for in vivo delivery of a protein or macromolecular cargo. Conjugation or fusion can be direct or with a spacer in between (chemical or peptide-based). A spacer can be any peptide linker. For example, a spacer can be GGGSGGGSGGGS (SEQ ID NO: 210), KKYKPYVPVTTN (SEQ ID NO: 211) from DkTx, EPKSSDKTHT (SEQ ID NO: 212) from human IgG3 or any variant or fragment thereof. Cell-penetrating peptides include, but are not limited to, short amphipathic or cationic short peptides with a positive net charge and are capable of penetrating cellular membrane and transferring a molecular or cargo either covalently or non-covalently attached to the peptides into a cell. Such cell-penetrating peptides can be synthesized or derived from known proteins, such as penetratin, Tat peptide, pVEC, or chimeric peptides, such as transportan, MPG, Pep-1, or synthetic peptides, such as polyarginines, MAP, and R6W3(SEQ ID NO: 287).
- In some embodiments, peptides can comprise at least one or more cell penetrating peptide sequences for improved cell penetration. For example, a cell penetrating peptide can include maurocaline (GDCLPHLKLCKENKDCCSKKCKRRGTNIEKRCR; SEQ ID NO: 168), imperatoxin (GDCLPHLKRCKADNDCCGKKCKRRGTNAEKRCR; SEQ ID NO: 169), hadrucalcin (SEKDCIKHLQRCRENKDCCSKKCSRRGTNPEKRCR; SEQ ID NO: 170), hemicalcin (GDCLPHLKLCKADKDCCSKKCKRRGTNPEKRCR; SEQ ID NO: 171), opicalcin-1 (GDCLPHLKRCKENNDCCSKKCKRRGTNPEKRCR; SEQ ID NO: 172), opicalcin-2 (GDCLPHLKRCKENNDCCSKKCKRRGANPEKRCR; SEQ ID NO: 173), midkine (62-104) (CKYKFENWGACDGGTGTKVRQGTLKKARYNAQCQETIRVTKPC; SEQ ID NO: 174), MCoTI-II (SGSDGGVCPKILKKCRRDSDCPGACICRGNGYCG; SEQ ID NO: 175), or chlorotoxin (MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR; SEQ ID NO: 176). In some embodiments, the cell penetrating peptide can have at least 80%, 90%, 95%, or 99% sequence identity with any sequence of SEQ ID NO: 168-SEQ ID NO: 176. In some embodiments, the cell penetrating peptide sequence can be appended to either the N-terminus or the C-terminus of a peptide. In some embodiments, the cell penetrating peptide can be appended to the N-terminus of any TEAD-binding peptide of the present disclosure following an N-terminal GS dipeptide and preceding, for example, a GGGS (SEQ ID NO: 203) spacer. In some embodiments, a cell-penetrating tag peptides, such as any one of SEQ ID NO: 168-SEQ ID NO: 176, can be appended to either the N-terminus or C-terminus of any peptide disclosed herein using a peptide linker such as GxSy (SEQ ID NO: 283) peptide linker, wherein x and y can be any whole number, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. In some embodiments, the peptide linker comprises GGS (SEQ ID NO: 209), GGSSG (SEQ ID NO: 204), GGGGG (SEQ ID NO: 205), GSGSGSGS (SEQ ID NO: 206), GSGG (SEQ ID NO: 207), GGGGS (SEQ ID NO: 208), GGGS (SEQ ID NO: 203), GGGSGGGSGGGS (SEQ ID NO: 210), or a variant or fragment thereof. Additionally, KKYKPYVPVTTN (SEQ ID NO: 211) from DkTx, and EPKSSDKTHT (SEQ ID NO: 212) from human IgG3 can be used as a peptide linker. In other embodiments, the cell penetrating peptide can be appended to the peptide at any amino acid residue. In further embodiments, the cell penetrating peptide can be appended to the peptide at any amino acid residue without interfering with TEAD-binding activity. In some embodiments, the cell penetrating peptide is appended via conjugation, linking, or fusion techniques. In other embodiments, the cell penetrating peptide can be appended to the peptide at any amino acid residue. Additional exemplary cell penetrating Tandem-Cysteine Dense Peptide (Tandem-CDP) sequences that can improve cell penetration are in TABLE 3.
-
TABLE 3 Exemplary Cell Penetrating Tandem-Cysteine Dense Peptide Sequences Fusion* SEQ ID NO: Sequence GS-Chlorotoxin- SEQ ID NO: 116 GSMCMPCFTTDHQMARKCDDCCGGKGRGKC GlySer linker-SEQ ID YGPQCLCRGGGSGGGSGGGSPDEYIERAKECC NO: 9 KKQDIQCCLRIFDESKDPNVMLICLFCW GS-Chlorotoxin- SEQ ID NO: 117 GSMCMPCFTTDHQMARKCDDCCGGKGRGKC DkTx-SEQ ID NO: 9 YGPQCLCRKKYKPYVPVTTNPDEYIERAKECC KKQDIQCCLRIFDESKDPNVMLICLFCW GS-Chlorotoxin- SEQ ID NO: 118 GSMCMPCFTTDHQMARKCDDCCGGKGRGKC hIgG3-SEQ ID NO: 9 YGPQCLCREPKSSDKTHTPDEYIERAKECCKKQ DIQCCLRIFDESKDPNVMLICLFCW GS-Maurocalcine- SEQ ID NO: 119 GSGDCLPHLKLCKENKDCCSKKCKRRGTNIEK GlySer linker-SEQ ID RCRGGGSGGGSGGGSPDEYIERAKECCKKQDI NO: 9 QCCLRIFDESKDPNVMLICLFCW GS-Maurocalcin- SEQ ID NO: 120 GSGDCLPHLKLCKENKDCCSKKCKRRGTNIEK DkTx-SEQ ID NO: 9 RCRKKYKPYVPVTTNPDEYIERAKECCKKQDI QCCLRIFDESKDPNVMLICLFCW GS-Maurocalcin- SEQ ID NO: 121 GSGDCLPHLKLCKENKDCCSKKCKRRGTNIEK hIgG3-SEQ ID NO: 9 RCREPKSSDKTHTPDEYIERAKECCKKQDIQCC LRIFDESKDPNVMLICLFCW GS-Imperatoxin- SEQ ID NO: 122 GSGDCLPHLKRCKADNDCCGKKCKRRGTNAE GlySer linker-SEQ ID KRCRGGGSGGGSGGGSPDEYIERAKECCKKQD NO: 9 IQCCLRIFDESKDPNVMLICLFCW GS-Imperatoxin- SEQ ID NO: 123 GSGDCLPHLKRCKADNDCCGKKCKRRGTNAE DkTx-SEQ ID NO: 9 KRCRKKYKPYVPVTTNPDEYIERAKECCKKQD IQCCLRIFDESKDPNVMLICLFCW GS-Imperatoxin- SEQ ID NO: 124 GSGDCLPHLKRCKADNDCCGKKCKRRGTNAE hIgG3-SEQ ID NO: 9 KRCREPKSSDKTHTPDEYIERAKECCKKQDIQC CLRIFDESKDPNVMLICLFCW GS-Hemicalcin- SEQ ID NO: 125 GSGDCLPHLKLCKADKDCCSKKCKRRGTNPEK GlySer linker-SEQ ID RCRGGGSGGGSGGGSPDEYIERAKECCKKQDI NO: 9 QCCLRIFDESKDPNVMLICLFCW GS-Hemicalcin-DkTx- SEQ ID NO: 126 GSGDCLPHLKLCKADKDCCSKKCKRRGTNPEK SEQ ID NO: 9 RCRKKYKPYVPVTTNPDEYIERAKECCKKQDI QCCLRIFDESKDPNVMLICLFCW GS-Hemicalcin- SEQ ID NO: 127 GSGDCLPHLKLCKADKDCCSKKCKRRGTNPEK hIgG3-SEQ ID NO: 9 RCREPKSSDKTHTPDEYIERAKECCKKQDIQCC LRIFDESKDPNVMLICLFCW GS-Opicalcin 1- SEQ ID NO: 128 GSGDCLPHLKRCKENNDCCSKKCKRRGTNPEK GlySer linker-SEQ ID RCRGGGSGGGSGGGSPDEYIERAKECCKKQDI NO: 9 QCCLRIFDESKDPNVMLICLFCW GS-Opicalcin 1-DkTx- SEQ ID NO: 129 GSGDCLPHLKRCKENNDCCSKKCKRRGTNPEK SEQ ID NO: 9 RCRKKYKPYVPVTTNPDEYIERAKECCKKQDI QCCLRIFDESKDPNVMLICLFCW GS-Opicalcin 1- SEQ ID NO: 130 GSGDCLPHLKRCKENNDCCSKKCKRRGTNPEK hIgG3-SEQ ID NO: 9 RCREPKSSDKTHTPDEYIERAKECCKKQDIQCC LRIFDESKDPNVMLICLFCW GS-Opicalcin 2- SEQ ID NO: 131 GSGDCLPHLKRCKENNDCCSKKCKRRGANPEK GlySer linker-SEQ ID RCRGGGSGGGSGGGSPDEYIERAKECCKKQDI NO: 9 QCCLRIFDESKDPNVMLICLFCW GS-Opicalcin 2-DkTx- SEQ ID NO: 132 GSGDCLPHLKRCKENNDCCSKKCKRRGANPEK SEQ ID NO: 9 RCRKKYKPYVPVTTNPDEYIERAKECCKKQDI QCCLRIFDESKDPNVMLICLFCW GS-Opicalcin 2- SEQ ID NO: 133 GSGDCLPHLKRCKENNDCCSKKCKRRGANPEK hIgG3-SEQ ID NO: 9 RCREPKSSDKTHTPDEYIERAKECCKKQDIQCC LRIFDESKDPNVMLICLFCW GS-Hadrucalcin- SEQ ID NO: 134 GSSEKDCIKHLQRCRENKDCCSKKCSRRGTNPE GlySer linker-SEQ ID KRCRGGGSGGGSGGGSPDEYIERAKECCKKQD NO: 9 IQCCLRIFDESKDPNVMLICLFCW GS-Hadrucalcin- SEQ ID NO: 135 GSSEKDCIKHLQRCRENKDCCSKKCSRRGTNPE DkTx-SEQ ID NO: 9 KRCRKKYKPYVPVTTNPDEYIERAKECCKKQD IQCCLRIFDESKDPNVMLICLFCW GS-Hadrucalcin- SEQ ID NO: 136 GSSEKDCIKHLQRCRENKDCCSKKCSRRGTNPE hIgG3-SEQ ID NO: 9 KRCREPKSSDKTHTPDEYIERAKECCKKQDIQC CLRIFDESKDPNVMLICLFCW GS-Midkine(62-104)- SEQ ID NO: 137 GSCKYKFENWGACDGGTGTKVRQGTLKKARY GlySer linker-SEQ ID NAQCQETIRVTKPCGGGSGGGSGGGSPDEYIER NO: 9 AKECCKKQDIQCCLRIFDESKDPNVMLICLFCW GS-Midkine(62-104)- SEQ ID NO: 138 GSCKYKFENWGACDGGTGTKVRQGTLKKARY DkTx-SEQ ID NO: 9 NAQCQETIRVTKPCKKYKPYVPVTTNPDEYIER AKECCKKQDIQCCLRIFDESKDPNVMLICLFCW GS-Midkine(62-104)- SEQ ID NO: 139 GSCKYKFENWGACDGGTGTKVRQGTLKKARY hIgG3-SEQ ID NO: 9 NAQCQETIRVTKPCEPKSSDKTHTPDEYIERAK ECCKKQDIQCCLRIFDESKDPNVMLICLFCW GS-MCoTI-II-GlySer SEQ ID NO: 140 GSSGSDGGVCPKILKKCRRDSDCPGACICRGNG linker-SEQ ID NO: 9 YCGGGGSGGGSGGGSPDEYIERAKECCKKQDI QCCLRIFDESKDPNVMLICLFCW GS-MCoTI-II-DkTx- SEQ ID NO: 141 GSSGSDGGVCPKILKKCRRDSDCPGACICRGNG SEQ ID NO: 9 YCGKKYKPYVPVTTNPDEYIERAKECCKKQDI QCCLRIFDESKDPNVMLICLFCW GS-MCoTI-II-hIgG3- SEQ ID NO: 142 GSSGSDGGVCPKILKKCRRDSDCPGACICRGNG SEQ ID NO: 9 YCGEPKSSDKTHTPDEYIERAKECCKKQDIQCC LRIFDESKDPNVMLICLFCW Chlorotoxin-Gly S er SEQ ID NO: 253 MCMPCFTTDHQMARKCDDCCGGKGRGKCYG linker-SEQ ID NO: 9 PQCLCRGGGSGGGSGGGSPDEYIERAKECCKK QDIQCCLRIFDESKDPNVMLICLFCW Chlorotoxin-DkTx- SEQ ID NO: 254 MCMPCFTTDHQMARKCDDCCGGKGRGKCYG SEQ ID NO: 9 PQCLCRKKYKPYVPVTTNPDEYIERAKECCKK QDIQCCLRIFDESKDPNVMLICLFCW Chloro toxin-hIgG3- SEQ ID NO: 255 MCMPCFTTDHQMARKCDDCCGGKGRGKCYG SEQ ID NO: 9 PQCLCREPKSSDKTHTPDEYIERAKECCKKQDI QCCLRIFDESKDPNVMLICLFCW Maurocalcine-GlySer SEQ ID NO: 256 GDCLPHLKLCKENKDCCSKKCKRRGTNIEKRC linker-SEQ ID NO: 9 RGGGSGGGSGGGSPDEYIERAKECCKKQDIQC CLRIFDESKDPNVMLICLFCW Maurocalcin-DkTx- SEQ ID NO: 257 GDCLPHLKLCKENKDCCSKKCKRRGTNIEKRC SEQ ID NO: 9 RKKYKPYVPVTTNPDEYIERAKECCKKQDIQC CLRIFDESKDPNVMLICLFCW Maurocalcin-hIgG3- SEQ ID NO: 258 GDCLPHLKLCKENKDCCSKKCKRRGTNIEKRC SEQ ID NO: 9 REPKSSDKTHTPDEYIERAKECCKKQDIQCCL RIFDESKDPNVMLICLFCW Imperatoxin-GlySer SEQ ID NO: 259 GDCLPHLKRCKADNDCCGKKCKRRGTNAEKR linker-SEQ ID NO: 9 CRGGGSGGGSGGGSPDEYIERAKECCKKQDIQ CCLRIFDESKDPNVMLICLFCW Imperatoxin-DkTx- SEQ ID NO: 260 GDCLPHLKRCKADNDCCGKKCKRRGTNAEKR SEQ ID NO: 9 CRKKYKPYVPVTTNPDEYIERAKECCKKQDIQ CCLRIFDESKDPNVMLICLFCW Imperatoxin-hIgG3- SEQ ID NO: 261 GDCLPHLKRCKADNDCCGKKCKRRGTNAEKR SEQ ID NO: 9 CREPKSSDKTHTPDEYIERAKECCKKQDIQCCL RIFDESKDPNVMLICLFCW Hemicalcin-GlySer SEQ ID NO: 262 GDCLPHLKLCKADKDCCSKKCKRRGTNPEKRC linker-SEQ ID NO: 9 RGGGSGGGSGGGSPDEYIERAKECCKKQDIQC CLRIFDESKDPNVMLICLFCW Hemicalcin-DkTx- SEQ ID NO: 263 GDCLPHLKLCKADKDCCSKKCKRRGTNPEKRC SEQ ID NO: 9 RKKYKPYVPVTTNPDEYIERAKECCKKQDIQC CLRIFDESKDPNVMLICLFCW Hemicalcin-hIgG3- SEQ ID NO: 264 GDCLPHLKLCKADKDCCSKKCKRRGTNPEKRC SEQ ID NO: 9 REPKSSDKTHTPDEYIERAKECCKKQDIQCCLRI FDESKDPNVMLICLFCW Opicalcin 1-GlySer SEQ ID NO: 265 GDCLPHLKRCKENNDCCSKKCKRRGTNPEKRC linker-SEQ ID NO: 9 RGGGSGGGSGGGSPDEYIERAKECCKKQDIQC CLRIFDESKDPNVMLICLFCW Opicalcin 1-DkTx- SEQ ID NO: 266 GDCLPHLKRCKENNDCCSKKCKRRGTNPEKRC SEQ ID NO: 9 RKKYKPYVPVTTNPDEYIERAKECCKKQDIQC CLRIFDESKDPNVMLICLFCW Opicalcin 1-hIgG3- SEQ ID NO: 267 GDCLPHLKRCKENNDCCSKKCKRRGTNPEKRC SEQ ID NO: 9 REPKSSDKTHTPDEYIERAKECCKKQDIQCCLRI FDESKDPNVMLICLFCW Opicalcin 2-GlySer SEQ ID NO: 268 GDCLPHLKRCKENNDCCSKKCKRRGANPEKR linker-SEQ ID NO: 9 CRGGGSGGGSGGGSPDEYIERAKECCKKQDIQ CCLRIFDESKDPNVMLICLFCW Opicalcin 2-DkTx- SEQ ID NO: 269 GDCLPHLKRCKENNDCCSKKCKRRGANPEKR SEQ ID NO: 9 CRKKYKPYVPVTTNPDEYIERAKECCKKQDIQ CCLRIFDESKDPNVMLICLFCW Opicalcin 2-hIgG3- SEQ ID NO: 270 GDCLPHLKRCKENNDCCSKKCKRRGANPEKR SEQ ID NO: 9 CREPKSSDKTHTPDEYIERAKECCKKQDIQCCL RIFDESKDPNVMLICLFCW Hadrucalcin-GlySer SEQ ID NO: 271 SEKDCIKHLQRCRENKDCCSKKCSRRGTNPEK linker-SEQ ID NO: 9 RCRGGGSGGGSGGGSPDEYIERAKECCKKQDI QCCLRIFDESKDPNVMLICLFCW Hadrucalcin-DkTx- SEQ ID NO: 272 SEKDCIKHLQRCRENKDCCSKKCSRRGTNPEK SEQ ID NO: 9 RCRKKYKPYVPVTTNPDEYIERAKECCKKQDI QCCLRIFDESKDPNVMLICLFCW Hadrucalcin-hIgG3- SEQ ID NO: 273 SEKDCIKHLQRCRENKDCCSKKCSRRGTNPEK SEQ ID NO: 9 RCREPKSSDKTHTPDEYIERAKECCKKQDIQCC LRIFDESKDPNVMLICLFCW Midkine(62-104)- SEQ ID NO: 274 CKYKFENWGACDGGTGTKVRQGTLKKARYN GlySer linker-SEQ ID AQCQETIRVTKPCGGGSGGGSGGGSPDEYIERA NO: 9 KECCKKQDIQCCLRIFDESKDPNVMLICLFCW Midkine(62-104)- SEQ ID NO: 275 CKYKFENWGACDGGTGTKVRQGTLKKARYN DkTx-SEQ ID NO: 9 AQCQETIRVTKPCKKYKPYVPVTTNPDEYIERA KECCKKQDIQCCLRIFDESKDPNVMLICLFCW Midkine(62-104)- SEQ ID NO: 276 CKYKFENWGACDGGTGTKVRQGTLKKARYN hIgG3-SEQ ID NO: 9 AQCQETIRVTKPCEPKSSDKTHTPDEYIERAKE CCKKQDIQCCLRIFDESKDPNVMLICLFCW MCoTI-II-GlySer SEQ ID NO: 277 SGSDGGVCPKILKKCRRDSDCPGACICRGNGY linker-SEQ ID NO: 9 CGGGGSGGGSGGGSPDEYIERAKECCKKQDIQ CCLRIFDESKDPNVMLICLFCW MCoTI-II-DkTx-SEQ SEQ ID NO: 278 SGSDGGVCPKILKKCRRDSDCPGACICRGNGY ID NO: 9 CGKKYKPYVPVTTNPDEYIERAKECCKKQDIQ CCLRIFDESKDPNVMLICLFCW MCoTI-II-hIgG3- SEQ ID NO: 279 SGSDGGVCPKILKKCRRDSDCPGACICRGNGY SEQ ID NO: 9 CGEPKSSDKTHTPDEYIERAKECCKKQDIQCCL RIFDESKDPNVMLICLFCW *IgG3 = SEQ ID NO: 212 (peptide linker) DkTx = SEQ ID NO: 211 (peptide linker) GlySer linker = SEQ ID NO: 210 (peptide linker)
*IgG3=SEQ ID NO: 212 (peptide linker)
DkTx=SEQ ID NO: 211 (peptide linker)
GlySer linker=SEQ ID NO: 210 (peptide linker) - In some embodiments, nuclear localization signals can be couple to, conjugated to, linked to, or fused to a peptide described herein to promote nuclear localization. In some embodiments, TEAD-binding peptides are conjugated to, linked to, or fused to a nuclear localization signal, such as a four-residue sequence of K-K/R-X-K/R (SEQ ID NO: 202), wherein X can be any amino acid, or a variant thereof. In some embodiments, TEAD-binding peptides are conjugated to, linked to, or fused to a nuclear localization signal as described in Lange et al, J Biol Chem. 2007 Feb. 23; 282(8):5101-5, such as PKKKRRV (SEQ ID NO: 197) or KRPAATKKAGQAKKKK (SEQ ID NO: 198). In some embodiments, a peptide described herein is conjugated to, linked to, or fused to a nuclear localization signal comprising KxRy (SEQ ID NO: 288), wherein x and y independently can be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, such as KKRR (SEQ ID NO: 199), KKKRR (SEQ ID NO: 200), or KKKK (SEQ ID NO: 201). Other cell penetrating moieties can also be linked to, conjugated to, linked to, or fused to the peptides described herein, including, but not limited to, polycations, polyorganic acids, endosomal releasing polymers, poly(2-propylacrylic acid), poly(2-ethylacrylic acid), or any combination thereof.
- In other embodiments, TAT or dfTAT can be conjugated to, linked to, or fused to a peptide described herein, allowing the linked, conjugate, or fusion peptide or protein to use the endocytic pathway as a route of in vivo delivery or a way to penetrate a cell or nucleus. In some embodiments, it is contemplated that dfTAT can facilitate cytosolic delivery of TEAD-binding peptides. Co-delivery of dfTAT with TEAD-binding peptide can facilitate cytosolic uptake of TEAD-binding peptide into a cell. Efficient cell penetration of the peptides as described herein can interact with TEAD to downregulate or suppress genes, such as oncogenes, driven by YAP/TAZ-TEAD transcriptional activation.
- In other embodiments, cell penetration can be increased by using high dosage of a peptide described here, such as up to 10 μM, or 10 μM or more of the peptide. In some cases, an Arg patch can be fused, conjugated to, linked to, or co-delivered with a peptide. Up 10 μM, or 10 μM or more Arg patch may be co-delivered with a peptide to facilitate cell penetration. Protein transfection agents can also be used to increase cell penetration of a peptide. In some embodiments, direct cytosolic expression of a peptide can be used. In other embodiments, physical disruption methods such as electroporation can be used to improve delivery of a peptide into a cell.
- In some embodiments, cell penetrance of a peptide described herein can be improved. For example, the binding interface of a peptide described herein can be grafted on a scaffold that is naturally cell-penetrant, such as a calcine. Some non-limiting examples of calcines can be imperatoxin-A, maurocalcine, hemicalcin,
opiclacin 1,opicalcin 2, and hadrucalcin. The scaffold can comprise at least 60%, 70%, 80%, 90%, 95%, or 98% with any one of SEQ ID NO: 168-SEQ ID NO: 176. In some embodiments, the cell penetrance peptide can be calcines, modified calcines, derivatizes of calcines, or fragments thereof, which can be used to increase cell penetration. - Modified calcines, derivatives of calcines, or fragments can be screened for cell penetration activity such as activation of sarcoplasmic reticulum ryanodine receptors, activity on ryanodine-sensitive Ca2+ channels RyR1, Ryr2, or both, or as a selective agonist of the foregoing. Moreover, modified calcines can include substitution, addition or reduction of Lysine residues, or other charged residues, within a native calcine in order to modify activity and optimize such calcine cell-penetration activity or activity on the RyR1 or RyR2 receptors. As an example, the six amino acid portion of helix 3 (MLICLF; SEQ ID NO: 221), which can be a major component of SEQ ID NO: 9 binding to TEAD, can be transplanted onto a calcine or modified calcine scaffold to produce a bi-functional peptide that retains the cell penetration of the calcine with the novel SEQ ID NO: 9 TEAD binding function. As another example, a peptide as described herein can have improved cell penetrating capabilities using cis-acting elements, including inclusion of K/R-rich sequences like TAT or octa-arginine (SEQ ID NO: 146), intra-helical arginine patches, or fusion to larger fragments of proteins identified in cell penetration screening like penetratin or melittin.
- In some cases, peptides can penetrate into a target cell or a nucleus of a target cell. Examples of target cells include cancerous cells, tumors, and other cell types wherein the HIPPO pathway is dysregulated. The target cell can be a human cell, a mammalian cell, a human or mammalian cell line, a cancer cell line, a cell extracted from a subject, in vivo, or in vitro.
- In some instances, the peptide can contain only one lysine residue, or no lysine residues. In some instances, some or all of the lysine residues in the peptide are replaced with arginine residues. In some instances, some or all of the methionine residues in the peptide are replaced by leucine or isoleucine. Some or all of the tryptophan residues in the peptide can be replaced by phenylalanine or tyrosine. In some instances, some or all of the asparagine residues in the peptide are replaced by glutamine. In some embodiments, some or all of the aspartic acid residues can be replaced by glutamic acid residues. In some cases, the N-terminus of the peptide is blocked, such as by an acetyl group. Alternatively or in combination, in some instances, the C-terminus of the peptide is blocked, such as by an amide group. In some embodiments, the peptide is modified by methylation on free amines. For example, full methylation can be accomplished through the use of reductive methylation with formaldehyde and sodium cyanoborohydride.
- In some cases, GS can be added as the first two N-terminal amino acids, as shown in SEQ ID NO: 1-SEQ ID NO: 42, or such N-terminal amino acids (GS) can be absent as shown in SEQ ID NO: 43-SEQ ID NO: 84, or can be substituted by any other one or two amino acids. In some embodiments, GS is used as a linker or used to couple to a linker to make a protein conjugate or fusion. In some embodiments, the linker comprises a GxSy (SEQ ID NO: 283) peptide, wherein x and y independently can be any whole number, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. In some embodiments, the peptide linker comprises (GS)x (SEQ ID NO: 282), wherein x can be any whole number, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. In some embodiments, the peptide linker comprises GGSSG (SEQ ID NO: 204), GGGGG (SEQ ID NO: 205), GSGSGSGS (SEQ ID NO: 206), GGGGS (SEQ ID NO: 208), GGGS (SEQ ID NO: 203), or a variant or fragment thereof.
- In some cases, the C-terminal Arg residues of a peptide is modified to another residue such as Ala, Asn, Asp, Gln, Glu, Gly, His, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. For example, the C-terminal Arg residue of a peptide can be modified to Ile. Alternatively, the C-terminal Arg residue of a peptide can be modified to any non-natural amino acid. This modification can prevent clipping of the C-terminal residue during expression, synthesis, processing, storage, in vitro, or in vivo including during treatment, while still allowing maintenance of a key hydrogen bond. A key hydrogen bond can be the hydrogen bond formed during the initial folding nucleation and is critical for forming the initial hairpin.
- In some cases the peptide comprises the sequence of any one of SEQ ID NO: 1-SEQ ID NO: 84. A peptide can be a fragment comprising a contiguous fragment of any one of SEQ ID NO: 1-SEQ ID NO: 84 that is at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46 at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, at least 65, at least 66, at least 67, at least 68, at least 69, at least 70, at least 71, at least 72, at least 73, at least 74, at least 75, at least 76 residues long, at least 77, at least 78, at least 79, at least 80, or at least 81 residues long, wherein the peptide fragment is selected from any portion of the peptide. In some embodiments, the peptide sequence is flanked by additional amino acids. One or more additional amino acids can, for example, confer a desired in vivo charge, isoelectric point, chemical conjugation site, stability, or physiologic property to a peptide.
- In some instances, peptides capable of disrupting YAP-TEAD interact comprise no more than 60 amino acids in length, or no more than 50, no more than 45, no more than 40, no more than 35, no more than 30, no more than 25, no more than 20, no more than 15, or no more than 10 amino acids in length.
- In some embodiments, peptide sequences comprise primarily beta-sheets and/or alpha-helix structures. In some embodiments, designed or engineered TEAD-binding peptides of the present disclosure are small, compact mini-proteins stabilized by intra-chain disulfide bonds (mediated by cysteines) and a well-packed hydrophobic core. In some embodiments, engineered TEAD-binding peptides have structures comprising helical bundles with at least one disulfide bridge between each of the alpha helices, thereby stabilizing the peptides. In other embodiments, the engineered TEAD-binding peptides comprise structures with three alpha helices and three intra-chain disulfide bonds, one between each of the three alpha helices in the bundle. In certain embodiments, one alpha helix in the bundle, comprising at least two helical turns, can present the leucine-X1-X2-leucine-phenylalanine (LX1X2LF, SEQ ID NO: 217) motif on the surface of the folded structure of the engineered TEAD-binding peptide, wherein X1 and X2 can be any amino acid. The LX1X2LF (SEQ ID NO: 217) motif is a key binding motif found in the YAP sequence and is at the core of the binding interface between YAP and TEAD.
- In other embodiments, peptides can be conjugated to, linked to, or fused to a carrier or a molecule with targeting or homing function for a cell of interest or a target cell. In other embodiments, peptides can be conjugated to, linked to, or fused to a molecule that extends half-life or modifies the pharmacodynamic and/or pharmacokinetic properties of the peptides, or any combination thereof.
- In some instances, a peptide comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 positively charged residues, such as Arg or Lys, or any combination thereof. In some instances, one or more lysine residues in the peptide are replaced with arginine residues. In some cases, peptides comprise one or more Arg patches. In some embodiments, an Arg patch is positioned in the N-terminus of a peptide. In other aspects, an Arg patch is positioned in the C-terminus of a peptide. In some embodiments, an Arg patch comprises 8 consecutive Arg residues (SEQ ID NO: 146). In some cases, 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, or 10 or more Arg or Lys residues are solvent exposed on a peptide. In some embodiments, an Arg patch can be two or more consecutive Arg residues. In some embodiments, an Arg patch comprises one or more Arg substituted with Lys.
- The peptides of the present disclosure can further comprise neutral amino acid residues. In some cases, the peptide has 35 or fewer neutral amino acid residues. In other cases, the peptide has 81 or fewer neutral amino acid residues, 70 or fewer neutral amino acid residues, 60 or fewer neutral amino acid residues, 50 or fewer neutral amino acid residues, 40 or fewer neutral amino acid residues, 36 or fewer neutral amino acid residues, 33 or fewer neutral amino acid residues, 30 or fewer neutral amino acid residues, 25 or fewer neutral amino acid residues, or 10 or fewer neutral amino acid residues.
- The peptides of the present disclosure can further comprise negative amino acid residues. In some cases the peptide has 6 or fewer negative amino acid residues, 5 or fewer negative amino acid residues, 4 or fewer negative amino acid residues, 3 or fewer negative amino acid residues, 2 or fewer negative amino acid residues, or 1 or fewer negative amino acid residues. While negative amino acid residues can be selected from any negatively charged amino acid residues, in some embodiments, the negative amino acid residues are either E, or D, or a combination of both E and D.
- In some cases, a peptide comprises no Cys or disulfides. In some cases, a peptide comprises 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more Cys or disulfides. In other embodiments, 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more Cys residues have been replaced with Ser residues. In some embodiments, 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more Cys residues have been replaced with Thr residues.
- In some instances, some or all of the methionine residues in the peptide are replaced by leucine or isoleucine. In some instances, some or all of the tryptophan residues in the peptide are replaced by phenylalanine or tyrosine. In some instances, some or all of the asparagine residues in the peptide are replaced by glutamine. In some cases, the N-terminus of the peptide is blocked, such as by an acetyl group. Alternatively or in combination, in some instances, the C-terminus of the peptide is blocked, such as by an amide group. In some embodiments, the peptide is modified by methylation on free amines. For example, full methylation may be accomplished through the use of reductive methylation with formaldehyde and sodium cyanoborohydride. In some cases, the C-terminal Arg residues of a peptide is modified to another residue such as Ala, Asn, Asp, Gln, Glu, Gly, His, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. For example, the C-terminal Arg residue of a peptide can be modified to Ile. Alternatively, the C-terminal Arg residue of a peptide can be modified to any non-natural amino acid. This modification can prevent clipping of the C-terminal residue during expression, synthesis, processing, storage, in vitro, or in vivo including during treatment, while still allowing maintenance of a key hydrogen bond. A key hydrogen bond can be the hydrogen bond formed during the initial folding nucleation and is critical for forming the initial hairpin.
- Generally, the NMR solution structures of related structural homologs can be used to inform mutational strategies that may improve the folding, stability, manufacturability, while maintaining a particular biological function. They can be used to predict the 3D pharmacophore of a group of structurally homologous scaffolds, as wells as to predict possible graft regions of related proteins to create chimeras with improved properties. For example, this strategy was used to identify critical amino acid positions and loops that may be used to design peptides with improved cell penetrating properties, high affinity for either TEAD or YAP, high expression, high stability in vivo, or any combination thereof.
- In some embodiments, a peptide capable of disrupting YAP-TEAD interaction comprises a sequence with at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of the exemplary peptide sequences listed in TABLE 1, or a fragment thereof. Two or more peptides can share a degree of sequence identity or homology and share similar properties in vivo. For instance, a peptide can share a degree of sequence identity or homology with any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84. In some cases, one or more peptides of the disclosure can have up to about 20% pairwise sequence identity or homology, up to about 25% pairwise sequence identity or homology, up to about 30% pairwise sequence identity or homology, up to about 35% pairwise sequence identity or homology, up to about 40% pairwise sequence identity or homology, up to about 45% pairwise sequence identity or homology, up to about 50% pairwise sequence identity or homology, up to about 55% pairwise sequence identity or homology, up to about 60% pairwise sequence identity or homology, up to about 65% pairwise sequence identity or homology, up to about 70% pairwise sequence identity or homology, up to about 75% pairwise sequence identity or homology, up to about 80% pairwise sequence identity or homology, up to about 85% pairwise sequence identity or homology, up to about 90% pairwise sequence identity or homology, up to about 95% pairwise sequence identity or homology, up to about 96% pairwise sequence identity or homology, up to about 97% pairwise sequence identity or homology, up to about 98% pairwise sequence identity or homology, up to about 99% pairwise sequence identity or homology, up to about 99.5% pairwise sequence identity or homology, or up to about 99.9% pairwise sequence identity or homology. In some cases, one or more peptides of the disclosure can have at least about 20% pairwise sequence identity or homology, at least about 25% pairwise sequence identity or homology, at least about 30% pairwise sequence identity or homology, at least about 35% pairwise sequence identity or homology, at least about 40% pairwise sequence identity or homology, at least about 45% pairwise sequence identity or homology, at least about 50% pairwise sequence identity or homology, at least about 55% pairwise sequence identity or homology, at least about 60% pairwise sequence identity or homology, at least about 65% pairwise sequence identity or homology, at least about 70% pairwise sequence identity or homology, at least about 75% pairwise sequence identity or homology, at least about 80% pairwise sequence identity or homology, at least about 85% pairwise sequence identity or homology, at least about 90% pairwise sequence identity or homology, at least about 95% pairwise sequence identity or homology, at least about 96% pairwise sequence identity or homology, at least about 97% pairwise sequence identity or homology, at least about 98% pairwise sequence identity or homology, at least about 99% pairwise sequence identity or homology, at least about 99.5% pairwise sequence identity or homology, at least about 99.9% pairwise sequence identity or homology with a second peptide.
- Various methods and software programs can be used to determine the homology between two or more peptides, such as NCBI BLAST, Clustal W, MAFFT, Clustal Omega, AlignMe, Praline, or another suitable method or algorithm. Pairwise sequence alignment is used to identify regions of similarity that may indicate functional, structural and/or evolutionary relationships between two biological sequences (protein or nucleic acid), By contrast, multiple sequence alignment (MSA) is the alignment of three or more biological sequences. From the output of MSA applications, homology can be inferred and the evolutionary relationship between the sequences assessed. One of skill in the art would recognize as used herein, “sequence homology” and “sequence identity” and “percent (%) sequence identity” and “percent (%) sequence homology” have been used interchangeably to mean the sequence relatedness or variation, as appropriate, to a reference polynucleotide or amino acid sequence.
- In some instances, the peptide is any one of SEQ ID NO: 1-SEQ ID NO: 84 or a functional fragment thereof. In other embodiments, the peptide of the disclosure further comprises a peptide with 99%, 95%, 90%, 85%, or 80% sequence identity or homology to any one of SEQ ID NO: 1-SEQ ID NO: 84 or fragment thereof.
- In other instances, the peptide can be a peptide that is homologous to any one of SEQ ID NO: 1-SEQ ID NO: 84 or a functional fragment thereof. The term “homologous” is used herein to denote peptides having at least 70%, at least 80%, at least 90%, at least 95%, or greater than 95% sequence identity or homology to a sequence of any one of SEQ ID NO: 1-SEQ ID NO: 84 or a functional fragment thereof.
- In still other instances, the variant nucleic acid molecules that encode a peptide of any one of SEQ ID NO: 1-SEQ ID NO: 84 can be identified by either a determination of the sequence identity or homology of the encoded peptide amino acid sequence with the amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 84, or by a nucleic acid hybridization assay. Such peptide variants of any one of SEQ ID NO: 1-SEQ ID NO: 84 can be characterized as nucleic acid molecules (1) that remain hybridized with a nucleic acid molecule having the nucleotide sequence of any one of SEQ ID NO: 1-SEQ ID NO: 84 (or its complement) under highly stringent washing conditions, in which the wash stringency is equivalent to 0.1×-0.2×SSC with 0.1% SDS at 50-65° C., and (2) that encode a peptide having at least 70%, at least 80%, at least 90%, at least 95% or greater than 95% sequence identity or homology to the amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 84.
- In some embodiments, TEAD binding peptides as described herein contain no disulfides or Cys. In other embodiments, TEAD binding peptides comprise one or more Cys, or one or more disulfide bond. In some embodiments, the TEAD binding peptides are derived from knotted or knottin peptides. In some embodiments, such knotted peptides can bind TEAD, thereby preventing TEAD interactions, such as YAP-TEAD interactions. In some embodiments, a peptide that disrupts TEAD binding interactions comprises one or more properties of some knottin peptides, such as stability, resistance to proteolysis, resistance to reducing conditions, and/or ability to cross the blood brain barrier.
- In other embodiments, knotted peptides can be conjugated to, linked to, or fused to TEAD binding peptides, such as those described in TABLE 1, to provide homing or targeting function to a target cell, such as a cancer cell, pancreatic cell, liver cell, colon cell, ovarian cell, breast cell, lung cell, or any combination thereof. In some embodiments, such knotted peptides selectively target or home to a cancer cell, such as a breast cancer, liver cancer, colon cancer, brain cancer, or tumor cell.
- In some embodiments, such knotted peptides can home to or target an unhealthy or diseased cell or a cancer cell across the blood brain barrier. In some cases, knotted peptides are conjugated to, linked to, or fused to TEAD binding peptides and are capable of localizing TEAD binding peptides across the blood brain barrier to deliver TEAD binding peptides to target cells in the central nervous system. In some embodiments, such targeting or homing peptides or knotted peptides can be used to deliver a cytotoxic agent to the target cell or target TEAD in a target cell for degradation or inactivation, such as targeting TEAD for ubiquitination or other post-translation modification that targets TEAD for degradation or inactivation.
- Knottins are a class of peptides, usually ranging from about 11 to about 81 amino acids in length that are often folded into a compact structure. Knottins are typically assembled into a complex tertiary structure that is characterized by a number of intramolecular disulfide crosslinks and may contain beta strands, alpha helices, and other secondary structures. The presence of the disulfide bonds gives knottins remarkable environmental stability, allowing them to withstand extremes of temperature and pH and to resist the proteolytic enzymes of the blood stream. The presence of a disulfide knot may provide resistance to reduction by reducing agents. The rigidity of knottins also allows them to bind to targets without paying the “entropic penalty” that a floppy peptide accrues upon binding a target. For example, binding is adversely affected by the loss of entropy that occurs when a peptide binds a target to form a complex. Therefore, “entropic penalty” is the adverse effect on binding, and the greater the entropic loss that occurs upon this binding, the greater the “entropic penalty.” Furthermore, unbound molecules that are flexible lose more entropy when forming a complex than molecules that are rigidly structured, because of the loss of flexibility when bound up in a complex. However, rigidity in the unbound molecule also generally increases specificity by limiting the number of complexes that molecule can form. The knotted peptides can bind targets with antibody-like affinity, or with nanomolar or picomolar affinity. A wider examination of the sequence structure and sequence identity or homology of knottins reveals that they have arisen by convergent evolution in all kinds of animals and plants. In animals, they are often found in venoms, for example, the venoms of spiders and scorpions and have been implicated in the modulation of ion channels. The knottin proteins of plants can inhibit the proteolytic enzymes of animals or have antimicrobial activity, suggesting that knottins can function in the native defense of plants.
- The present disclosure provides peptides that comprise or are derived from these knotted peptides (or knottins). As used herein, the term “knotted peptide” is considered to be interchangeable with the terms “knottin” and “peptide.”
- The peptides of the present disclosure comprise cysteine amino acid residues. In some cases, the peptide has at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 cysteine amino acid residues. In some cases, the peptide has at least 8 cysteine amino acid residues. In other cases, the peptide has at least 10 cysteine amino acid residues, at least 12 cysteine amino acid residues, at least 14 cysteine amino acid residues or at least 16 cysteine amino acid residues.
- A knotted peptide can comprise disulfide bridges. A knotted peptide can be a peptide wherein 5% or more of the residues are cysteines forming intramolecular disulfide bonds. A disulfide-linked peptide can be a drug scaffold. In some embodiments, the disulfide bridges form a knot. A disulfide bridge can be formed between cysteine residues, for example, between
cysteines - The present disclosure further includes peptide scaffolds that, e.g., can be used as a starting point for generating additional peptides. In some embodiments, these scaffolds can be derived from a variety of knotted peptides (or knottins). In certain embodiments, knotted peptides are assembled into a complex tertiary structure that is characterized by a number of intramolecular disulfide crosslinks, and optionally contain beta strands and other secondary structures such as an alpha helix.
- For example, knotted peptides include, in some embodiments, small disulfide-rich proteins characterized by a disulfide through disulfide knot. This knot can be, e.g., obtained when one disulfide bridge crosses the macrocycle formed by two other disulfides and the interconnecting backbone. In some embodiments, the knotted peptides can include growth factor cysteine knots or inhibitor cysteine knots. Other possible peptide structures include peptide having two parallel helices linked by two disulfide bridges without β-sheets (e.g., hefutoxin).
- A knotted peptide can comprise at least one amino acid residue in an L configuration. A knotted peptide can comprise at least one amino acid residue in a D configuration. In some embodiments, a knotted peptide is 15-40 amino acid residues long. In other embodiments, a knotted peptide is 11-57 amino acid residues long. In still other embodiments, a knotted peptide is 11-81 amino acid residues long. In further embodiments, a knotted peptide is at least 20 amino acid residues long.
- Knotted peptides or peptides can be derived from a class of proteins known to be present or associated with toxins or venoms. In some cases, the peptide can be derived from toxins or venoms associated with scorpions or spiders. The peptide can be derived from venoms and toxins of spiders and scorpions of various genus and species. For example, the peptide can be derived from a venom or toxin of the Leiurus quinquestriatus hebraeus, Buthus occitanus tunetanus, Hottentotta judaicus, Mesobuthus eupeus, Buthus occitanus israelis, Hadrurus gertschi, Androctonus australis, Centruroides noxius, Heterometrus laoticus, Opistophthalmus carinatus, Haplopelma schmidti, Isometrus maculatus, Haplopelma huwenum, Haplopelma hainanum, Haplopelma schmidti, Agelenopsis aperta, Haydronyche versuta, Selenocosmia huwena, Heteropoda venatoria, Grammostola rosea, Omithoctonus huwena, Hadronyche versuta, Atrax robustus, Angelenopsis aperta, Psalmopoeus cambridgei, Hadronyche infensa, Paracoelotes luctosus, and Chilobrachys jingzhaoor another suitable genus or species of scorpion or spider. In some cases, a peptide can be derived from a Buthus martensii Karsh (scorpion) toxin.
- Percent sequence identity or homology is determined by conventional methods. See, for example, Altschul et al., Bull. Math. Bio. 48:603 (1986), and Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1992). Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the “BLOSUM62” scoring matrix of Henikoff and Henikoff (Id.). The sequence identity or homology is then calculated as: ([Total number of identical matches]/[length of the longer sequence plus the number of gaps introduced into the longer sequence in order to align the two sequences])(100).
- Additionally, there are many established algorithms available to align two amino acid sequences. For example, the “FASTA” similarity search algorithm of Pearson and Lipman is a suitable protein alignment method for examining the level of sequence identity or homology shared by an amino acid sequence of a peptide disclosed herein and the amino acid sequence of a peptide variant. The FASTA algorithm is described by Pearson and Lipman, Proc. Nat'l Acad. Sci. USA 85:2444 (1988), and by Pearson, Meth. Enzymol. 183:63 (1990). Briefly, FASTA first characterizes sequence similarity by identifying regions shared by the query sequence (e.g., SEQ ID NO: 1) and a test sequence that has either the highest density of identities (if the ktup variable is 1) or pairs of identities (if ktup=2), without considering conservative amino acid substitutions, insertions, or deletions. The ten regions with the highest density of identities are then rescored by comparing the similarity of all paired amino acids using an amino acid substitution matrix, and the ends of the regions are “trimmed” to include only those residues that contribute to the highest score.
- If there are several regions with scores greater than the “cutoff” value (calculated by a predetermined formula based upon the length of the sequence and the ktup value), then the trimmed initial regions are examined to determine whether the regions can be joined to form an approximate alignment with gaps. Finally, the highest scoring regions of the two amino acid sequences are aligned using a modification of the Needleman-Wunsch-Sellers algorithm (Needleman and Wunsch, J. Mol. Biol. 48:444 (1970); Sellers, Siam J. Appl. Math. 26:787 (1974)), which allows for amino acid insertions and deletions. Illustrative parameters for FASTA analysis are: ktup=1, gap opening penalty=10, gap extension penalty=1, and substitution matrix=BLOSUM62. These parameters can be introduced into a FASTA program by modifying the scoring matrix file (“SMATRIX”), as explained in
Appendix 2 of Pearson, Meth. Enzymol. 183:63 (1990). - FASTA can also be used to determine the sequence identity or homology of nucleic acid molecules using a ratio as disclosed above. For nucleotide sequence comparisons, the ktup value can range between one to six, preferably from three to six, most preferably three, with other parameters set as described above.
- Some examples of common amino acids that are a “conservative amino acid substitution” are illustrated by a substitution among amino acids within each of the following groups: (1) glycine, alanine, valine, leucine, and isoleucine, (2) phenylalanine, tyrosine, and tryptophan, (3) serine and threonine, (4) aspartate and glutamate, (5) glutamine and asparagine, and (6) lysine, arginine and histidine. The BLOSUM62 table is an amino acid substitution matrix derived from about 2,000 local multiple alignments of protein sequence segments, representing highly conserved regions of more than 500 groups of related proteins (Henikoff and Henikoff, Proc. Nat'l Acad. Sci. USA 89:10915 (1992)). Accordingly, the BLOSUM62 substitution frequencies can be used to define conservative amino acid substitutions that may be introduced into the amino acid sequences of the present invention. Although it is possible to design amino acid substitutions based solely upon chemical properties (as discussed above), the language “conservative amino acid substitution” preferably refers to a substitution represented by a BLOSUM62 value of greater than −1. For example, an amino acid substitution is conservative if the substitution is characterized by a BLOSUM62 value of 0, 1, 2, or 3. According to this system, preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 1 (e.g., 1, 2 or 3), while more preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 2 (e.g., 2 or 3).
- Determination of amino acid residues that are within regions or domains that are critical to maintaining structural integrity can be determined. Within these regions one can determine specific residues that can be more or less tolerant of change and maintain the overall tertiary structure of the molecule. Methods for analyzing sequence structure include, but are not limited to, alignment of multiple sequences with high amino acid or nucleotide identity or homology and computer analysis using available software (e.g., the Insight II® viewer and homology modeling tools; MSI, San Diego, Calif.), secondary structure propensities, binary patterns, complementary packing and buried polar interactions (Barton, G. J., Current Opin. Struct. Biol. 5:372-6 (1995) and Cordes, M. H. et al., Current Opin. Struct. Biol. 6:3-10 (1996)). In general, when designing modifications to molecules or identifying specific fragments determination of structure can typically be accompanied by evaluating activity of modified molecules.
- At physiological pH, peptides can have a net charge, for example, of −5, −4, −3, −2, −1, 0, +1, +2, +3, +4, or +5. When the net charge is zero, the peptide can be uncharged or zwitterionic. In some embodiments, the peptide contains one or more disulfide bonds and has a positive net charge at physiological pH where the net charge can be +0.5 or less than +0.5, +1 or less than +1, +1.5 or less than +1.5, +2 or less than +2, +2.5 or less than +2.5, +3 or less than +3, +3.5 or less than +3.5, +4 or less than +4, +4.5 or less than +4.5, +5 or less than +5, +5.5 or less than +5.5, +6 or less than +6, +6.5 or less than +6.5, +7 or less than +7, +7.5 or less than +7.5, +8 or less than +8, +8.5 or less than +8.5, +9 or less than +9.5, +10 or less than +10. In some embodiments, the peptide has a negative net charge at physiological pH where the net charge can be −0.5 or less than −0.5, −1 or less than −1, −1.5 or less than −1.5, −2 or less than −2, −2.5 or less than −2.5, −3 or less than −3, −3.5 or less than −3.5, −4 or less than −4, −4.5 or less than −4.5, −5 or less than −5, −5.5 or less than −5.5, −6 or less than −6, −6.5 or less than −6.5, −7 or less than −7, −7.5 or less than −7.5, −8 or less than −8, −8.5 or less than −8.5, −9 or less than −9.5, −10 or less than −10.
- In some embodiments, peptides of the present disclosure can have an isoelectric point (pI) value from 3 and 10. In other embodiments, peptides of the present disclosure can have a pI value from 4.3 and 8.9. In some embodiments, peptides of the present disclosure can have a pI value from 3-4. In some embodiments, peptides of the present disclosure can have a pI value from 3-5. In some embodiments, peptides of the present disclosure can have a pI value from 3-6. In some embodiments, peptides of the present disclosure can have a pI value from 3-7. In some embodiments, peptides of the present disclosure can have a pI value from 3-8. In some embodiments, peptides of the present disclosure can have a pI value from 3-9. In some embodiments, peptides of the present disclosure can have a pI value from 4-5. In some embodiments, peptides of the present disclosure can have a pI value from 4-6. In some embodiments, peptides of the present disclosure can have a pI value from 4-7. In some embodiments, peptides of the present disclosure can have a pI value from 4-8. In some embodiments, peptides of the present disclosure can have a pI value from 4-9. In some embodiments, peptides of the present disclosure can have a pI value from 4-10. In some embodiments, peptides of the present disclosure can have a pI value from 5-6. In some embodiments, peptides of the present disclosure can have a pI value from 5-7. In some embodiments, peptides of the present disclosure can have a pI value from 5-8. In some embodiments, peptides of the present disclosure can have a pI value from 5-9. In some embodiments, peptides of the present disclosure can have a pI value from 5-10. In some embodiments, peptides of the present disclosure can have a pI value from 6-7. In some embodiments, peptides of the present disclosure can have a pI value from 6-8. In some embodiments, peptides of the present disclosure can have a pI value from 6-9. In some embodiments, peptides of the present disclosure can have a pI value from 6-10. In some embodiments, peptides of the present disclosure can have a pI value from 7-8. In some embodiments, peptides of the present disclosure can have a pI value from 7-9. In some embodiments, peptides of the present disclosure can have a pI value from 7-10. In some embodiments, peptides of the present disclosure can have a pI value from 8-9. In some embodiments, peptides of the present disclosure can have a pI value from 8-10. In some embodiments, peptides of the present disclosure can have a pI value from 9-10.
- In some cases, the engineering of one or more mutations within a peptide yields a peptide with an altered isoelectric point, charge, surface charge, or rheology at physiological pH. Such engineering of a mutation to a peptide derived from a scorpion or spider can change the net charge of the complex, for example, by decreasing the net charge by 1, 2, 3, 4, or 5, or by increasing the net charge by 1, 2, 3, 4, or 5. In such cases, the engineered mutation can facilitate the ability of the peptide to penetrate a cell, an endosome, or the nucleus. Suitable amino acid modifications for improving the rheology and potency of a peptide can include conservative or non-conservative mutations.
- A peptide can comprise at most 1 amino acid mutation, at most 2 amino acid mutations, at most 3 amino acid mutations, at most 4 amino acid mutations, at most 5 amino acid mutations, at most 6 amino acid mutations, at most 7 amino acid mutations, at most 8 amino acid mutations, at most 9 amino acid mutations, at most 10 amino acid mutations, or another suitable number as compared to the sequence of the venom or toxin component that the peptide is derived from. In other cases, a peptide, or a functional fragment thereof, comprises at least 1 amino acid mutation, at least 2 amino acid mutations, at least 3 amino acid mutations, at least 4 amino acid mutations, at least 5 amino acid mutations, at least 6 amino acid mutations, at least 7 amino acid mutations, at least 8 amino acid mutations, at least 9 amino acid mutations, at least 10 amino acid mutations, or another suitable number as compared to the sequence of the venom or toxin component that the peptide is derived from. In some embodiments, mutations can be engineered within a peptide to provide a peptide that has a desired charge or stability at physiological pH.
- Generally, the NMR solution structures, the x-ray crystal structures, as well as the primary structure sequence alignment of related structural homologs or in silico design can be used to inform mutational strategies that can improve the folding, stability, and/or manufacturability, while maintaining a particular biological function. The general strategy for producing homologs or in silico designed peptides or proteins can include identification of a charged surface patch or conserved residues of a protein, mutation of critical amino acid positions and loops, and testing of sequences.
- This strategy can be used to design peptides with improved properties or to correct deleterious mutations that complicate folding and manufacturability. These key amino acid positions and loops can be retained while other residues in the peptide sequences can be mutated to improve, change, remove, or otherwise modify function, such as binding or ability to penetrate a cell, endosome, or nucleus in a cell, homing, or another activity of the peptide.
- The present disclosure also encompasses multimers of the various peptides described herein. Examples of multimers include dimers, trimers, tetramers, pentamers, hexamers, heptamers, and so on. A multimer may be a homomer formed from a plurality of identical subunits or a heteromer formed from a plurality of different subunits. In some embodiments, a peptide of the present disclosure is arranged in a multimeric structure with at least one other peptide, or two, three, four, five, six, seven, eight, nine, ten, or more other peptides. In certain embodiments, the peptides of a multimeric structure each have the same sequence. In alternative embodiments, some or all of the peptides of a multimeric structure have different sequences.
- The present disclosure further includes peptide scaffolds that, e.g., can be used as a starting point for generating additional peptides. In some embodiments, these scaffolds can be derived from a variety of knotted peptides or knottins. Some suitable peptides for scaffolds can include, but are not limited to, chlorotoxin, brazzein, circulin, stecrisp, hanatoxin, midkine, hefutoxin, potato carboxypeptidase inhibitor, bubble protein, attractin, α-GI, α-GID, ρ-PIIIA, ω-MVIIA, ω-CVID, χ-MrIA, ρ-TIA, conantokin G, contulakin G, GsMTx4, margatoxin, shK, toxin K, chymotrypsin inhibitor (CTI), and EGF epiregulin core. In some embodiments, the peptide sequence is flanked by additional amino acids. One or more additional amino acids can, for example, confer a desired in vivo charge, isoelectric point, chemical conjugation site, stability, or physiologic property to a peptide.
- A peptide can be chemically modified one or more of a variety of ways. In some embodiments, the peptide can be mutated to add function, delete function, or modify the in vivo behavior. For example, in some embodiments, peptides of the presenting disclosure may be chemically modified with a molecule that would lead to proteasomal degradation of TEAD (e.g., ubiquitin ligase engaging conjugate or fusion or cereblon-binding molecule). One or more loops between the disulfide linkages can be modified or replaced to include active elements from other peptides (such as described in Moore and Cochran, Methods in Enzymology, 503, p. 223-251, 2012). Amino acids can also be mutated, such as to increase half-life, modify, add or delete binding behavior in vivo, add new targeting function, modify surface charge and hydrophobicity, or allow conjugation sites. N-methylation is one example of methylation that can occur in a peptide of the disclosure. In some embodiments, the peptide is modified by methylation on free amines. For example, full methylation may be accomplished through the use of reductive methylation with formaldehyde and sodium cyanoborohydride.
- A chemical modification can, for instance, extend the half-life of a peptide or change the biodistribution or pharmacokinetic profile. A chemical modification can comprise a polymer, a polyether, polyethylene glycol, a biopolymer, a polyamino acid, a fatty acid, a dendrimer, an Fc region, a simple saturated carbon chain such as palmitate or myristolate, or albumin. A polyamino acid can include, for example, a poly amino acid sequence with repeated single amino acids (e.g., poly glycine), and a poly amino acid sequence with mixed poly amino acid sequences (e.g, gly-ala-gly-ala) that may or may not follow a pattern, or any combination of the foregoing.
- The peptides of the present disclosure can be modified such that the modification increases the stability and/or the half-life of the peptides. The attachment of a hydrophobic moiety, such as to the N-terminus, the C-terminus, or an internal amino acid, can be used to extend half-life of a peptide of the present disclosure. The peptides can also be modified to increase or decrease the gut permeability or cellular permeability of the peptide. The peptide of the present disclosure can include post-translational modifications (e.g., methylation and/or amidation and/or glycosylation), which can affect, e.g., serum half-life. In some embodiments, simple carbon chains (e.g., by myristoylation and/or palmitylation) can be conjugated to, linked to, the fusion proteins or peptides. The simple carbon chains can render the fusion proteins or peptides easily separable from the unconjugated material. For example, methods that can be used to separate the fusion proteins or peptides from the unconjugated material include, but are not limited to, solvent extraction and reverse phase chromatography. Lipophilic moieties can extend half-life through reversible binding to serum albumin. Conjugated moieties can, e.g., be lipophilic moieties that extend half-life of the peptides through reversible binding to serum albumin. In some embodiments, the lipophilic moiety can be cholesterol or a cholesterol derivative including cholestenes, cholestanes, cholestadienes and oxysterols. In some embodiments, the peptides can be conjugated to, linked to, myristic acid (tetradecanoic acid) or a derivative thereof. In other embodiments, the peptides of the present disclosure can be coupled (e.g., conjugated, linked, or fused) to a half-life modifying agent. Examples of half-life modifying agents can include, but is not limited to: a polymer, a polyethylene glycol (PEG), a hydroxyethyl starch, polyvinyl alcohol, a water soluble polymer, a zwitterionic water soluble polymer, a water soluble poly(amino acid), a water soluble polymer of proline, alanine and serine, a water soluble polymer containing glycine, glutamic acid, and serine, an Fc region, a fatty acid, palmitic acid, or a molecule that binds to albumin. Additionally, conjugation of the peptide to a near infrared dye, such as Cy5.5, or to an albumin binder such as Albu-tag can extend serum half-life of any peptide as described herein. In some embodiments, immunogenicity is reduced by using minimal non-human protein sequences to extend serum half-life of the peptide.
- In some embodiments, the first two N-terminal amino acids (GS) of SEQ ID NO: 1-SEQ ID NO: 84 serve as a spacer or linker in order to facilitate conjugation or fusion to another molecule, as well as to facilitate cleavage of the peptide from such conjugated to, linked to, or fused molecules. In some embodiments, the fusion proteins or peptides of the present disclosure can be conjugated to, linked to, or fused to other moieties that, e.g., can modify or effect changes to the properties of the peptides.
- In some embodiments, the peptides of the present disclosure can themselves be used to inhibit YAP binding to TEAD. In other embodiments, peptides of the present disclosure can also be used to deliver another active agent. Peptides according to the present disclosure can be conjugated to, linked to, or fused to an agent for use in the treatment of tumors and cancers. For example, in certain embodiments, the peptides described herein are fused to another molecule, such as an active agent that provides an additional functional capability. A peptide can be fused with an active agent through expression of a vector containing the sequence of the peptide with the sequence of the active agent. In various embodiments, the sequence of the peptide and the sequence of the active agent can be expressed from the same Open Reading Frame (ORF). In various embodiments, the sequence of the peptide and the sequence of the active agent can comprise a contiguous sequence. The peptide and the active agent can each retain similar functional capabilities in the fusion peptide compared with their functional capabilities when expressed separately. In certain embodiments, examples of active agents can include other peptides.
- As another example, in certain embodiments, the peptides described herein are attached to another molecule, such as an active agent that provides a functional capability. In some embodiments, TEAD-binding peptides can direct the active agent into the cell. In further embodiments, TEAD-binding peptides can direct the active agent into the nucleus. In some embodiments, the active agent has intrinsic tumor-homing properties or the active agent can be engineering to have tumor-homing properties. In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 active agents can be linked to a peptide. Multiple active agents can be attached by methods such as conjugating to multiple lysine residues and/or the N-terminus, or by linking the multiple active agents to a scaffold, such as a polymer or dendrimer and then attaching that agent-scaffold to the peptide (such as described in Yurkovetskiy, A. V., Cancer Res 75(16): 3365-72 (2015)). Examples of active agents include but are not limited to: a peptide, an oligopeptide, a polypeptide, a peptidomimetic, a polynucleotide, a polyribonucleotide, a DNA, a cDNA, a ssDNA, a RNA, a dsRNA, a micro RNA, an oligonucleotide, an antibody, a single chain variable fragment (scFv), an antibody fragment, an aptamer, a cytokine, an interferon, a hormone, an enzyme, a growth factor, a checkpoint inhibitor, a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA4 inhibitor, a CD antigen, a chemokine, a neurotransmitter, an ion channel inhibitor, an ion channel activator, a G-protein coupled receptor inhibitor, a G-protein coupled receptor activator, a chemical agent, a radiosensitizer, a radioprotectant, a radionuclide, a therapeutic small molecule, a steroid, a corticosteroid, an anti-inflammatory agent, an immune modulator, a complement fixing peptide or protein, a tumor necrosis factor inhibitor, a tumor necrosis factor activator, a tumor necrosis factor receptor family agonist, a tumor necrosis receptor antagonist, a Tim-3 inhibitor, a protease inhibitor, an amino sugar, a chemotherapeutic, a cytotoxic molecule, a toxin, a tyrosine kinase inhibitor, an anti-infective agent, an antibiotic, an anti-viral agent, an anti-fungal agent, an aminoglycoside, a nonsteroidal anti-inflammatory drug (NSAID), a statin, a nanoparticle, a liposome, a polymer, a biopolymer, a polysaccharide, a proteoglycan, a glycosaminoglycan, polyethylene glycol, a lipid, a dendrimer, a fatty acid, or an Fc region, or an active fragment or a modification thereof. In some embodiments, the peptide is covalently or non-covalently linked to an active agent, e.g., directly or via a linker. For example, cytotoxic molecules that can be used include auristatins, MMAE, MMAF, dolostatin, auristatin F, monomethylaurstatin D, DM1, DM4, maytansinoids, maytansine, calicheamicins, N-acetyl-γ-calicheamicin, pyrrolobenzodiazepines, PBD dimers, doxorubicin, vinca alkaloids (4-deacetylvinblastine), duocarmycins, cyclic octapeptide analogs of mushroom amatoxins, epothilones, and anthracylines, CC-1065, taxanes, paclitaxel, cabazitaxel, docetaxel, SN-38, irinotecan, vincristine, vinblastine, platinum compounds, cisplatin, methotrexate, and BACE inhibitors. Additional examples of active agents are described in McCombs, J. R., AAPS J, 17(2): 339-51 (2015), Ducry, L., Antibody Drug Conjugates (2013), and Singh, S. K., Pharm Res. 32(11): 3541-3571 (2015). Exemplary linkers suitable for use with the embodiments herein are discussed in further detail below.
- As compared to antibody-drug conjugates (e.g., Adcetris, Kadcyla, Mylotarg), in some aspects the peptide conjugated to, linked to, or fused to an active agent as described herein can exhibit better penetration of solid tumors due to its smaller size. In certain aspects, the peptide conjugated to, linked to, or fused to an active agent as described herein can carry different or higher doses of active agents as compared to antibody-drug conjugates. In still other aspects, the peptide conjugated to, linked to, or fused to an active agent as described herein can have better site specific delivery of defined drug ratio as compared to antibody-drug conjugates. In other aspects, the peptide can be amenable to solvation in organic solvents (in addition to water), which can allow more synthetic routes for solvation and conjugation of a drug (which often has low aqueous solubility) and higher conjugation yields, higher ratios of drug conjugated to, linked to, or fused to peptide (versus an antibody), and/or reduce aggregate/high molecular weight species formation during conjugation. Additionally, a unique amino acid residue(s) can be introduced into the peptide via a residue that is not otherwise present in the short sequence or via inclusion of a non-natural amino acid, allowing site specific conjugation to the peptide.
- The peptides or fusion peptides of the present disclosure can also be conjugated to, linked to, or fused to other moieties that can serve other roles, such as providing an affinity handle (e.g., biotin) for retrieval of the peptides from tissues or fluids. For example, peptides or fusion peptides of the present disclosure can also be conjugated to, linked to, or fused to biotin. In addition to extension of half-life, biotin can also act as an affinity handle for retrieval of peptides or fusion peptides from tissues or other locations. In some embodiments, fluorescent biotin conjugates that can act both as a detectable label and an affinity handle can be used. Non limiting examples of commercially available fluorescent biotin conjugates can include Atto 425-Biotin, Atto 488-Biotin, Atto 520-Biotin, Atto-550 Biotin, Atto 565-Biotin, Atto 590-Biotin, Atto 610-Biotin, Atto 620-Biotin, Atto 655-Biotin, Atto 680-Biotin, Atto 700-Biotin, Atto 725-Biotin, Atto 740-Biotin, fluorescein biotin, biotin-4-fluorescein, biotin-(5-fluorescein) conjugate, and biotin-B-phycoerythrin, Alexa fluor 488 biocytin, Alexa flour 546, Alexa Fluor 549, lucifer yellow cadaverine biotin-X, Lucifer yellow biocytin, Oregon green 488 biocytin, biotin-rhodamine and tetramethylrhodamine biocytin. In some other examples, the conjugates can include chemiluminescent compounds, colloidal metals, luminescent compounds, enzymes, radioisotopes, and paramagnetic labels. In some embodiments, the peptide described herein can also be attached to another molecule. For example, the peptide sequence also can be attached to another active agent (e.g., small molecule, peptide, polypeptide, polynucleotide, antibody, aptamer, cytokine, growth factor, neurotransmitter, an active fragment or modification of any of the preceding agents, fluorophore, radioisotope, radionuclide chelator, acyl adduct, chemical linker, or sugar). In some embodiments, the peptide can be conjugated to, linked to, or fused with, or covalently or non-covalently linked to an active agent.
- Additionally, more than one peptide sequence derived from a toxin or venom knottin protein can be present on, conjugated to, linked to, or fused with a particular peptide. A peptide can be incorporated into a biomolecule by various techniques. A peptide can be incorporated by a chemical transformation, such as the formation of a covalent bond, such as an amide bond. A peptide can be incorporated, for example, by solid phase or solution phase peptide synthesis. A peptide can be incorporated by preparing a nucleic acid sequence encoding the biomolecule, wherein the nucleic acid sequence includes a subsequence that encodes the peptide. The subsequence can be in addition to the sequence that encodes the biomolecule, or can substitute for a subsequence of the sequence that encodes the biomolecule.
- A peptide can be conjugated to, linked to, or fused to an agent used in imaging, research, therapeutics, theranostics, pharmaceuticals, chemotherapy, chelation therapy, targeted drug delivery, and radiotherapy. In some embodiments, a peptide is conjugated to, linked to, or fused with detectable agents, such as a fluorophore, a near-infrared dye, a contrast agent, a nanoparticle, a metal-containing nanoparticle, a metal chelate, an X-ray contrast agent, a PET agent, a metal, a radioisotope, a dye, radionuclide chelator, or another suitable material that can be used in imaging. In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 detectable agents can be linked to a peptide. Non-limiting examples of radioisotopes include alpha emitters, beta emitters, positron emitters, and gamma emitters. In some embodiments, the metal or radioisotope is selected from the group consisting of actinium, americium, bismuth, cadmium, cesium, cobalt, europium, gadolinium, iridium, lead, lutetium, manganese, palladium, polonium, radium, ruthenium, samarium, strontium, technetium, thallium, and yttrium. In some embodiments, the metal is actinium, bismuth, lead, radium, strontium, samarium, or yttrium. In some embodiments, the radioisotope is actinium-225 or lead-212. In some embodiments, the near-infrared dyes are not easily quenched by biological tissues and fluids. In some embodiments, the fluorophore is a fluorescent agent emitting electromagnetic radiation at a wavelength between 650 nm and 4000 nm, such emissions being used to detect such agent. Non-limiting examples of fluorescent dyes that could be used as a conjugating molecule in the present disclosure include DyLight-680, DyLight-750, VivoTag-750, DyLight-800, IRDye-800, VivoTag-680, Cy5.5, or indocyanine green (ICG). In some embodiments, near infrared dyes often include cyanine dyes (e.g., Cy7, Cy5.5, and Cy5). Additional non-limiting examples of fluorescent dyes for use as a conjugating molecule in the present disclosure include acradine orange or yellow, Alexa Fluors (e.g., Alexa Fluor 790, 750, 700, 680, 660, and 647) and any derivative thereof, 7-actinomycin D, 8-anilinonaphthalene-1-sulfonic acid, ATTO dye and any derivative thereof, auramine-rhodamine stain and any derivative thereof, bensantrhone, bimane, 9-10-bis(phenylethynyl)anthracene, 5,12-bis(phenylethynyl)naththacene, bisbenzimide, brainbow, calcein, carbodyfluorescein and any derivative thereof, 1-chloro-9,10-bis(phenylethynyl)anthracene and any derivative thereof, DAPI, DiOC6, DyLight Fluors and any derivative thereof, epicocconone, ethidium bromide, FlAsH-EDT2, Fluo dye and any derivative thereof, FluoProbe and any derivative thereof, Fluorescein and any derivative thereof, Fura and any derivative thereof, GelGreen and any derivative thereof, GelRed and any derivative thereof, fluorescent proteins and any derivative thereof, m isoform proteins and any derivative thereof such as for example mCherry, hetamethine dye and any derivative thereof, hoeschst stain, iminocoumarin, indian yellow, indo-1 and any derivative thereof, laurdan, lucifer yellow and any derivative thereof, luciferin and any derivative thereof, luciferase and any derivative thereof, mercocyanine and any derivative thereof, nile dyes and any derivative thereof, perylene, phloxine, phyco dye and any derivative thereof, propium iodide, pyranine, rhodamine and any derivative thereof, ribogreen, RoGFP, rubrene, stilbene and any derivative thereof, sulforhodamine and any derivative thereof, SYBR and any derivative thereof, synapto-pHluorin, tetraphenyl butadiene, tetrasodium tris, Texas Red, Titan Yellow, TSQ, umbelliferone, violanthrone, yellow fluroescent protein and YOYO-1. Other Suitable fluorescent dyes include, but are not limited to, fluorescein and fluorescein dyes (e.g., fluorescein isothiocyanine or FITC, naphthofluorescein, 4′,5′-dichloro-2′,7′-dimethoxyfluorescein, 6-carboxyfluorescein or FAM, etc.), carbocyanine, merocyanine, styryl dyes, oxonol dyes, phycoerythrin, erythrosin, eosin, rhodamine dyes (e.g., carboxytetramethyl-rhodamine or TAMRA, carboxyrhodamine 6G, carboxy-X-rhodamine (ROX), lissamine rhodamine B, rhodamine 6G, rhodamine Green, rhodamine Red, tetramethylrhodamine (TMR), etc.), coumarin and coumarin dyes (e.g., methoxycoumarin, dialkylaminocoumarin, hydroxycoumarin, aminomethylcoumarin (AMCA), etc.), Oregon Green Dyes (e.g., Oregon Green 488, Oregon Green 500, Oregon Green 514, etc.), Texas Red, Texas Red-X, SPECTRUM RED, SPECTRUM GREEN, cyanine dyes (e.g., CY-3, Cy-5, CY-3.5, CY-5.5, etc.), ALEXA FLUOR dyes (e.g., ALEXA FLUOR 350, ALEXA FLUOR 488, ALEXA FLUOR 532, ALEXA FLUOR 546, ALEXA FLUOR 568, ALEXA FLUOR 594, ALEXA FLUOR 633, ALEXA FLUOR 660, ALEXA FLUOR 680, etc.), BODIPY dyes (e.g., BODIPY FL, BODIPY R6G, BODIPY TMR, BODIPY TR, BODIPY 530/550, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY 630/650, BODIPY 650/665, etc.), IRDyes (e.g., IRD40, IRD 700, IRD 800, etc.), and the like. Additional suitable detectable agents are described in PCT/US14/56177. Non-limiting examples of radioisotopes include alpha emitters, beta emitters, positron emitters, and gamma emitters. In some embodiments, the metal or radioisotope is selected from the group consisting of actinium, americium, bismuth, cadmium, cesium, cobalt, europium, gadolinium, iridium, lead, lutetium, manganese, palladium, polonium, radium, ruthenium, samarium, strontium, technetium, thallium, and yttrium. In some embodiments, the metal is actinium, bismuth, lead, radium, strontium, samarium, or yttrium. In some embodiments, the radioisotope is actinium-225 or lead-212.
- Peptides can be conjugated to, linked to, or fused to a radiosensitizer or photosensitizer. Examples of radiosensitizers include but are not limited to: ABT-263, ABT-199, WEHI-539, paclitaxel, carboplatin, cisplatin, oxaliplatin, gemcitabine, etanidazole, misonidazole, tirapazamine, and nucleic acid base derivatives (e.g., halogenated purines or pyrimidines, such as 5-fluorodeoxyuridine). Examples of photosensitizers can include but are not limited to: fluorescent molecules or beads that generate heat when illuminated, nanoparticles, porphyrins and porphyrin derivatives (e.g., chlorins, bacteriochlorins, isobacteriochlorins, phthalocyanines, and naphthalocyanines), metalloporphyrins, metallophthalocyanines, angelicins, chalcogenapyrrillium dyes, chlorophylls, coumarins, flavins and related compounds such as alloxazine and riboflavin, fullerenes, pheophorbides, pyropheophorbides, cyanines (e.g., merocyanine 540), pheophytins, sapphyrins, texaphyrins, purpurins, porphycenes, phenothiaziniums, methylene blue derivatives, naphthalimides, nile blue derivatives, quinones, perylenequinones (e.g., hypericins, hypocrellins, and cercosporins), psoralens, quinones, retinoids, rhodamines, thiophenes, verdins, xanthene dyes (e.g., eosins, erythrosins, rose bengals), dimeric and oligomeric forms of porphyrins, and prodrugs such as 5-aminolevulinic acid. Advantageously, this approach can allow for highly specific targeting of diseased cells (e.g., cancer cells) using both a therapeutic agent (e.g., drug) and electromagnetic energy (e.g., radiation or light) concurrently. In some embodiments, the peptide is conjugated to, linked to, fused with, or covalently or non-covalently linked to the agent, e.g., directly or via a linker. Exemplary linkers suitable for use with the embodiments herein are discussed in further detail below.
- Peptides according to the present disclosure can be attached to another moiety (e.g., an active agent or an detectable agent), such as a small molecule, a second peptide, a protein, an antibody, an antibody fragment, an aptamer, polypeptide, polynucleotide, a fluorophore, a radioisotope, a radionuclide chelator, a polymer, a biopolymer, a fatty acid, an acyl adduct, a chemical linker, or sugar or other active agent or detectable agent described herein through a linker, or directly in the absence of a linker. In the absence of a linker, for example, an active agent or an detectable agent can be conjugated to, linked to, or fused to the N-terminus or the C-terminus of a peptide to create an active agent or detectable agent fusion peptide. In other embodiments, the link can be made by a peptide fusion via reductive alkylation. In some embodiments, a cleavable linker is used for in vivo delivery of the peptide, such as a linker that can be cleaved or degraded upon entry in a cell, endosome, or a nucleus. In some embodiments, in vivo delivery of a peptide requires a small linker that does not interfere with penetration of a cell or localization to a nucleus of a cell. A linker can also be used to covalently attach a peptide as described herein to another moiety or molecule having a separate function, such a targeting, cytotoxic, therapeutic, homing, imaging, or diagnostic functions.
- Direct attachment can be through covalent attachment of a peptide to a region of the other molecule. For example, an active agent or a detectable agent can be conjugated to, linked to, or fused to the N-terminus or the C-terminus of a peptide to create an active agent or detectable agent fusion peptide. As another example, the peptide can be attached at the N-terminus, an internal lysine, glutamic acid, or aspartic acid residue, or the C-terminus to a terminus of the amino acid sequence of the other molecule by a linker. If the attachment is at an internal lysine residue, the other molecule can be linked to the peptide at the epsilon amine of the internal lysine residue. In some further examples, the peptide can be attached to the other molecule by a side chain, such as the side chain of a lysine, serine, threonine, cysteine, tyrosine, aspartic acid, a non-natural amino acid residue, or glutamic acid residue. A linker can be an amide bond, an ester bond, an ether bond, a carbamate bond, a carbonate bond, a carbon-nitrogen bond, a triazole, a macrocycle, an oxime bond, a thioester bond, a thioether bond a hydrazone bond, a carbon-carbon single, double, or triple bond, a disulfide bond, a two carbon bridge between two cysteines, a three carbon bridge between two cysteines, or a thioether bond. In still other embodiments, the peptide can comprise a non-natural amino acid, wherein the non-natural amino acid can be an insertion, appendage, or substitution for another amino acid, and the peptide can be linked to the active agent at the non-natural amino acid by a linker. In some embodiments, similar regions of the disclosed peptide(s) itself (such as a terminus of the amino acid sequence, an amino acid side chain, such as the side chain of a lysine, serine, threonine, cysteine, tyrosine, aspartic acid, a non-natural amino acid residue, or glutamic acid residue, via an amide bond, an ester bond, an ether bond, a carbamate bond, a carbon-nitrogen bond, a triazole, a macrocycle, an oxime bond, a hydrazone bond, a carbon-carbon single, double, or triple bond, a disulfide bond, a thioether bond, or other linker as described herein) can be used to link other molecules.
- Attachment via a linker involves incorporation of a linker moiety between the other molecule and the peptide. The peptide and the other molecule can both be covalently attached to the linker. The linker can be cleavable, non-cleavable, self-immolating, hydrophilic, or hydrophobic. The linker has at least two functional groups, one bonded to the other molecule, and one bonded to the peptide, and a linking portion between the two functional groups. Some example linkers are described in Jain, N., Pharm Res. 32(11): 3526-40 (2015), Doronina, S. O., Bioconj Chem. 19(10): 1960-3 (2008), Pillow, T. H., J Med Chem. 57(19): 7890-9 (2014), Dorywalksa, M., Bioconj Chem. 26(4): 650-9 (2015), Kellogg, B. A., Bioconj Chem. 22(4): 717-27 (2011), and Zhao, R. Y., J Med Chem. 54(10): 3606-23 (2011).
- Non-limiting examples of the functional groups for attachment can include functional groups capable of forming, for example, an amide bond, an ester bond, an ether bond, a carbonate bond, a carbamate bond, a carbon-nitrogen bond, a triazole, a macrocycle, an oxime bond, a hydrazone bond, a carbon-carbon single, double, or triple bond, a disulfide bond or a thioether bond. Non-limiting examples of functional groups capable of forming such bonds include amino groups; carboxyl groups; aldehyde groups; azide groups; alkyne and alkene groups; ketones; hydrazides; hydrazines; acid halides such as acid fluorides, chlorides, bromides, and iodides; acid anhydrides, including symmetrical, mixed, and cyclic anhydrides; carbonates; carbonyl functionalities bonded to leaving groups such as cyano, succinimidyl, and N-hydroxysuccinimidyl; maleimides; linkers containing maleimide groups that are designed to hydrolyze; maleimidocaproyl; MCC ([N-maleimidomethyl]cyclohexane-1-carboxylate); N-ethylmaleimide; maleimide alkane; mc-vc-PABC; DUBA (DuocarmycinhydroxyBenzamide-Azaindole linker); SMCC Succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate; SPDP (N-succinimidyl-3-(2-pyridyldithio) propionate); SPDB N-succinimidyl-4-(2-pyridyldithio) butanoate; sulfo-SPDB N-succinimidyl-4-(2-pyridyldithio)-2-sulfo butanoate; SPP N-succinimidyl 4-(2-pyridyldithio)pentanoate; a dithiopyridylmaleimide (DTM); a hydroxylamine, a vinyl-halo group; haloacetamido groups; bromoacetamido; hydroxyl groups; sulfhydryl groups; and molecules possessing, for example, alkyl, alkenyl, alkynyl, allylic, or benzylic leaving groups, such as halides, mesylates, tosylates, triflates, epoxides, phosphate esters, sulfate esters, and besylates.
- Non-limiting examples of the linking portion can include alkylene, alkenylene, alkynylene, polyether, such as polyethylene glycol (PEG), polyester, polyamide, polyamino acids, polypeptides, cleavable peptides, Val-Cit, Phe-Lys, Val-Lys, Val-Ala, other peptide linkers as given in Doronina et al., 2008, linkers cleavable by beta glucuronidase, linkers cleavable by a cathepsin or by cathepsin B, D, E, H, L, S, C, K, O, F, V, X, or W, Val-Cit-p-aminobenzyloxycarbonyl, glucuronide-MABC, aminobenzylcarbamates, D-amino acids, and polyamine, any of which being unsubstituted or substituted with any number of substituents, such as halogens, hydroxyl groups, sulfhydryl groups, amino groups, nitro groups, nitroso groups, cyano groups, azido groups, sulfoxide groups, sulfone groups, sulfonamide groups, carboxyl groups, carboxaldehyde groups, imine groups, alkyl groups, halo-alkyl groups, alkenyl groups, halo-alkenyl groups, alkynyl groups, halo-alkynyl groups, alkoxy groups, aryl groups, aryloxy groups, aralkyl groups, arylalkoxy groups, heterocyclyl groups, acyl groups, acyloxy groups, carbamate groups, amide groups, urethane groups, epoxides, charged groups, zwitterionic groups, and ester groups. Other non-limiting examples of reactions to link, fuse, or conjugate molecules together include click chemistry, copper-free click chemistry, HIPS ligation, Staudinger ligation, and hydrazine-iso-Pictet-Spengler.
- Non-limiting examples of linkers include:
- wherein each n is independently 0 to about 1,000; 1 to about 1,000; 0 to about 500; 1 to about 500; 0 to about 250; 1 to about 250; 0 to about 200; 1 to about 200; 0 to about 150; 1 to about 150; 0 to about 100; 1 to about 100; 0 to about 50; 1 to about 50; 0 to about 40; 1 to about 40; 0 to about 30; 1 to about 30; 0 to about 25; 1 to about 25; 0 to about 20; 1 to about 20; 0 to about 15; 1 to about 15; 0 to about 10; 1 to about 10; 0 to about 5; or 1 to about 5. In some embodiments, each n is independently 0, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41, about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, or about 50. In some embodiments, m is 1 to about 1,000; 1 to about 500; 1 to about 250; 1 to about 200; 1 to about 150; 1 to about 100; 1 to about 50; 1 to about 40; 1 to about 30; 1 to about 25; 1 to about 20; 1 to about 15; 1 to about 10; or 1 to about 5. In some embodiments, m is 0, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41, about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, or about 50, or any linker as disclosed in Jain, N., Pharm Res. 32(11): 3526-40 (2015) or Ducry, L., Antibody Drug Conjugates (2013).
- In some cases a linker can be a succinic linker, and a drug can be attached to a peptide via an ester bond or an amide bond with two methylene carbons in between. In other cases, a linker can be any linker with both a hydroxyl group and a carboxylic acid, such as hydroxy hexanoic acid or lactic acid.
- In some embodiments, the linker can release the active agent in an unmodified form. In other embodiments, the active agent can be released with chemical modification. In still other embodiments, catabolism can release the active agent still linked to parts of the linker and/or peptide.
- The linker can be a noncleavable linker or a cleavable linker. In some embodiments, the noncleavable linker can slowly release the conjugated moiety by an exchange of the conjugated moiety onto the free thiols on serum albumin. In some embodiments, the use of a cleavable linker can permit release of the conjugated moiety (e.g., a therapeutic agent) from the peptide, e.g., after administration to a subject in need thereof. In other embodiments, the use of a cleavable linker can permit the release of the conjugated therapeutic from the peptide. In some cases the linker is enzyme cleavable, e.g., a valine-citrulline linker. In some embodiments, the linker contains a self-immolating portion. In other embodiments, the linker includes one or more cleavage sites for a specific protease, such as a cleavage site for matrix metalloproteases (MMPs), thrombin, cathepsins, peptidases, or beta-glucuronidase. Alternatively or in combination, the linker is cleavable by other mechanisms, such as via pH, reduction, or hydrolysis.
- The rate of hydrolysis or reduction of the linker can be fine-tuned or modified depending on an application. For example, the rate of hydrolysis of linkers with unhindered esters can be faster compared to the hydrolysis of linkers with bulky groups next to an ester carbonyl. A bulky group can be a methyl group, an ethyl group, a phenyl group, a ring, or an isopropyl group, or any group that provides steric bulk. In some cases, the steric bulk can be provided by the drug itself, such as by ketorolac when conjugated, linked, or fused via its carboxylic acid. The rate of hydrolysis of the linker can be tuned according to the residency time of the conjugate or fusion in the target location. For example, when a peptide is cleared from a tumor, or the brain, relatively quickly, the linker can be tuned to rapidly hydrolyze. When a peptide has a longer residence time in the target location, a slower hydrolysis rate would allow for extended delivery of an active agent. “Programmed hydrolysis in designing paclitaxel prodrug for nanocarrier assembly”
Sci Rep 2015, 5, 12023 Fu et al., provides an example of modified hydrolysis rates. - A peptide of the present disclosure can be stable in various biological or physiological conditions, such as the pH or reducing environments inside a cell, in the cytosol, in a cell nucleus, or endosome. For example, any peptide of SEQ ID NO: 1-SEQ ID NO: 84 can exhibit resistance to reducing agents, proteases, oxidative conditions, or acidic conditions.
- In some cases, biologic molecules (such as peptides and proteins) can provide therapeutic functions, but such therapeutic functions are decreased or impeded by instability caused by the in vivo environment. (Moroz et al. Adv Drug Deliv Rev 101:108-21 (2016), Mitragotri et al. Nat Rev Drug Discov 13(9):655-72 (2014), Bruno et al. Ther Deliv (11):1443-67 (2013), Sinha et al. Crit Rev Ther Drug Carrier Syst. 24(1):63-92 (2007), Hamman et al. BioDrugs 19(3):165-77 (2005)). For instance, the GI tract can contain a region of low pH (e.g. pH˜1), a reducing environment, or a protease-rich environment that can degrade peptides and proteins. Proteolytic activity in other areas of the body, such as the mouth, eye, lung, intranasal cavity, joint, skin, vaginal tract, mucous membranes, and serum, can also be an obstacle to the delivery of functionally active peptides and polypeptides. Additionally, the half-life of peptides in serum can be very short, in part due to proteases, such that the peptide can be degraded too quickly to have a lasting therapeutic effect when administering reasonable dosing regimens. Likewise, proteolytic activity in cellular compartments such as lysosomes and reduction activity in lysosomes and the cytosol can degrade peptides and proteins such that they may be unable to provide a therapeutic function on intracellular targets. Therefore, peptides that are resistant to reducing agents, proteases, and low pH may be able to provide enhanced therapeutic effects or enhance the therapeutic efficacy of co-formulated or conjugated, linked, or fused active agents in vivo.
- Additionally, oral delivery of drugs can be desirable in order to target certain areas of the body (e.g., disease in the GI tract such as colon cancer, irritable bowel disorder, infections, metabolic disorders, and constipation) despite the obstacles to the delivery of functionally active peptides and polypeptides presented by this method of administration. For example, oral delivery of drugs can increase compliance by providing a dosage form that is more convenient for patients to take as compared to parenteral delivery. Oral delivery can be useful in treatment regimens that have a large therapeutic window. Therefore, peptides that are resistant to reducing agents, proteases, and low pH can allow for oral delivery of peptides without nullifying their therapeutic function.
- Peptide Resistance to Reducing Agents.
- Peptides of this disclosure can contain one or more cysteines, which can participate in disulfide bridges that can be integral to preserving the folded state of the peptide. Exposure of peptides to biological environments with reducing agents can result in unfolding of the peptide and loss of functionality and bioactivity. For example, glutathione (GSH) is a reducing agent that can be present in many areas of the body and in cells, and can reduce disulfide bonds. As another example, a peptide can become reduced during trafficking of a peptide across the gastrointestinal epithelium after oral administration. A peptide can become reduced upon exposure to various parts of the GI tract. The GI tract can be a reducing environment, which can inhibit the ability of therapeutic molecules with disulfide bonds to have optimal therapeutic efficacy, due to reduction of the disulfide bonds. A peptide can also be reduced upon entry into a cell, such as after internalization by endosomes or lysosomes or into the cytosol, or other cellular compartments.
- Reduction of the disulfide bonds and unfolding of the peptide can lead to loss of functionality or affect key pharmacokinetic parameters such as bioavailability, peak plasma concentration, bioactivity, and half-life. Reduction of the disulfide bonds can also lead to loss of functionality due to increased susceptibility of the peptide to subsequent degradation by proteases, resulting in rapid loss of intact peptide after administration. In some embodiments, a peptide that is resistant to reduction can remain intact and can impart a functional activity for a longer period of time in various compartments of the body and in cells, as compared to a peptide that is more readily reduced.
- In certain embodiments, the peptides of this disclosure can be analyzed for the characteristic of resistance to reducing agents to identify stable peptides. In some embodiments, the peptides of this disclosure can remain intact after being exposed to different molarities of reducing agents such as 0.00001 M-0.0001 M, 0.0001 M-0.001 M, 0.001 M-0.01 M, 0.01 M-0.05 M, 0.05 M-0.1 M, for 15 minutes or more. In some embodiments, the reducing agent used to determine peptide stability can be dithiothreitol (DTT), Tris(2-carboxyethyl)phosphine HCl (TCEP), 2-Mercaptoethanol, (reduced) glutathione (GSH), or any combination thereof. In some embodiments, at least 5%-10%, at least 10%-20%, at least 20%-30%, at least 30%-40%, at least 40%-50%, at least 50%-60%, at least 60%-70%, at least 70%-80%, at least 80%-90%, or at least 90%-100% of the peptide remains intact after exposure to a reducing agent. In some embodiments, peptides are completely resistant to GSH reducing conditions and are partially resistant to degradation in DTT reducing conditions. In some embodiments, peptides described herein can withstand or are resistant to degradation in physiological reducing conditions.
- Peptide Resistance to Proteases.
- The stability of peptides of this disclosure can be determined by resistance to degradation by proteases. Proteases, also referred to as peptidases or proteinases, are enzymes that can degrade peptides and proteins by breaking bonds between adjacent amino acids. Families of proteases with specificity for targeting specific amino acids can include serine proteases, cysteine proteases, threonine proteases, aspartic proteases, glutamic proteases, and asparagine proteases. Additionally, metalloproteases, matrix metalloproteases, elastase, carboxypeptidases, Cytochrome P450 enzymes, and cathepsins can also digest peptides and proteins. Proteases can be present at high concentration in blood, in mucous membranes, lungs, skin, the GI tract, the mouth, nose, eye, and in compartments of the cell. Misregulation of proteases can also be present in various diseases such as rheumatoid arthritis and other immune disorders. Degradation by proteases can reduce bioavailability, biodistribution, half-life, and bioactivity of therapeutic molecules such that they are unable to perform their therapeutic function. In some embodiments, peptides that are resistant to proteases can better provide therapeutic activity at reasonably tolerated concentrations in vivo.
- In some embodiments, peptides of this disclosure can resist degradation by any class of protease. In certain embodiments, peptides of this disclosure resist degradation by pepsin (which can be found in the stomach), trypsin (which can be found in the duodenum), serum proteases, or any combination thereof. In some embodiments, the proteases used to determine peptide stability can be pepsin, trypsin, chymotrypsin, or any combination thereof. In certain embodiments, peptides of this disclosure can resist degradation by lung proteases (e.g., serine, cysteinyl, and aspartyl proteases, metalloproteases, neutrophil elastase, alpha-1 antitrypsin, secretory leucoprotease inhibitor, and elafin), or any combination thereof. In some embodiments, at least 5%-10%, at least 10%-20%, at least 20%-30%, at least 30%-40%, at least 40%-50%, at least 50%-60%, at least 60%-70%, at least 70%-80%, at least 80%-90%, or at least 90%-100% of the peptide remains intact after exposure to a protease.
- Peptide Stability in Acidic Conditions.
- Peptides of this disclosure can be administered in biological environments that are acidic. For example, after oral administration, peptides can experience acidic environmental conditions in the gastric fluids of the stomach and gastrointestinal (GI) tract. The pH of the stomach can range from about 1-4 and the pH of the GI tract ranges from acidic to normal physiological pH descending from the upper GI tract to the colon. In addition, the vagina, late endosomes, and lysosomes can also have acidic pH values, such as less than
pH 7. These acidic conditions can lead to denaturation of peptides and proteins into unfolded states. Unfolding of peptides and proteins can lead to increased susceptibility to subsequent digestion by other enzymes as well as loss of biological activity of the peptide. In certain embodiments, the peptides of this disclosure can resist denaturation and degradation in acidic conditions and in buffers, which simulate acidic conditions. In certain embodiments, peptides of this disclosure can resist denaturation or degradation in buffer with a pH less than 1, a pH less than 2, a pH less than 3, a pH less than 4, a pH less than 5, a pH less than 6, a pH less than 7, or a pH less than 8. In some embodiments, peptides of this disclosure remain intact at a pH of 1-3. In certain embodiments, at least 5%-10%, at least 10%-20%, at least 20%-30%, at least 30%-40%, at least 40%-50%, at least 50%-60%, at least 60%-70%, at least 70%-80%, at least 80%-90%, or at least 90%-100% of the peptide remains intact after exposure to a buffer with a pH less than 1, a pH less than 2, a pH less than 3, a pH less than 4, a pH less than 5, a pH less than 6, a pH less than 7, or a pH less than 8. In other embodiments, at least 5%-10%, at least 10%-20%, at least 20%-30%, at least 30%-40%, at least 40%-50%, at least 50%-60%, at least 60%-70%, at least 70%-80%, at least 80%-90%, or at least 90%-100% of the peptide remains intact after exposure to a buffer with a pH of 1-3. In other embodiments, the peptides of this disclosure can be resistant to denaturation or degradation in simulated gastric fluid (pH 1-2). In some embodiments, at least 5%-10%, at least 10%-20%, at least 20%-30%, at least 30%-40%, at least 40%-50%, at least 50%-60%, at least 60%-70%, at least 70%-80%, at least 80%-90%, or at least 90%-100% of the peptide remains intact after exposure to simulated gastric fluid. In some embodiments, low pH solutions such as simulated gastric fluid can be used to determine peptide stability. - In some embodiments, the peptides described herein are resistant to degradation in vivo, in the serum of a subject, or inside a cell. In some embodiments, the peptides are stable at physiological pH ranges, such as about
pH 7, about pH 7.5, between aboutpH 5 to 7.5, between about 6.5 to 7.5, between aboutpH 5 to 8, or between aboutpH 5 to 7. In some embodiments, the peptides described herein are stable in acidic conditions, such as less than or equal to aboutpH 5, less than or equal to aboutpH 3, or within a range from about 3 to about 5. In some embodiments, the peptides are stable in conditions of an endosome or lysosome, or inside a nucleus. - Peptide Stability at High Temperatures.
- Peptides of this disclosure can be administered in biological environments with high temperatures. For example, after oral administration, peptides can experience high temperatures in the body. Body temperature can range from 36° C. to 40° C. High temperatures can lead to denaturation of peptides and proteins into unfolded states. Unfolding of peptides and proteins can lead to increased susceptibility to subsequent digestion by other enzymes as well as loss of biological activity of the peptide. In some embodiments, a peptide of this disclosure can remain intact at temperatures from 25° C. to 100° C. High temperatures can lead to faster degradation of peptides. Stability at a higher temperature can allow for storage of the peptide in tropical environments or areas where access to refrigeration is limited. In certain embodiments, 5%-100% of the peptide can remain intact after exposure to 25° C. for 6 months to 5 years. 5%-100% of a peptide can remain intact after exposure to 70° C. for 15 minutes to 1 hour. 5%-100% of a peptide can remain intact after exposure to 100° C. for 15 minutes to 1 hour. In other embodiments, at least 5%-10%, at least 10%-20%, at least 20%-30%, at least 30%-40%, at least 40%-50%, at least 50%-60%, at least 60%-70%, at least 70%-80%, at least 80%-90%, or at least 90%-100% of the peptide remains intact after exposure to 25° C. for at least 6 months to 5 years. In other embodiments, at least 5%-10%, at least 10%-20%, at least 20%-30%, at least 30%-40%, at least 40%-50%, at least 50%-60%, at least 60%-70%, at least 70%-80%, at least 80%-90%, or at least 90%-100% of the peptide remains intact after exposure to 70° C. for 15 minutes to 1 hour. In other embodiments, at least 5%-10%, at least 10%-20%, at least 20%-30%, at least 30%-40%, at least 40%-50%, at least 50%-60%, at least 60%-70%, at least 70%-80%, at least 80%-90%, or at least 90%-100% of the peptide remains intact after exposure to 100° C. for 15 minutes to 1 hour.
- Peptide Production and Purification.
- In some embodiments, sequences from the peptide library generated from computational design can be synthesized using expression vectors or solid phase or solution phase peptide synthesis methods. For example, TEAD-binding peptides, or peptides, and Siderocalin-YAP can be cloned into a secreted, soluble protein production/expression vector and purified, as per Bandaranayake et al., 2011. Purification methods include, but are not limited to, affinity purification columns, ion exchange (cation and/or anion columns), reversed-phase, hydrophobic interaction, and size exchange columns. SDS-PAGE followed by Coomassie staining and reverse phase HPLC can be used to analyze a sample of the purified protein. Protein concentrations were determined by UV spectral absorption and/or amino acid analysis.
- Surface Display Vector Construction.
- In various embodiments, surface display vectors, SDGF and SDPR (a variant of the SDGF vector, but with all basic and aromatic residues within the stalk removed to prevent trypsin/chymotrypsin cleavage, and with a 6×His tag (SEQ ID NO: 284) added to the C-terminus of the peptide) based on the original Daedalus vector (Bandaranayake et al., 2011), can be used to clone and express recombinant peptides as described herein. Peptides can be cloned or expressed with a modified coding sequence and without an IRES-GFP. In some cases, the coding sequence of the vector comprises: GFP; the transmembrane domain of the single pass Type II transmembrane protein FASLG (human Fas ligand); a poly-GGGS spacer (SEQ ID NO: 203); a 9-residue bovine rhodopsin antigen; a poly-GGGS spacer (SEQ ID NO: 203); a TEV-cleavage site, including a GS-linker; the displayed peptide; and for SDPR only, a 6×His tag (SEQ ID NO: 284). As with the original Daedalus vector, the entire construct, in some embodiments, can be cloned with lentiviral LTRs, and introduced to cells by transient transfection or transduction. Peptide sequences can be inserted between unique BamHI and NotI cut sites for SDGF vector, or between unique BamHI and AgeI cut sites for SDPR. In either SDGF or SDPR construct, a number of standard cloning strategies can be used to insert a desired coding sequence, including restriction digestion (BamHI and NotI, NEB; T4 DNA Ligase, Invitrogen), In-Fusion (Clontech), or Gibson Assembly (NEB), with all transformations using Stellar chemically competent cells (Clontech), or electrocompetent cells (NEB 10-beta cells), transformed by electroporation. DNA can be PCR-amplified using exemplary primers such as: SDGF Forward primer: TGTACTTCCAGGGAGGATCC (SEQ ID NO: 213); SDGF Reverse primer: AATGGTGATGAGCGGCC (SEQ ID NO: 214); SDPR Forward primer: CCAGCAGGAGGTGGAAGCG (SEQ ID NO: 215); SDPR Reverse primer: ATGATGGTGATGATGGTGAGATCCTC (SEQ ID NO: 216).
- Mammalian Surface Display.
- Validation of peptides or single candidates for binding to TEAD can be validated using a suspension of HEK-293 cells. In some embodiments, cells are transfected with 2.5 μg SDGF vector comprising a putative or candidate peptide and 3.5 μg polyethyleneimine to 2E6 cells in 1 mL media, in a 24-well suspension tissue culture dish. After incubation of cells, all pooled screening can be performed in 293T cells transduced with lentivirus (VSV-G coated, produced by standard methods in 293T cells), delivering the SDGF construct, at an MOI of approximately 1, or up to 5. Transduced or transfected suspension HEK-293 cells can be pelleted (500×g, 5 min) and resuspended at up to 8E6 cells/mL in Flow Buffer (PBS with 0.5% BSA and 2 mM EDTA) containing DAPI and target protein, with or without Alexa Fluor 647-conjugated streptavidin (ThermoFisher) in equimolar quantity to the target protein. All staining incubations took place at 4 C for 30 mins with mild agitation. For the low stringency protocol (initial assay validation and pooled screening), 200 nM target protein can be used, and streptavidin can be pre-mixed with target protein. Cells can be incubated, diluted 10-fold with Flow Buffer, pelleted (500×g, 5 min), and resuspended in fresh Flow Buffer (up to 6.5E6 cells/mL) before flow cytometry. For the medium stringency protocol (SSM maturation), only 20 nM target protein can be used, and cells can be incubated with target protein alone, diluted 10-fold with Flow Buffer, pelleted, and then resuspended with 20 nM streptavidin. Cells were incubated again, diluted 10-fold with Flow Buffer, pelleted (500×g, 5 min), and resuspended in fresh Flow Buffer (up to 6.5E6 cells/mL) before flow cytometry. The high stringency protocol is identical to the medium stringency protocol, except that an additional Flow Buffer-only wash step is included immediately after target protein staining. In some cases, flow sorting is performed on a Beckton-Dickinson Aria II, while analysis is performed on a combination of Beckton-Dickson LSR II and Acea NovoCyte flow cytometers. Data analysis can be performed on FlowJo (FlowJo, LLC) and Excel (Microsoft).
- SDPR Protease Resistance Testing.
- In some embodiments, SDPR protease resistance testing can be used with sequencing-grade enzymes, including Trypsin and Chymotrypsin. Trypsin and trypsin inhibitor can be used for HPLC analysis.
- Next Generation Sequencing.
- In some embodiments, screens for enrichment or depletion of variants affecting TEAD binding can be assessed by Illumina sequencing. Such sequencing method involves collecting cell pellets (1.5E6, 3 technical replicates) resuspended in 50 μL Terra Direct PCR Mix (from Clontech) and amplified for 16 cycles using the original cloning primers. Up to four aliquots can be diluted 16-fold into 60 μL Phusion DNA Polymerase reactions and amplified using distinct Illumina primers, containing adaptor sequences for flow cell adherence. Forward primers can include a 6 bp barcode for multiplexing.
Illumina HiSeq 2500 in rapid mode can be used to run samples, which Bowtie2 software can be used for mapping, and Excel (Microsoft) and MATLAB (MathWorks) used for data analysis. - His-Avi-TEAD Production, Purification, and Biotinylation.
- In some embodiments, in vitro assays are used to analyze candidate peptides for ability to inhibit or interfere with YAP-TEAD interaction, or ability to bind to TEAD and thereby sequester TEAD from interaction with YAP. In some cases, biotinylated, His-Avi-TEAD(194-411) can be expressed in Hi5 insect cells using the BacMagic system (EMD Millipore), as per manufacturer protocols. The transgene can be cloned into the pIEX-BAC3 vector and then cotransfected with BacMagic-3 DNA (100 μg vector, 1 μL BacMagic-3) using calfectin II into Sf9 cells in a 12-well dish. Baculovirus encoding His-Avi-TEAD can be amplified in Sf9 cells, and viral supernatant (5 mL) can be used to transduce 2.5E8 Hi5 cells in 250 mL Express Five media supplemented with L-glutamine. Transduced cells can be grown for 72 hrs (expanding to 500 mL) at 27° C. and 140 RPM before collecting the cell pellets for analysis.
- To harvest, cells can be pelleted (2000×g, 10 min) and resuspended in I-PER buffer (Invitrogen) containing protease inhibitor cocktail (ThermoFisher), benzonase at 1:10,000 (Millipore), 0.5 mM TCEP, and 20 mM imidazole. Lysate can be clarified (10,000×g, 30 min), using nickel NTA resin to purify GST-TEAD. Protein can be buffer exchanged (Zeba spin columns, 5 mL capacity) into thrombin cleavage buffer (25 mM Tris pH 8.4, 150 mM NaCl, 0.1% Triton X100, 10% glycerol, 2.5 mM CaCl2)). Half of the 4 mL eluate can be treated with 5 μL restriction grade thrombin (EMD) overnight at room temperature. TEAD can be re-purified on nickel resin and then by FPLC on a
Superdex 200 10/300 GL size exclusion chromatography (SEC) column (GE Healthsciences). SEC running buffer can contain 10 mM phosphate buffer pH 7.2, 50 mM NaCl, 0.5 mM TCEP. Purified TEAD can be biotinylated using the BirA-500 kit (Avidity) as per manufacturer's protocol, followed by a final buffer exchange into PBS containing 5% glycerol, and storage in small aliquots at −80° C. - Fluorophore Conjugation.
- In some embodiments, screening peptides or a library of peptides involves labeling of a protein of interest or a protein partner with a fluorophore or any other detectable moiety, such that detection of a signal from the fluorophore or detectable moiety is indicative of binding to the peptide. An example of a fluorophore that can be used is
Alexa Fluor 647 NHS Ester (Life Technologies), which can be used to label a protein of interest or a protein partner, such as TEAD or YAP, as per manufacturer's protocol. Saturation is approximately 1 fluorophore per molecule, as determined by spectrometry. - Surface Plasmon Resonance (SPR) Interaction Analyses.
- In some embodiments, TEAD binding can be assessed using surface plasmon resonance. YAP is unstable and precipitates if cleaved from siderocalin, such that it is used as a fusion protein for SPR validation of TEAD-binding. All other peptides are TEV-cleavable and can be analyzed as independent, soluble proteins.
- SPR Experiments can be Performed Using Biacore T100 Instrument.
- In some cases, biotinylated TEAD is injected over a flow cell at a specified rate to capture ˜300 resonance units (RUs). A reference surface is generated by capturing a molar equivalent of biotinylated human transferrin receptor ectodomain. For analytes that can reach steady-state, serial two-fold dilutions can be prepared in running buffer at concentration ranges that cover the span of each peptide's dissociation constant (KD). Duplicate samples, interspersed with multiple buffer blanks, can be randomly injected for further testing. Regeneration can be accomplished with buffer flow alone. Double-referenced data can fit with either a 1:1 affinity or kinetics binding model using BIAevaluation 2.0.4 software (GE Healthcare). Two samples, SEQ ID NO: 9 and SEQ ID NO: 10 (with GS at the N-terminus), or SEQ ID NO: 51 and SEQ ID NO: 52 (without GS at the N-terminus), can be performed using a single cycle kinetics protocol in the T100 Control 2.0.4 software. Serial 3-fold dilutions (3.6 nM to 0.044 nM) of these peptides can be prepared in running buffer and injected at increasing concentration order with 7 minutes of injection time and 15 minutes dissociation. Two buffer blank cycles for referencing can be run prior to analyte injection and one buffer blank cycle followed which allowed time for complete analyte dissociation prior to the next analyte injection. Double-referenced data were fit with the 1:1 binding model for single cycle kinetics using BIAevaluation 2.0.4 software (GE Healthcare). Figures were made in Prism 7 (GraphPad) for Mac OS X version 7.0a.
- YAP-TEAD Disruption and Co-Immunoprecipitation.
- To assay peptides as described herein for ability to disrupt YAP-TEAD interaction, disruption of co-immunoprecipitation of TEAD and YAP can be used. 293T cells can be transfected with either Myc-tagged TEAD expression plasmid pRK5-Myc-TEAD1 or the FLAG-tagged YAP expression plasmid pFLAG-YAP1. After 2 days of growth, cells are lysed with RIPA buffer (ThermoFisher), and lysates are used as follows: 125 μL aliquots of anti-Myc agarose resin (Sigma) can be prepared and used to pull down Myc-TEAD from Myc-TEAD-transfected cell lysate. TEAD-bound beads are then incubated for 30 min at 4 C with 50 μL FLAG-YAP-transfected cell lysate, which is pre-mixed with competitive TEAD-binding peptides, in a final volume of 100 μL. Resin is then washed twice with 500 μL PBS, and then resuspended in 20
μL 2×LDS sample buffer. Beads are then boiled before analyzing the sample using SDS-PAGE and either silver stain or Western Blot using anti-FLAG M2, Sigma, at 1:2000 and/or anti-Myc tag antibody, Abcam, at 1:2000; LiCor secondary antibodies at 1:10,000. - Described herein are various embodiments of peptides, or peptides, with varying affinity for TEAD. Peptides that bind TEAD make TEAD unavailable for binding to YAP, thus inhibiting the YAP-TEAD interaction.
- Peptide Library Computational Design: Scaffold Construction.
- The input topology parameters used for scaffold construction can be as follows: minimum and maximum sequence length: 30 and 41 residues, respectively; secondary structure types: helix, helix, helix; secondary structure length ranges: 6-18 residues; turn lengths: 2-4 residues; number of disulfides: 3; disulfide topology: H1-H2, H1-H3, and H2-H3. Several hundred thousand independent design simulations can be performed to build a large library of candidate scaffolds, which can then be filtered by sequence-structure compatibility, packing, satisfaction of polar groups, and disulfide score. At the start of each design simulation, helix and turn lengths can be sampled randomly from the corresponding length ranges, fixing the secondary structure of the design, which can then be used to select backbone fragments for a low-resolution fragment assembly simulation. At the end of the low-resolution simulation, the protein backbone can be scanned for residue pairs that could be linked by disulfide connections using a library of N—Ca-C backbone transforms derived from disulfide bonds in the protein structure database. Backbones with matching residue pairs that satisfied the disulfide topology constraints can be used to initiate an all-atom sequence design simulation consisting of two cycles of alternating fixed-backbone sequence design and fixed-sequence structure relaxation. Final designs can be filtered for packing (sasapack score <0.5), satisfaction of buried polar groups (using a 1.0 A probe radius), and sorted by energy per residue. The top 10% of the filtered designs can be assessed for sequence-structure compatibility by an in silico refolding test in which the design sequence can be used to initiate 3000 independent structure prediction simulations. Success can be measured by assessing the fraction of low-energy structure prediction models within 2 Å Cα-RMSD of the design model.
- Peptide Library Computational Design: Interface Design.
- The crystal structure of the YAP-TEAD complex (PDB ID 3KYS) can be examined to identify binding patches on TEAD and corresponding backbone elements on YAP to serve as templates for interface design. The following backbone residue segments can be selected as superposition targets for orienting design scaffolds: 3KYS/B/53-55, 3KYS/B/55-57, 3KYS/B/64-68, 3KYS/B/64-69, 3KYS/B/86-89, 3KYS/B/94-96 (given as: PDB ID/chain/residue numbers). For each peptide scaffold, design simulations can be conducted targeting each YAP backbone segment selected for superposition. Each design simulation can consist of the following steps: (1) superimposing the scaffold backbone onto the YAP backbone segment using a scaffold backbone element with matching secondary structure, (2) random small perturbations to generate diversity and relieve backbone clashes, (3) all-atom sequence design alternating between fixed-backbone sequence selection and fixed-sequence structure relaxation. Final interface designs were filtered for satisfaction of polar groups (using a 1.0 A probe radius), interface surface complementarity (sc score>0.5), and interface quality (predicted binding energy per 100 Å of buried SASA<−1.1), and sorted by predicted binding energy. Top-scoring designs can be assessed by an in silico redocking test in which the redesigned scaffold peptide can be removed from TEAD, randomly reoriented, and redocked onto the TEAD protein structure. Success can be measured as the fraction of low-energy redocking simulations that reached a final state close to the designed interface conformation.
- Circular Dichroism.
- Protein secondary structures can be assessed using Circular Dichrosim (CD). CD spectra can be measured with a Jasco J-720W spectropolarimeter using a 1.0 mm path length cell. Protein samples in 10 mM phosphate buffer (pH=7.4) can be at 25-30 uM protein concentration. Samples can be analyzed at wavelength ranges of 260-190 nM. Data can be expressed in terms of relative ellipticity [θ]; (mdeg). To determine thermal stability of proteins, samples can be subjected to incremental increase in temperature at a ramp of 2° C./min from 20° C. to 95° C. Stability and protein unfolding were monitored at 220 and 215 for α-helix and β-sheet secondary structures, respectively. Data can be expressed in terms of relative ellipticity [θ], reported in mdeg.
- Thermal Shift Assay.
- Protein melting temperature (Tm) determination can be performed by monitoring protein unfolding using SYPRO Orange dye (Molecular Probes). In brief, 0.1 mg/mL protein sample in 20 μL total volume PBS buffer can be mixed with 2 μL of 10×SYPRO Orange dye. Dye intercalation into the hydrophobic protein core following protein unfolding was assayed using the C1000 Touch Thermal Cycler with CFX96 Deep Well Real-Time System (BioRad). Samples were heated from 20° C. to 95° C. with stepwise increments of 0.5° C. per minute and a 5 see hold step for every point, followed by fluorescence reading. Tm were calculated by analyzing the derivatives of Relative florescence Units (RFU).
- Cytosolic Peptide Expression.
- Peptides, FLAG-tagged or not, can be cloned into a mammalian expression vector consisting of a CMV promoter, then a monocistronic mCherry-T2a-peptide sequence. These can be transfected, along with (where indicated) pFLAG-YAP1 and 8×GTIIC-luciferase (Addgene plasmid #34615) into 293T cells. 24 hrs post-transfection, cells can be either harvested for luminescence (ONE-Glo, Promega) or Western blot (anti-FLAG M2, Sigma).
- Protein Transfection with dfTAT Reagent.
- Solution was diluted to 50 μM in PBS for a 10× working stock, for a final concentration of 5 μM in culture wells. Peptides as disclosed herein can be fluoresceinated with DyLight 488 NHS-ester (ThermoFisher), with final dye:peptide labeling ratios between 0.8 and 1.4 as assessed by A280 and A488 on a Nanodrop spectrometer (Thermo Scientific). For confirmation of peptide cell penetration, 293T and HeLa cells can be plated in a 96-well plate in DMEM with 10% FBS, 1× penicillin/streptomycin (Pen/Strep) and grown overnight to ˜50% confluence. Cells can be gently washed 3 times with PBS containing 1 mM CaCl2) and 0.5 mM MgCl2, then 2 times in serum-free DMEM. Wells (50 μL total) received either 5 μM (final) peptide in PBS, or PBS alone, and can also receive either 5 μM (final) dfTAT reagent in PBS, or PBS alone, before a 60 minute incubation at 37° C. and 5% CO2 in a humidified tissue culture incubator. After incubation, cells can be gently washed 3 times in PBS, which can be followed by fixation at 4° C. for 10 minutes with 4% formaldehyde in PBS. Fixed samples can be washed 3 times with cold PBS, then can be permeabilized at room temperature for 10 minutes with 0.25% Triton X-100 in PBS; permeabilization was done for consistency with later proximity ligation assays. Samples can be rinsed three more times in PBS prior to imaging on an Evos FL microscope (Life Technologies) with a 20× objective. Images were processed in ImageJ for brightness/contrast adjustment.
- Proximity Ligation Assay.
- TEAD-binding peptides can use any peptide as disclosed herein, and can be a 1:1 mix of unaltered peptide and peptide reacted with DyLight 488 NHS-ester, as above. HeLa cells can be seeded in an 8-well chamber slide (Nunc Lab-Tek II) in DMEM+10% FBS and 1× Pen/Strep, and can be grown overnight, reaching ˜50% confluence. Cells can be gently washed 3 times with PBS containing 1 mM CaCl2 and 0.5 mM MgCl2, then 2 times in serum-free DMEM. Wells (120 μL total) can receive either 5 μM (final) peptide in PBS, or PBS alone, and can also receive either 5 μM (final) dfTAT reagent in PBS, or PBS alone, before a 90 minute incubation at 37° C. and 5% CO2 in a humidified tissue culture incubator. After incubation, cells can be gently washed 3 times in PBS, followed by fixation at 4° C. for 10 minutes with 4% formaldehyde in PBS. Fixed samples can be washed 3 times with cold PBS, then can be permeabilized at room temperature for 10 minutes with 0.25% Triton X-100 in PBS. Samples can be rinsed three more times in PBS prior to proximity ligation assay (PLA).
- PLA can be performed using the Duolink In Situ Fluorescence (Far Red) kit according to manufacturer's instructions, using supplied buffers without substitution and at recommended volumes for 1 cm2 samples. All incubations can take place at 37° C. in a humidified chamber. Samples can be blocked for 30 minutes, which can be followed by incubation for 1 hour with primary antibodies against human YAP (1:100 rabbit anti-YAP1, AbCam catalog number ab52771) and/or human TEAD (1:200 mouse anti-TEF-1, BD Biosciences catalog number 610923). Samples can be washed twice (well dividers can be removed after these washes, and further washes can take place in a Coplin jar), and then ligation can be performed for 30 minutes. After ligation, samples can be washed twice prior to the 100 minute amplification reaction. The slide can then be washed, briefly dried, and mounted with supplied mounting media and a coverslip. Imaging can take place on a DeltaVision Elite (GE) with a 40× objective, and complete Z-stacks can be acquired and deconvolved. For quantitation of nuclear speckles in ImageJ, UV and Cy5.5 filtered images can be Z-projected (maximum intensity), and can be processed using a custom macro to identify nuclear boundaries (UV channel) and speckles (Cy5.5 channel). Overlap and speckle counting can be automated used the Biovoxxel toolbox (Brocher, 2015) with the Speckle Inspector tool. Plots, confidence intervals, and significance calculations can be produced in Prism 7 (GraphPad).
- Various expression vector/host systems can be utilized for the recombinant expression of peptides described herein. Non-limiting examples of such systems include microorganisms such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing a nucleic acid sequence encoding peptides or peptide fusion proteins/chimeric proteins described herein, yeast transformed with recombinant yeast expression vectors containing the aforementioned nucleic acid sequence, insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the aforementioned nucleic acid sequence, plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus (CaMV), tobacco mosaic virus (TMV)), or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing the aforementioned nucleic acid sequence, or animal cell systems infected with recombinant virus expression vectors (e.g., adenovirus, vaccinia virus, lentivirus) including cell lines engineered to contain multiple copies of the aforementioned nucleic acid sequence, either stably amplified (e.g., CHO/dhfr, CHO/glutamine synthetase) or unstably amplified in double-minute chromosomes (e.g., murine cell lines). Disulfide bond formation and folding of the peptide could occur during expression or after expression or both.
- A host cell can be adapted to express one or more peptides described herein. The host cells can be prokaryotic, eukaryotic, or insect cells. In some cases, host cells are capable of modulating the expression of the inserted sequences, or modifying and processing the gene or protein product in the specific fashion desired. For example, expression from certain promoters can be elevated in the presence of certain inducers (e.g., zinc and cadmium ions for metallothionine promoters). In some cases, modifications (e.g., phosphorylation) and processing (e.g., cleavage) of peptide products can be important for the function of the peptide. Host cells can have characteristic and specific mechanisms for the post-translational processing and modification of a peptide. In some cases, the host cells used to express the peptides secrete minimal amounts of proteolytic enzymes.
- In the case of cell- or viral-based samples, organisms can be treated prior to purification to preserve and/or release a target polypeptide. In some embodiments, the cells are fixed using a fixing agent. In some embodiments, the cells are lysed. The cellular material can be treated in a manner that does not disrupt a significant proportion of cells, but which removes proteins from the surface of the cellular material, and/or from the interstices between cells. For example, cellular material can be soaked in a liquid buffer, or, in the case of plant material, can be subjected to a vacuum, in order to remove proteins located in the intercellular spaces and/or in the plant cell wall. If the cellular material is a microorganism, proteins can be extracted from the microorganism culture medium. Alternatively, the peptides can be packed in inclusion bodies. The inclusion bodies can further be separated from the cellular components in the medium. In some embodiments, the cells are not disrupted. A cellular or viral peptide that is presented by a cell or virus can be used for the attachment and/or purification of intact cells or viral particles. In addition to recombinant systems, peptides can also be synthesized in a cell-free system prior to extraction using a variety of known techniques employed in protein and peptide synthesis.
- In some cases, a host cell produces a peptide that has an attachment point for a drug. An attachment point could comprise a lysine residue, an N-terminus, a cysteine residue, a cysteine disulfide bond, a glutamic acid or aspartic acid residue, a C-terminus, or a non-natural amino acid. The peptide could also be produced synthetically, such as by solid-phase peptide synthesis, or solution-phase peptide synthesis. Peptide synthesis can be performed by fluorenylmethyloxycarbonyl (Fmoc) chemistry or by butyloxycarbonyl (Boc) chemistry. The peptide could be folded (formation of disulfide bonds) during synthesis or after synthesis or both. Peptide fragments could be produced synthetically or recombinantly. Peptide fragments can be then be joined together enzymatically or synthetically.
- In other aspects, the peptides of the present disclosure can be prepared by conventional solid phase chemical synthesis techniques, for example according to the Fmoc solid phase peptide synthesis method (“Fmoc solid phase peptide synthesis, a practical approach,” edited by W. C. Chan and P. D. White, Oxford University Press, 2000).
- In some embodiments, the peptides of this disclosure can be more stable during manufacturing. For example, peptides of this disclosure can be more stable during recombinant expression and purification, resulting in lower rates of degradation by proteases that are present in the manufacturing process, a higher purity of peptide, a higher yield of peptide, or any combination thereof. In some embodiments, the peptides can also be more stable to degradation at high temperatures and low temperatures during manufacturing, storage, and distribution. For example, in some embodiments peptides of this disclosure can be stable at 25° C. In other embodiments, peptides of this disclosure can be stable at 70° C. or higher than 70° C. In some embodiments, peptides of this disclosure can be stable at 100° C. or higher than 100° C.
- A pharmaceutical composition of the disclosure can be a combination of any peptide as described herein with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, antioxidants, solubilizers, buffers, osmolytes, salts, surfactants, amino acids, encapsulating agents, bulking agents, cryoprotectants, and/or excipients. The pharmaceutical composition facilitates administration of a peptide described herein to an organism. In some cases, the pharmaceutical composition comprises factors that extend half-life of the peptide and/or help the peptide to penetrate the target cells.
- Pharmaceutical compositions can be administered in therapeutically-effective amounts as pharmaceutical compositions by various forms and routes including, for example, intravenous, subcutaneous, intramuscular, rectal, aerosol, parenteral, ophthalmic, pulmonary, transdermal, vaginal, optic, nasal, oral, sublingual, inhalation, dermal, intrathecal, intratumoral, intranasal, and topical administration. A pharmaceutical composition can be administered in a local or systemic manner, for example, via injection of the peptide described herein directly into an organ, optionally in a depot.
- Parenteral injections can be formulated for bolus injection or continuous infusion. The pharmaceutical compositions can be in a form suitable for parenteral injection as a sterile suspension, solution or emulsion in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Pharmaceutical formulations for parenteral administration include aqueous solutions of a peptide described herein in water-soluble form. Suspensions of peptide-antibody complexes described herein can be prepared as oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. The suspension can also contain suitable stabilizers or agents which increase the solubility and/or reduce the aggregation of such peptide-antibody complexes described herein to allow for the preparation of highly concentrated solutions.
- Formulations or approaches to increase cell penetration or a peptide as describe herein can include, but not limited to, using high dosage of a peptide as described herein, such as up to 10 μM; conjugating or fusing a Tat peptide or a cell-penetrating peptide, or a variant or derivative thereof to a peptide; co-delivering a Tat peptide or a cell-penetrating peptide, or a variant or derivative thereof with a peptide; conjugating or fusing an Arg patch to a peptide; or co-delivering a peptide with an Arg patch peptide, such as up to 10 μM. In some embodiments, protein transfection agents, direct cytosolic expression of the peptide, or electrophoration of the peptide can be used to increase cell penetration. In some embodiments, other excipients can be formulated with a peptide in order to increase the cell penetration of the peptide, such as those approaches described in “Protein and Peptide Drug Delivery: Oral Approaches” Indian J. Pharm. Sci., Shaji and Patole, v70(3) 269-277, 2008. Any combination of these formulations or approaches can be used to increase cell penetration of a peptide as described herein.
- Alternatively, the peptide described herein can be lyophilized or in powder form for re-constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. In some embodiments, a purified peptide is administered intravenously. A peptide described herein can be administered to a subject, home, target, migrate to, or be directed to cancerous cell, a tumor, or a cell with dysregulated HIPPO pathway. In some embodiments, a peptide can be conjugated to, linked to, or fused to another peptide that provides a targeting function to a specific target cell type in the central nervous system or across the blood brain barrier.
- A peptide of the disclosure can be applied directly to an organ, or an organ tissue or cells, such as brain or brain tissue or cells, during a surgical procedure. The recombinant peptide described herein can be administered topically and can be formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams, and ointments. Such pharmaceutical compositions can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
- In practicing the methods of treatment or use provided herein, therapeutically-effective amounts of a peptide described herein can be administered in pharmaceutical compositions to a subject suffering from a condition that affects the immune system. In some embodiments, the subject is a mammal such as a human or a primate. A therapeutically-effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compounds used, and other factors.
- In some embodiments, a peptide is cloned into a viral or non-viral expression vector. Such expression vector can be packaged in a viral particle, a virion, or a non-viral carrier or delivery mechanism, which is administered to patients in the form of gene therapy. In other embodiments, patient cells are extracted and modified to express a peptide capable of inhibiting YAP-TEAD interaction ex vivo before the modified cells are returned back to the patient in the form of a cell-based therapy, such that the modified cells will express the peptide once transplanted back in the patient.
- Pharmaceutical compositions can be formulated using one or more physiologically-acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compounds into preparations that can be used pharmaceutically. Formulation can be modified depending upon the route of administration chosen. Pharmaceutical compositions comprising a peptide described herein can be manufactured, for example, by expressing the peptide in a recombinant system, purifying the peptide, lyophilizing the peptide, mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or compression processes. The pharmaceutical compositions can include at least one pharmaceutically acceptable carrier, diluent, or excipient and compounds described herein as free-base or pharmaceutically-acceptable salt form.
- Methods for the preparation of peptide described herein comprising the compounds described herein include formulating peptide described herein with one or more inert, pharmaceutically-acceptable excipients or carriers to form a solid, semi-solid, or liquid composition. Solid compositions include, for example, powders, tablets, dispersible granules, capsules, cachets, and suppositories. These compositions can also contain minor amounts of nontoxic, auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and other pharmaceutically-acceptable additives.
- Non-limiting examples of pharmaceutically-acceptable excipients can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. 1975; Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999), each of which is incorporated by reference in its entirety.
- Pharmaceutical compositions can also include permeation or absorption enhancers (Aungst et al. AAPS J. 14(1):10-8. (2012) and Moroz et al. Adv Drug Deliv Rev 101:108-21. (2016)). Permeation enhancers can facilitate uptake of molecules from the GI tract into systemic circulation. Permeation enhancers can include salts of medium chain fatty acids, sodium caprate, sodium caprylate, N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC), N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), hydrophilic aromatic alcohols such as phenoxyethanol, benzyl alcohol, and phenyl alcohol, chitosan, alkyl glycosides, dodecyl-2-N,N-dimethylamino propionate (DDAIPP), chelators of divalent cations including EDTA, EGTA, and citric acid, sodium alkyl sulfate, sodium salicylate, lecithin-based, or bile salt-derived agents such as deoxycholates,
- Compositions can also include protease inhibitors including soy bean trypsin inhibitor, aprotinin, sodium glycocholate, camostat mesilate, vacitracin, or cyclopentadecalactone,
- In some embodiments, the method includes administering an effective amount of a peptide as described herein to a subject in need thereof.
- In one embodiment, the method includes administering an effective amount of a peptide as described herein to a subject in need thereof.
- The term “effective amount,” as used herein, refers to a sufficient amount of an agent or a compound being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. Compositions containing such agents or compounds can be administered for prophylactic, enhancing, and/or therapeutic treatments. An appropriate “effective” amount in any individual case may be determined using techniques, such as a dose escalation study.
- The methods, compositions, and kits of this disclosure may comprise a method to prevent, treat, arrest, reverse, or ameliorate the symptoms of a condition. The treatment may comprise treating a subject (e.g., an individual, a domestic animal, a wild animal, or a lab animal afflicted with a disease or condition) with a peptide of the disclosure. The disease may be a cancer or tumor. In treating the disease, the peptide may contact the tumor or cancerous cells. The subject may be a human. Subjects can be humans; non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like. A subject can be of any age. Subjects can be, for example, elderly adults, adults, adolescents, pre-adolescents, children, toddlers, infants, and fetuses in utero.
- Treatment may be provided to the subject before clinical onset of disease. Treatment may be provided to the subject after clinical onset of disease. Treatment may be provided to the subject after 1 day, 1 week, 6 months, 12 months, or 2 years or more after clinical onset of the disease. Treatment may be provided to the subject for more than 1 day, 1 week, 1 month, 6 months, 12 months, 2 years or more after clinical onset of disease. Treatment may be provided to the subject for less than 1 day, 1 week, 1 month, 6 months, 12 months, or 2 years after clinical onset of the disease. Treatment may also include treating a human in a clinical trial. A treatment can comprise administering to a subject a pharmaceutical composition, such as one or more of the pharmaceutical compositions described throughout the disclosure. A treatment can comprise a once daily dosing. A treatment can comprise delivering a peptide of the disclosure to a subject, either intravenously, subcutaneously, intramuscularly, by inhalation, dermally, topically, by intra-articular injection, orally, sublingually, intrathecally, transdermally, intranasally, via a peritoneal route, directly into a tumor, e.g., injection directly into a tumor, directly into the brain, e.g., via and intracerebral ventricle route, or directly onto a joint, e.g., via topical, intra-articular injection route. A treatment can comprise administering a peptide-active agent complex to a subject, either intravenously, subcutaneously, intramuscularly, by inhalation, by intra-articular injection, dermally, topically, orally, intrathecally, transdermally, intransally, parenterally, orally, via a peritoneal route, nasally, sublingually, or directly onto cancerous tissues.
- Disruption of the YAP-TEAD interaction can have implications in a number of diseases, condition, or disorders associated to dysregulated cell growth, cell proliferation, angiogenesis, organogenesis, tumor progression, and/or metastasis. Compositions comprising any one of the peptides that bind TEAD, or a pharmaceutical composition thereof, can be used in a method of treating a cancer, tumor progression, and/or dysregulated cell growth. Exemplary diseases, disorder, or condition include: multiple myeloma, plastic anemia, myelodysplasia, and related bone marrow failure syndromes, myeloproliferative diseases, acute and chronic myeloid leukemia, malignancies of lymphoid cells, hematologic malignancies, plasma cell disorders, skeletal muscle disorder, myopathy, muscular dystrophy (e.g., Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumoeral muscular dystrophy, Myotonia congentia, and myotonic dystrophy), and chronic obstructive pulmonary disorder. In some embodiments, compositions/peptides disclosed herein are used to treat dysregulated cell growth, cancer, tumor, and/or metastasis associated with any of the following cell, tissue, or organ types: brain, lung, liver, spleen, kidney, lymph node, small intestine, blood cell, pancreatic, colon, stomach, cervix, breast, endometrial, prostate, testicle, ovarian, skin, head and neck, esophageal, oral tissue, and bone marrow. In further embodiments, compositions/peptides disclosed herein are used to treat nay of the following: osteosarcoma, hepatocellular carcinoma, malignant mesothelioma, schwannoma, meningioma, renal carcinoma, cholangiocarcinoma, bile duct hamartoma, soft tissue carcinoma, ovarian carcinoma, colonic adenoma, T cell acute lymphoblastic leukaemia, gastrointestinal hyperplasia, fibrosarcoma, pancreatic ductal metaplasia, squamous cell carcinoma, kaposis sarcoma, and HIV-induced non-Hodgkin's lymphoma.
- In some embodiments, the peptides of this disclosure (SEQ ID NO: 1-SEQ ID NO: 84) can be used to access and treat these disorders due to their enhanced stability in various biological environments, including low pH, protease-rich environments, acidic environments, reducing environments, or environments with varying temperatures.
- In some embodiments, compositions comprise any one of the peptides disclosed herein that modulates one or more factors of the HIPPO pathway, and is used to treat a condition or disease associated with a dysregulated HIPPO pathway.
- In one aspect, peptides described herein can be provided as a kit. In another embodiment, peptide conjugates described herein can be provided as a kit. In another embodiment, a kit comprises amino acids encoding a peptide described herein, a vector, a host organism, and an instruction manual. In some embodiments, a kit includes written instructions on the use or administration of the peptides.
- The following examples are included to further describe some aspects of the present disclosure, and should not be used to limit the scope of the invention.
- This example describes the manufacture of the peptides described herein. Peptides derived from proteins were generated in mammalian cell culture using a published methodology. (A. D. Bandaranayke, C. Correnti, B. Y. Ryu, M. Brault, R. K. Strong, D. Rawlings. 2011. Daedalus: a robust, turnkey platform for rapid production of decigram quantities of active recombinant proteins in human cell lines using novel lentiviral vectors. Nucleic Acids Research. (39)21, e143).
- The peptide sequence was reverse-translated into DNA, synthesized, and cloned in-frame with siderocalin using standard molecular biology techniques (M. R. Green, Joseph Sambrook. Molecular Cloning. 2012 Cold Spring Harbor Press). The resulting construct was packaged into a lentivirus, transduced into HEK-293 cells, expanded, isolated by immobilized metal affinity chromatography (IMAC), cleaved with tobacco etch virus protease, and purified to homogeneity by reverse-phase chromatography. Following purification, each peptide was lyophilized and stored frozen.
- This example describes expression of the peptides using a mammalian expression system. Peptides were expressed according to the methods described in in Bandaranayake et al., Nucleic Acids Res. 2011 November; 39(21): e143. Peptides were cleaved from siderocalin using tobacco etch virus protease and purified by FPLC on a size exclusion chromatography (SEC) column using an isocratic elution over four column volumes in 1×DPBS. Peptides were then stored at 4° C.
- This example describes production of TEAD-binding peptides. To identify TEAD binders from a designed library, soluble TEAD (194-411) was produced with two C-terminal tags: 6×His (SEQ ID NO: 284), and AviTag. To confirm the stability and YAP-binding capability of His-Avi-TEAD, YAP (50-171) was produced as a soluble siderocalin fusion.
FIG. 1 illustrates validation and functional analysis of the produced biotinylated TEAD and Siderocalin-fused YAP.FIG. 1A illustrates and SDS-PAGE with a band near 55 kDa indicating presence of the Siderocalin-YAP.FIG. 1B illustrates surface plasmon resonance (SPR) data showing that Siderocalin-fused YAP binds biotinylated TEAD immobilized on an SPR chip with a dissociation constant (KD) of 570 nM.FIG. 1C illustrates that HEK-293 cells expressing surface-tethered YAP (50-171) is stained by Alexa Fluorophore (AF)-647 conjugated to Streptavidin (AF657-Streptavidin) bound to biotinylated TEAD. Cells expressing the Machupo virus (MACV) glycoprotein, a specific ligand for human transferrin receptor, are not stained by AF-647, indicating that TEAD does not bind MACV. - This example describes mammalian surface display of TEAD-binding peptides of the present disclosure. Screening for TEAD binders was performed by transfecting or transducing mammalian cells to display candidate peptides followed by screening with biotinylated TEAD conjugated to Alexa Fluorophore 647 (AF647). Mammalian cells had improved fidelity in folding disulfide crosslinked proteins, making them a suitable cell type for display of the peptides of the present disclosure.
FIG. 2 illustrates that the surface display GFP FasL (SDGF) vector is an effective mammalian display vector for peptide expression and evaluation of knottin peptide binding to another moiety.FIG. 2A illustrates a schematic of the SDGF vector. Cytosolic, N-terminal GFP is connected to the extracellular domain via the transmembrane domain of human FasL. A bovine rhodopsin C9 tag follows, separated by a short linker from the C-terminal knottin (elafin is shown here as a representative example, however any peptide can be used). Specific binding partners (elastase to elafin is shown here as a representative example, however any peptide or library of peptides can be used) will bind to the knottin, and if the binding partner is fluorescently tagged, will confer that fluorescence to the cell.FIG. 2B illustrates flow cytometry histograms showing that HEK-293 suspensions cells expressing SDGF-elafin are stained by AF647-conjugated elastase. Negative control experiments with cells expressing either SDGF-YAP (50-171) or SDGF-MACV glycoprotein are not stained by AF647 elastase. -
FIG. 17 further illustrates the method of using mammalian surface display screening for identifying TEAD-binding peptides.FIG. 17A shows a detailed scheme for the screening strategy using a surface display GFP FasL (SDGF) vector. In the vector, FasL-TM is the transmembrane domain of the FasL protein. More specifically, the designed peptides are cloned as a pool into SDGF, which are then made into lentivirus. 293F cells are transduced with this library at a multiplicity of infection of 1, and after three days of growth, the pool of transduced cells are incubated with Alexa647-labeled TEAD. A percentage of the highest-staining APC-positive cells, from GFP and APC double-positive cells, are sorted and expanded. At every expansion, a portion of the cells are collected, and at the end, the enriched peptides are identified by sequencing. - This example describes screening for TEAD-binding peptides using the mammalian surface display system of EXAMPLE 4. Potential TEAD-binding peptides were cloned into SDGF and effective binders were screened using 200 nM TEAD-streptavidin.
FIG. 3 illustrates screening a designed library for TEAD-binding peptides.FIG. 3A illustrates a schematic of the screening steps for SDGF peptide libraries.FIG. 3B illustrates flow cytometry plots showing the fluorescence of peptide construct expression (GFP) on the x-axis and TEAD (AF647) on the y-axis. Double-positive cells (upper right hand quadrant) indicate peptide-expressing cells that are bound to TEAD. HEK-293 cells were transduced with the SDGF TEAD-binder library and stained with 200 nM AF547-Streptavidin-TEAD. Flow cytometry plots show unsorted cells, cells sorted after 1, 2, or 3 rounds of screening. - Peptide gene sequences were PCR-amplified out of the transduced cells, and candidate TEAD binders were identified by conventional Sanger sequencing and Illumina deep sequencing.
FIG. 3C illustrates Illumina sequencing data plotting the abundance of each library member versus its abundance prior to the screening and sorting (“input”) afterround FIG. 3D illustrates flow cytometry plots showing peptide construct expression (GFP) on the x-axis and TEAD (AF647) on the y-axis. Double-positive cells (upper right hand quadrant) indicate peptide-expressing cells that are bound to TEAD. HEK-293 suspension cells were transfected with hits from the screen cloned into the SDGF vector and stained with 200 nm AF647-Streptavidin-TEAD. Peptides of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 expressed by HEK-293 cells displayed binding to TEAD, as demonstrated by cells that fall into the GFP+AF647+ region of the flow cytometry plots. -
FIG. 17E illustrates the TEAD-binding abilities of 293F cells transfected with surface display GFP FasL (SDGF)-SEQ ID NO: 1 compared to cells displaying alanine substitution mutants at sites found at the modeled TEAD interface (SDGF-SEQ ID NO: 4, SDGF-SEQ ID NO: 6, SDGF-SEQ ID NO: 5, and SDGF-SEQ ID NO: 7). The variant with all Cys converted to Ser (6CS) to eliminate disulfide bonds was also tested (SEQ ID NO: 184). Binding was assessed by quantifying Alexa647 levels in transfected cells using flow cytometry. Shown are the median ±95% confidence intervals, normalized to that of cells displaying the parent peptide.FIG. 17F illustrates the TEAD-binding abilities of 293F cells transfected with surface display GFP FasL (SDGF)-SEQ ID NO: 2 compared to cells displaying alanine substitution mutants at sites found at the modeled TEAD interface (SDGF-SEQ ID NO: 39, SDGF-SEQ ID NO: 40, SDGF-SEQ ID NO: 41, and SDGF-SEQ ID NO: 42). The variant with all Cys converted to Ser (6CS) to eliminate disulfide bonds were also tested (SEQ ID NO: 185). Binding was assessed by quantifying Alexa647 levels in transfected cells using flow cytometry. Shown are the median ±95% confidence intervals, normalized to that of cells displaying the parent peptide. - This example describes binding of TEAD to peptides of this disclosure and variants of peptides of the present disclosure. Peptides of SEQ ID NO: 1 and SEQ ID NO: 2 were designed to bind to TEAD at the same site at which YAP binds (Site 2). Both peptides of SEQ ID NO: 1 and SEQ ID NO: 2 contain the LX1X2LF (SEQ ID NO: 217) motif that is also present in
YAP helix 2, wherein X1 and X2 can be any amino acid.FIG. 4 illustrates peptides of SEQ ID NO: 1 and SEQ ID NO: 2 and the modeled TEAD interface with YAP and binding of TEAD to variants of SEQ ID NO: 1 and SEQ ID NO: 2.FIG. 4A illustrates that YAP and peptides of SEQ ID NO: 1 and SEQ ID NO: 2 are predicted to bind TEAD at the same site (Site 2). The YAP-TEAD structure (protein data bank (PDB) ID: 3KYS) is from the Research Collaboratory for Structural Bioinformatics (RCSB) PDB. SEQ ID NO: 1 and SEQ ID NO: 2 were modeled bound to the TEAD structure from RCSB 3KYS.FIG. 4B illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 2 versus TEAD binding to HEK-293 suspension cells transfected with SDGF-L23A variant of SEQ ID NO: 2 (lysine to alanine variant of SEQ ID NO: 2 at position 23). Position L23 of SEQ ID NO: 2, analogous to the L65 residue of YAP, when mutated to alanine resulted in loss of binding to TEAD.FIG. 4C illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 2 versus TEAD binding to HEK-293 suspension cells transfected with SDGF-L26A variant of SEQ ID NO: 2 (lysine to alanine variant of SEQ ID NO: 2 at position 26). Position L26 of SEQ ID NO: 2, analogous to the L68 residue of YAP, when mutated to alanine resulted in loss of binding to TEAD.FIG. 4D illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 2 versus TEAD binding to HEK-293 suspension cells transfected with SDGF-F27A variant of SEQ ID NO: 2 (phenylalanine to alanine variant of SEQ ID NO: 2 at position 27). Position F27 of SEQ ID NO: 2, analogous to the F69 residue of YAP, when mutated to alanine resulted in loss of binding to TEAD.FIG. 4E illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 2 versus TEAD binding to HEK-293 suspension cells transfected with SDGF-6×CS variant of SEQ ID NO: 2 (a variant of SEQ ID NO: 2 in which all 6 cysteines are mutated to serines). Mutation of cysteines to serines resulted in loss of binding to TEAD.FIG. 4F illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 4 (SDGF-E25A variant of SEQ ID NO: 1, which is a glutamic acid to alanine variant of SEQ ID NO: 1 at position 25). Position E25 of SEQ ID NO: 1, when mutated to alanine, resulted in loss of binding to TEAD.FIG. 4G illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 6 (SDGF-M33A variant of SEQ ID NO: 1, which is a methionine to alanine variant of SEQ ID NO: 1 at position 33). Position M33 of SEQ ID NO: 2, when mutated to alanine, resulted in loss of binding to TEAD.FIG. 4H illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 5 (SDGF-L37A variant of SEQ ID NO: 1, which is a leucine to alanine variant of SEQ ID NO: 1 at position 37). Position L37 of SEQ ID NO: 1, analogous to the L68 residue of YAP, when mutated to alanine, resulted in a marginal loss of binding to TEAD.FIG. 4I illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 7 (SDGF-F38A variant of SEQ ID NO: 1, which is a phenylalanine to alanine variant of SEQ ID NO: 1 at position 38). Position F38 of SEQ ID NO: 1, analogous to the F69 residue of YAP, when mutated to alanine, resulted in loss of binding to TEAD.FIG. 4J illustrates flow cytometry plots showing TEAD binding to HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 versus TEAD binding to HEK-293 suspension cells transfected with a peptide of SEQ ID NO: 184 (SDGF-6×CS variant of SEQ ID NO: 1, which is a variant of SEQ ID NO: 1 in which all 6 cysteines are mutated to serines). Mutation of cysteines to serines resulted in loss of binding to TEAD. - Soluble TEAD-binding peptides made using methods of EXAMPLE 1 and then were evaluated for binding by incubation of a dilution series varying from 150 μM to 44 μM (concentration range was varied depending on the TEAD-binding peptide being tested) of TEAD-binding peptides with 2 μg/mL TEAD, capturing ˜300 resonance units (RUs) of protein for surface plasmon resonance (SPR, Biacore) experiments.
FIG. 5 illustrates binding of soluble TEAD-binding peptides and variants to TEAD. Gels show peptides in reducing conditions in NuPAGE at one-tenth the final volume, in which DTT is at 50 mM. HPLC shows peptides in reducing conditions in Dulbecco's phosphate-buffered saline (DPBS) with a final DTT concentration of 40 mM. Non-reducing conditions are designated as “NR” and reducing conditions are designated as “R.”FIG. 5A illustrates an SDS-PAGE gel of a peptide of SEQ ID NO: 1 in non-reducing conditions and reducing conditions.FIG. 5B illustrates HPLC chromatograms showing peaks representing a peptide of SEQ ID NO: 1 in non-reducing conditions and in reducing conditions with DTT.FIG. 5C illustrates SPR binding assay data of a peptide of SEQ ID NO: 1 to biotinylated TEAD immobilized on an SPR chip with a dissociation constant (KD) of 31 nM.FIG. 5D illustrates an SDS-PAGE gel of a peptide of SEQ ID NO: 5 in non-reducing conditions and reducing conditions.FIG. 5E illustrates HPLC chromatograms showing peaks representing a peptide of SEQ ID NO: 5 in non-reducing conditions and in reducing conditions with DTT.FIG. 5F illustrates SPR binding assay data of a peptide of SEQ ID NO: 5 to biotinylated TEAD immobilized on an SPR chip with a dissociation constant (KD) of 280 nM.FIG. 5G illustrates an SDS-PAGE gel of a peptide of SEQ ID NO: 7 in non-reducing conditions and reducing conditions.FIG. 5H illustrates HPLC chromatograms showing peaks representing a peptide of SEQ ID NO: 7 in non-reducing conditions and in reducing conditions with DTT.FIG. 5I illustrates SPR binding assay data of a peptide of SEQ ID NO: 7 to biotinylated TEAD immobilized on an SPR chip with a dissociation constant (KD) of 23 μM.FIG. 5J illustrates an SDS-PAGE gel of a peptide of SEQ ID NO: 3 in non-reducing conditions and reducing conditions.FIG. 5K illustrates HPLC chromatograms showing peaks representing a peptide of SEQ ID NO: 3 in non-reducing conditions and in reducing conditions with DTT.FIG. 5L illustrates SPR binding assay data of a peptide of SEQ ID NO: 3 to biotinylated TEAD immobilized on an SPR chip with a dissociation constant (KD) of 12 μM. A peptide of SEQ ID NO: 5 had reduced affinity for TEAD as compared to a peptide of SEQ ID NO: 1. A peptide of SEQ ID NO: 7 also had reduced affinity for TEAD as compared to a peptide of SEQ ID NO: 1. A peptide of SEQ ID NO: 5 had reduced binding to TEAD as compared to a peptide of SEQ ID NO: 1. A peptide of SEQ ID NO: 3 also showed lower binding affinity for TEAD as compared to a peptide of SEQ ID NO: 1. Since the peptide of SEQ ID NO: 3 was not designed for binding to TEAD, it is possible that the lower affinity for binding to TEAD was a result of poor folding of the peptide. - This example describes disruption of YAP-TEAD binding by a peptide of this disclosure. A peptide of SEQ ID NO: 1 was evaluated for disruption of YAP binding to TEAD by co-immunoprecipitation. Two separate populations of HEK-293T suspension cells were transfected with either Myc-TEAD or FLAG-YAP and cells were lysed. Myc-TEAD lysate was incubated with anti-Myc resin to generated TEAD bound resin, which was subsequently incubated for 30 minutes with the YAP lysate and peptides of SEQ ID NO: 1 or SEQ ID NO: 7. Beads were washed and analyzed by a silver stain or a Western blot. A peptide of SEQ ID NO: 1, which comprises the LX1X2LF (SEQ ID NO: 217) sequence, demonstrated the ability to bind TEAD, thereby preventing YAP from binding TEAD and being pulled down with the TEAD-bound resin.
FIG. 6A illustrates a Silver stain and Western blot showing that FLAG-YAP was not pulled down with Myc-TEAD resins in the presence of a peptide of SEQ ID NO: 1, but was pulled down with the Myc-TEAD resins in the presence of a peptide of SEQ ID NO: 7.FIG. 6B illustrates a Western blot showing a dilution series of a peptide of SEQ ID NO: 1 demonstrating dose-dependent inhibition of FLAG-YAP binding to Myc-TEAD resins.FIG. 6C illustrates quantified densitometry data plotted fromFIG. 6B . Error bars show standard deviation from quantification of signal in four lanes per sample in one experiment. FLAG-YAP signal was normalized to Myc-TEAD signal by taking the ratio of each of the four blot lanes of YAP signal (not shown) to the TEAD signal. - This example illustrates site saturation mutagenesis (SSM) of peptides of this disclosure to identify beneficial or deleterious mutations. Site saturation mutagenesis was performed on a peptide of SEQ ID NO: 1. All possible single amino acid substitutions of SEQ ID NO: 1 were cloned except for cysteine residues, which were conserved and not substituted. A peptide of SEQ ID NO: 1 has 34 non-cysteine residues (not counting the N-terminal “GS”). With 18 non-cysteine substitute residues possible at a given position, the SSM library contained 612 total variants of SEQ ID NO: 1, with the library also containing an un-mutated peptide of SEQ ID NO: 1. TEAD binding of mammalian cells expressing peptides of the SSM library was performed as described in EXAMPLE 4 and EXAMPLE 5, but with a higher stringency protocol. The higher stringency protocol included a lower concentration of TEAD (20 nM) and staining in two separate steps—first with biotinylated TEAD followed by AF647-streptavidin. After four rounds of sorting, nearly the entire cell population expressing variants displayed improved binding to TEAD.
FIG. 7 illustrates the results of a site-saturation mutagenesis screen in SEQ ID NO: 1 variants with improved binding activity to TEAD. Flow cytometry plot show the fluorescence of peptide construct expression on the x-axis (GFP) and TEAD (AF647) on the y-axis. Double-positive cells (upper right hand quadrant) indicate peptide-expressing cells that are bound to TEAD. Panels labeled “SSM01” indicate cells transduced with the full library of peptide variants.FIG. 7A illustrates a flow cytometry plot showing HEK-293 cells expressing a peptide of SEQ ID NO: 1 alone.FIG. 7B illustrates a flow cytometry plot showing HEK-293 cells expressing a peptide of SEQ ID NO: 1 incubated with AF647-streptavidin alone, in the absence of biotinylated-TEAD.FIG. 7C illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 (site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants) incubated with TEAD before sorting.FIG. 7D illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 (site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants) incubated with TEAD after 1 round of sorting.FIG. 7E illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 (site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants) incubated with TEAD after 2 rounds of sorting.FIG. 7F illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 (site-saturation mutagenesis “SSM01” library containing the original peptide of SEQ ID NO: 1 and 612 variants) incubated with AF647-streptavidin alone, in the absence of biotinylated-TEAD after two rounds of sorting. Results showed that after two rounds of sorting, double positive cells (upper right hand quadrant) were enriched, indicating enhanced inhibition of YAP-TEAD binding.FIG. 19 also illustrates the results of a site-saturation mutagenesis screen in SEQ ID NO: 1 variants with improved binding activity to TEAD. Flow cytometry plot show the fluorescence of peptide construct expression on the x-axis (GFP) and TEAD (AF647) on the y-axis. Double-positive cells (upper right hand quadrant) indicate peptide-expressing cells that are bound to TEAD. Panels labeled “SSM” indicate cells transduced with the full library of peptide variants.FIG. 19A illustrates a flow cytometry plot showing HEK-293 cells expressing a peptide of SEQ ID NO: 1 alone. SEQ ID NO: 1 binding was apparent but weak under a 20 nM TEAD concentration and 2-step staining binding conditions.FIG. 19B illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 (site-saturation mutagenesis “SSM” library containing the original peptide of SEQ ID NO: 1) incubated with TEAD before sorting.FIG. 19C illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 incubated with TEAD after 1 round of sorting.FIG. 19D illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 incubated with TEAD after 2 rounds of sorting.FIG. 19E illustrates a flow cytometry plot showing HEK-293 cells transduced with a library of variants of SEQ ID NO: 1 incubated with AF647-streptavidin alone, in the absence of biotinylated-TEAD, after two rounds of sorting. The distribution of TEAD-binding peptides was evaluated after two rounds of screening were completed.FIG. 8 illustrates enrichment scores at each position for the variants of SEQ ID NO: 1 generated in the site-saturation (SSM) mutagenesis screen and a structural model of the binding interface between the peptide or variant peptide and TEAD.FIG. 8A illustrates a matrix of variants of a peptide of SEQ ID NO: 1 generated in the SSM screen. The x-axis shows the sequence of a peptide of SEQ ID NO: 1, and the y-axis shows each amino acid substitution tested at each position (all non-cysteine residues). The level of enrichment for each single point mutation is indicated in the matrix table after two rounds of sorting. The enrichment score (log 2 change in relative abundance after two rounds of sorting versus input abundance) is indicated on a greyscale and as numerical values. Positive or high enrichment scores (lighter shades of grey) correspond to residues that are more tolerant to substitutions. Examples of residues that are more tolerant of substitutions include residues corresponding topositions - TABLE 4 and TABLE 5 below illustrate another representation of
FIG. 8A , showing the SSM screen for improved variants of SEQ ID NO: 1, which provided insight into the structure and tolerance to mutation at each position of the peptide. In the matrix of TABLE 4 and TABLE 5, each amino acid residue of SEQ ID NO: 1 sequence is shown in the columns, with all the substituted non-Cys residues shown in the rows, after two rounds of sorting. Grey shading (or cells without numbers) indicates either the native amino acid at the position or an unchanged Cys. The level of enrichment for each single point mutation is indicated as a numerical score in the TABLE 4 and TABLE 5. TABLE 4 shows amino acid residues at positions 1-20 of SEQ ID NO: 1. TABLE 5 shows amino acid residues at positions 21-40 of SEQ ID NO: 1. -
TABLE 4 SSM Screen of Positions 1-20 of SEQ ID NO: 1 P01 D02 E03 Y04 I05 E06 R07 A08 K09 E10 G 1.70 −0.32 −0.62 −2.21 −3.97 −1.15 1.31 −4.11 −0.48 −0.44 D −0.65 0.80 −1.79 −3.47 −0.60 −2.25 −4.17 −0.58 −0.89 E 1.12 1.16 −6.52 −1.23 −0.16 −2.66 3.95 H −0.88 −1.05 −0.31 −1.90 −2.99 −1.57 −0.32 −7.27 −1.50 −1.97 K −0.29 −1.07 −0.50 −1.58 −1.50 −1.13 0.47 −4.73 −2.30 R −2.10 −7.12 −1.81 −0.94 −3.27 −1.78 −5.84 −1.30 −2.84 M −1.02 −1.86 2.57 −0.68 −1.87 −2.04 −1.06 −10.14 −3.56 −0.34 N −0.49 −0.16 0.58 0.04 −1.34 −0.82 0.34 −9.20 3.31 −0.45 Q −0.84 −0.20 −1.35 0.29 −1.23 −2.41 −0.48 −6.00 1.10 −1.94 S 0.13 −1.01 −0.41 −0.74 −2.04 −1.09 0.31 −2.79 −0.91 −2.47 T −0.57 −0.52 1.19 −0.87 −1.77 −0.92 −4.07 −3.84 2.68 −1.57 A 0.36 −1.43 −2.02 0.26 −1.20 −0.68 0.28 −1.27 −0.24 I −2.27 −0.70 −0.26 −0.41 −1.56 −3.98 −8.31 −3.03 −0.65 L −2.90 −3.53 0.32 −1.81 −0.38 −0.40 −0.39 −9.93 −11.17 −1.83 V −0.59 −2.34 −1.39 −0.75 −0.27 −1.55 −2.31 −4.43 −8.88 −1.77 F −1.30 −3.41 0.32 0.67 −8.36 −1.96 −1.04 −4.33 −3.52 −1.60 W −9.10 −2.95 −1.40 −2.47 −7.46 −1.53 −1.28 −5.46 −4.41 −1.58 Y −3.33 −1.63 −0.36 −10.86 −2.33 −1.01 −3.35 −4.96 −5.61 P −2.11 −0.40 1.02 −0.43 −2.84 −2.49 −4.70 −4.50 −3.72 X −1.28 −1.68 −0.28 −1.13 −2.98 −1.46 −1.01 −5.63 −2.17 −1.79 C11 C12 K13 K14 G15 D16 I17 Q18 C19 C20 G 0.70 1.11 −9.54 −5.40 −2.03 D 0.43 1.27 −0.26 −9.42 −0.19 E −0.10 1.00 1.99 −3.60 −0.30 −0.84 H −0.44 0.53 3.18 −4.55 −3.33 −4.39 K 4.43 −6.95 −4.53 −1.54 R −0.81 −1.06 0.91 −5.59 0.46 −3.67 M −0.40 −0.92 1.64 −4.12 −2.95 −9.52 N 0.60 1.51 3.06 −2.70 0.47 −0.16 Q 2.23 0.17 2.50 −3.47 −3.10 S 1.43 1.61 2.37 −2.71 −2.10 −1.25 T 1.49 3.18 2.65 −10.01 2.21 −2.28 A 1.94 −0.22 1.89 −5.23 −4.36 −1.53 I −1.54 −0.99 −1.96 −6.42 −11.42 L −1.37 −0.89 −0.59 −8.99 1.28 −4.91 V −1.65 0.08 0.99 −7.81 4.17 −0.77 F −1.14 −0.50 −1.98 −1.86 −3.50 −4.21 W −2.99 −2.64 −4.75 −2.30 −10.45 −11.11 Y −1.29 −0.68 −1.14 −3.84 −9.48 −8.35 P −10.43 −10.61 −1.25 −4.62 −2.41 0.69 X −0.74 −0.45 0.76 −5.24 −2.93 −3.75 -
TABLE 5 SSM Screen of Positions 21-40 of SEQ ID NO: 1 L21 R22 Y23 F24 E25 E26 S27 G28 D29 P30 G −6.04 0.72 −1.35 −11.45 −10.71 −3.06 −1.27 −3.23 −10.38 D −4.87 1.03 1.00 −10.21 5.78 −0.94 −3.00 1.32 −6.54 E −5.16 −0.55 2.72 −11.11 −10.80 3.12 −3.44 −0.10 H −2.71 0.40 −0.37 −2.83 −9.49 −0.94 −1.68 3.83 −4.07 −4.72 K −11.54 1.23 0.76 −5.89 −9.40 1.62 −2.37 6.22 −8.65 −9.22 R −3.83 1.66 −10.68 −10.77 −1.95 −3.49 −1.11 −11.33 −8.66 M −2.66 −0.86 3.09 −6.01 −10.47 2.48 −2.36 −2.46 −9.80 −8.62 N −8.42 1.24 2.61 −8.70 −2.44 −0.22 −3.25 4.02 −1.65 −9.89 Q −5.92 0.67 4.09 −6.77 −5.86 −0.68 −5.40 4.51 −2.48 −3.42 S −10.77 −1.07 3.56 −3.57 −5.06 −0.37 2.13 −3.79 −3.21 T −3.23 −1.35 4.48 −10.48 −4.88 −1.77 −0.14 −0.15 −6.20 −5.80 A −9.76 −0.15 4.15 −4.74 −9.29 −1.38 −4.71 0.21 −10.78 −4.30 I −0.71 −5.68 4.38 −11.76 −10.99 −0.29 −4.20 −4.03 −6.90 −10.47 L −8.23 −1.38 −4.46 −8.91 −1.15 −10.71 −2.53 −1.03 −11.39 V −2.18 −3.73 4.92 −9.81 −6.97 −1.52 −3.78 −2.57 −10.45 −4.69 F −8.97 −4.07 −0.40 −8.76 −3.85 −3.57 −5.70 −8.95 −6.69 W −10.86 −4.72 −0.77 −3.21 −10.07 −10.26 −6.16 −6.69 −7.27 −8.91 Y −9.22 −2.70 −0.95 −11.33 −6.03 −4.30 −3.28 −10.93 −9.27 P −4.12 −4.67 −4.23 −1.77 −9.08 −8.38 −11.47 −4.98 −6.75 X −6.16 −1.81 1.61 −6.91 −7.71 −2.15 −4.59 −0.45 −6.54 −7.02 N31 V32 M33 L34 I35 C36 L37 F38 C39 P40 G −4.80 −7.60 −11.71 −9.49 −4.09 −1.96 −10.92 3.87 D −0.20 −11.61 −10.83 −12.01 −7.62 −4.30 −5.37 4.44 E −2.46 −8.12 −3.64 −11.48 −0.21 −6.21 −6.43 5.48 H −1.85 −8.47 −6.40 −10.33 −5.99 0.32 −8.33 4.09 K −3.93 −7.31 −5.62 −9.75 −7.49 −10.57 −11.79 5.91 R −10.78 −11.16 −3.96 −9.48 −11.49 −7.75 −4.30 4.09 M −7.50 −2.51 −3.58 −1.06 −1.77 −10.63 3.56 N −10.56 −9.95 −1.67 −6.55 −3.48 −11.59 5.11 Q −1.74 −11.11 −4.00 −7.26 −3.15 −1.02 −2.36 5.32 S −2.24 −3.67 −10.55 −11.06 −10.07 −4.45 −5.70 5.70 T −5.82 −6.67 −10.18 −6.24 −5.66 −9.84 −10.82 4.96 A −8.06 −6.43 −9.17 −10.71 −9.78 −2.56 −7.69 4.30 I −5.43 −0.08 −3.16 −1.19 −8.87 −10.17 4.96 L −6.98 −5.60 −10.20 −5.22 −10.27 2.46 V −10.99 −4.70 −2.09 0.30 −3.80 −8.31 4.10 F −11.40 −6.92 −11.51 −7.21 −1.52 −6.98 4.42 W −12.78 −12.64 −11.42 −10.92 −11.53 −10.52 −9.40 5.56 Y −6.41 −8.77 −10.21 −10.36 −5.39 −5.54 −5.12 2.50 P −8.99 −10.01 −11.25 −7.30 −10.21 −12.22 −5.33 X −6.24 −7.74 −8.25 −7.90 −5.93 −5.64 −8.03 4.49 - Overall, G15 and G28 (present in the interhelix loop) mutations to hydrophilic amino acid residues displayed a higher enrichment score indicating better binding. This is likely due to improved folding kinetics or improved solubility. A mutation at E25 to aspartate lead better binding, and this was the most enriched variant after four rounds of screening. Mutations at Y23 were overall beneficial for improving binding, with the exception of mutations to aromatic residues. This may likely be due to the fact that the Y23 residue is in part shielded from solvent and in part exposed to solvent. Thus, substitutions to smaller aliphatic residues may improve interhelix interactions and substitutions to hydrophilic residues may improve solubility. Mutations at the P40 residue improved binding, and may be due to improved stability by eliminating the proline-induced kink in the alpha helix.
FIG. 8B illustrates a model of the SEQ ID NO: 1-TEAD interface, in which shading intensity on a greyscale indicates the average enrichment score at each residue. Positive or high enrichment scores (lighter shades of grey) correspond to residues that are more tolerant to substitutions. Negative or lower enrichment scores (darker shades of grey) correspond to residues that are less tolerant to substitution, such as residues that are important to binding. Black indicates cysteine residues. This model indicated that residues exposed to solvent were more tolerant of mutations at a given position, whereas residues on the interior of the TEAD binding region or residues at the peptide-TEAD interface where less tolerant to mutations at a given position. Mutations of SEQ ID NO: 1 at G15, Y23, and P40 all resulted in average enrichment scores greater than zero. - This example describes TEAD binding of SSM-generated variant TEAD-binding peptides made in EXAMPLE 8. SSM screening generated many beneficial mutations, from which we selected five especially beneficial mutations to a peptide of SEQ ID NO: 1 including G15Q, Y23I, E25D, G28K, and P40W. Variants of SEQ ID NO: 1 with these mutations were made in which ten triple mutants were made including all combinations in which three of the five mutations described above, five quadruple mutants were made including all combinations in which four of the five mutations described above, and the quintuple mutant. The TEAD binding assays described in EXAMPLE 4 and EXAMPLE 5 tested at the same stringency as was used in EXAMPLE 8. TEAD binding assays were also described in which an extra wash step was introduced between incubation with biotinylated TEAD and incubation with the AF647-streptavidin. Altered binding due to an additional wash step informed us about the kinetics of a candidate peptide's binding, specifically the koff value, to TEAD.
-
FIG. 9 illustrates that combinations of enriched mutations identified in a peptide of SEQ ID NO: 1 by SSM result in improved TEAD binding.FIG. 9A illustrates a schematic of the staining protocols used to evaluate TEAD binding. Both the “Normal” and “Extra Wash” protocols use 20 nM of TEAD.FIG. 9B illustrates flow cytometry plots showing HEK-293 suspension cells expressing SDGF-SEQ ID NO: 1, SDGF-SEQ ID NO: 9 (QIDKW variant of SEQ ID NO: 1), and YAP. Five-letter codes (e.g. QIDKW) represent variants of a peptide of SEQ ID NO: 1 at residues 15 (G or Q), 23 (Y or I), 25 (E or D), 28 (G or K), and 40 (P or W).FIG. 9C illustrates quantification of the mean fluorescence intensity (MFI) of cells that fall in the “slice” gate indicated inFIG. 9B . The x-axis indicates the variant that was tested and all MFI values are normalized to the MFI value for a peptide of SEQ ID NO: 1. Shaded groups are clusters with particular combinations of mutations: XXDKW; XXDGW; XXDKP. The quintuple variant “QIDKW” performed the best, but only marginally better than those variants in which three or four mutations were made and contained at least E25D, G28K, and P40W. E25D is a conservative mutation, or, in other words, a biochemically similar mutation (i.e., glutamic acid and aspartic acid are residues with negatively charged side chains), at a salt bridge modeled to be formed with K152 on TEAD. Residue G28 of a peptide of SEQ ID NO: 1, whether or not mutated to K, does not appear to directly bind TEAD as predicted by the computational model. However, improved binding may be a result of the mutation G28K stabilizing the peptide, thereby mitigating any entropic penalty from binding and dimerization. All variants in which the E25D and P40W mutation was made but G28 was retained (XXDGW box) had only marginally lower binding than those variants containing all three mutations. All variants have the mutations E25D and G28K but retaining P40 resulted in lower binding in the screen with the extra wash step. This indicated that the P40W mutation may result in a slower off rate. - Three variants were tested as soluble peptides including peptides of SEQ ID NO: 9 (quintuple mutant, G15Q, Y23I, E25D, G28K, P40W), SEQ ID NO: 10 (quadruple mutant without the G28K mutation), and SEQ ID NO: 11 (quadruple mutant without P40W). These peptides may be amphipathic, resulting in longer retention times observed by HPLC.
FIG. 10 illustrates binding to TEAD by variants of a peptide of SEQ ID NO: 1 as soluble peptides. Non-reducing conditions are designated as “NR” and reducing conditions are designated as “R.”FIG. 10A illustrates an SDS-PAGE of a soluble peptide of SEQ ID NO: 9 in non-reduced (NR) and reduced (R) conditions.FIG. 10B illustrates an HPLC chromatogram of a peptide of SEQ ID NO: 9 in non-reduced or reduced conditions. InFIG. 10B ,FIG. 10E , andFIG. 10H , early peaks (<3 mins) seen on the reduced (R) peptide HPLC chromatograms are reduced and oxidized DTT species.FIG. 10C illustrates SPR data showing binding of a peptide of SEQ ID NO: 9 to biotinylated TEAD immobilized on an SPR chip. SPR experiments for a peptide of SEQ ID NO: 9 were conducted by single cycle kinetic analysis and the KD was determined to be 368 μM.FIG. 10D illustrates an SDS-PAGE of a soluble peptide of SEQ ID NO: 10 in non-reduced (NR) or reduced (R) conditions.FIG. 10E illustrates an HPLC chromatogram of a peptide of SEQ ID NO: 10 in non-reduced or reduced conditions.FIG. 10F illustrates SPR data showing binding of a peptide of SEQ ID NO: 10 to biotinylated TEAD immobilized on an SPR chip. SPR experiments for a peptide of SEQ ID NO: 10 were conducted by single cycle kinetic analysis and the KD was determined to be 372 μM.FIG. 10G illustrates an SDS-PAGE of a soluble peptide of SEQ ID NO: 11 in non-reduced (NR) and reduced (R) conditions.FIG. 10H illustrates an HPLC chromatogram of a peptide of SEQ ID NO: 11 in non-reduced or reduced conditions.FIG. 10I illustrates SPR data showing binding of a peptide of SEQ ID NO: 11 to biotinylated TEAD immobilized on an SPR chip. SPR experiments for a peptide of SEQ ID NO: 11 were conducted by steady state analysis and the KD was determined to be 3.8 nM. Overall, the data also shows that the three variants had better binding to TEAD than the parent peptide of SEQ ID NO: 1. Furthermore, the diminished binding observed when the extra wash step was incorporated for a peptide of SEQ ID NO: 11 as opposed to what was observed for SEQ ID NO: 9 and SEQ ID NO: 10, was driven by the faster off rate of a peptide of SEQ ID NO: 11. - This example describes competitive binding of peptides of this disclosure to TEAD, or disruption of TEAD binding to surface-displayed YAP. HEK-293 suspension cells expressing SDGF-YAP were first incubated with either a peptide of SEQ ID NO: 1 or SEQ ID NO: 9. The cell culture was next stained with 5 nM of biotinylated TEAD as shown in
FIG. 11 . -
FIG. 11 illustrates inhibition of YAP binding to TEAD with a soluble peptide of SEQ ID NO: 9 as compared to inhibition of YAP binding to TEAD with a soluble peptide of SEQ ID NO: 1.FIG. 11A illustrates flow cytometry plots showing HEK-293 suspension cells transfected with SDGF-YAP and incubated with 0 nM, 10 nM, or 100 nM of a peptide of SEQ ID NO: 1, followed by incubation with 5 nM biotinylated TEAD, and 5 nM AF647-streptavidin.FIG. 11B illustrates flow cytometry plots showing HEK-293 suspension cells transfected with SDGF-YAP and incubated with 0 nM, 10 nM, or 100 nM of a peptide of SEQ ID NO: 9, followed by incubation with 5 nM biotinylated TEAD, and 5 nM AF647-streptavidin.FIG. 11C illustrates a dose response curve quantifying the MFI of cells falling within the “slice” gate shown inFIG. 11A andFIG. 11B . Doses below 5 nM TEAD staining does not provide data relevant to IC50 or Ki determination, as cells were stained with 5 nM TEAD.FIG. 11D illustrates a flow cytometry plot of cells expressing SDGF-YAP that were incubated with 5 nM TEAD and then washed. Cells were immediately stained with AF647-streptavidin and analyzed for YAP-expressing cells that have bound TEAD.FIG. 11E illustrates a flow cytometry plot of cells expressing SDGF-YAP that were incubated with 5 nM TEAD and then washed. Cells were incubated on ice for 1 hour, stained with AF647-streptavidin and analyzed for YAP-expressing cells that have bound TEAD.FIG. 11F illustrates a flow cytometry plot of cells expressing SDGF-YAP that were incubated with 5 nM TEAD and then washed. Cells were incubated on ice for 1 hour with 100 nM of a peptide of SEQ ID NO: 1, stained with AF647-streptavidin and analyzed for YAP-expressing cells that have bound TEAD.FIG. 11G illustrates a flow cytometry plot of cells expressing SDGF-YAP that were incubated with 5 nM TEAD and then washed. Cells were incubated on ice for 1 hour with 100 nM of a peptide of SEQ ID NO: 9, stained with AF647-streptavidin and analyzed for YAP-expressing cells that have bound TEAD. - The results of flow cytometry analysis of the competitive binding assay demonstrated that ˜30 nM of a peptide of SEQ ID NO: 1 resulted in half-maximal inhibition of TEAD binding to YAP. This confirmed previously obtained results as shown in EXAMPLE 6, in which it was determined that a peptide of SEQ ID NO: 1 had a KD of 31 nM. The results of flow cytometry analysis of the competitive binding assay also demonstrated that a peptide of SEQ ID NO: 9 resulted in near complete elimination of TEAD binding to YAP, as indicated by the lack of staining of YAP-displaying cells by TEAD-AF647. The same results of near complete elimination of TEAD binding to YAP was also observed when YAP-displaying cells are first incubated with TEAD prior to the addition of a peptide of SEQ ID NO: 9.
- This example describes stability of peptides under reducing conditions. Peptides that target TEAD in the nucleus are exposed to reducing conditions in the cytosolic compartment of cells. Thus, it is advantageous for peptides of this disclosure to display stability in reducing conditions. Stability of peptides of this disclosure was tested in 10 mM DTT and 10 mM GSH. GSH is a more physiologically relevant reducing agent for testing peptide stability in intracellular conditions. As shown in
FIG. 12B , when peptides of SEQ ID NO: 1 and SEQ ID NO: 9 were exposed to reducing conditions under GSH, a reducing agent that is more representative of the reducing environment in the cellular cytosolic compartment, both SEQ ID NO: 1 and SEQ ID NO: 9 were resistant to GSH reducing conditions, as neither peptide displayed peaks that were significantly shifted as observed by HPLC in comparison to non-reduced peptides. In a stronger reducing condition, such as in 10 mM DTT, as shown inFIG. 10B , a peptide of SEQ ID NO: 9 was partially resistant to DTT reduction. In line mass spectrometry of a peptide of SEQ ID NO: 9 in DTT reducing conditions revealed fragments within ˜6 Da of the non-reduced peptide, thus demonstrating that a peptide of SEQ ID NO: 9 is partially resistant to reduction in DTT. -
FIG. 12 illustrates stability of TEAD-binding peptides to reducing agents.FIG. 12A illustrates HPLC chromatograms of a peptide of SEQ ID NO: 9 in non-reducing conditions and in 10 mM DTT reducing conditions. A representative mass spectrometry peak profile is shown in the inset.FIG. 12B illustrates HPLC chromatograms of peptides of SEQ ID NO: 1 and SEQ ID NO: 9 in with or without incubation in 10 mM glutathione (GSH). - Peptides of this disclosure were also tested to evaluate if binding to TEAD was affected by exposure of peptide to reducing conditions. HEK-293T suspension cells were incubated with SDGF-SEQ ID NO: 1 or SDGF-SEQ ID NO: 9. Cultures were grown for two days followed by incubation in 10 mM GSH or 10 mM DTT. Finally, cells were stained with TEAD.
FIG. 13 illustrates binding to TEAD after cells expressing SDGF-SEQ ID NO: 9 are exposed to a reducing agent.FIG. 13A illustrates a flow cytometry plot showing binding of HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 1 (GFP) incubated for 5 minutes in PBS, 10 mM DTT, or 10 mM glutathione (GSH) before staining with 20 nM biotinylated TEAD and 20 nM AF647-streptavidin.FIG. 13B illustrates a flow cytometry plot showing binding of HEK-293 suspension cells transfected with SDGF-SEQ ID NO: 9 (GFP) incubated for 5 minutes in PBS, 10 mM DTT, or 10 mM glutathione (GSH) before staining with 20 nM biotinylated TEAD and 20 nM AF647-streptavidin.FIG. 13C illustrates quantification of the AF647 MFI of cells falling within the “slice” gate shown inFIG. 13A andFIG. 13B . The results of the binding assay indicated that cells displaying a peptide of SEQ ID NO: 1 showed partial loss in binding to TEAD after DTT treatment and no loss in binding to TEAD after GSH treatment. The results of the binding assay also indicated that cells displaying a peptide of SEQ ID NO: 9 showed no loss in binding to TEAD regardless of whether DTT or GSH was used as the reducing agent. - This example illustrates stability of peptides of this disclosure to proteases. Tumor environments generally contain a high amount of proteases. Furthermore, resistance to proteolysis (degradation or cleaving by proteases) reduces the likelihood that a peptide will be degraded and then displayed to the immune system by MHC. In addition, resistance to proteolysis can increase peptide half-life in serum after administration prior to trafficking to a tumor. Thus, it is advantageous for peptides of the present disclosure to be resistant to degradation by proteases.
- Soluble peptides were exposed to 500 U/mL porcine trypsin and analyzed by HPLC. Protease resistance was also assessed by using SDPR-displaying peptides. The SDPR vector is similar to the SDGF vector, but contains a C-terminal 6×His tag (SEQ ID NO: 284) and all basic or aromatic amino acid residues on the stalk removed. Protease resistance is then tested by incubation of cells displaying peptides with trypsin or chymotrypsin, followed by incubation in 10 mM DTT, and staining with an anti-6×His fluorophore-labeled antibody. If peptides are uncleaved, they retain the His tag and are stained with by the antibody. A control protease-sensitive knottin peptide (SK) was used as a positive control. Cells displaying peptides were treated with up to 40 μg/ml trypsin or chymotrypsin.
-
FIG. 14 illustrates protease resistance of a peptide of SEQ ID NO: 9.FIG. 14A illustrates HPLC chromatograms of a peptide of SEQ ID NO: 9 after incubation with 500U trypsin (T), which was then quenched with trypsin inhibitor (I) and placed in non-reducing (NR) conditions or reducing (R) conditions with 10 mM DTT. The products were then run on HPLC. The chromatograms appear similar (though not identical) to those seen in experiments lacking trypsin.FIG. 14B illustrates a schematic of the SDPR vector, a variant of the SDGF vector shown inFIG. 2A , but with all basic or aromatic residues within the stalk removed to prevent trypsin/chymotrypsin cleavage, and with a 6×His (SEQ ID NO: 284) tag added to the C-terminus. In the schematic ofFIG. 14B , the modified surface display vector was designed to be capable of assessment of protease or reduction resistance, which can be accomplished by staining for anti-6×His. In various embodiments, in experiments using this construct, cells expressing the constructs can be incubated with a protease, such as trypsin or chymotrypsin, followed by treatment with a reducing agent. After treatment with the protease and reducing agent, any linearized peptide product or degradation product resulting from reduction and/or proteolysis by treatment with a protease can be detected or analyzed by staining against the 6×His tag (SEQ ID NO: 284). For example, a peptide can become linearized in the presence of a reducing agent, which can make it more susceptible to proteolysis, or a reduction-resistant peptide can be cleaved by a protease. The presence of a single cleavage event in the peptide backbone can result in a linearized, displayed peptide, which can lose the 6×His tag (SEQ ID NO: 284) on the C-terminus, causing cells with such peptides to lose staining against 6×His (SEQ ID NO: 284). -
FIG. 14C ,FIG. 14D ,FIG. 14E , andFIG. 14F illustrate the flow cytometry analyses of HEK-293 suspension cells transfected with either a protease sensitive knottin peptide SK cloned into the SDPR construct (SDPR-SK) or SEQ ID NO: 9 cloned into the SDPR construct, and treated with 0 or 40 μg/ml trypsin or chymotrypsin for 20 minutes, and then stained with an AF647 anti-6×HIS antibody. Loss of anti-6×HIS signal is indicative of peptide destabilization or degradation.FIG. 14C illustrates a flow cytometry plot of HEK-293 suspension cells transfected with protease sensitive SDPR-SK peptide and then treated with 0 or 40 μg/ml trypsin for 20 minutes, and stained with an AF647 anti-6×HIS antibody. InFIG. 14C , a knottin previously characterized as protease-sensitive (SK), displayed a loss of staining after treatment with trypsin or chymotrypsin (visualized as a reduction in APC signal when cells are stained with Alexa647-conjugated anti-6×His antibody.FIG. 14D illustrates a flow cytometry plot of HEK-293 suspension cells transfected with SDPR-SEQ ID NO: 9 peptide and then treated with 0 or 40 μg/ml trypsin for 20 minutes, and stained with an AF647 anti-6×HIS antibody.FIG. 14E illustrates a flow cytometry plot of HEK-293 suspension cells transfected with protease sensitive SDPR-SK peptide and then treated with 0 or 40 μg/ml chymotrypsin for 20 minutes, and stained with an AF647 anti-6×HIS antibody.FIG. 14F illustrates a flow cytometry plot of HEK-293 suspension cells transfected with SDPR-SEQ ID NO: 9 peptide and then treated with 0 or 40 μg/ml chymotrypsin for 20 minutes, and stained with an AF647 anti-6×HIS antibody.FIG. 14G illustrates quantification of flow cytometry data comparing SDPR-SK peptide transfected cells and SDPR-SEQ ID NO: 9 peptide transfected cells, both treated with trypsin at various concentrations.FIG. 14H illustrates quantification of flow cytometry data comparing SDPR-SK peptide transfected cells and SDPR-SEQ ID NO: 9 peptide transfected cells, both treated with chymotrypsin at various concentrations. The results of exposure to protease indicated that a peptide of SEQ ID NO: 9 was partially resistant to cleavage by proteases. - This example describes the radiolabeling of peptides. Several peptides were radiolabeled by reductive methylation with 14C formaldehyde and sodium cyanoborohydride with standard techniques (such as those described in Jentoft et al. J Biol Chem. 254(11):4359-65. 1979). The sequences were engineered to have the amino acids, “G” and “S” at the N terminus. See Methods in Enzymology V91:1983 p. 570 and JBC 254(11):1979 p. 4359. An excess of formaldehyde was used to drive complete methylation (dimethylation of every free amine). The labeled peptides were isolated via solid-phase extraction on Strata-X columns (Phenomenex 8B-S100-AAK), rinsed with water with 5% methanol, and recovered in methanol with 2% formic acid. Solvent was subsequently removed in a blowdown evaporator with gentle heat and a stream of nitrogen gas.
- This example describes the dye labeling of peptides. A peptide of the disclosure is expressed recombinantly or chemically synthesized, and then the N-terminus of the peptide is conjugated to, linked to, or fused to a detectable agent via an NHS ester using DCC or EDC to produce a peptide-detectable agent conjugate. The detectable agent is the fluorophore dye is a cyanine dye, such as Cy5.5 or an Alexa fluorophore, such as Alexa647.
- The peptide detectable agent conjugates are administered to a subject. The subject can be a human or a non-human animal. After administration, the peptide detectable agent conjugates home to the kidneys. The subject, or a biopsy from the subject, is imaged to visualize localization of the peptide detectable agent conjugates to the kidney. In some aspects, diagnosis of renal disorders is based on the visualization of the peptide detectable agent conjugates in kidneys after administration.
- This example illustrates treatment of cancer using peptides of the present disclosure. A peptide of the present disclosure is recombinantly expressed or chemically synthesized and used directly. The peptide is administrated in a pharmaceutical composition to a subject in need thereof as a therapeutic for cancer. The peptide is selected from any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84. The peptide can be SEQ ID NO: 9. One or more peptides are administered to a subject. The subject can be a human or an animal. The pharmaceutical composition is administered intravenously, subcutaneously, intramuscularly, orally, or injected directly into the tumor microenvironment. The peptides disrupt YAP-TEAD interactions and TAZ-TEAD interactions by binding to TEAD, and precluding subsequent binding by YAP or TAZ. The peptides disrupt YAP-TEAD and TAZ-TEAD interactions by competing with bound YAP or TAZ, resulting in YAP or TAZ dissociation from TEAD and peptide binding to TEAD. The administered peptides, which disrupt YAP-TEAD and TAZ-TEAD interactions, treat a cancer condition in the subject. The cancer condition may be breast cancer, liver cancer, colon cancer, or brain cancer.
- The same method can also be adapted for or used to treat diabetes Type I and II.
- This example illustrates peptide delivery by gene therapy-modified cells. Peptides of the present disclosure can be directed to the tumor microenvironment (e.g., immune infiltrates or a cancerous cell) by delivery mediated by gene therapy-modified cells. A gene therapy composition comprising a viral vector that selectively infects or targets cancer cells and carrying a gene encoding a peptide of the present disclosure can be administered to a subject to selectively express the peptide in cancer cells or a tumor. Alternatively, cells expressing the peptide of the present disclosure are modified ex vivo using gene therapy, followed by transplanting the modified cells back into the subject. The subject is a human or an animal. After transplantation, the modified cells migrate to a tumor microenvironment or cancer cells to disrupt TEAD binding in vivo. The pharmaceutical composition is administered intravenously, subcutaneously, or orally.
-
FIGS. 18A and 18B illustrate an example of SEQ ID NO: 1 and SEQ ID NO: 9 expression in target cells.FIG. 18A illustrates the relative luminescence units of SEQ ID NO: 1 or SEQ ID NO: 9 expressed directly into the cytosol as part of an mCherry-T2a-peptide fusion construct, co-transfected with YAP and 8×GTIIC (TEAD luciferase reporter). This was done in 24-well plate wells, in which 293F cells were transfected with 50 ng FLAG-YAP, 300 ng 8×GTIIC, and either 100 or 250 ng mCherry-T2a-peptide plasmids. *: P<0.05, **: P<0.005 vs. YAP only. Reporter activity was reduced (P=0.003) when SEQ ID NO: 12 was expressed.FIG. 18B illustrates the FLAG-tagged SEQ ID NO: 7, FLAG-tagged SEQ ID NO: 1, FLAG-tagged SEQ ID NO: 9, or FLAG-tagged SEQ ID NO: 184 in the mCherry-T2a-peptide construct SDS-PAGE gel mobility shift upon DTT reduction by Western blot (anti-FLAG M2 antibody). Shown are the bands corresponding to the size of the uncleaved fusion protein. SEQ ID NO: 184 is SEQ ID NO: 9-6×CS, in which all six cysteines were mutated to serines, simulating non-oxidizable sulfhydryls. While the FLAG-tagged, mCherry-fused versions showed a subtle, cysteine-dependent mobility shift in SDS-PAGE upon DTT reduction, the T2a-cleaved SEQ ID NO: 1 variants were not visible (FIG. 23 ). This suggests that the cysteines in SEQ ID NO: 1 and its variants can become oxidized to cystines in the cytosol, but its stability when directly expressed in the cytosol may be compromised without a fusion partner like mCherry. - Upon expression of the peptide, the peptide disrupts YAP/TAZ interactions with TEAD by binding to TEAD and precluding subsequent binding by YAP or TAZ, which downregulates oncogenes. The peptide disrupts YAP-TEAD and TAZ-TEAD interactions by competing with bound YAP or TAZ, resulting in YAP/TAZ dissociation from TEAD. The administered gene therapy encoding the peptide, which disrupts YAP/TAZ-TEAD interactions, is used to treat a cancer condition in the subject. The cancer condition may be breast cancer, liver cancer, colon cancer, or brain cancer.
- The gene therapy can also be used to treat diabetes Type I and II using gene therapy vectors that selectively target pancreatic cells.
- This example illustrates surface plasmon resonance (SPR) analysis of peptide binding interactions. Various peptides of the present disclosure were analyzed for binding affinity to TEAD. Briefly, binding affinity was analyzed by SPR experiments, which were performed at 25° C. on a Biacore T100 instrument (GE Healthcare) with Series S SA chips. HBS-EP+ (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% surfactant P20) was used as a running buffer in the experiments with 0.1 mg/mL bovine serum albumin (BSA). Biotinylated TEAD was injected over a flow cell at a concentration of 2 μg/mL and at a rate of 10 μL/min to capture TEAD corresponding to ˜300 resonance units (RUs) on the SPR chip. A reference surface was generated by capturing a molar equivalent of biotinylated human transferrin receptor ectodomain. For peptides which were capable of reaching steady-state, serial two-fold dilutions of the peptides were prepared in the running buffer described above at concentration ranges which widely spanned and covered each peptide's KD. Duplicate samples, interspersed with multiple buffer blanks, were randomly injected at 50 μL/minute with 2-5 minutes of association and 2-5 minutes of dissociation. Regeneration was accomplished by flowing buffer alone over the SPR chip. Double-referenced data were fit with either a 1:1 affinity or kinetics binding model using BIAevaluation 2.0.4 software (GE Healthcare). Two peptide samples (SEQ ID NO: 9 and SEQ ID NO: 10) were run using a single cycle kinetics protocol in the T100 Control 2.0.4 software. Serial three-fold dilutions (3.6 nM to 0.044 nM) of peptides of SEQ ID NO: 9 and SEQ ID NO: 10 were prepared in running buffer and injected at a rate of 50 μL/minute in increasing concentration order with 7 mins of injection time and 15 minutes dissociation time. Two buffer only blank cycles for referencing were run prior to peptide injection and one buffer only blank cycle followed which allowed time for complete peptide dissociation prior to the injection of the next peptide. Double-referenced data were fit with the 1:1 binding model for single cycle kinetics using BIAevaluation 2.0.4 software (GE Healthcare). TABLE 6 illustrates the SPR method conditions for assessing peptide binding to captured biotinylated TEAD.
-
TABLE 6 SPR Method Conditions Ligand: Captured Biotinylated TEAD Reference: Captured Biotinylated hTfR(ED) SEQ Capture Analyte: Peptide ID Running Flow Rate Conc. Injection Level Flow Rate Injection Dissociation Analysis NO Buffer (μL/min) (μg/mL) Time (s) (RU) (μL/min) Conc. Time (s) Time (s) Model 1 HBS- 10 1.7 430 330 50 2 μM → 180 180 Steady- EP+ with 10 2 390 882 0.12 nM in State 0.1 duplicate mg/mL serial 2× BSA dilutions, random injections 5 HBS- 10 1.7 430 330 50 10 μM → 180 180 Steady- EP+ with 10 2 390 882 0.6 nM in State 0.1 duplicate mg/mL serial 2× BSA dilutions, random injections 7 HBS- 10 1.7 430 330 50 125 μM → 120 120 Steady- EP+ with 10 2 390 882 980 nM in State 0.1 duplicate mg/mL serial 2× BSA dilutions, random injections 8 HBS- 10 1.7 430 330 50 1 μM → 180 180 Steady- EP+ with 10 2 390 882 0.06 nM in State 0.1 duplicate mg/mL serial 2× BSA dilutions, random injections 9 HBS- 10 2 60 250 50 0.044, 420 900 Single EP+ with 10 2 84 700 0.133, 0.4, Cycle 0.1 1.2, 3.6 Kinetics mg/mL nM BSA 10 HBS- 10 2 60 250 50 0.044, 420 900 Single EP+ with 10 2 84 700 0.133, 0.4, Cycle 0.1 1.2, 3.6 Kinetics mg/mL nM BSA 11 HBS- 10 2 60 250 50 200 nM → 300 300 Steady- EP+ with 10 2 84 700 49 pM in State 0.1 duplicate mg/mL serial 2× BSA dilutions, random injections 11 HBS- 10 2 60 250 50 50 nM → 300 300 Kinetics EP+ with 10 2 84 700 390 pM in 1:1 0.1 duplicate binding mg/mL serial 2× BSA dilutions, random injections -
FIG. 15 shows the results of SPR experiments.FIG. 15A shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 1 at various concentrations.FIG. 15B illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics.FIG. 15C shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 5 at various concentrations.FIG. 15D illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics.FIG. 15E shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 7 at various concentrations.FIG. 15F illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics.FIG. 15G shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 8 at various concentrations.FIG. 15H illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics.FIG. 15I shows the raw data from SPR experiments illustrating binding of SEQ ID NO: 11 at various concentrations.FIG. 15J illustrates the data from SPR fit with the 1:1 binding model for single cycle kinetics.FIG. 16 illustrates data from SPR experiments illustrating binding of peptides of the present disclosure to TEAD.FIG. 16A illustrates binding of SEQ ID NO: 9 to TEAD using a single cycle kinetics protocol.FIG. 16B illustrates binding of SEQ ID NO: 10 to TEAD using a single cycle kinetics protocol.FIG. 16C illustrates binding of SEQ ID NO: 11 to TEAD using a steady-state kinetics protocol. - TABLE 7 shows the results of SPR experiments for each peptide tested, including quantification of association (ka), dissociation (kd) and the dissociation constant (KD). A lower KD value indicates higher affinity and better binding.
-
TABLE 7 SPR Analysis Results SEQ ID Analysis NO ka (M−1 s−1) kd (s−1) KD (M) Model 1 3.1(2) × 10−8 Steady- State 5 2.8(2) × 10−7 Steady- State 7 2.28(5) × 10−5 Steady- State 8 3.9(2) × 10−8 Steady- State 9 2.21(2) × 107 8.14(6) × 10−3 3.68(4) × 10−10 Single Cycle Kinetics 10 2.06(2) × 107 7.67(7) × 10−3 3.72(5) × 10−10 Single Cycle Kinetics 11 6.3(4) × 10−9 Steady- State 11 3.10(3) × 107 0.117(1) 3.78(5) × 10−9 Kinetics 1:1 Binding * reported ka is approaching the limits that can be measured by the instrument - This example describes cell-penetrating peptide fusions. A TEAD-binding peptide of the present disclosure is recombinantly expressed as a fusion to a cell penetrating peptide moiety. The TEAD-binding peptide is selected from any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84.
- The cell penetrating peptide moiety is one or multiple Arg residues, such as an RRRRRRRR (SEQ ID NO: 146) sequence conjugated to, linked to, or fused at the N-terminus, or a Tat peptide with the sequence YGRKKRRQRRR (SEQ ID NO: 195) that is conjugated to, linked to, or fused to the N-terminus of any TEAD-binding peptide of the present disclosure. Alternatively, the cell penetrating peptide moiety is selected from maurocaline, imperatoxin, hadrucalcin, hemicalcin, oplicalin-1, opicalcin-2, midkine (62-104), MCoTI-II, or chlorotoxin, which is fused to the N-terminus of any TEAD-binding peptide of the present disclosure. Alternatively, the cell penetrating peptide moiety is selected from TAT (SEQ ID NO: 143), CysTAT (SEQ ID NO: 144), S19-TAT (SEQ ID NO: 145), R8 (SEQ ID NO: 146), pAntp (SEQ ID NO: 147), Pas-TAT (SEQ ID NO: 148), Pas-R8 (SEQ ID NO: 149), Pas-FHV (SEQ ID NO: 150), Pas-pAntP (SEQ ID NO: 151), F2R4 (SEQ ID NO: 152), B55 (SEQ ID NO: 153), azurin (SEQ ID NO: 154), IMT-P8 (SEQ ID NO: 155), BR2 (SEQ ID NO: 156), OMOTAGI (SEQ ID NO: 157), OMOTAG2 (SEQ ID NO: 158), pVEC (SEQ ID NO: 159), SynB3 (SEQ ID NO: 160), DPV1047 (SEQ ID NO: 161), C105Y (SEQ ID NO: 162), transpotan (SEQ ID NO: 163), MTS (SEQ ID NO: 164), hLF (SEQ ID NO: 165), PFVYLI (SEQ ID NO: 166), or yBBR (SEQ ID NO: 167), which is fused to the N-terminus of any TEAD-binding peptide of the present disclosure. Alternatively, the cell penetrating peptide moiety is fused to the N-terminus of any TEAD-binding peptide of the present disclosure by a linker. The linker is selected from GGGSGGGSGGGS (SEQ ID NO: 210), KKYKPYVPVTTN (SEQ ID NO: 211) (linker from DkTx), or EPKSSDKTHT (SEQ ID NO: 212) (linker from human IgG3), any linker of SEQ ID NO: 203-SEQ ID NO: 212, or any other linker. Alternatively, the TEAD-binding peptide, the cell penetrating peptide moiety, and, optionally, the linker are joined by other means. For example, the other means includes, but is not limited to, chemical conjugation at any location, fusion of the cell penetrating peptide moiety and/or the linker to the C-terminus of the TEAD-binding peptide, co-formulation with liposomes, or other methods.
- Cell-penetrating peptide fusions or conjugates are administered to a subject in need thereof. The subject is a human or animal and has a disease, such as cancer or diabetes (Type I or Type II). Upon administration, cell-penetrating peptide fusions traverse cellular membranes to access intracellular compartments and subsequently bind TEAD, preventing YAP association with TEAD.
- This example describes peptide fusions to promote nuclear localization. A TEAD-binding peptide of the present disclosure is recombinantly expressed or chemically synthesized. The peptide is selected from any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84. TEAD-binding peptides are conjugated to, linked to, or fused to a nuclear localization signal, such as a four-residue sequence of K-K/R-X-K/R (SEQ ID NO: 202), wherein X can be any amino acid, or a variant thereof (Lange et al, J Biol Chem. 2007 Feb. 23; 282(8):5101-5). Peptide fusions are administered to a subject in need thereof. The subject is a human or animal and has a disease, such as cancer or diabetes (Type I or Type II). Upon administration, peptide fusions traffick to the nucleus, where they efficiently prevent YAP association with TEAD.
- This example describes the promotion of cytosolic delivery or cellular penetration of the peptide. A TEAD-binding peptide of the present disclosure is recombinantly expressed or chemically synthesized. The peptide is selected from any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84. TEAD-binding peptides are conjugated to, linked to, or fused to a dfTAT and/or co-delivered with dfTAT. A nuclear localization signal, such as a four-residue sequence of K-K/R-X-K/R (SEQ ID NO: 202), wherein X can be any amino acid, or a variant thereof (Lange et al, J Biol Chem. 2007 Feb. 23; 282(8):5101-5), can be further conjugated to, linked to, or fused to the TEAD-binding peptide. Peptide fusions are administered to a subject in need thereof. The subject is a human or animal and has a disease, such as cancer or diabetes (Type I or Type II). Upon administration, peptide fusions are expressed in the cytosol and interact with TEAD in the cytosol and nucleus to disrupt TEAD binding to transcription coactivators, such as YAP or TAZ.
- For example, SEQ ID NO: 9 was co-administered with dfTAT, a small dimeric peptide that facilitates endosomal escape of cargoes up to 150 kDa without noticeable effects on viability or gene expression profiles. Using SEQ ID NO: 9 conjugated to DyLight 488 for visualization, co-incubation of HeLa cells with both SEQ ID NO: 9 and dfTAT yielded accumulation of SEQ ID NO: 9 in cells in a disperse pattern. More specifically,
FIGS. 18-18I show that SEQ ID NO: 9 significantly reduces YAP:TEAD dimers in the nucleus. SEQ ID NO: 9-DyLight488 was introduced to the cytosol/nucleus of HeLa cells using 5 μM dfTAT, which induces endosomal leakage. dfTAT was visible in the TRITC channel (FIG. 18C ), while SEQ ID NO: 9-DyLight488 was seen in the FITC channel (FIG. 18D ). Proximity ligation assay (PLA) in HeLa cells was performed using primary antibodies against YAP and TEAD, in which speckles (APC channel) overlapping DAPI-stained nuclei (UV channel) were produced.FIG. 18E shows a representative image of cells treated with 5 μM dfTAT only.FIG. 18F shows a representative image of cells treated with 5 μM dfTAT and 5 μM SEQ ID NO: 9.FIG. 18G shows a representative image of a control proximity ligation assay (PLA) reaction with anti-YAP primary antibodies omitted in which some speckles were non-specific to YAP:TEAD dimers.FIG. 18H shows a representative image of a control PLA reaction with anti-TEAD primary antibodies omitted in which some speckles were non-specific to YAP:TEAD dimers.FIG. 18I illustrates a dot graph of automated counting of YAP:TEAD PLA speckles per nucleus of HeLa cells that were treated with 5 μM dfTAT and/or 5 μM TEAD-binding peptides. Each dot represents a single nucleus, with the bars representing the median ±95% confidence intervals. A line was drawn at the sum of the two antibody omission samples' average speckle counts, representing the approximate value attributable to non-specific speckles. ****: P<0.0001 vs. any other sample. All P-values were determined by two-tailed T-test. The speckles per nucleus were significantly reduced in cells that were treated with the peptide of SEQ ID NO: 9 combined with dfTAT, which is supportive that the treatment may have reduced the interactions of YAP and TEAD in the nucleus of the treated cells. - This example illustrates combination treatment of cancer using peptides of the present disclosure. A peptide of the present disclosure is recombinantly expressed or chemically synthesized and used directly. The peptide is administrated in a pharmaceutical composition to a subject in need thereof as a therapeutic for cancer. The peptide is selected from any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84. One or more peptides are administered to a subject along with a treatment regimen of standard small molecule or chemotherapy, such as cisplatin, methotrexate, docetaxel, and etoposide, among others. The subject is a human or an animal. The pharmaceutical composition is administered intravenously, subcutaneously, intramuscularly, orally, or injected directly into the tumor microenvironment. The peptides disrupt YAP-TEAD interactions by binding to TEAD, and precluding subsequent binding by YAP. The administered peptides with standard small molecule therapy, treats a cancer condition in the subject. The cancer condition may be breast cancer, liver cancer, colon cancer, or brain cancer.
- This example illustrates analysis of a patient's cancer and treatment with peptides. Biopsies are taken from a subject in need thereof and are analyzed for mutations in the YAP/TAZ-TEAD pathway, such as mutations that result in YAP overexpression. A peptide of the present disclosure is recombinantly expressed or chemically synthesized and used directly. The peptide is administrated in a pharmaceutical composition to a subject in need thereof as a therapeutic for cancer. The peptide is selected from any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84. One or more peptides are administered to a subject. The subject is a human. The pharmaceutical composition is administered intravenously, subcutaneously, intramuscularly, orally, or injected directly into the tumor microenvironment. The peptides disrupt YAP/TAZ-TEAD interactions by binding to TEAD, and precluding subsequent binding by YAP or TAZ. The cancer condition may be breast cancer, liver cancer, colon cancer, or brain cancer.
- This example illustrates mutation of peptides to decrease the off rate and/or increase the on rate. A peptide of the present disclosure is mutated using Site Saturation Mutagenesis (SSM) or any random mutagenesis method to decrease the off rate and/or increase the on rate, thereby increasing or improving the binding affinity. The peptide is selected from any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84. Alternatively, any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84 is mutated or grafted to comprise LX1X2LF (SEQ ID NO: 217) sequence or motif to improve binding/antagonist activity on TEAD. The LX1X2LF (SEQ ID NO: 217) is mutated or grafted on the peptide at any position along the sequence which allows for improve binding/antagonist activity on TEAD.
- The example illustrates a method for the computational design of a peptide library of scaffold peptides with three disulfide cross-links that bind to TEAD. Initial candidates were identified either by searching for specific peptide properties or through peptide design. The Rosetta software package was used for peptide design to identify de novo scaffold construction: candidate scaffold peptides with three disulfide cross-links were constructed by de novo fold design, optimizing only for folding and stability without regard to binding functionality. The input topology parameters used for scaffold construction were as follows: minimum and maximum sequence length: 30 and 41 residues, respectively; secondary structure types: helix, helix, helix; secondary structure length ranges: 6-18 residues; turn lengths: 2-4 residues; number of disulfides: 3; disulfide topology: H1-H2, H1-H3, and H2-H3. Several hundred thousand independent design simulations were performed to build a large library of candidate scaffolds, which was then be filtered by sequence-structure compatibility, packing, satisfaction of polar groups, and disulfide score. At the start of each design simulation, helix and turn lengths were sampled randomly from the corresponding length ranges, fixing the secondary structure of the design, which were then used to select backbone fragments for a low-resolution fragment assembly simulation. At the end of the low-resolution simulation, the protein backbone was scanned for residue pairs that could be linked by disulfide connections using a library of N—Cα-C backbone transforms derived from disulfide bonds in the protein structure database. Backbones with matching residue pairs that satisfied the disulfide topology constraints were used to initiate an all-atom sequence design simulation consisting of two cycles of alternating fixed-backbone sequence design and fixed-sequence structure relaxation. Final designs were filtered for packing (sasapack score <0.5), satisfaction of buried polar groups (using a 1.0 A probe radius), and sorted by energy per residue. The top 10% of the filtered designs were assessed for sequence-structure compatibility by an in silico refolding test in which the design sequence were used to initiate 3000 independent structure prediction simulations. Success was measured by assessing the fraction of low-energy structure prediction models within 2 Å Cα-RMSD of the design model. Promising peptides identified by de novo scaffold construction, as well as 75 native knottin structures from the Protein Data Bank (PDB) of 30-50 residues in length, were then used as scaffolds for interface design targeting the YAP footprint on TEAD. Scaffold sequence redesign in the second stage targeted interface side chains while preserving the core amino acids and disulfide-forming residues. Additionally, the crystal structure of the YAP-TEAD complex (PDB ID 3KYS) was examined to identify binding patches on TEAD. Corresponding backbone elements on YAP were observed and selected to serve as templates for the interface design of each promising peptide in order to retain binding to TEAD. More specifically, the following backbone residue segments were selected as superposition targets for orienting design scaffolds: 3KYS/B/53-55, 3KYS/B/55-57, 3KYS/B/64-68, 3KYS/B/64-69, 3KYS/B/86-89, 3KYS/B/94-96 (given as: PDB ID/chain/residue numbers). For each peptide scaffold, 150 design simulations were conducted targeting each YAP backbone segment selected for superposition. Each design simulation consisted of the following steps: (1) superimposing the scaffold backbone onto the YAP backbone segment using a scaffold backbone element with matching secondary structure, (2) random small perturbations to generate diversity and relieve backbone clashes, and (3) all-atom sequence design alternating between fixed-backbone sequence selection and fixed-sequence structure relaxation. Final interface designs were filtered for satisfaction of polar groups (using a 1.0 A probe radius), interface surface complementarity (sc score>0.5), and interface quality (predicted binding energy per 100 Å of buried SASA<−1.1), and sorted by predicted binding energy. Top-scoring designs were assessed by an in silico redocking test in which the redesigned scaffold peptide was removed from TEAD, randomly reoriented, and redocked onto the TEAD protein structure. Success was measured as the fraction of low-energy redocking simulations that reached a final state close to the designed interface conformation. This process identified both SEQ ID NO: 1 and SEQ ID NO: 2 as potential soluble peptides with three disulfide cross-links that bind to TEAD, but only SEQ ID NO: 1 was found to be monodisperse and stable.
-
FIG. 17B illustrates the modeled TEAD interface for the YAP-TEAD structure from Protein Data Bank (PDB ID) 3KYS.FIG. 17C illustrates the modeled TEAD interface for SEQ ID NO: 1 modeled with the TEAD structure fromFIG. 17A .FIG. 17D illustrates the modeled TEAD interface for SEQ ID NO: 2 modeled with the TEAD structure fromFIG. 17A . - This example illustrates methods for improving cell penetrance of a peptide. A peptide whose binding partner is located within a cell needs to enter/penetrate a cell in order to exert its activity.
- One method to overcome this is to graft a binding interface of a designed peptide identified by the methods in EXAMPLE 24 onto a cell penetrating peptide scaffold. A naturally cell-penetrant peptide is used as the scaffold, such as a calcine or a modified cell-penetrant peptide (such as a modified calcine or calcine derivative). Some peptides that are used include, but are not limited to, imperatoxin, maurocalcine, hemicalcin,
opiclacin 1,opicalcin 2, midkine (62-104), MCoTI-II, chlorotoxin, and hadrucalcin. Such scaffolds used are also modified derivatives of the foregoing calcines as described herein. As an example, the six amino acid portion of helix 3 (MLICLF; SEQ ID NO: 221), a major component of SEQ ID NO: 9 binding to TEAD, is transplanted onto a calcine scaffold and a bi-functional peptide that retains the cell penetration of the calcine with the novel SEQ ID NO: 9 TEAD binding function is produced. This method is used to improve the cell penetrance of any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84. - Alternatively, cis-acting elements, including inclusion of K/R-rich sequences like TAT or octa-arginine (SEQ ID NO: 146), intra-helical arginine patches, or fusion to larger fragments of proteins identified in cell penetration screening like penetratin or melittin are used to improve cell penetrance of a peptide. This method is used to improve the cell penetrance of any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84.
- Alternately, site saturation mutagenesis is used to improve the binding of a calcine based-TEAD binding peptide. Alternatively, peptides that are not calcines but that have similar surface charge distributions to calcines are designed, containing a TEAD binding pharmacophore. As an additional alternative, selenocysteine is substituted for some or all cysteine residues in the peptides to result in bridges that are more stable to cytosolic reducing conditions than disulfide bonds. As a further alternative, activity on ryanoride receptors is mutated out of the peptide.
- The example illustrates a method for the computational design of a peptide library of scaffold cell penetrating peptides. Initial candidates are identified either by searching for specific peptide properties (such as cell penetration) or through peptide design. The Rosetta software package is used for peptide design to identify de novo scaffold construction: candidate cell-penetrating scaffold peptides with are constructed by de novo fold design, optimizing only for folding and stability without regard to binding functionality. Promising peptides identified by de novo scaffold construction, as well as known cell-penetrating peptides of 30-50 residues in length, are then used as scaffolds for interface design targeting the SEQ ID NO: 9 footprint on TEAD. Interface side chains of the scaffold peptide redesign sequence are targeted in the second stage preserving the core amino acids and disulfide-forming residues. Additionally, the crystal structure of the SEQ ID NO: 9-TEAD complex is examined to identify binding patches on TEAD. Corresponding backbone elements on SEQ ID NO: 9 are observed and are selected to serve as templates for the interface design of the peptide in order to retain binding to TEAD. From this, specific backbone residue segments are selected as superposition targets for orienting design scaffolds. For each peptide scaffold, multiple design simulations are conducted targeting each SEQ ID NO: 9 backbone segment selected for superposition. The following steps are followed for each design simulation: (1) superimposing the scaffold backbone onto the SEQ ID NO: 9 backbone segment using a scaffold backbone element with matching secondary structure, (2) random small perturbations to generate diversity and relieve backbone clashes, and (3) all-atom sequence design alternating between fixed-backbone sequence selection and fixed-sequence structure relaxation. Final interface designs are filtered for satisfaction of polar groups (using a 1.0 A probe radius), interface surface complementarity (sc score>0.5), and interface quality (predicted binding energy per 100 k of buried SASA<−1.1), and sorted by predicted binding energy. Top-scoring designs are assessed by an in silico redocking test in which the redesigned scaffold peptide was removed from TEAD, randomly reoriented, and redocked onto the TEAD protein structure. Success is measured as the fraction of low-energy redocking simulations that reached a final state close to the designed interface conformation. Cell-penetrating peptides that bind to TEAD are identified.
- This example shows peptides of this disclosure are stable in extreme heat. Protein secondary structures were assessed using Circular Dichrosim (CD). CD spectra were measured with a Jasco J-720W spectropolarimeter using a 1.0 mm path length cell. Protein samples in 10 mM phosphate buffer (pH=7.4) were at 25-30 μM protein concentration. Samples were analyzed at wavelength ranges of 260-190 nM. Data were expressed in terms of relative ellipticity [θ]; (mdeg). To determine thermal stability of proteins, samples were subjected to incremental increase in temperature at a ramp of 2° C./min from 20° C. to 95° C. Stability and protein unfolding were monitored at 220 and 215 for α-helix and β-sheet secondary structures, respectively. Data are expressed in terms of relative ellipticity [θ], reported in mdeg. For SEQ ID NO: 9 and its point mutant variants, no changes to the ca-helix-dominated structure were observed upon heating up to 95° C.
FIG. 20A illustrates that the CD spectra of SEQ ID NO: 9 demonstrated that the structure was dominated by α-helical elements, and that this secondary structure signature was identical before (Pre) and after (Post) incubation at 95° C. The inset shows relative ellipticity at 220 nm during heating from 20° C. to 95° C.FIG. 20B illustrates that the circular dichroism spectra of SEQ ID NO: 10 demonstrated the structure is dominated by α-helical elements, and that this secondary structure signature was identical before (Pre) and after (Post) incubation at 95° C. This inset also shows relative ellipticity at 220 nm during heating from 20° C. to 95° C.FIG. 20C illustrates that the circular dichroism spectra of SEQ ID NO: 11 demonstrated the structure was dominated by α-helical elements, and that this secondary structure signature was identical before (Pre) and after (Post) incubation at 95° C. Again, the inset shows relative ellipticity at 220 nm during heating from 20° C. to 95° C. Additionally, protein melting temperature (Tm) determination was performed by monitoring protein unfolding using SYPRO Orange dye (Molecular Probes). In brief, 0.1 mg/mL protein sample in 20 μL total volume PBS buffer were mixed with 2 μL of 10×SYPRO Orange dye. Dye intercalation into the hydrophobic protein core following protein unfolding was assayed using the C1000 Touch Thermal Cycler with CFX96 Deep Well Real-Time System (BioRad). Samples were heated from 20° C. to 95° C. with stepwise increments of 0.5° C. per minute and a 5 see hold step for every point, followed by fluorescence reading. Tm was calculated by analyzing the derivatives of Relative florescence Units (RFU).FIG. 20D illustrates this SYPRO Orange melting assay of peptides. Human siderocalin (HuScn) demonstrated an expected melting temperature of 79° C., as interpreted by the peak of its RFU vs. temperature slope. Conversely, no melting temperature could be determined for the three peptides tested (SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11). Thus, the SYPRO Orange thermal shift assay showed no evidence of protein unfolding, and therefore, SEQ ID NO: 9 and its point variants were shown to be stable at high temperatures. - This example describes peptide conjugates to promote cellular penetration of the peptide. A TEAD-binding peptide of the present disclosure is recombinantly expressed or chemically synthesized. The peptide is selected from any one of the peptides of SEQ ID NO: 1-SEQ ID NO: 84. TEAD-binding peptides are conjugated to maurocaline (SEQ ID NO: 168), imperatoxin (SEQ ID NO: 169), hadrucalcin (SEQ ID NO: 170), hemicalcin (SEQ ID NO: 171), oplicalin-1 (SEQ ID NO: 172), opicalcin-2 (SEQ ID NO: 173), midkine (62-104) (SEQ ID NO: 174), MCoTI-II (SEQ ID NO: 175), chlorotoxin (SEQ ID NO: 176), DRI-TAT31 (rrrqrrkkrgy, wherein the lowercase notation indicates D-amino acids; SEQ ID NO: 280), cyclic heptapeptide cyclo (cFΦR4) (FΦRRRRQ, where (1 is 1-2-naphthylalanine, the entire moiety is cyclized, and Gln serves as a conjugation handle and can be substituted for other functional groups such as Lys (for amine coupling) or Cys (for sulfhydryl coupling); SEQ ID NO: 281), or myristate. In some cases, the peptide is linked to the cell penetrating moeity by a linker, in which amine coupling is used to attach the linker/functional group to amines on a TEAD-binding peptide of the present disclosure. Any or all Lys residues of a TEAD-binding peptide of the present disclosure may be mutated to Arg to homogenize chemical conjugation and/or enhance cell penetration.
- Cell penetration of peptide conjugates are tested for functional impairment of TEAD signaling in 293T cells transfected with a luciferase reporter responsive to YAP:TEAD signaling (8×GTIIC), and for inhibition of YAP:TEAD dimerization in HeLa cells by proximity ligation assay (PLA). Liposomal formulation of successful peptide conjugates is investigated. Additionally, in some peptide conjugates, a disulfide bridge, a furin cleavage site (RX[K/R]R), and/or a cathepsin cleavage site is introduced into the linker.
- A peptide conjugate is administered to a subject in need thereof. The subject is a human or animal and has a disease, such as cancer or diabetes (Type I or Type II). Upon administration, target cells are penetrated by peptide conjugates and interact with TEAD to disrupt TEAD binding to transcription coactivators, such as YAP or TAZ.
- This example shows a method of extending the serum half life of a peptide as disclosed herein. A peptide of any one of SEQ ID NO: 1-SEQ ID NO: 142 and SEQ ID NO: 222-SEQ ID NO: 279 is modified in order to increase its serum half life. Conjugation of the peptide to a near infrared dye, such as Cy5.5 is used to extend serum half life of the peptide conjugate. Alternatively, conjugation of the peptide to an albumin binder, such as Albu-tag, is used to extend serum half-life. Optionally, serum half-life is extended as a result of reduced immunogenicity by using minimal non-human protein sequences.
- This example describes small scale and large scale production of TEAD Binder-Cell Penetrating Peptide fusions (CPP fusions) and Tandem-Cysteine Dense Peptides (Tandem-CDPs). CPP fusions and Tandem-CDPs were cloned in a Daedalus vector, which is a lentivector that drives secretion of siderocalin-tagged proteins. The siderocalin produced by this vector is 6×His-tagged (SEQ ID NO: 284) and contains the linker that has a TEV cleavage site, leaving only “GS” behind on the peptide's N-terminus after cleavage. The cloned vector sequence was verified using Sanger sequencing (Genewiz), and the verified vectors were then purified at small (1 mL in 96-well deep well blocks) volumes or large (400 mL) volumes. VSV-G pseudotyped lentivirus was then produced through standard methods.
Suspension 293F cells were transduced with the VSV-G pseudotyped lentivirus and were grown in FreeStyle (ThermoFisher) expression media. For small scale production, 1×106 cells were then transduced in 1 mL with 100 μL viral supernatant and shaken at 1,000 rpm until harvest (˜7 days). 3 mM valproic acid was added after 5 days. For large scale production, 1×107 cells were transduced with VSV-G pseudotyped lentivirus in 10 mL with 1 mL viral supernatant (target multiplicity of infection is ˜10), after which the culture (shaken at 125 rpm) was expanded over the course of 8-10 days to 400 mL final volume. CPP fusions and Tandem-CDPs were collected from culture media after pelleting cells and 0.22 μm filtration of debris, followed by nickel resin purification and TEV protease cleavage. For large scale production, an additional SEC purification was performed and monitored at wavelengths of 205, 214, and 280 nm. For both small scale production and large scale production, quality control was performed by SDS-PAGE followed by Coomassie staining. Protein concentrations were determined by UV spectral absorption at 214 or 280 nm. -
FIG. 25 illustrates SDS-PAGE gels of CPP fusions and Tandem-CDPs under non-reduced (NR) and reduced (R) conditions. The tested CPP fusions were SEQ ID NO: 96, SEQ ID NO: 95, SEQ ID NO: 85, SEQ ID NO: 97, SEQ ID NO: 105, SEQ ID NO: 111, SEQ ID NO: 100, SEQ ID NO: 94, SEQ ID NO: 109, SEQ ID NO: 99, and SEQ ID NO: 108. The tested Tandem-CDPs were SEQ ID NO: 134, SEQ ID NO: 124, SEQ ID NO: 117, SEQ ID NO: 125, SEQ ID NO: 132, SEQ ID NO: 119, SEQ ID NO: 141, SEQ ID NO: 130, and SEQ ID NO: 138. The CPP fusions and Tandem-CDPs were produced at small scale in 1 mL cultures and TEV-cleaved to separate the peptide (lower band(s) inFIG. 25 ) from the siderocalin carrier (middle band(s) inFIG. 25 ). Uncleaved fusion proteins appear as the top-most band (s). Molecular weight markers (MWMs) are shown in kiloDalton (kDa) in the lane immediately to the right of the (non-reduced) NR and (reduced) R lanes for each sequence. -
FIG. 26 illustrates non-reduced SDS-PAGE gels of CPP fusions and Tandem-CDPs. From left to right,FIG. 26 shows four controls including hadrucalcin (SEQ ID NO: 170), imperatoxin (SEQ ID NO: 169), opicalcin-2 (SEQ ID NO: 173), and chlorotoxin (SEQ ID NO: 176) were tested.FIG. 26 additionally shows the TEAD Binder of (SEQ ID NO: 9), CPP fusions of SEQ ID NO: 95 and SEQ ID NO: 96, and Tandem-CDPs of SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 124, SEQ ID NO: 125, and SEQ ID NO: 134. Molecular weight markers (MWMs) are shown in kiloDalton (kDa) in the left most lane. - This example shows the use of a chloroalkane penetration assay (CAPA) to determine cell penetration and cytosolic access of the Tandem CDP of SEQ ID NO: 124.
- HeLa cells expressing the HaloEnzyme (a modified bacterial haloalkane dehalogenase, further modified to target to the cytosol-facing side of the outer mitochondrial membrane) were grown in 24 well dishes until ˜60% confluent. Cells were rinsed with PBS and then incubated with solutions comprising no HaloTag (HT) or 1 μM HT, or with 1 μM HT-SEQ ID NO: 176, HT-SEQ ID NO: 9, HT-SEQ ID NO: 232, or HT-SEQ ID NO: 124 in Opti-MEM serum free buffer for 4 hours. After incubation, cells were rinsed and incubated with Opti-MEM for 30 minutes, and were then incubated with 5 μM HT-TAMRA ligand (Promega G8251) for 30 minutes. An additional control with no HT-TAMRA was tested. After this incubation, cells were rinsed with PBS and then imaged on a fluorescent microscope in FITC/green (all cells) and TRITC/red (HT-TAMRA accumulation) channels. Cells without color indicated that the intracellular HaloEnzyme was occupied by HT, and thus, the tested HT-ligand-labeled peptide comprises a peptide that was cell penetrating. Cells with color indicated that the HaloEnzyme was unoccupied and HT-TAMRA was able to accumulate in cells, and thus the tested HT-ligand-labeled peptide was not cell penetrating.
-
FIG. 27 illustrates microscopy images of HeLa cells evaluated for cell penetration with a Halo assay. The top left image shows the fluorescence of cells treated with a test solution with 1 μM HT (no protein). The top right image shows the fluorescence of cells treated with buffer only. The bottom left image shows the fluorescence of cells treated with 1 μM HT-SEQ ID NO: 9 (bottom left). The bottom right image shows the fluorescence of cells treated with 1 μM HT-SEQ ID NO: 124 (bottom right). The peptide of SEQ ID NO: 124 (bottom right) exhibited high cell penetration. -
FIG. 28 illustrates cell-by-cell quantitation of average fluorescence in the red channel of cells in a CAPA. Cells were incubated with no HaloTag (HT) (not shown in figure; used for calibration as 0 cell penetration score (CPS) indicating no cell penetration), 1 μM HT (not shown in graph; used for calibration as 1 CPS indicating total cell penetration), 1 μM HT-SEQ ID NO: 9 (a control TEAD binder), 1 μM SEQ ID NO: 94, 1 μM HT-SEQ ID NO: 95, 1 μM HT-SEQ ID NO: 96, 1 μM HT-SEQ ID NO: 119, 1 μM HT-SEQ ID NO: 124, 1 μM HT-SEQ ID NO: 125, or 1 μM HT-SEQ ID NO: 134. A high CPS (the inverse of the cells' fluorescence, calibrated to the no HT (0 CPS) and 1 μM HT (1 CPS) controls) indicated that the intracellular HaloEnzyme was occupied by HT, and thus, the tested HT-ligand-labeled peptide comprised a peptide that was cell penetrating. A low CPS indicated that the intracellular HaloEnzyme was unoccupied allowing for accumulation of HT-TAMRA in cells, and that, therefore, the tested HT-ligand-labeled peptide was not cell penetrating. A CPS above the original TEAD binder (SEQ ID NO: 9) suggests an improvement in cell penetration. - While preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/873,510 US20230151068A1 (en) | 2017-01-18 | 2022-07-26 | Peptide compositions and methods of use thereof for disrupting tead interactions |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762447864P | 2017-01-18 | 2017-01-18 | |
US201762510719P | 2017-05-24 | 2017-05-24 | |
PCT/US2018/014203 WO2018136614A1 (en) | 2017-01-18 | 2018-01-18 | Peptide compositions and methods of use thereof for disrupting tead interactions |
US201916478672A | 2019-07-17 | 2019-07-17 | |
US17/873,510 US20230151068A1 (en) | 2017-01-18 | 2022-07-26 | Peptide compositions and methods of use thereof for disrupting tead interactions |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/478,672 Continuation US11548923B2 (en) | 2017-01-18 | 2018-01-18 | Peptide compositions and methods of use thereof for disrupting TEAD interactions |
PCT/US2018/014203 Continuation WO2018136614A1 (en) | 2017-01-18 | 2018-01-18 | Peptide compositions and methods of use thereof for disrupting tead interactions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230151068A1 true US20230151068A1 (en) | 2023-05-18 |
Family
ID=62909226
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/478,672 Active US11548923B2 (en) | 2017-01-18 | 2018-01-18 | Peptide compositions and methods of use thereof for disrupting TEAD interactions |
US17/873,510 Pending US20230151068A1 (en) | 2017-01-18 | 2022-07-26 | Peptide compositions and methods of use thereof for disrupting tead interactions |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/478,672 Active US11548923B2 (en) | 2017-01-18 | 2018-01-18 | Peptide compositions and methods of use thereof for disrupting TEAD interactions |
Country Status (6)
Country | Link |
---|---|
US (2) | US11548923B2 (en) |
EP (1) | EP3571215A4 (en) |
JP (2) | JP7191025B2 (en) |
AU (2) | AU2018210157B2 (en) |
CA (1) | CA3049262A1 (en) |
WO (1) | WO2018136614A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
BR112018004536A2 (en) | 2015-09-09 | 2018-12-11 | Blaze Bioscience Inc | cartilage addressing peptides |
AU2018210157B2 (en) | 2017-01-18 | 2022-10-06 | Fred Hutchinson Cancer Center | Peptide compositions and methods of use thereof for disrupting TEAD interactions |
KR102670432B1 (en) | 2017-02-08 | 2024-05-28 | 브리스톨-마이어스 스큅 컴퍼니 | Modified relaxin polypeptides containing pharmacokinetic enhancers and uses thereof |
JP7280193B2 (en) | 2017-03-16 | 2023-05-23 | ブレイズ バイオサイエンス, インコーポレイテッド | Cartilage homing peptide conjugates and methods of use thereof |
EP3638290A4 (en) | 2017-06-15 | 2021-04-07 | Blaze Bioscience, Inc. | Renal-homing peptide conjugates and methods of use thereof |
US11866466B2 (en) | 2017-12-19 | 2024-01-09 | Blaze Bioscience, Inc. | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof |
WO2019209662A1 (en) * | 2018-04-23 | 2019-10-31 | Fred Hutchinson Cancer Research Center | Conjugates of cartilage-homing peptides |
CN110189794B (en) * | 2019-04-16 | 2021-01-01 | 浙江工业大学 | Residue contact guided loop perturbation population protein structure prediction method |
CN111091871B (en) * | 2019-12-19 | 2022-02-18 | 上海交通大学 | Protein signal peptide and method for realizing prediction of cleavage site thereof |
EP4085066A4 (en) * | 2020-01-05 | 2023-09-27 | Technion Research & Development Foundation Limited | Conus-based toxin peptides, nucleic acids encoding same and uses thereof in modulating nmda receptors |
WO2021194228A1 (en) * | 2020-03-23 | 2021-09-30 | 주식회사 엘베이스 | Pharmaceutical composition for prevention or treatment of cancer |
KR102348728B1 (en) * | 2020-03-23 | 2022-01-12 | 주식회사 엘베이스 | Pharmaceutical Composition for the Prevention or Treatment of Cancer |
JP2024510293A (en) * | 2021-03-17 | 2024-03-06 | エル-ベース カンパニー リミテッド | Pharmaceutical composition for enhancing the anticancer effect of anticancer drugs |
WO2022203219A1 (en) * | 2021-03-22 | 2022-09-29 | 주식회사 엘베이스 | Pharmaceutical composition for prevention or treatment of cancer |
CN116444678B (en) * | 2022-10-18 | 2024-02-02 | 百葵锐(深圳)生物科技有限公司 | Novel polypeptide with fungus antibacterial and bacteriostatic properties |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0932417T3 (en) | 1996-10-17 | 2003-04-14 | Immunomedics Inc | Non-antigenic toxin conjugate and fusion protein of internalizing receptor system |
US7507413B2 (en) * | 2001-04-12 | 2009-03-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CN1655675A (en) | 2002-03-26 | 2005-08-17 | 综合医院公司 | Combination therapy using trefoil peptides |
US20060088899A1 (en) | 2002-05-31 | 2006-04-27 | Alvarez Vernon L | Combination chemotherapy with chlorotoxin |
FR2877946B1 (en) | 2004-11-12 | 2011-02-11 | Commissariat Energie Atomique | MAUROCALCIN-DERIVED PEPTIDES FOR USE AS VECTORS FOR INTRACELLULAR ADDRESSING OF MOLECULES OF INTEREST |
CN101583370A (en) | 2005-09-27 | 2009-11-18 | 阿穆尼克斯公司 | Proteinaceous pharmaceuticals and uses thereof |
US7592009B2 (en) | 2006-10-10 | 2009-09-22 | Ecole Polytechnique Federale De Lausanne (Epfl) | Polypeptide ligands for targeting cartilage and methods of use thereof |
EP2211913A4 (en) | 2007-10-12 | 2010-12-22 | Transmolecular Inc | Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors |
PL2531206T3 (en) | 2010-02-04 | 2017-12-29 | Morphotek, Inc. | Chlorotoxin polypeptides and conjugates and uses thereof |
AU2011253424B2 (en) | 2010-05-11 | 2016-02-04 | Fred Hutchinson Cancer Center | Chlorotoxin variants, conjugates, and methods for their use |
US20130280281A1 (en) | 2010-07-02 | 2013-10-24 | Jean-Paul Castaigne | Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
US10844106B2 (en) | 2010-11-08 | 2020-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Fusion proteins comprising an engineered knottin peptide and uses thereof |
WO2013078250A2 (en) | 2011-11-22 | 2013-05-30 | The Board Of Trustees Of The Leland Stanford Junior University | Cystine knot peptides that bind alpha-v-beta-6 integrin |
US10426850B2 (en) | 2011-11-22 | 2019-10-01 | The Johns Hopkins University | Collagen mimetic peptides for targeting collagen strands for in vitro and in vivo imaging and therapeutic use |
JP5724937B2 (en) | 2012-04-23 | 2015-05-27 | ニプロ株式会社 | Peptides and preparations that show kidney accumulation |
WO2014063012A1 (en) | 2012-10-19 | 2014-04-24 | The Board Of Trustees Of The Leland Stanford Junior University | Conjugated knottin mini-proteins containing non-natural amino acids |
AU2013359426A1 (en) | 2012-12-10 | 2015-07-09 | Fred Hutchinson Cancer Research Center | Lipocalin fusion partners |
DK2994153T3 (en) | 2013-05-07 | 2018-11-26 | Merck Patent Gmbh | NON-TARGETING PEPTIDES AND PEPTID ACTIVE CONJUGATE |
WO2015022283A1 (en) | 2013-08-12 | 2015-02-19 | F. Hoffmann-La Roche Ag | Yap-tead inhibitors |
US10526385B2 (en) | 2013-10-17 | 2020-01-07 | Bao Kang Biomedical Healthcare Inc | YAP protein inhibiting polypeptide and application thereof |
EP2868326A1 (en) * | 2013-11-04 | 2015-05-06 | Université Pierre et Marie Curie (Paris 6) | Peptide inhibitors of TEAD/YAP-TAZ interaction |
CA2949535C (en) | 2014-05-21 | 2023-09-12 | President And Fellows Of Harvard College | Ras inhibitory peptides and uses thereof |
WO2016112208A2 (en) | 2015-01-09 | 2016-07-14 | Kineta One, Llp | Topical applications of kv1.3 channel blocking peptides to treat skin inflammation |
US20180021323A1 (en) | 2015-01-22 | 2018-01-25 | Bioventures, Llc | Flip - a selective molecular target of senescent cells |
EP3302557B1 (en) * | 2015-06-01 | 2024-01-31 | MaineHealth | Antagonist of collagen for enhancing the therapeutic activity of an immune checkpoint inhibitor in the treatment of melanoma |
CA2987636A1 (en) | 2015-06-26 | 2016-12-29 | Fred Hutchinson Cancer Research Center | Therapeutic peptides and methods of use thereof |
CN106380521B (en) | 2015-07-02 | 2020-12-29 | 博际生物医药科技(杭州)有限公司 | Interleukin-15 fusion protein for tumor targeted therapy |
BR112018004536A2 (en) | 2015-09-09 | 2018-12-11 | Blaze Bioscience Inc | cartilage addressing peptides |
CN106589064A (en) | 2015-10-15 | 2017-04-26 | 上海宝恒泓康生物技术有限公司 | High-activity tumor inhibitor as well as preparation method and application thereof |
EP3156404A1 (en) | 2015-10-15 | 2017-04-19 | Inventiva | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma |
US20200330603A1 (en) | 2015-12-11 | 2020-10-22 | Fred Hutchinson Cancer Research Center | Peptides for renal therapy |
CA3053242A1 (en) | 2016-02-19 | 2017-08-24 | Dignity Health | Antibody fusion protein and related compositions for targeting cancer |
WO2018049285A1 (en) | 2016-09-09 | 2018-03-15 | Fred Hutchinson Cancer Research Center | Stable peptides and methods of use thereof |
WO2018119001A1 (en) | 2016-12-19 | 2018-06-28 | Fred Hutchinson Cancer Research Center | Peptide-antibody compositions and methods of use thereof |
AU2018210157B2 (en) | 2017-01-18 | 2022-10-06 | Fred Hutchinson Cancer Center | Peptide compositions and methods of use thereof for disrupting TEAD interactions |
JP7280193B2 (en) | 2017-03-16 | 2023-05-23 | ブレイズ バイオサイエンス, インコーポレイテッド | Cartilage homing peptide conjugates and methods of use thereof |
-
2018
- 2018-01-18 AU AU2018210157A patent/AU2018210157B2/en active Active
- 2018-01-18 US US16/478,672 patent/US11548923B2/en active Active
- 2018-01-18 EP EP18741953.6A patent/EP3571215A4/en active Pending
- 2018-01-18 JP JP2019534346A patent/JP7191025B2/en active Active
- 2018-01-18 WO PCT/US2018/014203 patent/WO2018136614A1/en unknown
- 2018-01-18 CA CA3049262A patent/CA3049262A1/en active Pending
-
2022
- 2022-07-26 US US17/873,510 patent/US20230151068A1/en active Pending
- 2022-10-14 JP JP2022165397A patent/JP2022191413A/en active Pending
- 2022-12-20 AU AU2022291464A patent/AU2022291464A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2018210157A1 (en) | 2019-07-04 |
EP3571215A1 (en) | 2019-11-27 |
JP7191025B2 (en) | 2022-12-16 |
JP2022191413A (en) | 2022-12-27 |
US20190345211A1 (en) | 2019-11-14 |
WO2018136614A1 (en) | 2018-07-26 |
US11548923B2 (en) | 2023-01-10 |
EP3571215A4 (en) | 2020-12-30 |
AU2022291464A1 (en) | 2023-02-16 |
JP2020505326A (en) | 2020-02-20 |
CA3049262A1 (en) | 2018-07-26 |
AU2018210157B2 (en) | 2022-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230151068A1 (en) | Peptide compositions and methods of use thereof for disrupting tead interactions | |
US11648290B2 (en) | Cartilage-homing peptides | |
US20220048961A1 (en) | Transferrin receptor targeting peptides | |
JP7280193B2 (en) | Cartilage homing peptide conjugates and methods of use thereof | |
US20180371033A1 (en) | Therapeutic peptides and methods of use thereof | |
EP3386530A2 (en) | Peptides for renal therapy | |
US20220098260A1 (en) | BH4 Stabilized Peptides And Uses Thereof | |
US20240287147A1 (en) | Pd-l1 binding peptides and peptide complexes and methods of use thereof | |
US20190292243A1 (en) | Peptides and methods of use thereof | |
KR102436012B1 (en) | Novel use of chemotherapeutic prodrug conjugate | |
WO2022125673A1 (en) | Cell-penetrating peptides and peptide complexes and methods of use | |
US20210252159A1 (en) | Conjugates of cartilage-homing peptides | |
KR20210143127A (en) | A Novel Nucleolin-Binding Peptide and Uses Thereof | |
CN115916234A (en) | Molecules targeting RAS proteins | |
CN117615774A (en) | PD-L1 binding peptides and peptide complexes and methods of use thereof | |
Burns | Specific Delivery of Therapeutics to Cancer Cells Using pHLIP |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: FRED HUTCHINSON CANCER CENTER, WASHINGTON Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:FRED HUTCHINSON CANCER RESEARCH CENTER;FRED HUTCHINSON CANCER CENTER;REEL/FRAME:061754/0199 Effective date: 20220330 Owner name: FRED HUTCHINSON CANCER RESEARCH CENTER, WASHINGTON Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:OLSON, JAMES M.;CROOK, ZACHARY;BRADLEY, PHILIP H.;REEL/FRAME:061513/0725 Effective date: 20171031 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: FRED HUTCHINSON CANCER CENTER, WASHINGTON Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:FRED HUTCHINSON CANCER RESEARCH CENTER;SEATTLE CANCER CARE ALLIANCE;REEL/FRAME:063592/0512 Effective date: 20220330 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |